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ABSTRACT 
Changes in oxygen levels, due to the environment or disease initiates a plethora of acute 
and chronic responses in the body to enable optimal physiological adaptation to 
overcome impaired oxygen delivery.  Homeostatic regulation mechanisms in the 
cardiovascular and respiratory systems rapidly act to maintain oxygen supply to sustain 
normal metabolism; prolonged exposure to a low oxygen tension initiates changes in 
gene expression.  In control of many of these responses is a transcription factor 
(hypoxia-inducible factor, HIF). Among other responses it induces changes in 
erythropoiesis, glycolysis and angiogenesis.  This study primarily aimed to elucidate the 
conditions of hypoxia, local or systemic, which would initiate capillary growth in different 
tissues, and determine whether manipulation of the pathway (by HIF stabilisation) would 
enhance this response.  A systemic response to hypoxia led to increased capillarity in the 
heart and diaphragm, and in both the local and systemic models changes in vascularity 
varied with degree of hypoxia, though manipulation of the HIF pathway had no effect.  
HIF upregulation under conditions of normoxia with muscle overload, also failed to show 
effects of manipulation of the HIF pathway.  Therefore, ablation of individual enzymes 
controlling levels of HIF was utilised.  A number of genes associated with angiogenesis 
and protein remodelling were upregulated, as seen with gene arrays, though histological 
evidence for the former was poor, suggesting a delay in gene expression and translation 
into downstream effects.  We examined whether changes in plasma EPO expression were 
predictive of sickness upon ascent to altitude, and whether leukocytes could be used as a 
circulating indicator of HIF-mediated gene expression.  EPO was enhanced in all subjects 
following exposure to hypoxia, and it may be one marker for AMS, but individual 
variation in gene responses to hypoxia suggests leukocytes may not be a viable indicator 
of the circulating systemic response to hypoxia.  This study emphasises the complexity of 
the HIF pathway, highlighting the multitude of its effects both on a molecular and 
physiological level. 
ACKNOWLEDGEMENTS 
 
I would firstly like to would like to acknowledge and extend my gratitude to Dr Stuart 
Egginton, for his continual support, guidance and patience throughout the last three 
years, which has made the completion of this project possible.  
 
Thanks to Professor Chris Pugh and members of the lab at the Henry Wellcome Building 
for Molecular Physiology in Oxford, for their continual patience and help during my time 
there.  I also wish to thank Jennifer Marshall, Phillip Antczak, Kai Toellner, Clare Ray and 
Ian Ricketts in Birmingham, and Helen Lockstone in Oxford, along with members of the 
Angiogenesis Research Group and Department of Physiology for their significant 
contribution in helping me to achieve this thesis.   
 
The Birmingham Medical Research Expeditionary Society has provided immeasurable 
support and encouragement, along with some extremely memorable expeditions.  Thank 
you also to Professor Ian Maclennan for his support, intellectual and financial input, Ian 
Chesner for funding the high altitude research, and Professor Damian Bailey for the use 
of the hypoxic chamber for the high altitude study.  
 
Thank you to the Rowbotham Request for funding this work, and to Alison Kewley and 
George Rodway for their help in final editing. 
 
Finally, I wish to thank the rest of my family for their continued support and faith in me, 
throughout. 
 
 
 
 315 
1   CHAPTER 1: GENERAL INTRODUCTION 1 
1.1 Hypoxia 1 
1.1.1 Systemic hypoxia 1 
1.1.3 Local hypoxia 5 
1.2 Hypoxia inducible factor (HIF) 7 
1.2.1 HIF activity and regulation 7 
1.2.2 HIF-mediated responses to systemic hypoxia: adapatation to high altitude
 11 
1.3 Angiogenesis 12 
1.3.1  Background 12 
1.3.2  The history of angiogenesis 13 
1.3.3  Types of Angiogenesis 14 
1.3.4 Mechanisms of blood vessel growth 16 
1.3.5 Angiogenic stimuli 19 
1.4.7  Angiogenesis and disease 22 
1.4.8 Therapeutic angiogenesis 23 
1.5 Hypothesis and aims 24 
CHAPTER 2: METHODS 26 
2.1 Dimethyloxalylglycine 27 
2.1.1 Protocol 28 
2.1.2 Product research and development 28 
2.2 Skeletal muscle sampling 30 
2.2.1 Procedure 31 
2.3 Freezing tissue and cryosectioning 32 
2.3.1 Freezing tissue 32 
2.3.2 Cryosectioning 32 
2.4 Immunohistochemical staining and capillary counting 32 
2.4.1 Lectin staining 32 
2.4.1.1 Protocol 33 
2.4.2 VEGF triple stain 33 
2.4.2.1 Solutions 33 
2.4.2.2 Protocol 34 
2.4.3 Capillary and fibre counting 34 
2.4.3.1 Lectin stain 34 
2.4.3.2 VEGF/lectin/DAPI triple stain 35 
2.5 RNA extraction 36 
2.5.1.1 Tissue homogenisation 36 
2.5.1.2 Cell homogenisation 36 
2.5.2 Determination of RNA purity 37 
2.5.2.1 RNA electrophoresis gel solutions 38 
2.5.2.2 Protocol 38 
Gel preparation (1%) 38 
Sample preparation 38 
Assembling the gel 38 
2.6 Real-Time RT-PCR and cDNA synthesis 39 
 316 
2.6.1 Synthesis of cDNA 39 
2.6.2 RT-PCR 39 
2.6.2 Testing primers and probes 41 
2.6.3 Using RT-PCR with the genes of interest 42 
2.7 ELISA methodology 44 
2.8 Western Blot 44 
2.8.1 Controls 44 
2.8.2 Solutions 45 
2.8.3.1 Tissue homogenisation 47 
2.8.3.2 Protein assay 47 
2.8.4 Western Blotting Protocol 47 
2.8.4.1 Gel Preparation 47 
2.8.4.2 Sample preparation 49 
2.8.4.3 Blotting Transfer 49 
2.8.4.4 Immuno-detection 50 
2.8.4.5 Stripping membranes 50 
2.8.4.6 Coomassie staining 50 
2.8.4.7 Ponceau stain 51 
2.9 Cell and Tissue culture 51 
2.9.1 Cell culture 51 
2.9.2 Tissue Culture 51 
2.10 Statistical Analyses 52 
CHAPTER 3: SYSTEMIC HYPOXIA 53 
3.1 Introduction 54 
3.2 Methods 58 
3.2.1 Study design: 10%/12% normobaric hypoxia 58 
3.2.1.1 Tissue processing 58 
3.2.1.2 Western blotting 59 
3.2.2 Study design: 10% hypoxia 59 
3.2.2.1 Blood and tissue collection and processing 60 
3.2.2.2 RNA extraction and RT-PCR 61 
3.3 Results 62 
3.3.1 The effect of systemic hypoxia at 10% and 12% for 1, 2 and 4 weeks
 62 
3.3.1.1 Body mass changes 62 
3.3.1.2 Effects of hypoxia on cardiac tissue and diaphragm 63 
3.3.1.3 Effects of hypoxia on hindlimb skeletal muscles 66 
3.3.1.3.1 Lectin staining for changes in C:F, CD and MFA 66 
3.3.1.3.2 VEGF staining 68 
3.3.2 The effect of systemic hypoxia at 10% on gene expression and 
plasma EPO. 71 
3.3.2.1 Changes in tissue specific mRNA expression under 10% hypoxia 71 
3.3.2.2 General tissue responses to 10% systemic hypoxia 82 
3.3.2.3 Tissue-specific mRNA responses 83 
3.3.2.3.1 HIF-1! 83 
 317 
3.3.2.3.2 EPO 83 
3.3.2.3.3 VEGF 83 
3.3.2.3.4 Flk-1 84 
3.3.2.3.5 Flt-1 84 
3.3.2.3.6 iNOS 84 
3.3.2.3.7 ALD-A 84 
3.3.2.3.8 Carbonic Andydrase IX (CAIX) 85 
3.3.2.3.9 HMOX-1 85 
3.3.2.3.10 TGF-! 85 
3.4 Discussion 87 
3.4.1 Physiological effects 87 
3.4.1.1 Changes in body mass 87 
3.4.1.2 Mechanical stretch effects in the heart and diaphragm 88 
3.4.1.2.1 Cardiac hypertrophy 88 
3.4.1.2.2 Angiogenesis in the heart and diaphragm 89 
3.4.1.2.3 Induction of HIF under hypoxic and non-hypoxic conditions 91 
3.4.1.3 Effects of hypoxia in the hindlimb 92 
3.4.1.3.1 Hypoxia failed to elicit significant angiogenesis 92 
3.4.1.3.2 Exercise and hypoxia 93 
3.4.1.3.3 Lactic acid and haemodynamics 94 
3.4.2 Confounding factors 94 
3.4.2.1 The threshold for HIF induction 94 
3.4.2.2 Mouse strain 96 
3.4.2.3 DMOG and the HIF-system 97 
3.4.2.4 PHD2 is the key O2 sensor and PHD overactivation during chronic hypoxia 
reduces HIF-" levels 100 
3.4.2.4.1 PHD regulation of HIF 100 
3.4.2.4.2 Increased levels of PHDs under chronic hypoxia 101 
3.4.3 Gene expression under hypoxia 102 
3.4.3.1 EPO mRNA and protein expression 103 
3.4.3.2 Control of EPO by the HIF-system: An emerging role for HIF-2" 104 
3.4.3.3 iNOS mRNA 104 
3.5 Conclusions 108 
3.6 Future experiments 109 
Chapter 4: FEMORAL ARTERY LIGATION 110 
4.1 Introduction 111 
4.1.1 Hypoxia Inducible Factor (HIF) 112 
4.1.2 Therapeutic angiogenesis 112 
4.2.1 Study design: Femoral artery ligation 115 
4.2.1.2 Surgery 115 
4.2.1.3 Tissue processing 117 
4.3 Results 119 
4.4 Discussion 122 
4.4.1 Effects of ligation in the hindlimb 122 
4.4.2 The inefficiency of DMOG 124 
4.4.3 The confounding factor of mouse strain 125 
4.4.4 Trauma following surgery and inflammation-induced angiogenesis 127 
 318 
4.4.5 Upregulation of anti-angiogenic factors 129 
4.5 Conclusions 131 
4.6 Future experiments 132 
Chapter 5: EXTIRPATION 133
  
5.1 Introduction 134 
5.1.2 Sensing stretch 134 
5.1.3 Endothelial cell gene responses and capillary network remodelling 137 
5.1.31 Endothelial cells 137 
5.1.3.2 Capillary network remodelling 137 
5.1.3.3 The role of non-hypoxically inducible HIF in stretch-induced angiogenesis
 138 
5.1.4 Skeletal muscle hypertrophy and capillarity 138 
5.2 Methods 141 
5.2.1 Study design: extirpation 141 
5.2.1.1 Surgery 141 
5.2.1.2 Tissue processing 141 
5.3 Results 143 
5.3.1 Capillary changes in skeletal muscle following extirpation surgery 143 
5.3.1.1 Lectin staining 143 
5.4 Discussion 145 
5.4.1 Effects of extirpation in the hindlimb 145 
5.4.1.1 Removal of a synergist muscle stimulates capillary growth 145 
5.4.1.2 Changes in muscle mass associated with extirpation surgery 146 
5.4.2 Oxygen supply and demand 147 
5.4.2.1 Upregulation of protein synthesis and maintenance of blood flow 147 
5.4.2.2 Chemical manipulation of the HIF pathway with DMOG: Evidence for the 
upregulation of HIF-1! and HIF-2! under non-hypoxic stretch 147 
5.4.3 DMOG 148 
5.4.3.1 Multiple targets of DMOG 148 
5.4.3.2 The confounding factor of DMOG efficiency 148 
5.5 Conclusions 150 
5.6 Further experiments 151 
Chapter 6: GENE ARRAYS 152
  
6.1 introduction 153 
6.1.1 Differential involvement of PHDs in capillary growth following muscle 
overload 153 
6.1.2 Genetic manipulation of mouse models 153 
6.1.2.1 Knockouts 153 
6.1.2.2 PHD knockout mice 154 
6.2 Methods 156 
6.2.1 Deriving knockouts 156 
 319 
6.2.2 Genotyping (carried out at the university of Birmingham, Department of 
Physiology) 156 
6.2.2.1 Protocol 156 
6.2.2.2 Primers for PCR 157 
6.2.2.3 PCR protocol 158 
6.2.2.4 Gel electrophoresis 159 
6.2.2.4.2 Protocol 159 
6.2.3 Study design: PHD knockouts 160 
6.2.3.1 Tissue processing 160 
6.2.4 Gene arrays 160 
6.2.4.1 RNA extraction 160 
6.2.4.2 Gene arrays (carried out at the Wellcome Laboratories in the University of 
Oxford) 160 
6.3 Results 162 
6.3.1.1 Changes in capillarity 162 
6.3.1.2 Gene arrays 162 
6.3.1.2.1 Validity of samples 164 
6.3.1.2.1.1 RNA quality control (QC) (Carried out at the Wellcome Laboratories at 
the University of Oxford) 164 
6.3.1.2.1.2 Log intensity plots following gene array 164 
6.3.1.2.1.3 Principal component analysis (PCA) 167 
6.3.1.2.2 Validation of knockdown 168 
6.3.1.2.3 Comparisons between groups 169 
6.3.1.2.3.1 WT EXT vs. WT 170 
6.3.1.2.3.2 PHD1 K/O vs. WT 171 
6.3.1.2.3.3 PHD1 K/O EXT vs. PHD1 K/O 171 
6.3.1.2.3.3 PHD1 K/O EXT vs. WT EXT 174 
6.3.1.2.3.4 PHD3 K/O EXT vs. WT EXT 174 
6.3.1.2.3.5 PHD1 K/O EXT vs. PHD3 K/O EXT 176 
6.3.1.2.4 Analysis of upregulated gene expression across groups 178 
6.3.1.2.5 Analysis of down-regulated gene expression across groups 181 
6.4 Discussion 183 
6.4.1 Changes in hindlimb capillarity 183 
6.4.2 Gene expression 183 
6.4.2.1 Validity of samples 183 
6.4.2.2 Cross-intervention analysis 184 
6.4.2.2.3 Inflammatory pathways 184 
6.4.2.2.4 Upregulation of energy producing pathways provides fuel for an 
increase in protein synthesis 185 
6.4.2.2.5 Upregulation of angiogenic factors and cell adhesion molecules 186 
6.4.2.2.6 Down-regulated functions 189 
6.5 Conclusions 190 
6.6 Future directions 191 
Chapter 7: SYSTEMIC HYPOXIA 192
  
7.1 Introduction 193 
7.1.1 Physiological impairment caused by ascent to altitude 194 
 320 
7.1.2 Stimulation and control of erythropoiesis in response to hypoxia 195 
7.1.3 The multifaceted regulatory role of HIF in response to hypoxia 197 
7.1.4 Individual variability in the EPO response to hypoxia and its association with 
AMS 198 
7.1.5 Diurnal EPO variation, and associations with sex and age 199 
7.1.6 Normobaric hypoxia vs. hypobaric hypoxia 201 
7.2 Methods 202 
7.2.1 Experimental design 202 
7.2.2 Plasma separation from blood 203 
7.2.3 mRNA extraction from leukocytes 204 
7.3 Results 205 
7.3.1 Changes on a physiological level 205 
7.3.1.1 AMS 205 
7.3.1.2 Oxygen saturation 205 
7.3.2 Changes on a molecular level: plasma protein 207 
7.3.2.1 Changes in plasma EPO protein under acute and chronic hypoxia 209 
7.3.2.2 Change in plasma VEGF 210 
7.3.2.3 Change in plasma sFlt 211 
7.3.2.4 Inconsistent changes in plasma EPO, VEGF and sFlt 213 
7.3.2.5 Plasma protein changes in AMS+ and AMS- individuals 218 
7.3.3 Changes on a molecular level: hypoxia-regulated gene expression 219 
7.3.3.1 Changes in leukocyte Aldolase-A  (ALD-A) gene expression 219 
7.3.3.2 Changes in leukocyte inducible nitric oxide synthase (iNOS) gene 
expression 220 
7.3.3.3 Changes in leukocyte haemoxygenase (HMOX-1) gene expression 221 
7.3.3.4 Changes in leukocyte fms-like tyrosine kinase-1 (Flk-1) gene expression
 222 
7.3.3.5 Changes in leukocyte vascular endothelial growth factor (VEGF) gene 
expression 223 
7.3.3.6 Changes in leukocyte erythropoietin (EPO) gene expression 224 
7.3.3.7 Changes in leukocyte hypoxia inducible factor-1! (HIF-!) gene expression
 225 
7.3.3.8 Summary of changes in mRNA levels of genes regulated by HIF-1! 226 
7.3.4 Association between physiological and molecular changes 227 
7.3.4.1 Relationship between plasma EPO expression and individuals diagnosed 
with AMS 227 
7.3.4.2 Relationship between changes in plasma EPO with changes in PO2, Hct, 
Hb and O2 saturation (%) 227 
7.3.4.3 Regression analyses of changes in plasma EPO with downstream hypoxia-
activated gene expression 230 
7.4 Discussion 233 
7.4.1 Physiological changes under systemic hypoxia 233 
7.4.1.1 Sickness at altitude 233 
7.4.1.2 Gender difference and sickness at altitude 234 
7.4.1.3 Age effect at altitude 235 
7.4.2 Response and adaptation to hypoxia: the HIF system 235 
7.4.3 Molecular effects of systemic hypoxia 236 
 321 
7.4.3.1 EPO plasma protein: using EPO as a surrogate marker for HIF activation 
and hypoxic up-regulation 236 
7.4.3.1.2 Classifying EPO responders and looking at correlations with altitude 
sickness 237 
7.4.3.1.2 Relationship between EPO and AMS with O2 saturation and 
haematological changes 238 
7.4.3.2 Inability to predict the hypoxic response of an individual using 
leukocytes as a circulating marker of gene expression 242 
7.4.3.2.1 Significant inter- and intra-individual variability in gene expression 
under hypoxia 243 
7.4.3.2.2 Using HIF-1! mRNA to predict the plasma EPO response 244 
7.4.3.2.3 Using plasma EPO protein to predict the HIF-regulated gene response
 244 
7.4.3.3 VEGF and sFlt plasma protein 245 
7.4.3.3.1 Changes in VEGF 245 
7.4.3.3.2 Changes in sFlt 247 
7.4.3.4 Confounding factors from the study 248 
7.4.3.4.1 Control of EPO by the HIF-system: An emerging role for HIF-2! 248 
7.4.3.4.2 Controversy surrounding the determination of clinical AMS 249 
7.5 Conclusion 250 
7.6 Future directions 252 
CHAPTER 8: DISCUSSION 253
 253 
FUTURE WORK 260 
APPENDICES 263 
APPENDIX I 264 
A.1.1 Mean mouse mass (g) 12% hypoxia ± SEM (n=6 per group) 264 
A.1.2 Mean mouse mass (g) under 10% hypoxia ± SEM (n=12 per group) 264 
APPENDIX II 265 
A.2.1 HIF protein extraction from WBCs 265 
A.2.1.1 White blood cell isolation from whole blood 265 
A.2.1.2 HIF nuclear protein extraction 265 
A.2.1.2.1 Solutions 266 
A.2.1.2.2 Protocol 267 
A.2.1.3 HIF ELISA 267 
A.3.1 Data from exposure to 12% in the normobaric hypoxic chamber, 
Phase I 268 
A.3.1.1 Venous blood 268 
A.3.1.2 Arterialised capillary 269 
 322 
A.3.2 Data from exposure to 4392m, Phase II 270 
A.3.2.1 Venous blood 270 
A.3.3 AMS scores and O2 saturation 271 
A.3.3.1 Phase I 271 
A.3.3.2 Phase II 272 
A.3.4 Plasma protein concentrations as determined by ELISA 273 
A.3.4.1 EPO (mIU/ml) 273 
A.3.4.2 sFLT  (pg/ml) 274 
A.3.4.3 VEGF  (pg/ml) 275 
APPENDIX IV 276 
APPENDIX V 278 
A.5.1 Gene lists 278 
A.5.1.1 WT vs. WT EXT 278 
A.5.1.1.2 Upregulated 278 
A.5.1.1.2 Down-regulated 279 
A.5.1.2 PHD1 K/O vs. WT 280 
A.5.1.2.1 Upregulated 280 
A.5.1.2.2 Down-regulated 282 
A.5.1.3 PHD1 K/O EXT vs. PHD1 K/O 285 
A.5.1.3.1 Upregulated 285 
A.5.1.3.2 Down-regulated 289 
A.5.1.4 PHD1 K/O EXT vs. WT EXT 290 
A.5.1.4.1 Upregulated genes 290 
A.5.1.4.1 Downregulated genes 294 
A.5.1.5 PHD3 K/O EXT vs. WT EXT 296 
A.5.1.5.1 Upregulated genes 296 
A.5.1.5.1 Downregulated genes 297 
A.5.1.6 PHD1 K/O EXT vs. PHD3 K/O EXT 298 
A.5.1.6.1 Upregulated 298 
A.5.1.6.2 Down-regulated 301 
APPENDIX VI 305 
A.6.1 Functional tables from DAVID 305 
A.6.1.1 WT EXT vs. WT 305 
A.6.1.2 PHD1 K/O vs. WT 306 
A.6.1.3 PHD1 K/O EXT vs. PHD1 K/O 306 
A.6.1.4 PHD1 K/O EXT vs. WT EXT 308 
A.6.1.6 PHD1 EXT K/O vs. PHD3 EXT K/O 309 
APPENDIX VII 311 
  
 
FIGURES 
Figure 1.1  Illustration of acute and chronic responses to hypoxia   2 
Figure 1.2  Genes controlled by HIF-1       8 
Figure 1.3   Structure of HIF-1 subunits       9 
Figure 1.4   Oxygen sensing as demonstrated by the hydroxylation of HIF-1! 10 
Figure 1.5  Mechanisms of blood vessel growth      18 
Figure 1.6  The angiogenic balance       21 
Figure 2.1 Illustration of how DMOG interacts with HIF under hypoxia  28 
Figure 2.2 A comparison of DMOG, using NMR, synthesised in Oxford  29 
 and a commercial source 
Figure 2.3  Values obtained for the ‘DMOG peak’ in mass spectrometry  30 
Figure 2.4 Location of the muscles used for tissue sampling    31 
Figure 2.5  An example of spectra produced by the nanodrop in a collection 37 
 of pure samples 
Figure 2.6  The Taqman system        40 
Figure 2.7  Illustration of the fluorescent signal yielded by "-actin from   41 
  the cDNA of human WBCs 
Figure 3.1  Three autocrine loops determine HIF-1! expression in chronic   55 
   hypoxia 
Figure 3.2    Representation of a selection of factors upregulated by HIF   56 
   under hypoxia 
Figure 3.3      Change in body mass over time at 12% hypoxia    63 
Figure 3.4       Illustration of lectin staining in the subepicardium   64 
Figure 3.5  Lectin staining n the EDL muscle      66 
Figure 3.6 Figure 3.6 (a) Ilustration of the VEGF, and (b) DAPI and lectin              69 
immunohistochemical stain 
 
Figure 3.7   Western blot of HIF-2!       70 
Figure 3.8   Western analysis of PHD2 in the hindlimb     70 
Figure 3.9  Average CT values obtained from the study of HIF-1!    72 
Figure 3.10  Average CT values obtained from the study of EPO   73 
Figure 3.11  Average CT values obtained from the study of VEGF   74 
Figure 3.12  Average CT values obtained from the study of Flk-1   75 
Figure 3.13  Average CT values obtained from the study of iNOS   76 
Figure 3.14    Average CT values obtained from the study of ALD-A   77 
 
Figure 3.15    Average CT values obtained from the study of CAIX   78 
Figure 3.16     Average CT values obtained for the study of HMOX-1   79 
Figure 3.17    Average CT values obtained for TGF-B     80 
Figure 3.18    Average CT values obtained for Flt-1     81 
Figure 3.19    Plasma EPO levels         86 
Figure 3.20    Changes in cardiac gene expression occuring in response   89 
       to chronic  mechanical overload  
Figure 3.21    Illustration of the increased distance to the subepicardium  95 
Figure 3.22 A graph illustrating how myocyte hypoxia increases VEGF secretion. 85 
Figure 3.23  HIF-1! and HIF-2! operate via both common and specific targets 99 
Figure 3.24 NO-dependent mechanisms       106 
Figure 4.1     Location of the area for incision before ligation of the femoral artery 116 
Figure 4.2     Flow probe data from an unligated femoral artery    117 
Figure 4.3     Flow probe data from the ligated femoral artery    117 
Figure 4.4  Illustration of the cross talk between HIF-1! and NF#B under   129 
hypoxia  
Figure 5.1 Mechanisms of mechanotransduction within and between   135 
endothelial cells 
Figure 5.2  Illustration of cellular mechano-responsiveness and connections  136 
between the ECM, cells, cytoskeletal networks, and nuclei 
Figure 6.1  Illustration of a gel        159 
Figure 6.2  Electropherogram indicating regions indicative of RNA quality  164 
Figure 6.3  Illustration of samples with poor quality     165 
Figure 6.4  Illustration of good quality samples      165 
Figure 6.5  Dendrogram illustrating a group of outliers and a boxplot   166 
illustrating normalised data 
Figure 6.6  PCA of all samples in this study      167 
Figure 6.7  Log scale intensity plotted against PHD3 gene expression  168 
Figure 6.8  Log scale intensity plotted against PHD1 gene expression  169 
Figure 6.9  A heat map illustrating genes up- and downregulated in WT   170 
mice with EXT vs. WT 
Figure 6.10 A heat map illustrating genes up- and downregulated in   172 
  PHD1 K/O mice vs. WT 
Figure 6.11  A heat map illustrating genes up- and downregulated    173 
PHD1 K/O EXT vs. PHD1 K/O mice 
Figure 6.12  A heat map illustrating genes up- and downregulated    175 
PHD1 K/O EXT vs. WT EXT 
Figure 6.13  A heat map illustrating genes up- and downregulated             176 
in PHD3 K/O EXT vs. WT EXT mice 
Figure 6.14  A heat map illustrating genes up- and downregulated              177 
PHD1 K/O EXT vs. PHD3 K/O EXT  
Figure 7.1 Schematic diagram of the rapid HIF regulation during normoxia,  196 
hypoxia, and reoxygenation 
Figure 7.2  Graph showing HIF-1! kinetics      198 
Figure 7.3 Ascent profile in Chile       202 
Figure 7.4  Change in % O2 saturation       206 
Figure 7.5  Relative fold changes in plasma EPO concentration   207 
Figure 7.6  Relative fold change in EPO plasma for individuals between   208 
phase I and II 
Figure 7.7  Spread of change in plasma [EPO] between phase I and II  208 
Figure 7.8  Relative changes in plasma EPO between phase I and II   209 
Figure 7.9  Relative fold changes in plasma [VEGF]     210 
Figure 7.10  Change in VEGF plasma protein during phase I and phase II  211 
Figure 7.11  Relative fold change in plasma [sFlt-1]     212 
Figure 7.12  Change in sFlt protein concentration     212 
Figure 7.13   Regression analyses of change in plasma EPO protein against   214 
 sFlt plasma protein 
Figure 7.14  Regression analyses of change in plasma EPO vs. change in VEGF  215 
Figure 7.15  Regression analyses showing change in plasma sFlt vs. VEGF  216 
Figure 7.16   Illustration of the changing relationship between plasma    217 
VEGF and sFlt  protein 
Figure 7.17  Relative fold change in leukocyte ALD-A expression   219 
Figure 7.18   Relative fold change in leukocyte iNOS expression    220 
Figure 7.19   Relative fold change in leukocyte HMOX-1 expression   221 
Figure 7.20   Relative fold change in leukocyte Flk-1 expression    222 
Figure 7.21   Relative fold change in leukocyte VEGF expression    223 
Figure 7.22   Relative fold change in leukocyte EPO expression    224 
Figure 7.23   Relative fold change in leukocyte HIF-1 expression   225 
Figure 7.24   Relationship between O2 saturation and plasma EPO   228 
Figure 7.25   Relationship between change in plasma EPO protein   229 
Figure 7.26   Relationship between change in plasma EPO protein with Hct and Hb 229 
Figure 7.27   A positive relationship between changes in VEGF mRNA and   231 
 plasma EPO protein and illustration of the lack of relationship  
 between changes in iNOS mRNA and EPO plasma protein 
Figure 7.28   Time course of hypothesised EPO and Hct changes under hypoxia 241 
 
TABLES 
 
Table 1.1  Representation of muscle fibre types      5 
Table 1.2  Summary of the molecular basis underlying new blood    17 
vessel growth  
Table 1.3   Disease characterised or caused by abnormal or excessive   22 
angiogenesis 
Table 2.1  Plate design for testing primers and probes    42 
Table 2.2 2 Different primary antibodies used to detect hypoxically regulated      45 
proteins 
Table 2.3 Recipe for resolving gel       48 
Table 2.4 Recipe for 1 think stacking gel       48 
Table 2.5 Gel percentage separation guide for protein samples   49 
Table 3.1  Heart mass and relative heart mass for experimental groups   64 
under hypoxia 
Table 3.2.  Capillary density for heart in control and hypoxic animals   65 
± DMOG at 10% and 12% hypoxia  
Table 3.3. C:F and CD for control and hypoxic diaphragm ± DMOG at   66 
10% and 12% hypoxia  
Table 3.4  Capillarity, mean fibre area, relative EDL and body mass for all  67 
experimental groups subjected to systemic hypoxia  
Table 3.5  C:F, CD and MFA for soleus under 10% and 12% hypoxia ± DMOG 68 
Table 3.6  Ratios for VEGF/lectin and DAPI/lectin staining in diaphragm,   69 
EDL and soleus at 10% hypoxia 
Table 3.7 Summary of significant changes observed in gene expression with 82 
individual tissues 
Table 4.1  Summary of published clinical studies of therapeutic angiogenesis  114 
in patients with PAD 
Table 4.2  C:F, CD and MFA for the EDL muscle following femoral artery   119 
ligation in C57Bl6/J mice 
Table 4.3  C:F, CD and MFA for the EDL muscle following femoral artery   120 
ligation in C57BL10/J mice 
Table 4.4  C:F, CD and MFA for the EDL muscle in the femoral artery  121 
ligation in C57BL6/J mice with newly synthesised DMOG 
Table 5.1  C:F, CD and MFA for the EDL muscle in the extirpated leg in   143 
C57Bl6/J mice 
Table 5.2  C:F, CD and MFA for the EDL muscle in the extirpated leg in   144 
C57Bl10 mice 
Table 5.3  EDL mass in C57Bl6/J and C57Bl10/J mice     144 
Table 6.1  C:F and CD for PHD1 and PHD3 knockout and wild type animals  162 
Table 6.2  A subset of upregulated genes identified as potentially interesting        180 
following GO analysis 
Table 6.3 A subset of downregulated genes identified as potentially   182 
interesting following GO analysis 
Table 7.1  Individuals diagnosed with AMS      205 
Table 7.2        Mean plasma EPO in each phase      207 
Table 7.3  Individual response in plasma protein levels    213 
Table 7.4  Mean plasma protein values for EPO, VEGF and sFLT   218 
Table 7.5  Change in gene expression during Phase I and phase II   226 
Table 7.6  Regression values for changes in plasma EPO protein plotted against    230 
changes in mRNA expression of HIF-target genes 
Table 7.7  Illustration of ‘outliers’ revealed in regression analyses of   231 
EPO plasma protein with leukocyte mRNA changes 
APPENDICIES 
Appendix 1: Mouse mass under hypoxia       263 
Appendix II: HIF protein extraction and ELISA from white blood cells   265 
Appendix III: Data from exposure to 12% exposure to hypoxia (human)  268 
Appendix IV: Lake louise and ESQ scoring system     276 
Appendix V: Gene lists from gene array data      278 
Appendix VI: Gene array statistics        306 
Appendix VII: Heat maps from gene array data      312 
 
 
 
REFERENCES 
 
ABBREVIATIONS 
 
ALD-A   aldalase-A 
AMS   acute mountain sickness 
Ang-2   angiopoitein-2 
BM   basement membrane 
C:F   capillary to fibre ratio 
CAIX   carbonic anhydrase IX 
CBP   CREB binding protein 
CD   capillary density 
CO   cardiac output 
COPD   chronic obstructive pulmonary disease 
DMOG   dimethyloxalyglycine 
EC   endothelial cell 
ECM   extracellular matrix 
EDL   extensor digitorum longus 
EPC   endothelial progenitor cell 
EPO   erythropoietin 
ES   enrichment score 
ESQ-C   environmental symptoms questionnaire 
FA   femoral artery 
FC   fold change 
FDR   false discovery rate 
FIH   factor inhibiting HIF 
Flk-1   fms-like tyrosine kinase III (aka KDR) 
Flt-1   fms-like tyrosine kinase receptor I 
HACE   high altitude cerebral oedema  
HAPE   high altitude pulmonary oedema 
HB   haemoglobin 
HCT   haematocrit 
HIF   hypoxia inducible factor 
HMOX-1  haemoxygenase 
HRE   hypoxic response element 
HVR   hypoxic ventilatory response 
IHC   immunohistochemistry 
iNOS   inducible nitric oxide synthase  
K/O   knockout 
LL   lake louise scoring system  
MFA   mean fibre area 
MMP   matrix metalloproteinase 
NFkB   nuclear factor kB 
O2   oxygen 
ODD   oxygen-dependent degradation domain 
PAD   peripheral arterial occlusive disease 
PHD   prolyl hydroxylase 
PO2   partial pressure of oxygen 
PVD   peripheral vascular disease 
RBCC   red blood cell concentrate 
RM   relative mass 
ROS   reactive oxygen species 
SOL   soleus 
TA   tibialis anterior 
VEGF   vascular endothelial growth factor 
VHL   von Hippel Lindau complex 
WBC    white blood cell 
WT   wildtype 
 1 
A     B        C                               D                         E 
1   General Introduction 
1.1 Hypoxia 
1.1.1 Systemic hypoxia 
The fall in PO2 associated with ascent to altitude or impaired oxygen uptake due to 
disease lowers the alveolar and arterial O2 tension, causing hypoxia defence and 
compensatory mechanisms to become activated by a variety of O2-sensing and signal 
transduction pathways.  These occur both on an acute and chronic timescale, enabling 
immediate and acclimatory adjustments to the low O2 availability (Fig 1.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Illustration of acute and chronic responses to hypoxia. A: ventilatory changes, B: 
changes in pH, C: fluid shift, D: EPO response, E: angiogenesis 
 
 
 
 
Acute 
responses Chronic responses 
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1.1.1.1 Acute responses  
The carotid body O2 sensors initiate the primary responses and an enormous increase in 
ventilation occurs, known as the hypoxic ventilatory response (HVR), which protects the 
alveolar PO2 against decreasing inspired values (West, 1990).  The PO2 at sea level is 
about 160mmHg but on the summit of Mount Everest (8848m) is less than 30mmHg 
(West, 1982) reducing at a rate equivalent to a drop of approximately 2.5% in the air O2 
for every 1000m increase in altitude (Julian, 2007).  The increase in ventilation occurs 
within seconds, reaching full intensity within minutes, and a ventilatory acclimatisation 
occurs after continuous exposure over days (Lahiri et al. 2000).  Resting ventilation can 
increase up to 4 times at extreme altitude (greater than 6000m) (West, 1982).  
Hyperventilation lowers arterial PCO2 causing respiratory alkalosis and a left shift in the 
haemoglobin–O2 dissociation curve, decreasing the ventilatory drive.  This causes an 
increase in the affinity of Hb for O2, increasing O2 uploading by the pulmonary capillaries 
(West, 1990).  These ventilatory changes are closely followed by an increase in cardiac 
output (CO), ensuring that organs of higher priority receive a larger proportion of the 
blood flow compared to organs that can function sufficiently on a low blood flow, a 
phenomenon known as ‘blood flow steal’.   
Subsequently, the pulmonary vasculature O2 sensors initiate regulation of the 
hypoxic pulmonary vasoconstrictor response, increasing pulmonary vascular resistance 
by 30-500% (Mougdil et al. 2005) and resulting in improved ventilation–perfusion 
matching.  This vasoconstriction is mediated by K+ channel opening (Lee et al. 1998), 
and enables increased efficiency of O2 delivery by diverting flow to the better-aerated 
parts of the lungs.  A fluid shift also occurs on exposure to hypoxia, from the 
intravascular space to the interstitial and intracellular spaces, resulting in 
haemoconcentration (Berglund et al. 2002).  
 Low O2 delivery to cells induces a multitude of effects on a molecular level which 
take effect on both an acute and chronic timescales.  The precise way in which O2 levels 
are sensed is still an area of controversy, though it is postulated that the O2 sensors are 
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two-domain haem-based proteins: some are haemokinases, others are 
flavohaemoproteins (Bunn and Poyton, 1996).  O2 is thought to bind to these and be 
converted into a reactive O2 intermediate which then serves as a signaling molecule (Zhu 
et al. 2007; Coceani, 2000).  Mitochondrial O2 consumption is required for ATP generation 
and cell survival is threatened when cells are deprived of O2.  Mitochondria are also 
thought to function as O2-sensors and release reactive O2 species (ROS) to the cytoplasm 
from the electron transport chain: the primary site of ROS production during hypoxia 
appears to be complex III (Simon, 2006; Guzy and Schumacher, 2006).  Mitochondria 
are thought crucial for signaling hypoxic HIF-! stabilisation, the transcription factor 
involved in regulation of a host of genes involved in acclimatisation and adaptation to 
systemic hypoxia. 
1.1.1.2 Chronic responses 
Chronic hypoxic pulmonary vasoconstriction induces right ventricle hypertrophy as the 
heart works harder to overcome the increased pulmonary artery resistance.  This 
hypertophy may arise due to a combination of both pressure and volume-overload, the 
former resulting from an increased CO, and the latter due to the increased blood volume, 
mediated acutely by the splenic release of red blood cells (RBCs) (Kuwahira et al. 1999) 
and over a chronic timescale by EPO production.  The latter is a well-known characteristic 
of acclimatisation to hypoxia, first reported by Viault in 1890 (Smith et al. 2008).  It is 
released mainly from interstitial fibroblasts in the kidneys of the adult (Chavez et al. 
2006).  EPO is under control of the transcription factor HIF (Pugh et al. 1991), and as 
HIF is thought to be one of the main O2 sensors under hypoxia (above), it provides a 
direct link between changing O2 levels and EPO synthesis and release.  
 EPO is thus responsible for enhancing the O2-carrying capacity of the blood by 
increasing the production of RBC, causing polycythaemia.  Erythropoietin (EPO) 
production can be increased within hours of exposure to hypoxia (Eckhardt et al. 1989), 
though erythropoietic effects can take much longer to become evident, from weeks 
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(Barcroft et al. 1923) to months (Reynafarje et al. 1959), depending on the 
environmental conditions and additional external stress (e.g. exercise). 
Angiogenesis, the growth of new vessels from an existing network, is a further 
chronic adaptation to systemic hypoxia, increasing blood flow in deprived areas and thus 
enhancing O2 delivery (see 1.4).  It can occur due to a variety of factors such as 
mechanical strain and metabolic stress.  Despite vasoconstriction occurring in the lungs, 
the rest of the body undergoes systemic vasodilatation, mediated in part by adenosine 
release from tissues (Kobayashi et al. 2000), resulting, in one circumstance, in a 
modification of skeletal muscle blood flow.  The importance of capillary supply in 
maintaining the aerobic function of muscles is well-known, though there are many 
discrepancies in the literature.  Prolonged exposure to hypoxia causes a reduction in 
muscle mass, due to anorexia and energy deficits associated with adaptation to the 
lowered PO2, and this results in a lowered fibre size (Mathieu-Costello, 2001).  However, 
this was not originally taken into account on observation of an increase in the capillarity 
of skeletal muscle, hence there actually was no change, only a reduction in fibre size 
which subsequently increased the recorded capillary density (CD).  Several confounding 
factors can explain differences in the contrasting data from different studies, with some 
eliciting an angiogenic response in different muscles under chronic hypoxia, and others 
failing to show.  This level of hypoxia, alterations in dietary intake, animal growth (fibre 
cross-sectional area increases linearly with body weight) and the lethargy following 
exposure to a lowered PO2 (Mathieu-Costello, 2001), as well as regional variations in 
muscle composition (Deveci et al. 2001) may all be responsible for discrepancies in the 
data. 
The oxidative capacity of skeletal muscle varies depending on the composition of 
muscle fibres (Table 1.1): the extensor digitorum longus (EDL) in the hindlimb is 
composed of mixed muscle fibres, with a characteristically low proportion of mitochondria 
and a decreased capillary density when compared with an oxidative fibre type, such as 
those composing another hindlimb skeletal muscle, the soleus.  The features of these 
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skeletal muscles consequently result in differential changes under hypoxaemia: a number 
of studies have failed to show an increase in capillarity with systemic hypoxaemia in 
phasic muscles such as the EDL, though have shown significant increases in muscle with 
predominantly oxidative fibres such as the soleus (Deveci et al. 2001).  Furthermore, 
controversy surrounds the phenomenon of changes in the proportion of fibre-types under 
hypoxia: an enhanced population of fast-twitch glycolytic fibres have been reported in 
adult rats  (SIllau and Banchero, 1977), although proportions of fibre-types have been 
shown unchanged in human skeletal muscle with altitude adaptation (Green et al. 1989). 
 
  FIBRE TYPES  
Characteristic Type IIB Fast-twitch Type IIA Fast-Twitch Type I Slow-twitch 
Colour white White/red Red 
Capillary density low intermediate high 
Mitochondrial 
volume 
low intermediate high 
Glycolytic capacity high medium high 
Oxidative capacity low medium High 
Fatigue resistance low high high 
 
Table 1.1 Representation of muscle fibre types (taken from McArdle, W., Katch, F and Katch, V) 
 
 
1.1.3 Local hypoxia 
Local hypoxia or ischaemia occurs when the O2 supply to a region of tissue is limited or 
stopped, resulting in a metabolic error signal: a mismatch in the supply and/or demand 
to or from a tissue caused e.g. by a pathological state such as human peripheral arterial 
occlusive disease (PAD), which occurs subsequent to obstruction of large arteries, e.g. in 
the leg.  The reduction in blood flow causes a chronic deficiency of O2 supply to the 
surrounding tissues and subsequent changes in the metabolic and oxidative state of the 
tissue.  Angiogenesis is initiated via activation of HIF and a host of its downstream 
factors, which are subsequently involved in endothelial migration and proliferation, 
extracellular proteolysis, endothelial differentiation (capillary tube formation), and 
vascular wall remodelling (Buschmann & Schaper, 1999) (see 1.4).  It is an important 
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mechanism of restoring blood flow following limb ischaemia (to increase O2 tissue 
transport), allowing for an increase in enzymatic activity which supports adaptation to 
the low O2.  
1.1.3.1 Ischaemia-reperfusion injury  
Skeletal muscle ischaemia-reperfusion injury is a frequent occurrence following 
obstruction of blood flow in the femoral artery, when blood flow returns to the tissue 
after a period of absence.  Restoration of the circulation results in inflammation and 
oxidative damage through the induction of oxidative stress, rather than restoration of 
normal function.  One study followed the injury and recovery of mouse hindlimb tissue 
using MRI scanning, and illustrated how a time period of 21 days permitted a full 
recovery (Heemskerk et al. 2007).   
1.1.3.2 Inflammation following ischaemia 
Muscle regeneration is characterised by three distinct phases: necrosis of the muscle 
fibres, activation of inflammatory cells and an increase in permeability of the cells.  This 
is followed by activation of the muscle repair process and partial recovery of the muscle 
fibres.  Inflammation of the hindlimb following ligation is a well-studied phemonena as it 
has been shown that leukocyte infiltration following ischaemia is an important trigger for 
ischaemia-induced angiogenesis due to the subsequent angiogenic cytokines that are 
released (Egami et al. 2006).  However, there is controversy surrounding this issue as it 
has also been shown that limitation of the blood supply to the skeletal muscles does not 
necessarily lead to inflammation, based on staining for macrophage infiltration (Brown et 
al. 2003).  
              As mentioned, a single transcription factor is in control of many of the 
described processes and acts as a master regulator in governing the response to hypoxia 
on a molecular level, subsequently aiding adaptation of the body to the lowered O2 in the 
surrounding environment.  This transcription factor is known as hypoxia inducible factor 
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(HIF-1!), important in the upregulation of glycolysis under chronic hypoxia, the initiation 
of erythropoiesis, and the remodelling of the existent vasculature, among many other 
processes. 
 
1.2 Hypoxia inducible factor (HIF) 
1.2.1 HIF activity and regulation 
HIF controls the hypoxic expression of a wide range of genes (Table 1.2) involved in 
angiogenesis, glycolysis, erythropoiesis, iron metabolism, apoptosis and metastasis, 
among many others (William et al. 2004), and was first identified as a complex that 
binds to the hypoxia responsive enhancer element (HRE) in nuclear extracts of cells 
exposed to low O2 tension.  It is known to control at least 70 genes on a transcriptional 
level (Semenza, 2004), 40 of which have been identified either by activating or 
repressing their expression (Semenza, 2002).  HIF-1 is a heterodimeric protein complex 
consisting of an ! and " subunit and is of the Per-Arnt-Sim (PAS) family of basic helix-
loop-helix proteins (Cummins and Taylor, 2005).  The HIF-1" subunit is constitutively 
expressed whereas the HIF-1! subunit is tightly regulated by the availability of cellular 
O2.  There are a number of HIF isoforms: HIF-1! is the most ubiquitously expressed and 
is recognised as a key factor in hypoxic signalling (Bardos and Ashcrost, 2005).  HIF-2! 
has similar regulatory activities to HIF-1! but is only expressed in specific cells 
(Appelhoff et al. 2004).  HIF-1! and HIF-2! share only 48% identity: HIF-1!-null mice 
exhibit mid-gestation lethality and severe blood vessel defects, and despite HIF-2!-null 
mice exhibiting similar defects, they do sometimes survive post-natally (Uchida et al. 
(2004). 
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Figure 1.2 Genes controlled by HIF-1 (From Semenza et al. 2001) 
 
HIF-1! chains have a domain structure with different parts of the molecule fulfilling 
different functions.  The amino terminal part is involved in DNA binding and dimerisation.  
The carboxy-terminal half contains two regions termed the N-terminal (N-TAD) and the 
C-terminal (C-TAD) transactivation domains (Bardos and Ashcrost, 2005) (Fig 1.2).  
These mediate interactions with coactivators such as CREB binding protein (CBP), p300 
Ref-1, Jab-1, SCR-1 and TIF2 (Semenza, 2004):  p300 and CBP are homologous 
transcription adapters.  These co-activators form a DNA-binding complex with HIF-1! 
under hypoxic conditions, causing subsequent induction of one of the many hypoxia-
responsive genes (Bardos and Ashcrost, 2005), although dimerisation of the two HIF 
subunits is mandatory for this DNA-binding and transactivation activity under hypoxic 
conditions.  Under normoxic conditions, HIF-1! is very unstable and is degraded quickly, 
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having a half-life of less than five minutes (Semenza, 2004), but accumulates rapidly in 
hypoxia. 
 
 
 
 
Figure 1.3 Structure of HIF-1 subunits (Taken from Berchner-Pfannschmidt et al. 2008) 
 
The negative regulation of HIF-1! is acheived via modification of the O2-dependent 
degradation domain (ODD) within the HIF protein (Cummins and Taylor, 2005) (Fig 1.3) 
by members of the 2-oxo-glutarate-dependent dioxygenase superfamily; the prolyl 
hydroxylases (PHDs).  Three PHD isoforms have been identified (PHD 1-3) though the 
relative importance of each in regulating HIF activity is an area of current research.  The 
amino-terminal half of HIF-1! consists of basic helix-loop-helix (bHLH) and Per-ARNT-
Sim homology (PAS) domains.  The carboxy-terminal half contains the transactivation 
domains (TAD-N and TAD-C) (Fig. 1.3).  The proline residues 402 and 564 of the ! 
subunit undergo hydroxylation by the PHDs.  The residues share the sequence LXXLAP 
and are converted to 4-hydroxyproline.  This is required for the interaction of HIF-1! with 
the von Hippel-Lindau tumour-suppressor protein (VHL), which is the recognition 
component of an E3 ubiquitin-protein ligase that targets HIF-1! for proteasomal 
degradation and polyubiquitylation (William et al. 2004) (Fig. 1.4).  The hydroxylation 
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process requires O2, iron and 2-oxoglutarate for activity (Harris, 2002).  HIF is also under 
negative regulation in normoxia by factor-inhibiting HIF (FIH) which hydroxylates Asn803 
within the C-terminal transactivation domain (Tan et al. 2007).  During hypoxia, the 
hydroxylation system is inhibited allowing HIF protein to become transcriptionally 
activated and switch on downstream genes.  The PHDs are targeted by proteasomal 
degradation by Siah1a and Siah2 (E3 ligases), and the level of regulation determines the 
amount of HIF-1! activation (Nakayama et al. 2004).  Activation of HIF-1! is now known 
to occur under both hypoxic and non-hypoxic conditions (Semenza, 2002). 
 
 
Figure 1.4 Oxygen sensing as demonstrated by the hydroxylation of HIF-1! (From Semenza, 2004)  
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1.2.2 HIF-mediated responses to systemic hypoxia: adapatation to high altitude 
An array of HIF-mediated genes are involved in the systemic response to hypoxia which 
aid acclimatisation to the lowered PO2.  Many of these genes are multi-functional and 
play important roles not only in the erythropoietic, glycolytic and metabolic adaptations 
to whole-body deprivation of O2, but are involved in blood vessel adaptation, 
angiogenesis (see 1.3) under both chronic systemic and local hypoxia.  The role EPO 
plays under chronic systemic hypoxia has already been discussed, it being a major factor 
in enabling the body to increase its O2-carrying capacity under these conditions.  The 
necessity for HIF in pulmonary and systemic responses to chronic hypoxia has been 
demonstrated using HIF1!+/- mice (HIF1-!-/- mice are embryonically lethal, Carmeliet et 
al. 1998), further illustrating that HIF is crucial for normal development).  These studies 
have shown that polycythaemia was significantly impaired in HIF-1!+/- mice compared to 
wildtype, inline with studies confirming that HIF is in regulation of EPO under hypoxia (Yu 
et al. 1999).  Furthermore, partial HIF-1! deficiency had significant effects on the 
response of the pulmonary vasculature to chronic hypoxia whereas in the normal 
response, HIF-1!+/- mice showed no reduction in voltage-gated K+ channel activity in 
pulmonary arteriolar smooth muscle cells.  
 HIF-regulated genes occur under differing functional categories.  An example of a 
gene involved in metabolic adaptations to hypoxia is Aldolase-A, an enzyme responsible 
for catalysing one of the adol reactions involved in glycolyis, thus being responsible for 
an increase in ATP production.  Vascular adaptations such as vasodilatation are largely 
influenced by nitric oxide (NO) which is produced from arginine by inducible nitric oxide 
synthase (iNOS), the latter of which is targeted for upregulation by VEGF under normoxic 
conditions (Kroll and Waltenberger, 1998).  iNOS is important in the inflammatory 
response under hypoxia.  Many HIF-regulated genes exhibit inter-dependent 
relationships that are enhanced under normoxic and hypoxic conditions.  A significant 
number of these relationships involve VEGF, a multi-tasking cytokine involved in 
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stimulating differentiation, survival migration, proliferation, and vascular permeability 
(Zachary, 2003), thus being important in the angiogenic response to hypoxia.  One of its 
receptors, Flt-1 (VEGFR-1), is expressed on the surface of ECs and negatively modulates 
blood vessel formation and endothelial cell proliferation during embryonic development 
(Roberts et al. 2004).  Flk-1 (VEGFR-2), also expressed on ECs, is thought to be 
negatively regulated by Flt-1 (Rahimi et al. 2000).  VEGF and sFLT are thought to play a 
potential role in regulating permeability of blood vessels which may subsequently lead to 
high altitude cerebral oedema (HACE) or pulmonary oedema (HAPE) at high altitude, 
though there is a significant degree of controversy surrounding this, with some studies 
suggesting that an increased amount of free VEGF is associated with the effects of acute 
mountain sickness (AMS) (Tissot van Patot et al. 2005), with others showing no evidence 
(Pavlicek et al. 2000). 
 Haemoxygenase (HMOX-1), is also upregulated by HIF and is known to have anti-
inflammatory, anti-apoptotic and anti-proliferative effects.  It is also thought to regulate 
the synthesis and activity of VEGF, resulting in a positive feedback loop (Bussolati and 
Mason, 2006).  Transforming growth factor ! (TGF-!) is a multifunctional peptide that 
controls proliferation, differentiation and other functions in many cell types, and also 
stimulates VEGF production under hypoxia (Nakagawa et al. 2004).  Taken together, 
these genes, when upregulated, provide a sufficient representation of activation of the 
HIF-system. 
 
1.3 Angiogenesis 
1.3.1  Background 
Angiogenesis was first used to describe new blood vessel growth by John Hunter in 1787 
after he discovered that interrupting the blood flow in stag antlers resulted in newly 
formed blood vessels to carry the existent blood flow, and that gunshot wounds only 
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healed if there was an adequate blood supply (Greenberg and Jin, 2004).  Angiogenesis 
is observed to be a compensatory response to prolonged imbalances between the 
perfusion capabilities of the blood vessels and the metabolic requirements of the tissue 
cells (Adair et al. 1995).   It likely occurs at the venular end of capillaries and involves 
remodelling of the vasculature (Hudlicka 1991). 
There are three described processes of neovascularisation.  The formation of new 
blood vessels starts during embryonic development and is known as ‘vasculogenesis’, a 
process whereby angioblasts (endothelial cell precursors) migrate to discrete locations, 
differentiate into blood islands, proliferate within a previously avascular tissue and then 
coalesce to form a primitive capillary plexuses (Risau, 1997).  It is at this time that the 
vessel fate is decided.  The endothelial cells (ECs) have an exceptional plasticity 
(Carmeliet, 2003).  The second form of vascularisation is angiogenesis, the process 
whereby this primitive network  formed by vasculogenesis is developed and remodelled 
into a mature network (Hudlicka et al. 1992).  These vessels act to increase the surface 
area to volume ratio, decreasing the distance for O2 diffusion, thus optimising the speed 
at which O2 is available for use.  The third form of vascularisation occurs as the 
circulation commences, and is known as arteriogenesis: the formation of new arterioles 
and venules, which occurs by investing capillaries with vascular smooth muscle.  This 
process is necessary to cope with the increased blood flow and to maintain 
haemodynamic stability.  A natural system of pre-existing arteries is also present that 
can bypass sites of arterial occlusion by forming collateral bridges between arterial 
networks.  These vessels can extensively increase their lumen diameter to increase blood 
flow and perfusion to occluded areas, resulting in fully functional and structurally normal 
arteries (Buschmann and Schaper, 1999). 
1.3.2  The history of angiogenesis 
Factors known to be important for blood vessel growth have been a matter of 
controversy for a long time.  Landerer (cited by Marchant, 1901) talked about the 
 14 
importance of mechanical factors connected with changes in blood flow, evidential from 
the formation of sprouts in areas of least resistance in the vascular bed (Hudlicka and 
Tyler, 1986).  Similarly, Thoma (1893, 1911) described a combination of velocity of flow 
and/or pressure and growth of the surrounding tissue and resulting wall stress resulted in 
the formation of vascular sprouts, as studied in chick embryos.  Clark and Clark (1932) 
were highly influential in establishing the field of vascular biology.  Their initial 
experiments involved placing glass-windowed chambers in the rabbit ear, allowing them 
to make exquisite drawings of the branching patterns of the blood vessels that entered 
the wound.  Several scientists, including Loeb in 1893, have shown that metabolic factors 
are extremely important in eliciting an angiogenic response.  Adair et al. (1995) 
proposed that O2 was an important factor controlling the growth of blood vessels.  They 
found that decreased oxygenation caused the tissue to become hypoxic and this initiated 
a variety of signals that then lead to the growth of new blood vessels.  A negative 
feedback loop was suggested, so that when an adequate amount of O2 had been 
provided, further development of the vasculature was attenuated.  In the early 1970s, 
Judah Folkman proposed that angiogenesis and tumour growth might go hand in hand, 
and he subsequently demonstrated that tumour growth was halted if the tumour was 
deprived of a blood supply (Folkman, 2002).  Experiments done by Krogh in 1919 were 
the first to show that angiogenesis is controlled by metabolic regulation (Pugh and 
Ratcliffe, 2003).  
1.3.3  Types of Angiogenesis 
The endothelium is usually quiescent in healthy adults with only 0.01% of ECs 
undergoing division (Carmeliet, 2003).  Angiogenesis is only switched on under specific 
conditions.  Physiological angiogenesis is activated during embryogenesis and in the 
female reproductive system, for example.  Pathological vascular remodelling is found in 
tumour growth, atherosclerosis and diabetes, as prime examples.  There are thought to 
be major differences between the blood vessels associated with tumours and those 
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associated with physiological angiogenesis with the former being described as more leaky 
and less well organised compared to the normal vasculature (Liekens et al. 2001). 
1.3.3.1 Sprouting angiogenesis 
There are three described mechanisms of angiogenic growth, the main difference being 
the mode of stimulation for the production of new vessels.  The classical form of 
angiogenesis is sprouting angiogenesis which occurs when a stimulus from the abluminal 
side of the vessel, for example muscle overload (extirpation), initiates the release of 
cytokines and growth factors from skeletal muscle.  Proteolytic degradation of the 
extracellular matrix (ECM) occurs following an increase in the permeability or integrity of 
the basement membrane (BM), a barrier made of structural proteins that provides 
support to the capillaries (see 1.3.4 for more detail).  Disruption of the BM allows the 
growth and migration of the EC into new vessel architecture (Haas et al. 2000).  The BM 
breakdown is mediated by MMPs activated by vascular endothelial growth factor (VEGF) 
and new blood vessel growth then occurs via EC migration and differentiation.  The 
growth of tumour vessels occurs by this form of angiogenesis (Folkman, 1971). 
1.3.3.2 Splitting angiogenesis 
Splitting angiogenesis can also occur due to a luminal-triggered stimulus, for example an 
increase in blood flow, increasing shear stress and upregulating nitric oxide (NO) 
production.  There are two forms of splitting angiogenesis: intussusception occurs when 
a single capillary splits into two capillaries from within by the formation of a longitudinal 
divide on the luminal side of the capillary (Prior et al. 2004), and involves abluminal 
activation of mural cells such as fibroblasts.  The other form of splitting angiogenesis 
occurs whereby endothelial cells, as opposed to interstitial cells, send filopodial processes 
into the capillary lumen which then join and form a separate branch, and this 
subsequently propogates down the capillary (Zhou et al. 1998).   
 The main difference between the described mechanisms is that sprouting 
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angiogenesis requires BM and extracellular matrix degradation, allowing migration and 
proliferation of ECs, and thus the development of the sprouting tube.  Work done by 
Egginton et al. (2001) supports the notion that BM degradation is not a pre-requisite for 
splitting capillary growth.  
1.3.4 Mechanisms of blood vessel growth 
The sprouting growth of new capillaries is initiated via degradation of the BM underlying 
the ECs and this requires the cooperation of the plasminogen activator protease system 
(PA) and the matrix metalloproteinases (MMPs) (Conway et al. 2001), alongside a wide 
range of growth factors (Table 1.3, Fig 1.4).  MMPs play a critical role in breaking down 
the BM of the vessel and the ECM via release of ECM-bound growth factors.  The 
increased vascular permeability due to a combination of VEGF and the MMPs enables 
extravasation of plasma proteins that lay down a provisional scaffold for migrating cells 
(Carmeliet, 2003).  This also results in the release of other growth factors involved in 
stimulating angiogenesis and up-regulating VEGF mRNA expression, including insulin-like 
growth factor-1 (IGF-1), transforming growth factor ! (TGF-!), platelet-derived-growth-
factor (PDGF) and basic fibroblast growth factor (bFGF), among others.  PDGF is 
produced by a variety of cell types, and targets a range of cells including capillary cells, 
ECs and vascular smooth muscle, initiating the establishment of paracrine and autocrine 
loops for EC activation and proliferation (Dunn et al. 2000). 
 The formation of properly patterned and structurally stable microvascular networks 
requires the coordinated recruitment of pericytes to microvessels (Ponce and Price, 
2003) and it has been suggested that pericytes lead capillary sprouts into tissues.  
Pericytes are known as mural cells, involved in the formation of vasculature, and have 
the ability to differentiate into fibroblasts, smooth muscle cells or macrophages.   They 
have been shown to exist at the early stage of the angiogenesis and to induce 
proliferation of the endothelium, guiding migration and sprouting via VEGF-A secretion 
(Morikawa and Ezaki, 2005).  
 17 
Steps in angiogenesis 
 
Stimulatory factors Inhibitory factors 
Vasodilatation Nitric oxide synthases  
Increased vascular permeability VEGF 
(Flt-1, Kdr) 
Ang-1 (Tie-2) 
Extravasation of plasma proteins VEGF Ang-1 (Tie-2) 
Endothelial sprouting Ang-2 
Tie 2 
VEGF (Flk-1) 
 
Degradation of extracellular matrix MMPs & TIMPs (tissue 
inhibitors) 
Collagen prolyl-4-
hydroxylase 
 
PAI-1 
Liberation of growth factors uPA receptor Thrombospondin-1 
PAI-1 
Endothelial cell proliferation & 
migration 
VEGF, Ang 1&2, FGFs, PDGF  
Pericyte and smooth muscle 
recruitment 
PDGF  
Endothelial assembly and lumen 
acquisition 
VEGF, Ang-1 (Tie-2) 
Integrins 
Thrombospondin 
Stablilisation of nascent vessels PAI-1  
Maintenance of differentiation and 
remodelling 
Ang-1 (Tie-2) Ang-2 (Tie-2) 
 
Table 1.2 Summary of the molecular basis underlying new blood vessel growth (Receptors are 
indicated in brackets) (From Pugh and Ratcliffe, 2003).  
 
 
A number of factors contribute to the dissociation and movement of ECs through the 
matrix.  The Tie-2 receptor is a signalling system involved in vessel maintenance, growth 
and stabilisation.  Tie-2 is a membrane bound receptor tyrosine kinase that binds 
angiopoietins 1 and 2 (Ang1 and Ang2).  To enable ECs to dissociate from each other, 
competitive inhibition of Tie-2 by Ang2 occurs, initiating the loosening of matrix contacts 
and support cell interactions, thus allowing access for the above-mentioned growth 
factors and other angiogenic inducers (Hanahan, 1997).  Redistribution of intercellular 
adhesion molecules (platelet endothelial cell adhesion molecule (PECAM-1) and vascular 
endothelial (VE)-cadherin) also contributes to the dissociation of ECs from their 
neighbouring cells, causing them to undertake mitosis, and, due to loss of contact 
inhibition, start migrating throughout the matrix.  Proteinases also expose new epitopes 
in ECM proteins that induce migration, along with a matrix of fibronectin and fibrin, and 
another group of adhesion molecules called the integrins (!v"3 and !v"5) (Eliceiri and 
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Cheresh, 1999).  These all assist in guiding the ECs towards their objective sites 
(Carmeliet, 2003).      
 During the migration of the ECs to distant sites, there is a complex interplay and 
redundancy between VEGF, bFGF and angiopoietins. Via phosphorylation of Tie2, Ang1 
stimulates interactions between pericytes and ECs and induces sprouting of new 
capillaries (Conway et al. 2001), solidifying and stabilising a newly formed blood vessel.  
Initial breakages in the BM are repaired quickly as an intact BM was found around many 
EC sprouts (Egginton et al. 2001). 
 
 
 
 
Figure 1.5 Mechanisms of blood vessel growth via BM degradation, EC migration, differentiation 
and reformation into tubes that form new capillaries (Taken from Collinson and Donnelly, 2004) 
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1.3.5 Angiogenic stimuli 
A number of factors are responsible for the initiation of angiogenesis, and the nature of 
the stimulus determines the morphological characteristics that ensue.  There is a very 
fine balance between pro- and anti-angiogenic factors, and disruption of this balance 
provides the driving force for the development of new vessels (Fig 1.5).   
1.3.5.1 Metabolic and mechanical factors 
Metabolic factors are also responsible for the formation of new blood.  It is uncertain as 
to which type of angiogenesis is initiated by hypoxia, though it is possible that 
polycythaemia, caused by an increase in RBCs under hypoxia, could increase shear stress 
and initiate angiogenesis via luminal splitting (Deveci et al. 2002).   
Mechanical factors influencing angiogenesis include the increase in blood flow 
(leading to increased shear stress) that follows the initiation of exercise, cyclical wall 
tension in response to pulsatile blood pressure, and the strain imposed by muscle fibres 
if they increase in size (for example with exercise, training or imposed by conditions of 
overload).  Functional overload, due to the alteration in load bearing, is induced in the 
remaining muscle.  The disruption of the abluminal environment caused by stretch and 
conditions required for the increase in muscle mass, a phenomenon commonly observed, 
stimulates the sprouting form of angiogenesis (Zhou et al. 1998).  This extended network 
of capillaries is responsible for maintaining blood flow and O2 supplies to enable new 
protein synthesis for the elongation of muscle fibres (Goldspink et al. 1991). 
Any alterations in stretch or shear induce transformational changes in the blood 
vessel wall.  These changes are sensed by ECs and transmitted via stretch-activated ion 
channels (Lansman et al. 1987) to the cytoskeleton, which subsequently initiates 
changes in gene expression, altering the proliferation and survival of cells.  Several 
genes which initiate angiogenesis are upregulated, including MMP-2 and VEGF, both of 
which are involved in the breakdown of vessels, the starting point for the initiation of 
new vessel growth (Egginton et al. 1998).  Until recently, HIF expression was thought to 
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only be important under hypoxic conditions, but it is now known to be upregulated under 
non-hypoxic conditions such as stretch: Williams et al. (2006b) showed that HIF-1! was 
upregulated under both conditions of shear and stretch-induced angiogenesis.  
Subsequently, Milkiewicz et al. (2007) showed that both HIF-1! and HIF-2!, on a protein 
and mRNA level, play a core role in stretch-induced angiogenesis. 
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Figure 1.6 The angiogenic balance: a fine balance exists between pro and anti-angiogenic factors with a wide range of stimuli affecting the 
outcome. 
Pro-
angiogenic 
factors 
Anti-
angiogenic 
factors 
Hypoxia 
Shear 
stress 
Cytokines 
Muscle 
stretch 
pH 
Hypoglyc
-aemia 
Metabolic 
stress 
 22 
1.4.7  Angiogenesis and disease 
Angiogenesis was originally only implicated in the development of cancer, arthritis and 
psoriasis.  However, an increasing amount of research has been centered around 
understanding the molecular basis of this phenomenon, and it has become evident that 
excessive, insufficient or abnormal angiogenesis contributes to the pathogenesis of many 
other disorders.  Table 1.3 shows a range of diseases where angiogenesis is implicated 
as a major factor. 
 
ORGAN 
 
DISEASE 
Numerous organs 
 
Cancer (activation of oncogenes; loss of tumour 
suppressors); autoimmune disorders (activation 
leucocytes) 
Blood vessels Vascular malformations (tie2 mutation); 
DiGeorge syndrome (low VEGF and neuropilin-1 
expression) 
Adipose tissue Obesity  
Skin Psoriasis, warts, allergic dermatitis, scar keloids, 
blistering disease, Kaposi sarcoma in AIDS 
patients 
Eye Persistent hyperplastic vitreous syndrome (loss 
of ang-2 or VEGF164); diabetic retinopathy; 
retinopathy of prematurity 
Lung Primary pulmonary hypertension, asthma, nasal 
polyps 
Intestines Inflammatory bowel and periodontal disease, 
peritoneal adhesions 
Reproductive system Endometriosis, uterine bleeding, ovarian cysts 
Bone, joints Arthritis, synovitis, osteomyelitis 
 
Table 1.3  Disease characterised or caused by abnormal or excessive angiogenesis (From 
Carmeliet, 2003) 
 
Hypoxia plays a role in initiating many of the above-mentioned diseases.  One disease 
where hypoxia-stimulated angiogenesis plays an important role is in PAD, whereby the 
build up of an atherosclerotic plaque in the arteries supplying the heart such as the 
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femoral artery (FA), causes disease of the blood vessels, and the loss of blood flow to the 
immediate tissue initiates remodelling of the vasculature  (angiogenesis).  
1.4.8 Therapeutic angiogenesis 
A current challenge for therapeutic angiogenesis is to find the most efficient method of 
targeting ischaemic areas in need of revascularisation.  There have been a wide range of 
trials, including administration of growth factors such as VEGF and FGF.  Gene therapy is 
an extremely attractive form of gene administration, with differing administration routes: 
viral and non-viral.   Non-viral gene therapy is limited by a low transfection efficiency and 
low transgene expression (Bobek et al. 2006).  Viral vectors are a more attractive 
alternative as there are a range of possible vectors and the transfection efficiency is 
higher than with non-viral transmission.  Problems with gene therapy in humans arise 
due to the limited tissue diffusion of the vector and the greater volume of tissue present 
in humans, when compared to the animal models from which the methods were derived.   
Aside from gene therapy as an external method of manipulating blood vessel 
growth, the use of chemicals to manipulate molecular pathways involved in the 
angiogenic cascade are widely being trialled.  One of these is dimethyloxalylglycine 
(DMOG), a PHD and FIH inhibitor which upregulates HIF activity.  It has been shown to 
upregulate HIF-1! and downstream angiogenesis in a model of femoral artery ischaemia 
(Milkiewicz et al. 2005), and thus shows potential for use in mitigating the effects of 
chronic ischaemia. 
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1.5 Hypothesis and aims 
Aim 1: To elucidate the conditions of systemic hypoxia required to manipulate the HIF-
regulated genomic response in different mouse tissues, and in parallel to study the same 
host of genes in human leucocytes alongside the plasma EPO response to hypoxia. 
Objective 1: This was achieved by exposing mice to a stimulus of 10% hypoxia for 2 wks, 
and a two-phase study in humans consisting of an acute exposure to 4600m (~12%) and 
a chronic exposure to 4392m. 
Hypotheses: (1) Human leucocytes may be used as a viable circulating indicator of the 
systemic response to hypoxia, and (2) EPO may be used to determine the erythropoietic 
response and susceptibility to acute mountain sickness (AMS).   
 
Aim 2: To evaluate the levels of local or systemic, hypoxic or non-hypoxic stress required 
to initiate angiogenesis, and to evaluate whether chemical manipulation of HIF-1! 
stability would enhance these responses.   
Objective 2: This was investigated using (1) a model of femoral artery ligation in the 
mouse to study the effects of local hypoxia (ischaemia) with and without the addition of 
DMOG, and (2) mice were exposed to 10% and 12% hypoxia for 1, 2 and 4 wks to study 
the effects of systemic hypoxia.  
Hypotheses: (1) Chemically manipulating availability of HIF-1! via inhibition of the PHDs 
(with DMOG) would enhance angiogenesis and help to restore blood flow to the ischaemic 
muscle, (2) A similar effect of enhancing angiogenesis to that previously shown in a 
model of local hypoxia, would be seen in an array of tissues when the proximate signal is 
systemic.   
 
Aim 3: To elucidate whether the same HIF-1!-mediated pathways were operating under 
conditions of stretch-induced angiogenesis as seen under hypoxia. 
Objectives 3: DMOG was administered to mice subjected to unilateral extirpation.   
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Hypothesis: If HIF-regulated stretch-induced angiogenesis is operating via the same 
pathway as under local hypoxia, DMOG should also enhance capillary growth under 
normoxic conditions. 
 
Aim 4: To establish relationships between genomic and functional responses in skeletal 
muscle following genetic manipulation of molecular pathways leading to HIF-1! stability.   
Objective 4: This was achieved using PHD1 and PHD3 knockout mice and the established 
model of unilateral extirpation, using gene arrays to evaluate the genetic response.  
Hypothesis:  The PHDs working non-redundantly, and a differential gene response should 
be seen following specific PHD ablation. 
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2   Methods 
 
All experiments were performed in accordance with the Home Office Animals (Scientific 
Procedures) Act, 1986.  The Home Office license holder is Dr. Stuart Egginton and the 
number is 40/2872, and my personal license number is 40/8197.  All experiments and 
surgery, with the exception of the following, were conducted in the Department of 
Physiology in Birmingham: Western Blotting (Chapter 3), Gene array and analysis 
(Chapter 6) (Wellcome Laboratories, University of Oxford), Chapter 3 and 8, RT-PCR 
(IBR, Department of Immunology, University of Birmingham), Chapter 8 – Phase I in the 
University of Glamorgan, Phase II in Chile.  
2.1 Dimethyloxalylglycine 
Dimethyloxaloylglycine (DMOG) is a cell penetrant oxoglutarate analogue which inhibits 
all enzymes of the oxoglutarate-dependent dioxygenase class, including collagen prolyl 
hydroxylases, PHD 1–3 and FIH, thus inducing stabilisation of both HIF-1! and HIF-2! 
proteins.  This subsequently allows downstream gene expression, promoting capillary 
growth.  Its development as a regulator of HIF came following the characterisation of the 
PHDs (Mole et al. 2003).  The direct effect of DMOG is inhibition of enzyme activity: it is 
hydrolysed in cells to NOG which sits in the active site in place of 2OG, stopping the 
enzyme from turning over. There is no direct effect on the level of PHD protein 
concentration but an increase in HIF protein is seen.  
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 Figure 2.1 Illustration of how DMOG interacts with HIF under hypoxia 
2.1.1 Protocol 
DMOG (Frontier Scientific Europe Ltd-D1070) was administered via i.p injection to the 
C57Bl6/J strain of mouse, at a concentration of 16mg.ml-1 in saline, at a dose of 0.5ml 
every other day.  
2.1.2 Product research and development 
Initial experiments conducted using DMOG from Frontier Scientific failed to produce any 
observable changes in the capillary supply in the EDL muscle resulting from the femoral 
artery ligation, as expected from previous studies (Milikiewicz et al. 2005).  A detailed 
analysis was carried out in collaboration with the chemistry laboratory in Oxford to 
determine the similarity of the chemical to a previous batch used (Milkiewicz et al. 2005) 
which was synthesised in Oxford.  Mass spectrometry (MS) and nuclear magnetic 
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resonance (NMR) imaging were both employed and were carried out by Benedikt Kessler 
(Wellcome Centre for Molecular Biology in Oxford) and Chris Schofield (University of 
Oxford, Department of Chemistry).  MS identifies the chemical composition of a 
compound or sample on the basis of the mass-to-charge ratio of charged particles.  It 
involves fragmentation of the molecule and identification of the corresponding spectra 
that are produced that relate to the compounds mass and charge (Gross, 2004).  NMR 
involves resonance of protons to pulsed radiation in a magnetic field.  The protons on the 
molecule spin depending on the group present on the compound, and the protons shift 
differently depending on the environment, producing a series of peaks on a graph 
(Hornak, 1997).  
 A slight difference in the molecular makeup of the DMOG from Frontier Scientific 
was found compared to the DMOG used previously in studies (Fig. 2.2, 2.3).  The FS 
DMOG was not as pure as the original batch and although this may have no effect, it 
could disrupt the function of the DMOG.  To try and overcome this problem, a new batch 
of DMOG was synthesised at the original source and used in subsequent experiments.  
 
 
 
 
  
 
 
 
 
Figure. 2.2 A comparison of DMOG, using NMR, synthesised in Oxford and a commercial source. 
Circles demonstrate the different peaks obtained.  Both spectra show a small amount of monoester 
of DMOG with an additional NH proton at 7.8 ppm and only one methoxy group (OCH3) of methyl 
ester at the region around 4 ppm.  Despite the fact that both spectra show about 95% presence of 
DMOG, the ‘Oxford’ batch has been deemed to have a less noisy spectra and is therefore cleaner 
 
Oxford Frontier 
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Figure 2.3 Values obtained for the ‘DMOG peak’ in mass spectrometry  
 
 
2.2 Skeletal muscle sampling  
Following cervical dislocation at the end of experiments, skeletal muscle was removed 
from the hindlimb of the mouse (Fig 2.4).  The main tissue studied was the extensor 
digitorum longus (EDL) which is a pennate muscle that inserts into the middle and distal 
phalanges of the lateral four digits of the hindlimb.  Its action is the extension of the toes 
and ankle and is important for stability.  The EDL has a mixed fibre type composition 
(Zierath and Wallberg-Henriksson, 2002) and thus gives a good representation of 
response to both the hypoxic and non-hypoxic conditions in these experiments.   In the 
extirpation experiments, it was necessary to study the EDL as it is the synergist muscle 
to the TA muscle which is removed.   
The soleus was also studied in some of the experiments.  It is a powerful muscle 
in the back part of the lower leg and is involved in walking and is very important in 
posture when standing.  It is mainly composed of slow twitch oxidative muscle fibres 
(Hirofujl et al. 1992). 
 
Oxford 
Frontier 
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Only muscle from the affected limb was sampled and not that from the 
contralateral muscle.  It has been shown (Williams, unpublished) that as a consequence 
of surgery on the ipsilateral limb, the contralateral limb undergoes some physiological 
changes to compensate for the intervention on the ipsilateral limb.  Because of this, 
physiological readings from the affected limb are compared to untreated control animals. 
All this tissue sampling was performed in Birmingham. 
               
Figure 2.4 Location of muscles used for sampling tissue (Cook, 1965) 
 
2.2.1 Procedure 
An incision was made along the upper side of the hindlimb on top of the location of the 
TA. The tendon of the TA was identified and lifted up using a fine pair of forceps before 
being cut at the base.  A small amount of tension was placed on the TA and it was then 
carefully pulled upwards and separated by blunt dissection from the remaining muscles, 
before being cut at the top from underneath using a scalpel blade.  This left the EDL 
exposed and the same procedure was repeated.  The soleus rests around the back of the 
hindlimb and can be identified by the red colour of the muscle, indicative of its oxidative 
capacity and attachment to skin above the ankle.  
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2.3 Freezing tissue and cryosectioning  
Correct timing and efficiency of freezing the desired tissue is required to ensure freezing 
damage does not prevail.  Liquid nitrogen has a low specific heat capacity and thus the 
tissue is not frozen directly with it.  Due to the formation of an insulating layer of gas, ice 
crystals would form.  Instead, isopentane, cooled using liquid nitrogen, is a wetting agent 
used to freeze the muscle.  
2.3.1 Freezing tissue 
The desired tissue was placed on a cork disk with a pin stuck in the middle to maintain 
the correct orientation and coated with OCT (tissue tek, 4583) compound.  The tissue 
was then lined up against the pin to ascertain correct orientation, and dropped into cold 
isopentane.  Isopentane was cooled to its freezing point by liquid nitrogen.  The 
appropriate temperature was determined visually by an increase in viscosity and 
cloudiness.  After 30 s, the cork was removed from the isopentane and the pin taken out. 
The discs were stored in liquid nitrogen before transfer to the -80°C freezer. 
2.3.2 Cryosectioning 
Before sectioning, the tissue was removed from storage in liquid nitrogen and stuck onto 
a metal chuck. The microtome (at -20±3°C) was used to finely section the tissue at a 
thickness of 10!m and the section was then picked up on a glass slide. The slide was 
then left to sit at room temperature (RT) for 30 min to dry and ensure adequate binding.  
Slides were stored at -20°C or used immediately for staining. 
2.4 Immunohistochemical staining and capillary counting 
2.4.1 Lectin staining 
Lectins are sugar-binding proteins which are highly specific for different sugar moieties.  
Here, the fluorochrome conjugates, while mainly binding to the galactose residues 
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present in the glycocalyx lining the blood vessels, also faintly stains the sarcolemma of 
the muscle fibres which makes analysis of the capillary to fibre ratio easier.  
2.4.1.1 Protocol 
Sections were air dried for 30 min on removal from the freezer and encircled with a wax 
pen.  Sections were fixed in acetone and left to evaporate.  Fluorescein labelled Griffonia 
simplicifolia Lectin I (GSL I, BSL I) (Vector, FL-1101) was used at a concentration of 
5!g.ml-1 in 10mM phosphate buffered saline (PBS) (Sigma Aldrich, P5368).  PBS was 
used in combination with CaCl2 (1Mm CaCl2 in 10Mm PBS), 500!l per slide.  Slides were 
left for 1 h at RT out of direct light and subsequently rinsed 3 x 5 min washes with PBS, 
with a final rinse in distilled water. 
2.4.2 VEGF triple stain 
4',6-diamidino-2-phenylindole (DAPI) (Invitrogen, MP01036) is a fluorescent nuclear 
stain, excited by ultraviolet light and shows strong blue fluorescence when bound to 
DNA.  Co-localisation of VEGF-A by immunostaining with lectin and DAPI staining enables 
a comparison of those capillaries which are actively undergoing angiogenesis with those 
that are not.  Angiogenesis induces an increase in the number of endothelial cells and 
nuclei associated with them, thus by studying the proportion of DAPI and lectin stained 
cells, a measure of cellularity can be obtained, and the proportion of lectin-stained 
vessels that are VEGF positive, an indication of widespread or local angiogenic activation. 
2.4.2.1 Solutions 
0.5% PBS-Tween 
Primary antibody dilution buffer  
1% bovine serum albumin (BSA, Sigma Aldrich, 05491) in 0.5% PBS-Tween (0.5% 
tween in 10mM PBS) (Tween: Sigma Aldrich, P5927) 
 
 
 34 
Secondary antibody dilution buffer 
1.5% normal goat serum (NGS) (SantaCruz Biotechnology, sc-2043) + 1%BSA in PBS-
Tween.  
 
HEPES solution + Ca2+ 
1mM CaCl2 solution in 10mM HEPES solution 
2.4.2.2 Protocol 
Sections were air dried for 30 min prior to staining and then fixed in pre-cooled acetone 
for 10 min.  Slides were washed 3x for 5 min. in PBS and 1x 5 min. in PBS-Tween.  The 
slides were dried and the sections circled using a wax pen.  The primary antibody (VEGF 
147A20: targets VEGF-A, Santa Cruz sc-152) was diluted to a concentration of 1:100 in 
primary antibody dilution buffer, and the slides were incubated for 1 h at RT.  Slides were 
then washed 3x for 5 min in 0.5% PBS-tween. The secondary antibody (Alexafluor-488 
goat anti-rabbit: Invitrogen A11034) was diluted down in secondary antibody dilution 
buffer (0.01M PBS, 0.5% Tween, as described) to a concentration of 1:250, and the 
slides incubated for 1 hour at RT.  The slides were then washed 2x for 5 min in PBS-
Tween and 2x 5 min in PBS.  500!l of lectin (prepared as in 1.6.1.1) was then applied to 
each slide and left at RT for 1 hour.  Slides were washed 3x for 5 min. in PBS and 1x in 
distilled water.  1-2 drops of Vectashield with DAPI (1.5 !g.ml-1: Vector labs, H-1200) 
was added to each slide to stain nuclei, followed by a cover slip, taking care to make sure 
no air bubbles were present.  The slides were then visualised using a fluorescent 
microscope. 
2.4.3 Capillary and fibre counting 
2.4.3.1 Lectin stain 
Capillaries were visualised using a fluorescent microscope (Zeiss Axioskop 2 plus with the 
AxioVision programme 4.4).  One section of each piece of tissue was photographed at a 
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magnification of x20 using the FITC filter with an excitation filter boundary of 490/20nm 
(center wavelength/width of band) and an emission filter boundary of 528/38nm.  4 
photographs were taken to cover both the lateral and medial sections of the tissue to 
ensure that the naturally occurring variation in the number of capillaries due to fibre type 
(oxidative or glycolytic) were accounted for when counting.  Using Adobe Photoshop!, 
images could be digitally enhanced to aid accuracy of visualising the capillaries and 
fibres.  A sampling grid of 18x13 squares was randomly placed onto the image, and the 
number of capillaries and fibres within that area recorded.  Any capillaries or fibres lying 
on the top and right sides of the sampling square were included in the count. Any lying 
or touching the bottom and left sides of the square were excluded (Egginton, 1990).  The 
capillary density and fibre size were calculated from the estimation of the number of 
capillaries and fibres with this area of 93 600!m2, as determined by calibration with a 
graticule. 
2.4.3.2 VEGF/lectin/DAPI triple stain 
Capillaries were visualised (above) and the number of lectin stained capillaries recorded.  
VEGF positive capillaries were visualised with an excitation filter boundary of 555/28nm 
and an emission filter boundary of 617/73nm.  The DAPI staining was visualised using an 
excitation filter boundary of 360/40nm and an emission filter boundary of 457/50nm.  
Digital photos were obtained by multidimensional acquisition to record each channel as 
elements of a single image.  The proportion of lectin stained capillaries that were VEGF 
positive was determined, and the number of lectin stained capillaries that were lectin and 
DAPI positive was recorded.  The number of capillaries that had been stained with DAPI 
(shown by fluorescent blue staining) divided by the number of lectin stained capillaries is 
proportional to the cellularity of the vessel, and the proportion of lectin and VEGF, along 
with lectin and DAPI compared to lectin alone give an estimation of those capillaries 
actively undergoing angiogenesis. 
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2.5 RNA extraction 
The purification of RNA from samples is used as a starting point for further analyses such 
as RT-PCR and gene arrays. Qiagen and Trizol are both well described methods used to 
extract the RNA from cells and tissues.  To establish which would give the higher yield of 
RNA, an extraction was carried out using both. They gave similar yields though the 
Qiagen kit was used as it was more time efficient.  
2.5.1.1 Tissue homogenisation 
Glass homogenisers were placed in an oven at 200°C for 3 h to inactivate RNAses.  The 
worktop and all instruments involved were cleaned using RNAse zap.  The muscle to be 
used was wrapped in a small piece of foil and placed on a frozen metal block in a 
polystyrene box surrounded by liquid nitrogen.  The muscle was then crushed with a 
pestle and the powder transferred to the glass homogeniser on ice. It was then 
homogenised and the Qiagen RNeasy kit (Qiagen, Crawley, UK) used to extract the RNA 
using Appendix C from the handbook.  Eluted RNA was stored at -20°C. 
2.5.1.2 Cell homogenisation 
To remove adherent GC-1 cells (originating from mouse testicles and used as a positive 
control for PHD1) from the petri dish, all DMEM (Invitrogen, 31885-023) was removed 
with a pipette and 600!l of buffer RLT (RNA lysis tissue buffer)+ !-mercaptoethanol 
(Qiagen kit) was added.  After ensuring adequate spreading, the dish was checked under 
the microscope to determine if all the cells were in solution.  GC-1 cells were scraped off 
the plate and transferred into an Eppendorf and spun at 17,900g for 5 min.  
Subsequently, the protocol was then followed for RNA extraction from animal cells, from 
the Qiagen RNeasy protocol.  Eluted RNA was stored at -20°C. 
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2.5.2 Determination of RNA purity 
It is important to determine the purity of the RNA before further use, and this was 
determined via two methods.  RNA denaturing gel electrophoresis and the nanodrop was 
used for assurance of purity, and the latter to also determine the concentration of the 
RNA. Intact total RNA run on a denaturing gel will have sharp 28S and 18S rRNA bands.  
The 28S rRNA band should be approximately twice as intense as the 18S rRNA band.  
This 2:1 ratio (28S:18S) is a good indication that the RNA is intact.  Partially degraded 
RNA will have a smeared appearance, will lack the sharp rRNA bands, or will not exhibit a 
2:1 ratio.  The nanodrop is a full-spectrum spectrophotometer used to quantify nucleic 
acids, proteins, fluorescent dyes and other compounds. It requires 2!l of sample for 
determination and produces spectra as shown by the red line in Fig. 2.5.  If the sample is 
pure it will have a 260/280nm value of above 2.  Any spectra that give different values 
from this indicate impurity in the sample.  
 
 
 
Figure 2.5 An example of spectra produced by the nanodrop in a collection of pure samples, all 
with a 260/280nm ratio >=2 
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2.5.2.1 RNA electrophoresis gel solutions 
Gel loading buffer II – denaturing agarose, A 1-2X solution 
95% Formamide (Fisher Scientific, BP227-100), 18mM EDTA (5.3g EDTA, Sigma Aldrich, 
431788), 0.025% SDS (Fisher Scientific, BP166-100), Xylene Cyanol, and Bromophenol 
Blue (Sigma Aldrich G526). 
 
10X MOPS (1L) (autoclave and store in the dark at 4°C)  
41.8 g MOPS (Embi-Tec 1020) in 700 ml of sterile DEPC-treated H2O.  Adjust the pH to 
7.0 with 2 M NaOH.  Add 20 ml of DEPC-treated 1 M sodium acetate to 20 ml of DEPC-
treated 0.5 M EDTA (pH 8.0).  Adjust the volume to 1 litre with DEPC-treated H2O. 
2.5.2.2 Protocol 
Gel preparation (1%) 
2g of agarose was heated in 144ml water until dissolved, then cooled to 60°C.  20ml of 
10X MOPS running buffer and 36ml 37% formaldehyde (Sigma Aldrich, 252549) was 
added.  The plastic gel holder was taped along both ends, the gel was poured and the 
comb inserted. It was left to set for 20 min. 
Sample preparation 
Ethidium bromide was added to sample loading buffer at a final concentration of 10!g.ml-
1.  The loading buffer was then added to the RNA sample at a ratio of 1:1. This was 
heated at 65°C for 5 min. 
Assembling the gel 
The tape was removed from the ends of the gel holder and assembled in the tank.  
800ml of 1x MOPS running buffer was added to cover the gel and the comb was 
removed.  Samples were loaded onto the gel and it was run at 60V until bromophenol 
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bands were 2cm into gel, then the voltage was increased to 80V. This was run until 2/3 
length of the gel.  The gel was then visualised with a UV transilluminator (UVP!).  
2.6 Real-Time RT-PCR and cDNA synthesis 
Real time reverse-transcription-polymerase chain reaction (RT-PCR) is a very sensitive 
RNA quantification assay that involves two steps. Firstly, the complementary DNA (cDNA) 
is made from mRNA via reverse transcription.  This cDNA is then used as a template for 
the polymerase chain reaction (PCR), whereby the gene of interest is amplified until 
there are millions of copies.  DNA is much more stable than RNA so is a useful starting 
point for RT-PCR. 
2.6.1 Synthesis of cDNA 
RNA was extracted using the Qiagen RNeasy kit and eluted in water.  10!l of RNA was 
added to 1!l of oligo-dN6 (3!g.!l-1) (Roche, 13819820) and denatured for 10 min at 
70°C. This was shock cooled on ice and subsequently reverse transcribed using 9!l of the 
following mix: 0.5!l H20, 4!l 5X first strand buffer (Invitrogen, P/N Y00147), 2!l 0.1M 
DTT (Invitrogen, P/N Y02321), 1!l dNTP (10Mm)  (Promega, diluted to 10mM from 100mM 
stock provided), 0.5!l RNAse Inhibitor (RNAguard, Pharmacia, ~40 U.!l-1), 1!l M-MLV 
(Gibco) (1!l.!g-1 RNA, stock 200 U.!l-1).  The sample was heated for 1 h < 42°C (41°C, 
block control and heated lid in Hybaid PCR machine) and then for 10 min to 90°C to 
inactivate RT.  The sample was diluted with 80!l RNAse free water and stored at 4°C (-
20°C for longer periods).  
2.6.2 RT-PCR 
RT-PCR is a very sensitive technique for mRNA detection and quantification.  It involves 
the amplification and quantification of a specific DNA molecule. The quantitative data is 
collected at the point in which every sample is in the exponential phase of amplification.  
RT-PCR is the most sensitive method for the detection of low abundance mRNAs 
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compared to the two other commonly used techniques for quantifying mRNA levels, 
Northern blot analysis and RNase protection assay, and can be used to determine the 
amount of RNA present in a single cell.  Of the range of probes that are available, 
Taqman probes are used here. These are oligonucleotides with a fluorescent reporter dye 
attached to the 5’ end and a quencher dye attached to the 3’ end. The probes are 
designed so that they hybridise to the internal region of the PCR product.  The 
fluorescent increase with each cycle is proportional to the amount of probe cleavage that 
occurs every time the template is replicated (Fig. 2.6).   
 
 
 
Figure 2.6 The Taqman system.  DNA polymerase cleaves the TaqMan probe during the PCR.  
There is a reporter dye at the 5 ! end of the probe and a quencher dye at the 3 ! end.  Cleavage 
results in increased fluorescence of the reporter (TaqMan Gene Expression Assays, Applied 
Biosystems) 
 
 
 
The fluorescent signal can be directly measured using a laser and charged coupled device 
(CCD) camera, enabling real time detection of cDNA amplification (Fig. 2.7). 
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Figure 2.7 Illustration of the fluorescent signal yielded by !-actin from the cDNA of human WBCs. 
The cycle number is logged on the x-xis and the CT value is recorded on the y-axis. 
 
2.6.2 Testing primers and probes  
RT-PCR is typically referenced to an internal control gene. Currently, at least nine 
housekeeping genes (HK) are well described for the normalisation of expression signals 
(Stürzenbaum SR, Kille P. 2001.)  !2- microglobulin (MWG, Germany: Forward: 5'-
CATACGCCTGCAGAGTTAAGCA-3', Reverse: 5'-ATCACATGTCTCGATCCCAGTAGA-3', 
Probe: 5'-CAGTATGGCCGAGCCCAAGACCG-3' bound of CalFluor560 and Black Hole 
Quencher 1.) was used for the mouse gene RT-PCR (CHPT 3.2.2.1) and !-actin and 18S 
rRNA (small subunit of the two ribosomal subunits) were used for different human genes 
of interest (G of I) (CHPT 7.2.1.3).  These were all pre-optimised control probes.  In 
order to determine whether the primers and probes could be used in a multiplex array, 
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i.e. with both the HK gene and G of I in the same well, a plate was set up with a series of 
dilutions to determine cross reactivity.  Positive and negative control samples were run in 
this array, as opposed to the actual samples. 
For the study described in 3.2.2.1, mouse spleen was used as the positive control, as 
levels of G of I were significant in all organs as determined from genecard 
(www.genecard.com).  For the human study (CHPT 7), WBCs were extracted from 
normoxic human whole blood and used as the positive control for HIF1!, ALD-A, VEGF 
and HMOX-1.  Human umbilical vein endothelial  cells (HUVEC) were used as a positive 
control for iNOS expression, nasal polyps were used as a positive for Flt-1 and Flk-1, and 
a series of renal cancer cell lines were used as positive and negative controls for CAIX 
(Cancer Institute, Birmingham).   
A spreadsheet was used to calculate volumes of reagents and the 384-well plate 
was designed (Table 2.1) with samples in triplicate.  Analysis was carried out using 
Microsoft Excel. 
 
  1       2       3 5       6       7 9       10       11 
A 1:1 HK gene 1:1 G of I 1:1 HK gene + G of I 
C 1:3 HK gene 1:3 G of I 1:3 HK gene + G of I 
E 1:9 HK gene 1:9 G of I 1:9 HK gene + G of I 
G 1:27 HK gene 1:27 G of I 1:27 HK gene + G of I 
I 1:81 HK gene 1:81 G of I 1:81 HK gene + G of I 
K 1:243 HK gene 1:243 G of I 1:243 HK gene + G of I 
M 1:729 HK gene 1:729 G of I 1:729 HK gene + G of I 
O NTC HK gene NTC G of I NTC HK gene + G of I 
 
Table 2.1 Plate design for testing primers and probes 
 
2.6.3 Using RT-PCR with the genes of interest 
Relative quantification of specific cDNA species to !-actin/18S rRNA message was carried 
out in a multiplex PCR on the ABI 7900 real time PCR machine (Applied Biosystems, 
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Warrington, UK).  Desired volumes of reagents required were calculated from a prepared 
spreadsheet of previously chraracterised optimal conditions.  The RT-PCR was performed 
in 384 well plates with a total volume of 6!l per well (5!l buffer and 1!l cDNA) in 
triplicates, with ABI PCR 2X Master mix (Roche, 58003365-01).  The primers and probes 
to amplify up the G of I were TaqMan Gene Expression Assays (Applied Biosystems), and 
were used according to the manufacturers instructions. These were at a concentration of 
20x with the primer being at 18!M and the probe at 5!M.   
Mouse G of I (CHPT 3) were amplified in multiplex with mouse "2-microglobulin 
as the HK gene control.  The forward primer was CATACGCCTGCAGAGTTAAGCA (conc 
60!M), the reverse was ATCACATGTCTCGATCCCAGTAGA (conc 80!M) (MWG Biotech) 
and this had a Yakima-Yellow Black Hole Quencher 1 labelled probe 
(CAGTATGGCCGAGCCCAAGACCG (conc 175!M) (Eurogentec).  The human G of I (CHPT 
7.2.1.2) were amplified in multiplex using !-actin or 18S rRNA.  !-actin was amplified 
using the forward primer CCTGGCACCCAGCACAAT (conc 20!M), the reverse primer 
GCCGATCCACACGGAGTACT (conc 70!M), and a VIC TAMRA quencher labelled probe 
(ATCAAGATCATTGCTCCTCCTGAGCGC (conc 100!M)).  18S rRNA was amplified using the 
forward primer GCCGCTAGAGGTGAAATTCTTG, the reverse primer 
CATTCTTGGCAAATGCTTTCG, and a Yakima-Yellow Dark quencher labelled probe 
(CCGGCGCAAGACGGACCAGA), all at a concentration of 500!M.   RT-PCR cycling was 
performed as follows: 2 min. at 50°C, 10 min at 95°C, and then 44 cycles of 15s at 95°C 
(melting) and 1 min at 62°C (annealing/extending). 
Thresholds within the logarithmic phase of the PCR for G of I transcripts and the 
HK gene were set and the cycle number at which the threshold was reached (Ct) was 
determined. Ct for the HK gene was subtracted from the Ct for G of I. The relative 
amount was calculated as 2-#Ct. 
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2.7 ELISA methodology 
An enzyme-linked immunosorbent assay is a technique used to detect the presence of an 
antibody or antigen present in a sample.   All samples were run in duplicate.  The 
underlying principle of the kits used here employ the use of the specific monoclonal 
antibody being pre-coated onto the microplate.  The samples were then pipetted onto the 
plate and any protein present binds to the antibody.  After washing away excess 
substance, an enzyme-linked specific monoclonal antibody was added to the wells and 
left.  Following a further wash, a substrate solution was added which reacts to change 
colour depending on the amount of substrate present. The intensity of colour was then 
measured in proportion to the amount of the protein that initially bound to the antibody, 
using a microplate reader at 450nm, and the sample values were then read off a 
standard curve.  The substrate in all 3 kits used in these studies was horseradish 
peroxidase (conjugate) and the colour reagents used (substrate solution) were a 
combination of hydrogen peroxidase and tetramethylbenzidine (TMB) (ELISA kits from 
R&D systems, see specific chapters). 
2.8 Western Blot 
2.8.1 Controls 
Western blotting was used to determine protein expression levels under systemic hypoxia 
in the heart and EDL muscle.  PHD2 and HIF-2! were visualised on the membrane, but 
visualising HIF-1!, PHD1 and PHD3 was not possible.  A variety of antibodies were 
utilised (Table 2.2), along with using a large gel to try and detect HIF-1! as this had 
previously been successful with a different species, but without success.  Changing the 
time used for transfer, the surrounding conditions and the loading volume of proteins 
was also tried without success.  A western blot for the detection of GLUT-1, a 
downstream gene of HIF-1!, was also attempted without success.  A variety of positive 
controls were tested with these antibodies.  For HIF-1!, thyroid hormone-responsive rat 
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pituitary tumor (GC) cells ± DMOG. For HIF-2!: liver treated with carbon monoxide and 
without, PC12 cells (a cancer cell line derived from a pheochromocytoma of the rat 
adrenal medulla).  For PHD1: PHD1 knockout and wild-type testis, PHD1 knockout and 
wild-type mouse heart, 293T extract transfected with PHD1, radiolabeled proteins were 
produced by IVTT (Promega) utilizing [35S]methionine and plasmids encoding the cDNA. 
For PHD3: spa-tagged cells (tandem affinity tag - two tags and calmodulin binding 
peptide separated by aTEV protease cleavage site.), PHD3 knockout and wild-type mouse 
heart, radioactive (hot) IVTTs. 
 
Protein 1° Antibodies tested 
 
Concentration 
HIF-1! NB100-479     (novus) 
HIF-1! H-206 (Santa Cruz Biotechnology) 
PM14             (Oxford in-house antibody) 
1:1000 
1:1000 
1:1000 
PHD1 NB100-310     (novus) 
Anti-sense sera against rat PHD1 (Oxford in-house 
antibody - YFJK) 
Polyclonal unpurified antibody (Oxford in-house 
antibody) 
1:1000 
1:250 
 
1:250 
PHD3 NB100-139     (novus) 
NB100-303     (novus) 
1:2000 
1:2000 
GLUT-1 652-206         (abcam) 1:1000 
 
Table 2.2 Different primary antibodies used to detect hypoxically regulated proteins 
 
 
2.8.2 Solutions  
Urea/SDS 
120mM Tris-HCl  (Sigma Aldrich, T5941) pH 6.8, 4% SDS (Sigma Aldrich L3771), 4M 
Urea (Sigma Aldrich, UO631), 20% glycerol (Sigma Aldrich, G8773) 
 
0.5M Tris-HCl/0.45% SDS (pH 6.8) (see supplier as above) 
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1.5M Tris-HCl/0.45%SDS (pH 8.8) (see supplier as above) 
 
2x Sample buffer (some suppliers as above) 
4% SDS, 20% glycerol, 10% 2-mercaptoethanol (Sigma Aldrich M7154), 0.004% 
bromophenol blue (Sigma Aldrich, 114391), 0.125M Tris HCl. pH 6.8. 
 
1x running buffer  
25mM Tris base, 192Mm Glycine (Sigma Aldrich G8898), 0.1% SDS  
Make up to 1L with ddH2O  
 
1x Blotting Transfer Buffer 
25mM Tris base, 0.2M glycine, 20% methanol (Sigma-Aldrich, 179337) 
make up to 1L with ddH2O, do not adjust pH. 
 
Coomassie stain 
50% methanol, 10% acetic acid (Sigma-Aldrich, 314641), 0.1% 1g/L brilliant blue 
(Sigma Aldrich B6529), 40% ddH2O 
 
Coomassie destain 
50% methanol, 10% acetic acid, 40% ddH20,  
 
Ponceau stain 
0.1%w/v ponceau (Fisher Scientific BP103-10) in 5% v/v acetic acid 
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2.8.3 Urea/SDS method of total protein extraction 
2.8.3.1 Tissue homogenisation 
Urea/SDS buffer was added to each Eppendorf (150!l for EDL, 300!l for heart) and 
cooled on dry ice with the pestle and mortar.  A small amount of liquid nitrogen was 
transferred into the mortar, the tissue ground into a fine powder and quickly transferred 
to the prepared tube.  Tissue was homogenised with an electrical homogeniser for 3 x 
10s.  The solution was centrifuged for 10 min at RT at 17,900g.  The supernatant was 
removed and re-spun for 1 min at RT.  The supernatant was again removed and vortexed 
gently and briefly before being stored at -80°C. 
2.8.3.2 Protein assay 
A set of BSA dilutions of 0.1, 0.2, 0.4, 0.8, 1.6, 3.2 and 6.4!g/!l was constructed from 
an initial stock of 6.4!g/!l-1.  The protein concentration was determined using the Biorad 
Assay kit (Biorad, 500-0121).  5!l of samples and BSA were added to a 96 well plate in 
duplicates. 160!l reagent B was added to each well, followed by 20!l reagent A’ 
(Reagent A: 1ml A + 10!l S - Biorad).  This was left at RT for 15 mins and the 
absorbance measured at A650.  A standard curve was constructed and the protein 
concentration calculated. 
2.8.4 Western Blotting Protocol 
2.8.4.1 Gel Preparation 
Gels were made according to the percentage required (Table 2.3 and 2.4): 10% for PHD2 
and 6% for HIF-2!.  The lower percentage gel separates the larger proteins whereas the 
larger percentage gels separate the smaller proteins (Table 2.5).  Glass plates were 
assembled according to the manufacturers instructions and filled up to 1cm from the 
bottom of the comb with resolving gel, adding the TEMED (Sigma Aldrich, T92810) and 
APS (Sigma Aldrich, A3678) to the solution last.  This was overlaid with butanol/H20 (2ml 
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for a thick gel, 1ml for a thin gel) and left for 20 min to set.  Plates were tipped to one 
side to remove the butanol/H2O layer, absorbing excess liquid with filter paper. The 
stacking gel was poured in to the top of the glass plates and the comb inserted, this 
being left to polymerise for 20 min.  When set, the glass plates were assembled in the 
electrophoresis chamber (see manufacturers instructions) and 1x running buffer carefully 
poured into the cell to a level ensuring both electrodes were submerged.  A 1ml pipette 
was used to eject running buffer and clear each well. 
 
 6% 10% 
 
Tris/HCL/SDS pH 8.8 (ml) 2.5 2.5 
Acrylamide (37.5/1) (ml) 2.0 3.3 
ddH20 (ml) 5.45 4.16 
TEMED (!l) 9 9 
10% APS (!l) 42 42 
 
Table 2.3 Recipe for the resolving gel 
 
  
Tris/HCL/SDS pH 6.8 (ml) 1.25 
Acrylamide (30/0.8) (ml) 0.65 
ddH20 (ml) 3.05 
TEMED (!l) 6 
10% APS (!l) 31 
 
Table 2.4 Recipe for the 1 thick stacking gel 
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Percentage of acrylamide Range of protein separation 
 
5% 57-212kDa 
7.5% 36-94kDa 
10% 16-68kDa 
12% 13-50kDa 
15% 12-43kDa 
 
Table 2.5 Gel percentage separation guide for protein samples 
 
2.8.4.2 Sample preparation 
Each sample was spun down before use.  10!l rainbow marker (Biorad Precision Plus 
protein standards 161-0374) was loaded in lane 1.  The protein sample was heated at 
95°C for 5 min then put on ice for 5 min, before being vortexed and spun for a final time.  
50!g of protein/well diluted in 2x sample buffer was loaded, as calculated from the 
protein assay.  The gel was run at a constant current of 40mA for around 1 h 
2.8.4.3 Blotting Transfer 
3 pieces of filter paper and 1 piece of Hybond-ECL polyvinyl difluoride (PVDF, Amersham, 
RPN1416LFP) were cut to gel size.  The transfer blotting solution was made up and the 
fibre pads soaked in it, after washing them thoroughly in ddH2O.  The membrane was 
washed with methanol, rinsed 2 times with ddH2O and finally soaked in transfer buffer.  
The gel plates were removed from the holder and separated.  The resolving gel was cut 
away with a scalpel and the staking gel placed onto 1 piece of filter paper (already 
soaked in transfer buffer) lying on top of one fibre pad and the black side of the blotting 
cassette.  The membrane was carefully placed on top of the gel, making sure there were 
no bubbles underneath.  The remaining 2 pieces of filter paper were soaked and placed 
on top of the membrane.  Any air bubbles were removed by rolling a falcon tube over the 
top before placing the final fibre pad on top.  The cassette was closed and placed into the 
blotting tank, with the clear side of the cassette facing the red side of the holder in the 
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tank.  Tank was filled with 1x blotting transfer buffer (pre-cooled) and an ice pack and 
run at 100V for 1 h or 20V overnight (at 4°C). 
2.8.4.4 Immuno-detection 
The membrane was removed from the cassette minimised in size with a scalpel.  Non-
specific binding was blocked by immersing in 5% milk solution (made up in 0.5%PBS-
tween) for 1 h (or overnight at 4°C).  The membrane was then incubated with the 
primary antibody diluted in PBS-tween with a 2% milk solution for 1 h at RT (or 
overnight at 4°C).  This was then washed 3 x 5 mins in PBS-tween before being 
incubated with the secondary antibody diluted in PBS-tween with a 2% milk solution for 
1 h at RT (or overnight at 4°C).  The membrane was washed 3 x 5 mins in PBS-tween. 
 
1ml solution A was mixed with 25!l solution B (chemiluminescence reagents, Amersham, 
Biosciences, RPN2109).  The membrane was dried and placed onto a clear sheet with the 
solution on top, and a second piece of clear sheet on top.  This was left for 5 min, excess 
liquid drained off, the membrane sealed in a plastic wrap and developed using the gel 
doc software on the computer.  Densitometry was used to quantify the bands using a 
house-keeping gene such as !-tubulin.  
2.8.4.5 Stripping membranes 
The membrane may be stripped of bound antibodies and re-probed several times.  The 
membrane was submerged in stripping buffer (Pierce, 46430) and incubated for 30 min 
at 50°C.  Then wash 3 x 20 min at RT.  
2.8.4.6 Coomassie staining 
This stain was used to determine visually if the amount of protein loaded in each lane 
was equal.  Membrane was immersed in the stain for 2 min with agitation.  Excess liquid 
was poured off and rinsed with destain solution 3 times.  On the final wash with destain, 
the membrane was microwaved for 1 min. 
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2.8.4.7 Ponceau stain 
This is a reversible stain to determine whether the protein transfer has taken place.  The 
ponceau stain was added to the membrane and it agitated for 2 min.  It was destained 
with tap water. 
2.9 Cell and Tissue culture 
Cell culture was necessary in order to obtain enough PC12 cells (rat adrenal medulla 
pheochromocytoma cells) for use as a positive control in western blots.  
2.9.1 Cell culture 
50ml of fetal bovine serum (FBS Invitrogen-Gibco, 10091-130) was added to DMEM.  5ml 
of L-Glutamine (Invitrogen-Gibco, 25030164) and 5ml penicillin (Invitrogen-
Gibco,15140163) was added to this and it was mixed well.  Cells were thawed by 
immersion in a water bath.  They were added to 50ml of DMEM-Hi media (Invitrogen-
Gibco, 21063045) and spun for 5 mins at 110g.  The cells were subsequently transferred 
into a flask and into the incubator. 
2.9.2 Tissue Culture 
The DMEM was poured out of the petri dish and wash 2x with 1xPBS  (Sigma Aldrich).  
The petri dish was tilted onto one side to drain the remaining liquid, and any excess was 
removed with a pipette. 150!l buffer (SDS/urea) was added and a spreader used to 
distribute it around the dish.  This was then transferred to an Eppendorf and vortexed for 
30 secs to break the stickiness.  The solution was spun for 1 min to dissipate the foam 
then heated at 95°C for 5 min.  Finally, it was vortexed hard for 1 min and spun for a 
further 5 min. 
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2.10 Statistical Analyses  
Statistics are described in text and associated legends.  Statistics used in this thesis 
include ANOVA and Fishers or Dunnetts post hoc test, where appropriate, paired t-test, 
and the Mann Whitney U-test. 
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Chapter 3 
SYSTEMIC HYPOXIA
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3.1 Introduction 
A low PO2 in the air caused by ascent to high altitude, or impaired O2 uptake due to the 
presence of disease causes hypoxaemia in humans (or low O2 delivery to tissues and 
cells).  One of the primary responses to low blood PO2 occurs at the chemoreceptors 
which stimulate an increase in breathing, and this is closely followed by an increase in CO 
from the heart, an obligate aerobic organ.  The pulmonary artery vasoconstricts, 
increasing O2 delivery to well-ventilated areas of the lungs and inducing right ventricle 
hypertrophy.  Peripheral parts of the body undergo systemic vasodilatation, mediated in 
part by adenosine.  A similar qualitative response is assumed to occur in mice, although 
details may vary, for example scale-dependent changes will exist, influencing the 
diffusion distance for O2, among others.  
 Of the three described mechanisms of angiogenic growth, splitting angiogenesis is 
thought to be important in hypoxia-mediated capillary growth.  It has been postulated 
that the increase in the haematocrit (polycythaemia) could increase shear stress, 
initiating angiogenesis via the luminal side of the vessel (Deveci et al. 2002).   
 On a molecular level, HIF regulates the expression of 70 known genes on a 
transcriptional level (Semeza, 2004) (CHPT 1 Fig 1.1), which are responsible for aiding 
adaptation to the lowered availability of O2.  Although there is evidence for hypoxic 
induction of HIF-! mRNA levels in some cell types (Wang et al. 1995b), the predominant 
modes of HIF-! regulation occur post-translationally (Stolze et al. 2006).  Under hypoxic 
conditions, the hydroxylation of HIF is inhibited by prolyl hydroxylases (PHD) 1-3 and 
factor-inhibiting HIF (FIH), allowing the ! and " subunits of the protein to form a 
heterodimer which then translocates to the nucleus.  Here it activates downstream genes 
by binding to the hypoxia response element (HRE) located within their promoter region.  
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It has been shown that PHD2 is the key O2 sensor under hypoxic conditions (Berchner-
Pfannschmidt et al. 2008) and is the most abundant PHD in the cell cytoplasm during 
normoxia.  Qutub et al. (2007) proposed that three autocrine feedback loops determine 
intracellular HIF-1! levels under chronic hypoxia: PHD2, succinate (a product of HIF-1! 
hydroxylation by PHD2) and HIF-1! feedback, ultimately resulting in a reduction of HIF-
1! availability after a period of hours, allowing the system to adapt to the hypoxia (Fig 
3.1). 
 
 
 
 
 
 
 
 
       Adapted from Qutub et al. (2007) 
 
Figure 3.1 Three autocrine loops determine HIF-1! expression in chronic hypoxia 
 
 
A multitude of genes regulated by HIF are involved in both in the general adaptation to 
hypoxia, and the initiation of angiogenesis (described in CHPT 1.2.2).   Many of these 
HIF-regulated genes exhibit inter-dependent relationships that are enhanced under 
normoxic and hypoxic conditions (Fig. 3.2).  Taken together, these genes provide a 
representation of activation of pathways involved in angiogenesis, and adaptation to 
systemic hypoxia. 
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Figure 3.2 Representation of a selection of factors upregulated by HIF under hypoxia 
 
 
Experiments were conducted to determine whether a hypoxic stimulus of either 10% or 
12% O2 was sufficient to induce an angiogenic response in the hindlimb, heart and 
diaphragm of the C57Bl6/J mouse, and whether chemical manipulation of the availability 
of HIF-1! using DMOG would enhance the expected angiogenic repsonse.  DMOG is a cell 
penetrant oxoglutarate analogue which inhibits PHD 1–3 and factor inhibiting HIF (FIH), 
thereby increasing cellular levels of HIF protein.  In response to local hypoxia 
(ischaemia), HIF-signalling may be enhanced by preventing its in situ degradation, using 
DMOG (Milkiewicz et al. 2004).  Thus, we investigated whether a similar mechanism 
operates when the proximate stimulus is systemic hypoxaemia.  Furthermore, the HIF-
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regulated gene response to systemic hypoxia was studied along a time course to 
determine whether a common response was elicited in a variety of tissues, and 
furthermore to establish whether circulating leukocytes could be used as a minimally 
invasive marker of cellular hypoxia for use in a study of systemic hypoxia in humans 
(CHPT 7).  
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3.2 Methods 
The dose of DMOG used in this study (also in CHPT 4 and 5) was based upon previous 
literature that had studied DMOG in vivo (Milkiewicz et al. 2004), and in vitro (Jaakkola 
et al. 2001).  DMOG has been reported to stabilise HIF-1! at concentrations of >500 !M 
(Zhou et al. 2006), but dose-toxicity curves show that concentrations >1000!M caused  
disintegration of lung explants (Groenman et al. 2007).  
3.2.1 Study design: 10%/12% normobaric hypoxia  
Experiments were performed on groups of C57Bl6/J mice (n=12 in each experimental 
group), exposed to 12% normobaric hypoxia (a standard stimulus used widely in the 
literature, e.g. Mian and Marshall, 1996) with CO2 scrubbing (carbon sequestration).  Half 
of each group received DMOG (8mg.0.5mL-1 saline) (CHPT 2.1) via i.p. injection every 
other day, with the initial injection 2 days before exposure to hypoxia for 7, 14 and 28 d 
at 12% O2 (5% CO2 and 95% N2).  At the end of each experimental period, the mice were 
sacrificed via cervical dislocation, their body mass determined, and tissue samples taken: 
the heart was removed and total mass obtained.  The atria were dissected and the right 
ventricle carefully isolated and weighed.  The diaphragm was removed, along with the 
EDL and SOL muscles from the hindlimb.  The tissue was stored in different ways for 
subsequent analysis (CHPT 2.3).  The study was subsequently repeated at 10% O2 for 14 
d (initiated at 12%, then gradually reduced to 10% by the third day).   
3.2.1.1 Tissue processing 
Tissues were taken (CHPT 2.2) and stored at -80°C after being snap-frozen on corks in 
isopentane cooled in liquid nitrogen (CHPT 2.3), or directly snap-frozen in Eppendorf 
tubes in liquid nitrogen.  Tissue was sectioned and stained (CHPT 2.3) and capillary and 
fibre numbers (C:F) counted as described in CHPT 2.4, using lectin staining.  The number 
of capillaries actively undergoing angiogenesis was estimated using the lectin/VEGF/DAPI 
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triple stain (CHPT 2.4.2) in the diaphragm, soleus and EDL.  Western blots were used as 
a semi-quantitative method of examining changing protein levels within the heart and 
EDL muscles.   
3.2.1.2 Western blotting  
This method was used to study the presence of HIF-2! and PHD2 in the heart and 
skeletal muscle of mice under differing hypoxic conditions.  Attempts to study HIF-1!, 
PHD1 and PHD3 were unsuccessful, possibly due to technical difficulties associated with 
cross-species antibody reactivity.  Two methods of protein extraction were attempted: 
total protein and nuclear extraction methods.  Similar yields were produced, and the total 
protein extraction method chosen as it was less labour intensive.  Methods are described 
in CHPT 2.8. 
 HIF-2! was detected using an in-house antibody (Oxford), PM-9.  100!g of protein 
was run on a thick (1.5mm) 6% gel and the membrane probed with a polyclonal primary 
antibody concentration of 1:1000 and a secondary antibody concentration of 1:2000.  
PHD2 was detected using an in-house polyclonal primary antibody (Oxford) at a 
concentration of 1:3000 and the secondary antibody at a concentration of 1:2000 (Rabbit 
Igs HRP, Dakocytomation, P0399).  50!g of protein was loaded onto a 10% gel.  The 
PHD2 membrane was stripped and re-probed with monoclonal "-tubulin (primary 
antibody concentration 1:2000, secondary 1:2000) so that levels of protein could be 
normalised using densitometry.  
 
3.2.2 Study design: 10% hypoxia  
Experiments were performed on groups of C57Bl6/J mice (n=6 in each experimental 
group).  Groups were exposed to 10% hypoxia for 3, 6 12, 24, 72 h and 1 week.  At the 
end of the designated period, the mice were anaesthetised with 10mL.kg-1 
ketamine/xylazine (ketamine: 0.1mg.kg-1, xylazine: 0.01mg.kg-1) and a blood sample 
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taken via the inferior vena cava (~0.8mL) to obtain a plasma sample and leukocytes for 
RNA extraction (CHPT 2.5).  Mice were then sacrificed via cervical dislocation and tissue 
samples taken. The heart, liver, kidney, bone marrow, EDL and soleus were all removed 
and snap frozen in liquid nitrogen before being stored at -80°C.  
3.2.2.1 Blood and tissue collection and processing 
Blood was collected in a heparinised 1mL syringe.  A mid-line incision was made and the 
intestines and liver retracted with forceps.  The needle was bent at a right angle and 
inserted in an orientation parallel to the vein.  Blood was spun for 20 min at 2700g and 
the plasma removed, aliquoted and snap-frozen in liquid nitrogen.  It was analysed using 
an ELISA for mouse EPO (MEP00, R&D Systems).  The pellet was resuspended in 0.16M 
NH4Cl (cell lysis solution) and left for 10 min.  This was spun for 5 min at 2700g, the 
supernatant removed and 1.5mL of sterile 1X PBS (see CHPT 2 for more details) added.  
The solution was resuspended with a pipette to dissolve then re-spun for 5 min at 2700g.  
This step was repeated, followed by a final 5 min spin at 2700g.  The supernatant was 
removed and the leukocyte pellet frozen in liquid nitrogen.  All organs were washed with 
PBS before being snap frozen in liquid nitrogen.  Samples were stored at -80°C.    
For extraction of the bone marrow, the mouse was splayed on a platform and 
fixed with needles, and the skin removed from both legs to expose the leg bones (femur, 
tibia and fibula) and muscle.  Each leg was pulled at an angle to dislocate the hip from 
the pelvis.  Bones were separated and the foot removed at the ankle joint.  Incisions 
were made at the top and bottom of each bone, after removing any remaining bone and 
tissue, to expose the red bone marrow.  Approximately 2 mL magnesium-free PBS was 
flushed through the bore of each bone and collected into a 15mL Falcon tube until bones 
appeared white in colour.  The solution was aspirated with a 25 gauge needle and left for 
5 min until debris settled.  The solution was spun at 200g for 5 min (Hettich Zentrifugen 
EBA 12R), the supernatant removed and the pellet snap-frozen in liquid nitrogen.  
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3.2.2.2 RNA extraction and RT-PCR 
RNA was extracted using the Qiagen RNeasy kit (CHPT 2.5) and gene expression studied 
using RT-PCR (CHPT 2.6).  The following genes were studied, using TaqMan Gene 
Expression Assays (Applied Biosystems): HIF-1! (Mm00468869_m1), EPO 
(Mm00433126_m1), VEGF-A (Mm00437304_m1), Flk-1 (Mm00440099_m1), Flt-1 
(Mm01210866_m1), CAIX (Mm00519870_m1), HMOX-1 (Mm00516004_m1), iNOS 
(Mm00440485_m1), TGF-" (Mm03024053_m1) and Ald-A (Mm00833172_g1).  
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3.3 Results 
3.3.1 The effect of systemic hypoxia at 10% and 12% for 
1, 2 and 4 weeks 
3.3.1.1 Body mass changes 
A significant 4-5% decrease in body mass was observed over the first 2 days in mice 
exposed to 12% hypoxia for 1, 2 and 4 wks (Fig. 3.3).  After this time, the mass steadily 
increased to above the starting value by the end of the experimental period as mice 
regained their appetite and started to consume fluid again.  Mice exposed to 10% 
hypoxia also experienced a significant decrease in body mass over 5 d, with those not 
receiving DMOG showing a more pronounced and significant loss compared to those 
receiving DMOG (Appendix A.1.2).  After this time period, both groups increased mass 
steadily and by day 7 were back to around initial body mass.  The mean starting weight 
± SEM was 26.1 ± 0.262g.  Refer to A.1.1 for mean mass ± SEM at 12% and A.1.2 for 
mean mass ± SEM at 10%.  Statistical analyses were performed by ANOVA and Fishers 
post-hoc test was used. 
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Figure 3.3 Change in body mass over time at 12% hypoxia (n=6-12 per group, *= P<0.05, 0 d vs 
days after hypoxic stimulus) 
 
 
 
3.3.1.2 Effects of hypoxia on cardiac tissue and diaphragm 
The relative total heart mass was significantly increased in all animals exposed to 10% 
and 12% hypoxia at 2 wks compared to control values (Table 3.1).  By 4 wks, the body 
mass had increased beyond starting point so the effect of cardiac hypertrophy was no 
longer evident.  See Appendix A.1.3 for right ventricle mass. 
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Experiment 
 
Body mass (g) 
 
MH   (g) 
 
RMH   (%) 
 
Control            (n=6) 
 
26.0 ± 2.10 0.112 ± 0.006 0.43 ± 0.01 
 
Control D         (n=6) 
 
25.9 ± 1.01 0.115 ± 0.005 0.40 ± 0.01 
 
1 wk D12                 (n=6) 
 
25.1 ± 0.17 0.123 ± 0.003 0.48 ± 0.03 
 
1 wk no D12          (n=6) 
 
25.9 ± 0.34 0.123 ± 0.002 0.50 ± 0.01 
 
2 wk D10               (n=12) 
 
24.2 ± 0.24 0.144 ± 0.004 § 0.59 ± 0.02 § 
 
2 wk D12               (n=12) 
 
24.7 ± 0.37 0.141 ± 0.010 § 
 
0.54 ± 0.03 § 
 
2 wk no D10     (n=12) 
 
26.0 ± 0.52 
 
0.134 ± 0.004 § 
 
0.54 ± 0.02 § 
 
2 wk no D12      (n=12) 
 
27.3 ± 0.61 0.156 ± 0.009 § 0.61 ± 0.03 § 
 
4 wk D12                 (n=6) 
 
26.0 ± 0.52 
 
0.122 ± 0.003 0.44 ± 0.01 
 
4 wk no D12          (n=6) 
 
27.3 ± 0.61 0.100 ± 0.003 
 
0.37 ± 0.02 
Abbreviations: D10   = DMOG + 10% hypoxia, D12   = DMOG + 12% hypoxia, no D10  = hypoxia 
10%, no D12  = hypoxia 12%, MH  = total heart weight, RMH  = relative heart weight, § = P<0.05 
vs. control using ANOVA statistical analyses with Dunnetts post-hoc test. Mean ± standard error 
the mean (SEM), ‘n’ as stated in Table. 
 
Table 3.1. Heart mass (g) and relative heart mass for experimental groups under hypoxia 
 
 
There was no significant change in the capillary density (CD) in any region of the heart at 
12% hypoxia (Table 3.2), though a significant increase in CD was found in the 
subepicardium and right ventricle in the hearts of mice exposed to 10% hypoxia (Fig 
3.4). 
 
 
 
Figure 3.4 Illustration of lectin immunohistochemical staining in the subepicardium of the heart 
capillary 
50!m 
myocyte 
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Experiment 
 
Subendocardium 
 
Subepicardium 
 
Right ventricle  
Control            (n=6) 
 
2477 ± 90 
 
2274 ± 143 
 
2099 ± 132 
 
Control D         (n=6) 
 
2564 ± 120 
 
2321 ± 116 
 
2085 ± 109 
 
1 wk D12                 (n=6) 
 
2498 ± 75 
 
2812 ± 132 
 
2168 ± 121 
 
1 wk no D12          (n=6) 
 
2568 ± 123 
 
2956 ± 124 
 
2298 ± 143 
2 wk D10               (n=12) 
 
2796 ± 125 
 
3201 ± 107 § 
 
2783 ± 52 § 
2 wk D12               (n=12) 
 
2470 ± 299 
 
2521 ± 318 
 
2489 ± 255 
2 wk no D10     (n=12) 
 
3104 ± 271 
 
3113 ± 178 § 
 
2819 ± 76 § 
2 wk no D12     (n=12) 
 
2677 ± 324        
 
2503 ± 685 
 
2489 ± 674 
 
4 wk D12                (n=6) 
 
2766 ± 152 
 
2612 ± 211 
 
2451 ± 98 
 
4 wk no D12         (n=6) 
 
2745 ± 124 
 
2549 ± 157 
 
2844 ± 129 
Abbreviations: D10   = DMOG + 10% hypoxia, D12   = DMOG + 12% hypoxia, no D10  = hypoxia 
10%, no D12  = hypoxia 12%, § = P<0.05 vs. control.  Mean ± S.E.M, ‘n’ as stated in Table  
 
Table 3.2. Capillary density (cap.mm-2) for heart in control and hypoxic animals ± DMOG at 10% 
and 12% hypoxia  
 
 
There was a significant increase in the capillary to fibre ratio (C:F) of the diaphragm in 
mice exposed to 10% hypoxia compared to control animals, though not in those exposed 
to 12% (Table 3.3).  There was also a significant rise in the capillary density (CD) of mice 
at 10% hypoxia with DMOG compared to those at 10% without DMOG. 
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Experiment 
 
C:F 
 
CD  (cap.mm-2) 
 
MFA (!m2) 
 
Control          (n=6) 
 
1.37 ± 0.06 
 
1807 ± 190 
 
775 ± 65 
 
Control D      (n=6) 
 
1.36 ± 0.05 
 
1856 ± 141 
 
874 ± 58 
 
2 wk no D10      (n=6) 
 
1.41 ± 0.06  § 
 
1591 ± 87 
 
901 ± 67 
 
2 wk D10             (n=6) 
 
1.66 ± 0.052 § 
 
2158 ± 123 * 
 
808 ± 62 
 
2 wk no D12     (n=12) 
 
1.49 ± 0.08 
 
1772 ± 87 
 
848 ± 41 
 
2 wk D12            (n=12)  
 
1.42 ±0.03  
 
1704 ± 103 
 
854 ± 76 
Abbreviations: D10   = DMOG + 10% hypoxia, D12   = DMOG + 12% hypoxia, no D10  = hypoxia 
10%, no D12  = hypoxia 12%, § = P<0.05 vs. control.  * = P<0.05 D10 vs. no D10.  Mean ± S.E.M.  
CD = capillary density, C:F = capillary to fibre ratio, MFA = mean fibre area, ‘n’ as stated in table. 
 
Table 3.3. C:F and CD for control and hypoxic diaphragm ± DMOG at 10% and 12% hypoxia (2 
wks)  
 
3.3.1.3 Effects of hypoxia on hindlimb skeletal muscles   
3.3.1.3.1 Lectin staining for changes in C:F, CD and MFA 
There were no significant changes in the C:F (Fig. 3.5) of the extensor digitorum longus 
(EDL) in any of the experimental groups (Table 3.4).  With the control EDL mass at 9.1 ± 
0.4mg, the largest significant increase in EDL mass was seen in mice at 10% hypoxia 
without DMOG for 2 weeks. 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Lectin staining in the EDL muscle 
 
capillary 
fibre 
50!m 
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Experiment C:F  CD (cap.mm-2) MFA (!m2) RMEDL (%) 
 
 
Control  
(n=6) 
 
1.26 ± 0.02 
 
885 ± 67  
 
1521 ±102 
 
0.03 ± 0.002 
 
Control DMOG 
(n=6) 
 
1.19 ± 0.01 
 
937 ± 118 
 
1063 ± 86 
 
0.03 ± 0.003 
 
1 wk no D12     
(n=6) 
 
1.29 ± 0.07 
 
833 ± 32 
 
1755 ± 59 
 
0.03 ± 0.009 
 
1 wk D12            
(n=6) 
 
1.29 ± 0.05 
 
803 ± 68 
 
1678 ± 150 
 
0.04 ± 0.001 
 
2 wk no D10      
(n=12) 
 
1.29 ± 0.04 
 
1055 ± 74 
 
1266 ± 111 
 
0.08 ± 0.003§ 
 
2 wk D10            
(n=12) 
 
1.29 ± 0.04 
 
1157 ± 113 
 
1154 ± 77 
 
0.04 ± 0.005 
 
2 wk no D12     
(n=12) 
 
1.35 ± 0.03 
 
834 ± 40 
 
1629 ± 56 
 
0.04 ± 0.001 
 
2 wk D12            
(n=12)  
 
1.37 ± 0.03 
 
889 ± 39 
 
1628 ± 92 
 
0.04 ± 0.008 
 
4 wk no D12     
(n=6) 
 
1.27 ± 0.01 
 
821 ± 52 
 
1510 ± 74 
 
0.04 ± 0.004 
 
4 wk D12            
(n=6) 
 
1.21 ± 0.04 
 
887 ± 71 
 
1462 ± 93 
 
0.04 ± 0.002 
Abbreviations: D10   = DMOG hypoxia 10%, D12   = DMOG hypoxia 12%, no D10  = hypoxia 10%, no 
D12  = hypoxia 12%, Mean ± S.E.M.  CD = capillary density, C:F = capillary to fibre ratio, MFA = 
mean fibre area, mean ± SEM, § = P<0.05 as determined by ANOVA with Dunnetts post-hoc test, 
‘n’ as stated in table 
 
 
Table 3.4 Capillarity (C:F, CD), mean fibre area (MFA), relative EDL and body mass for all 
experimental groups subjected to systemic hypoxia  
 
 
A significant increase in C:F values was observed in the soleus muscle for mice exposed 
to 10% hypoxia with DMOG when compared to control values (Table 3.5).  There was a 
significant 1.3 fold increase in MFA when compared with control, in the soleus at 12% 
hypoxia.  
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Experiment C:F  
 
CD (mm-2) MFA  (!m2) 
 
 
Control          (n=10) 
 
1.52 ± 0.06 
 
1229 ± 87 
 
1272 ± 123 
 
2 wk no D10     (n=6) 
 
1.56 ± 0.05 
 
1098 ± 96 
 
1378 ± 95 
 
2 wk D10             (n=6) 
 
1.72 ± 0.10§  
 
1475 ± 69 
 
1180 ± 34 
 
2 wk no D12     (n=12) 
 
1.41 ± 0.07 
 
984 ± 61 § 
 
1452 ± 71 
 
2 wk D12            (n=12)  
 
1.49 ± 0.08 
 
916 ± 31 § 
 
1660 ± 104 § 
Abbreviations: D10   = DMOG hypoxia 10%, D12   = DMOG hypoxia 12%, no D10  = hypoxia 10%, no 
D12  = hypoxia 12%,  § = P<0.05 vs. control.  Mean ± S.E.M.  CD = capillary density, C:F = 
capillary to fibre ratio, MFA = mean fibre area, mean ± SEM 
 
Table 3.5. Capillarity and mean fibre area for soleus under 10% and 12% hypoxia ± DMOG (2 wk)  
 
3.3.1.3.2 VEGF staining 
 
Table 3.6 illustrates a 13% increase in VEGF stained capillaries in the diaphragm after 
exposure to 10% hypoxia for 2 wks, alongside a 45% increase in the EDL and a 21% 
increase in the soleus. All of these were significant, determined using a paired t-test.  
Fig. 3.6 illustrates immunohistochemical staining: the red stain of the VEGF is difficult to 
see when combined with lectin and DAPI so is shown alone here.  VEGF ‘hotspots’, 
identified as those stained significantly brighter than others, can clearly be seen. 
However, multi-acquisitional processing with the microscope enables efficient counting of 
capillaries with multiple staining. 
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Tissue VEGF/LECTIN  
 
DAPI/lectin 
Control diaphragm 0.38 ± 0.02 1.02 ± 0.05 
Diaphragm 10% hypoxia 0.43 ± 0.08§ 1.10 ± 0.03§ 
Control EDL 0.25 ± 0.07 1.16 ± 0.03 
EDL 10% hypoxia 0.38 ± 0.02§ 1.09 ± 0.08§ 
Control soleus 0.34 ± 0.01 1.13 ± 0.03 
Soleus 10% hypoxia 0.41 ± 0.02§  1.08 ± 0.07§ 
 
Table 3.6 Ratios for VEGF/lectin and DAPI/lectin staining in control diaphragm, EDL and soleus and 
at 10% hypoxia (mean of n = 4 ±SEM) § P<0.05, contol vs. 10% hypoxia as determined using a 
paired t-test. 
 
                 (a)                 (b) 
  
Figure 3.6 (a) Ilustration of the VEGF, and (b) DAPI and lectin immunohistochemical stain.  The 
yellow arrow on (a) marks a VEGF positive capillary, a ‘hotspot’, as defined in the text above.  
Lectin staining for the presence of a capillary is shown in (b) with a green fluorescence, and DAPI 
stains blue 
 
3.3.1.4 Changes at the protein level 
It has been documented that the level of HIF protein decreases fairly rapidly following an 
upregulation by hypoxia (Stroka et al. 2001).  Problems faced when trying to study the 
levels of HIF-1! and HIF-2! initiated a study designed to test whether detection of these 
proteins at 2 wks of hypoxia might not be possible.  Mice were put in the hypoxic 
50!m 
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chamber at 6% O2 to elicit a maximal response, and tissue samples were taken from the 
heart and EDL after 1 and 6 h.  Despite numerous attempts, using different primary 
antibodies, loading different amounts of protein onto the gel and using a different sized 
gel, detection of HIF-1! was not possible.  However, HIF-2! protein, with 48% sequence 
homology to HIF-1!, was clearly visible both in normoxic and hypoxic heart tissue (Fig. 
3.7).  
 
 
 
Figure 3.7  Western blot of HIF-2!.  Lane 1: positive control (PC12 rat liver cells), lane 2: normoxic 
heart tissue, lane 3: heart tissue after 1 hour at 6% hypoxia, lane 4: heart tissue after 6 h at 6% 
hypoxia 
 
An increase of 40% from control values in HIF-2! protein occurs following 1 h at 6% 
hypoxia, as determined by densitometry, subsequently decreasing by 15% after 6 h.  
This suggests that detection of the protein at 2 wks may not be possible due to the 
extremely low levels present, explaining why detection in any of the above mentioned 
experiments was not possible.  PHD2 however, was shown to be present in the heart, 
EDL and soleus (Fig. 3.8).   
 
 
 
 
 
 
 
Figure 3.8  Western analysis of PHD2 in the hindlimb after 2 wks at 10% hypoxia using the gel 
imaging machine (UVP"), showing protein bands. Lane 1 is WT heart, lane 2  was control EDL, lane 
3 EDL at 6% hypoxia after 1 hour, lane 4 EDL at 6% hypoxia after 6 h, lane 5 EDL at 10% hypoxia 
with no DMOG 2 wks, lane 6 EDL 10% hypoxia with DMOG 2 wks, lane 7 soleus control, lane 8 
soleus 10% hypoxia with DMOG, lane 9 soleus 10% hypoxia. 
 
 
Densitometry analysis (using #-tubulin as the reference protein) for the EDL from 3 mice 
(run twice on separate gels) was carried out using ImageJ (image analysis programme).  
The mean intensity of the protein band was measured and revealed the following fold 
105kDa 
        L1     L2    L3     L4 
   1       2        3       4       5       6       7       8       9 
46kDa 
#-tubulin 
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increases in PHD2 protein levels when compared to the control EDL, all values normalised 
to !-tubulin: EDL at 6% hypoxia, 1 h: 2x (mean±SEM, intensity of band = 105±3.4 
compared control at 52.66±2.4), 6 h: 1.5x (mean intensity of 79.1±3.2), EDL at 10% 
hypoxia, 2 wks no DMOG: 2.3x (mean intensity of 122±4.9), EDL at 10% hypoxia, 2 wks 
DMOG: 0.57x (30.1±1.4).  All of the changes under hypoxia for 1 and 6 h were 
significant when determined with ANOVA. Analysis of the soleus revealed a under 10% 
hypoxia with DMOG showed a slight decrease in expression of 0.7x, though a 2.6-fold 
increase (mean intensity of 215.2±4.9 when compared to control value of 82.8±5.2) 
when hypoxia alone was used, compared to control tissue, significantly increased when 
determined with ANOVA. 
3.3.2 The effect of systemic hypoxia at 10% on gene 
expression and plasma EPO. 
3.3.2.1 Changes in tissue specific mRNA expression under 10% hypoxia 
The mRNA expression of 10 different genes was studied along 7 different time points: 0, 
3, 6, 12, 24, 72 h and 1 wk (Fig. 3.9 - 3.18).  Average CT illustrating gene expression is 
expressed along the y axis and time is in h along the x axis.  Curves have been fitted by 
eye.  *=P<0.05 when compared to control animals at time point 1, determined by Mann-
Whitney U-tests.   
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Figure 3.9 Average CT values showing HIF1! gene expression following QRT-PCR of  mouse tissue 
from the liver, kidney, heart, bone marrow, EDL, soleus, and leukocytes after 0, 3, 6, 12, 24, 72 h 
and 1wk at 12% hypoxia  
Liver
 
 
 
 
  
Kidney 
Heart Bone marrow 
Soleus EDL 
leukocytes 
* 
* 
*     *    * 
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Figure 3.7 Average CT values obtained from the study of EPO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Average CT values showing EPO gene expression following QRT-PCR of mouse tissue 
from the liver, kidney, heart, bone marrow, EDL, soleus, and leukocytes after 0, 3, 6, 12, 24, 72 h 
and 1wk at 12% hypoxia (n=3) 
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Liver 
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Figure 3.11 Average CT values showing VEGF gene expression following QRT-PCR of mouse tissue 
from the liver, kidney, heart, bone marrow, EDL, soleus, and leukocytes after 0, 3, 6, 12, 24, 72 h 
and 1wk at 12% hypoxia (n=3) 
Bone 
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Kidney Liver 
Heart 
Leukocytes 
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Figure 3.12 Average CT values showing Flk-1 gene expression following QRT-PCR of  mouse tissue 
from the liver, kidney, heart, bone marrow, EDL, soleus, and leukocytes after 0, 3, 6, 12, 24, 72 h 
and 1wk at 12% hypoxia (n=3) 
Bone Marrow 
 Heart 
Kidney 
Liver 
EDL Soleus 
Leukocytes 
* 
*     *    * 
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Figure 3.13 Average CT values showing iNOS gene expression following QRT-PCR of mouse 
tissue from the liver, kidney, heart, bone marrow, EDL, soleus, and leukocytes after 0, 3, 6, 
12, 24, 72 h and 1wk at 12% hypoxia (n=3) 
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Figure 3.14 Average CT values showing aldolase-A gene expression following QRT-PCR of mouse 
tissue from the liver, kidney, heart, bone marrow, EDL, soleus, and leukocytes after 0, 3, 6, 12, 
24, 72 h and 1wk at 12% hypoxia (n=3) 
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Figure 3.15 Average CT values showing CAIX gene expression following QRT-PCR of mouse 
tissue from the liver, kidney, heart, bone marrow, EDL, soleus, and leukocytes after 0, 3, 6, 
12, 24, 72 h and 1wk at 12% hypoxia (n=3) 
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Figure 3.16 Average CT values showing HMOX gene expression following QRT-PCR of  
mouse tissue from the liver, kidney, heart, bone marrow, EDL, soleus, and leukocytes 
after 0, 3, 6, 12, 24, 72 h and 1wk at 12% hypoxia (n=3) 
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Figure 3.17 Average CT values showing TGF-! gene expression following QRT-PCR of mouse tissue 
from the liver, kidney, heart, bone marrow, EDL, soleus, and leukocytes after 0, 3, 6, 12, 24, 72 h 
and 1wk at 12% hypoxia (n=3) 
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Figure 3.18 Average CT values showing Flt-1 gene expression following QRT-PCR of mouse tissue 
from the liver, kidney, heart, bone marrow, EDL, soleus, and leukocytes after 0, 3, 6, 12, 24, 72 h 
and 1wk at 12% hypoxia (n=3) 
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3.3.2.2 General tissue responses to 10% systemic hypoxia 
Table 3.7 illustrates the overall tissue response to hypoxia for each gene studied, indicating whether there was a significant change 
in gene expression at any time point either in a negative or positive direction.  EPO and iNOS mRNA were the only two genes 
showing both positive and negative changes in all seven tissues. 
   
 
 
 
VEGF Flk-1 Flt-1 HIF EPO iNOS ALD-A CAIX HMOX-1 TGF-! 
Liver ! ! ! ! " " ! " " ! 
Kidney ! ! ! " " " ! " !  ! 
Heart ! ! ! ! " " ! " " ! 
Bone marrow " ! ! ! " " " " " ! 
EDL !  ! ! " " " ! !  !  ! 
Soleus " " " " " " ! " " ! 
Leukocytes " " !  !  " " " " !  ! 
 
 
Table 3.7 Summary of significant changes observed in gene expression with individual tissues (Mann-Whitney U-tests). " = significant changes 
observed, P<0.05, ! = no statistical significance  
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3.3.2.3 Tissue-specific mRNA responses 
3.3.2.3.1 HIF-1! 
No discernable changes were seen across the tissue, with the exception of the EDL where 
a significant increase from control values was seen at 1 wk only, and the soleus which 
showed a significant decrease in gene expression at 12 h, followed by a significant 
upregulation from 24 h to 1 week. 
3.3.2.3.2 EPO 
Different tissues showed differing basal levels of gene expression, though all responded 
to the hypoxic stimulus in either a positive or negative direction.  The liver, heart, soleus 
and leukocytes all exhibited a similar pattern, with an initial significant increase in gene 
expression, followed by a return to baseline values or below, by the 12 or 24 h time 
point.  However, the fold-changes seen in each tissue were noticeably different.  By 3 h, 
the liver had shown a 9.5-fold change, the heart a 13-fold change, the leukocytes an 
800-fold change and the soleus a 4000-fold change.  
The kidney had significantly raised EPO mRNA expression levels by 3 h, before 
showing a drop in expression to basal levels at 72 h.  The BM showed an initial significant 
decrease in gene expression until 72 h, and the EDL experienced a significant rise by 12 
h, followed by a decrease back to baseline values and then a greater than 100-fold 
change at 1 wk.  The transcription of EPO mRNA in the kidney mirrors the initial protein 
response seen in the plasma (Fig. 3.18), where the highest levels were seen at 3 h. 
3.3.2.3.3 VEGF 
Changes in gene expression remained unremarkable in all tissues with the exception of 
the BM where a significant decrease in gene expression was observed at 72 h, and the 
leukocytes which showed a significant decrease followed by return to baseline values by 
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12 h.  Basal levels in all tissues were within 100-fold of each other, with the exception of 
the leukocytes where expression levels were substantially lower. 
 
3.3.2.3.4 Flk-1 
No outstanding changes were seen other than a significant lowering of gene expression 
from 24 h onwards in leukocytes, and an initial decrease in expression in the soleus 
before return to baseline values.  Lack of changes in expression correlated with 
unchanging levels of VEGF mRNA. 
3.3.2.3.5 Flt-1  
Significant changes were seen in the soleus only, with an increase in gene expression at 
12 h.  In correlation with Flk-1, the soleus was the only tissue where changing levels are 
seen, albeit reciprocal.  
3.3.2.3.6 iNOS  
All tissues experienced significant changes in expression, demonstrated mostly by a 
decrease in expression followed by a significant increase.  A late response was common 
among all tissues, though with a wide range of basal values.  The EDL was the least 
responsive tissue, a characteristic also observed in a variety of other genes, with a late 
yet significant increase at 1 wk.   
3.3.2.3.7 ALD-A 
Unchanged expression levels were seen in all but the BM, which experienced a significant 
lowering of expression at 72 h, the soleus which showed an initial decrease in expression 
at 3 h followed by a return to baseline levels by 24 h and the leukocytes which showed 
significantly raised expression levels from 12 h on. 
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3.3.2.3.8 Carbonic Andydrase IX (CAIX) 
With the exception of the EDL, which experienced no change, gene expression was 
variable amongst tissues with the liver and heart showing a similar dip in expression at 
12 h, though absolute levels of expression differed, as seen with other genes.  
3.3.2.3.9 HMOX-1 
The liver, heart, and BM exhibited a similar pattern of expression, with an initial increase 
then a slight dip, followed by rising levels until the final time point.  The soleus showed a 
significant decrease at 6h followed by a significant increase at 24 h.  Changes in the 
remaining tissues were unremarkable.  
3.3.2.3.10 TGF-! 
No changes in gene expression were seen across any tissue at any time point. 
  
 
3.3.2.4 Plasma EPO expression under hypoxia 
Plasma EPO levels increased rapidly by 3 h, and fell thereafter (Fig. 3.19).  Protein levels 
at 3, 6, 12 and 24 h were all significantly raised compared to control values.  
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Figure 3.19 Plasma EPO levels as shown at control (0), 3, 6, 12, 24, 72 h and 1 wk at 10% O2. (* 
= P <0.005) as determined using ANOVA with Fishers post-hoc test. (n=3 per group) 
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3.4 Discussion 
This study was designed to determine whether a stimulus of 10% or 12% hypoxia was 
sufficient to induce angiogenic growth in the heart, diaphragm and hindlimb muscles of 
the C57Bl6/J mouse, and whether chemically manipulating the stability of HIF using 
DMOG could further enhance this response.  In response to local hypoxia (tissue 
ischaemia) it has previously been demonstrated that HIF-signalling may be enhanced by 
preventing its in situ degradation using DMOG (Milkiewicz et al. 2004).  This study 
therefore addressed the question of whether a similar pathway was operating under 
systemic hypoxaemia.  The study also aimed to determine the response of a range of 
HIF-regulated genes under systemic hypoxia, over a defined time course, and to 
determine whether circulating leukocytes could be used as a suitable indicator of gene 
expression under these conditions. 
3.4.1 Physiological effects 
3.4.1.1 Changes in body mass 
All animals showed an initial decrease in body mass (over the first 3 d at 12% and 5 d at 
10%) followed by an increase as they began to acclimatise to the hypoxic environment.  
Animals were studied whilst in the hypoxic chamber and shown to be extremely lethargic 
compared to normoxic animals, both in the light and the dark.  This hypokinetic state 
was probably in response to an inability to increase O2 supply sufficiently to match tissue 
O2 demand.  This rapid loss in body mass may have been due to dehydration and 
hypophagia because, as shown, body mass rapidly returned to starting point and beyond 
when the appetite had returned, on acclimatisation.  The subsequent increase in body 
mass from these time points reflects the initiation of chronic responses to sustained 
hypoxia to aid acclimatisation, such as the upregulation of genes controlled by HIF-1, for 
example EPO (increased RBC production), glucose-transporters GLUT1 and 3 (increasing 
glucose transport and therefore metabolism), and VEGF (angiogenesis).  
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3.4.1.2 Mechanical stretch effects in the heart and diaphragm 
3.4.1.2.1 Cardiac hypertrophy  
Hypoxia at both 10% and 12% O2 for 2 wks was an adequate stimulus to cause cardiac 
hypertrophy, a response enabling the heart to maintain a normal stroke volume despite 
an increased afterload (Morgan and Baker, 1991).  The pulmonary arteries are extremely 
sensitive to changing O2 levels and immediately contract on detection of a lowered O2 
(Julian, 2007).  In response to the increased resistance in the vessel, primarily the right 
ventricle, and to a lesser degree the left, undergo physiologic hypertrophy.  Pressure-
overload induced hypertrophy involves multiplication of the number of contractile muscle 
units resulting from an increased protein synthesis (Matsuo et al. 1998).  This results in 
an increased wall thickness and concentric hypertophy, athough the heart does not 
enlarge per se (Grossman et al. 1975).   
Volume-overload induced hypertrophy may also play a role: hypoxia causes an 
increase in the volume of circulating blood.  Splenic contraction is responsible for the 
initial rise in haematocrit, due to sympathetic stimulation as a response to low PO2 in the 
blood (Kuwahira et al. 1999).  In the longer term, this increased O2-carrying capacity is 
supplemented by erythropoietin (EPO) which is released from the kidney cells and causes 
an increase in the production of RBCs.  Klausen et al. (1991) found that that RBC counts 
had increased 4 days post-altitude.  The increased volume of blood not only increases 
the pressure-overload on the system, but volume-overload-induced hypertrophy also 
comes into play.  This results in repetition of sarcomeres in series, increasing mycoyte 
length and therefore chamber size, via eccentic hypertrophy (Grossman et al. 1975), 
resulting in enlargement of the whole heart (Fig. 3.20).  However, it is important to bear 
in mind that exposure to hypoxia generally also causes dehydration, reducing plasma 
volume (Bartsch and Saltin, 2008) and causing an increase in the viscocity and thus 
force required by the heart to pump blood.  It is therefore likely that a combination of 
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both pressure- and volume-overload hypertrophy have caused the observed enlargement 
of the heart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 Changes in cardiac gene expression occuring in response to chronic  mechanical 
overload (From Swynghedauw, 1989) 
 
 
3.4.1.2.2 Angiogenesis in the heart and diaphragm 
Cardiac angiogenesis has a critical involvement in the adaptive mechanism of cardiac 
hypertrophy (Sano et al. 2007).  The wide array of factors acting on the heart are likely 
to result in angiogenesis: mechanical stretch may be responsible for the angiogenesis 
seen in the right ventricle and the subepicardium, resulting in sprouting angiogenesis, 
and hyperaemia (initiated by hypoxia) results in an increase in tissue metabolites 
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followed by an increase in blood flow and vasodilatation, and this  may cause vessel 
splitting through an increase in shear stress.  
According to the LaPlace relationship, wall tension (T) is proportional to the product of 
intraventricular pressure (P) and ventricular radius (r), expressed by the following 
equation (Klabund, 2004). 
T ! P.r 
 
It can be extrapolated from this that the wall tension experienced by the subepicardium 
will be greater than that imposed on the subendocardium (as it is further away from the 
centre of the ventricle), and also as a result of the curvature of the ventricle (Fig. 3.21).  
Due to the increased wall tension experienced in the outer wall of the heart, a greater 
amount of stretch-induced angiogenesis could  be expected to occur in the 
subepicardium.  
 
  
Figure 3.21 Illustration of the increased distance to the subepicardium compared to the 
subendocardium from the centre of the ventricle, thus an increased wall tension 
(From Pocock and Richards, 2006) 
 
 
Subepicardium 
Subendocardium 
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The C:F of the diaphragm also increased significantly under 10% hypoxia.  The carotid 
body is sensitive to the partial pressure of O2 in the arterial blood (Gonzalez et al. 1992) 
and, on hypoxic stimulation, releases dopamine.  This enhances the action potential 
frequency in the sensory fibres of the carotid sinus nerve, resulting in an increase in the 
respiration rate and an increase in blood flow in the diaphragm (Mochizuki-Oda et al. 
1997).  In addition, the increased depth of breathing associated with exposure to hypoxia 
may be responsible for providing the mechanical stretch required to induce an increase in 
capillarity. 
3.4.1.2.3 Induction of HIF under hypoxic and non-hypoxic conditions 
There is growing evidence that the up-regulation of HIF-1 is not limited solely to hypoxic 
stress but can be induced by growth factors, cytokines, hormones and nitric oxide, along 
with mechanical factors (Richard et al. 2000).  Milkiewicz et al. (2007) showed that HIF-
1! mRNA level can be increased in non-hypoxic endothelial rat cells by mechanical 
stretch, confirming the in vivo data of Williams et al. (2006).  However, it is well known 
that HIF-1! is post-translationally regulated under hypoxia (Brahimi-Horn et al. 2005; 
Kaelin and Ratcliffe, 2008).  Kim et al. (2002) found that HIF-1 protein plays an 
important role in the induction of VEGF in non-ischaemic and mechanically stressed 
myocardium of the rat, being regulated by stretch-activated channels (Gd3+-sensitive 
stretch-activated cation channels).  Furthermore, Sano et al (2007) showed how 
pressure-overload, following severe transverse aorta constriction in the heart, promoted 
vascular growth by HIF-1-dependent induction of angiogenic factors.  HIF-1! was 
increased from day 3 and when using HIF-1! conditional knockout mice, caused a 
significant decrease in the angiogenic response and maladaptive hypertrophy during 
chronic pressure overload.  These data suggest that angiogenesis seen here may be due 
to stretch-induced HIF-regulated angiogenesis. 
 Whether hypoxia plays a role in the induction of angiogenesis seen in the heart is 
still to be determined.  As a result of cardiac hypertrophy, an increase in the diffusion 
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distance from capillaries to muscle fibres occurs, resulting in a reduced O2 supply within 
the myocardium (Sano et al. 2007) and thus a stimulus for the hypoxic induction of HIF.  
The effect of exercise on capillary growth in skeletal muscle has been well studied 
(Bigard et al. 1991; Abdelmalki et al. 1996).  The resulting tissue PO2 determined under 
conditions of physical activity in skeletal muscle (3-4mmHg, Wagner, 2001) provides 
strong evidence for the induction of HIF under hypoxia.  Whether the PO2 in active 
cardiac tissue reaches these low levels remains unknown.  Thus, a combination of both 
mechanical stretch and hypoxia may be responsible for initiating the upregulation of HIF 
under chronic systemic hypoxia, leading to the observed cardiac angiogenesis. 
3.4.1.3 Effects of hypoxia in the hindlimb 
3.4.1.3.1 Hypoxia failed to elicit significant angiogenesis 
Hypoxia at 10% or 12% failed to elicit any significant angiogenesis in the EDL with or 
without DMOG.  However, 10% hypoxia + DMOG was sufficient to increase C:F values in 
the soleus.  These findings are consistent with a number of studies that have failed to 
show an increase in capillarity with systemic hypoxaemia alone in phasic muscles such as 
the EDL, though have shown significant increases in the C:F in muscle with 
predominantly oxidative fibres such as the soleus.  However, there is much controversy 
associated with the latter finding.  A similar degree of hypoxaemia to that used here 
(12%) induced angiogenesis in the soleus muscle of the rat after 3 wks (Deveci et al. 
2001), although a longer exposure period of 6 wks induced regional capillarity in all 
skeletal muscles studied (Deveci et al. 2002).  Snyder et al. (1985) found no change in 
the C:F in the gastrocnemius and diaphragm muscles of rats exposed to hypoxia for 5 
wks, and similarly, Hoppeler et al. (1990) found no change in the C:F of human M. 
vastus lateralis in subjects exposed to >5000m (~11%) for 8 wks.  However, Olfert et al 
(2001) found that a stimulus of 12% O2 for 8 wks was sufficient to increase the C:F of 
the gastrocnemius muscle of the rat, the above studies illustrating the varying responses 
seen. 
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One of the main issues noted in a hypoxic environment is that the animals 
become fairly immobile with lethargy.  The EDL is composed of mixed fibre types and is a 
phasic muscle, thus only used when needed.  Thus, conditions rendering the animal 
hypoxic and lethargic may not be sufficient to induce a sufficient degree of oxidative 
stress, nor the level of physical activity required for the stimulation of angiogenesis.  
Being a mixed fibre type with a lower density of capillaries and mitochondria when 
compared to an oxidative fibre type, the EDL may be less sensitive to changes in the PO2 
of the surrounding environment and thus more likely to withstand changes in O2 delivery.  
Thus, a combination of a lack of movement and an insufficiently low blood PO2 suggest 
that threshold levels required to stimulate the pathways leading to angiogenesis in the 
EDL were not reached. 
The soleus is composed mainly of slow twitch oxidative fibres, with a large 
number of mitochondria and a high amount of myoglobin, along with a dense network of 
capillaries.  It functions in postural support and therefore is constantly active.  This 
investment in systems to maximise O2 diffusion suggests that the PO2 gradient is more 
critical here, with an increased sensitivity to changes in O2 levels, resulting in greater 
changes in the capillary supply as shown.  
3.4.1.3.2 Exercise and hypoxia 
The results of this study suggest that an additional stimulus to hypoxia is needed to 
reach the angiogenic threshold in a mixed muscle such as the EDL.  However, studies 
under conditions of both cold and hypoxia have still only shown changes in the capillarity 
of oxidative fibres such as the soleus (Banchero et al. 1985; Suzuki et al. 1997).  The 
additional stress of exercise on top of hypoxia culminates in remodelling of the skeletal 
muscle in some studies (Bigard et al. 1991; Abdelmalki et al. 1996; Wagner, 2001, Prior 
et al. 2003).  This, however, is another area of controversy, as other studies have shown 
no change in the capillarity after episodes of intense training at altitude (Truijens et al. 
2003; Ventura et al. 2003).  Care must be taken when interpreting studies that have not 
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accounted for changing fibre size with exercise and hypoxia.  Atrophy or hypertrophy of 
the muscle fibres, experienced under hypoxia or exercise respectively, will both lead to 
changes in capillary density, thus reflecting the change in functional capillarity but not 
necessarily a change in capillary growth. 
3.4.1.3.3 Lactic acid and haemodynamics 
It has been shown that catecholamines, released from the adrenal medulla in response to 
sympathetic nerve activation by hypoxia, stimulate lactate production in skeletal muscle 
(Qvisth et al. 2008).  The influence of catecholamines on the local blood flow in skeletal 
muscle is a controversial issue, however.  Studies have suggested vasoconstriction, 
vasodilatation, or no vascular reaction (Kurpad et al. 1995; Clark et al. 1995).  
Haemodynamic changes caused by lactic acid could therefore be another factor 
responsible for either the capillary changes shown in the soleus muscle or for the lack of 
capillary growth seen in the EDL muscle.  In respect to our model, if vasodilatation was 
induced by lactic acid accumulation, the resultant vasodilatation-induced shear stress 
may be responsible for switching on angiogenesis in the soleus.  This is because it will be 
working harder under hypoxia compared to a phasic muscle (such as the EDL) due to its 
tonic activity.  
3.4.2 Confounding factors 
3.4.2.1 The threshold for HIF induction 
Elucidating the actual threshold at which HIF is induced in vivo has proven difficult.  In 
tissue cultures, HIF-1 activity has been shown to be extremely variable from one cell line 
to another, though studies have shown that maximal HIF-activation occurs at 0.5% O2 
(Rosenburger et al. 2005), and half-maximal activation is found at 1.5-2% O2, 
corresponding to PO2 values of about 10 to 15 mm Hg (Jiang et al. 1996).  Ji et al. 
(2007) have shown threshold levels for inducing VEGF in myocytes (Fig. 3.21), and from 
this it may be possible to estimate levels at which HIF may be induced as it, along with 
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other stimuli such an inflammatory factors, is responsible for switching on VEGF under 
hypoxia.  
 
 
Figure 3.22 A graph illustrating how myocyte hypoxia increases VEGF secretion.  Secretion in 
hypoxic muscle fibers (<1 mmHg) is 6-fold greater compared to that in well-oxygenated muscle 
fibers (>20 mmHg). (Taken from Ji et al. 2007) 
 
 
 
There are many limitations associated with the methods currently available for measuring 
O2 in mammalian tissue and bodily fluids (Vanderkooi et al. 1991).  Despite the well-
established method of using polarographic microelectrodes to determine tissue PO2, the 
spatial resolution is low and it has been found that the electrode itself consumes O2 and 
ultimately disturbs and damages the tissue (Maxwell, 2003).  Using a blood gas analyser 
(GEM 4000, Instrumentation), the PO2 of venous blood in our control animals at 12% 
hypoxia was 42mmHg, and at 10% hypoxia was 21mmHg.  It has been shown that the 
arterial PO2 of rats at 8% is 30mmHg and at 12% is 45mmHg (Ray, unpublished), 
therefore it is reasonable to postulate that the tissue PO2 for the mice at 10% O2 lies 
somewhere between 35mmHg and 42mmHg.  However, being able to predict the actual 
threshold for HIF activation from in vitro experiments is complicated, and the current 
challenge is still to try and determine what the actual circumstances for HIF activation 
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are.  These observations suggest that a hypoxic stimulus of 10% O2 was not sufficient for 
HIF activation, as seen from the lack of angiogenesis in the hindlimb skeletal muscles.   
3.4.2.2 Mouse strain   
A range of studies have examined the strain-specific characteristics of mice.  Scholz et al. 
(2002) observed that the C57Bl6/J strain exhibited an early normalisation of blood flow 
following a femoral artery occlusion, suggesting that there was a denser pre-existing 
network of collateral vessels compared to the Balb/C strain that was also studied.  This 
observation may account for the lack of angiogenesis occurring in the EDL in chronic 
hypoxia: a pre-existing network of collaterals may increase the threshold for HIF-
mediated angiogenesis to be activated under hypoxic conditions, allowing maintenance of 
a sufficient blood flow through the tissue despite the hypoxic conditions.  
The ventilatory response to hypoxia depends on the pattern and intensity of 
hypoxic exposure and varies with the strain of animal (Powell et al. 1998).  Newborn and 
juvenile animals of a wide range of species show a characteristic biphasic response to 
hypoxia of an initial augmentation for 1-2 min, followed by a subsequent depression in 
minute ventilation (Bissonnette et al. 2001).  This study found that the depressive phase 
is lacking in the acute response of C57Bl6/J mice to hypoxia, from postnatal days 1-3.  
Intermittent hypoxia and reoxygenation occur under many pathological conditions, and 
the respiratory response to this varies with time.  The different time courses of these two 
components, causing a return to pre-hypoxic ventilatory baseline values, are defined as 
short term potentiation (STP), and studies carried out by Han et al. (2000) show the 
absence of STP in the BL6 strain of mouse.  This further supports the presence of the 
unusual respiratory phenotype as proposed by Bissonnette et al. (2001).  Comparative 
morphology of lung structure suggests that C57 mice have a relatively large mass-
specific lung volume compared with other inbred strains (Zwemer et al. 2007).  Zhangm 
et al. (2004) showed that hypoxic conditioning of this strain caused a reduction in 
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pulmonary vascular permeability, proposing a protective role to maintain pulmonary 
diffusive capacitance.   
On exposure to hypoxia, some mammals will try to maximise the efficiency of 
their O2 usage, whereas others will lower their metabolic demand for O2.  Zwemer et al. 
(2007) found that the C57BL6/J strain was naturally more tolerant to hypoxia  compared 
to another strain, CD-1, on the basis of differential metabolic changes when subjected to 
hypoxic conditioning.  The C57BL6/J switched to metabolising ketones, a more efficient 
fuel.  D-!-hydroxybutyrate was found to increase 5 minutes post hypoxic simulus, though 
by 30 min had declined again, as opposed to the CD-1 strain which showed no change.  
Taken together, the combination of these factors may account for the improved hypoxic 
response in this strain of mouse, and thus the lack of change in capillary growth in the 
hindlimb, as the animal works to counteract physiological changes occuring due to the 
low P02.  
3.4.2.3 DMOG and the HIF-system 
DMOG is a small peptide that inhibits the actions of prolyl hydroxylases on the HIF 
transcription factor, mimicking hypoxia.  Consequently, DMOG may only be effective in 
inducing HIF-mediated angiogenesis if the hypoxia threshold is not reached by the P02 of 
the environment itself.  The effect of DMOG in vivo under hypoxic conditions is still 
uncertain though it targets PHDs 1-3 and FIH, all of which are involved in degradation of 
the HIF-1" subunit under normoxic conditions, but it also targets all members of the 
prolyl hydroxylase family, possibly having abrogating effects.  One of the members of the 
PHD family is involved in collagen synthesis (C-P4H), and as collagen is a component of 
the BM, repression of this PHD may interfere with new BM formation during angiogenesis, 
thus leading to neovascular instability and possible regression.   
The DMOG used in these experiments was from Frontier Science and its purity 
shown to be slightly different from a batch used in previous experiments from a different 
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source (CHPT 2).  However, time did not permit using a newly synthesised batch of 
DMOG from Oxford on repeated experiments in the hypoxic chamber.  
Targeting the ‘HIF-system’ involves HIF-1!, HIF-2! and HIF-3!.  HIF-1! was the 
original isoform identified, though it was subsequently shown that there were several 
interaction partners with HIF-1".  One was a novel bHLH-PAS protein originally named 
EPAS-1, now known as HIF-2!, which shares 48% sequence homology with HIF-1! (Tian 
et al. 1997).  It has been shown to form a functional heterodimer with HIF-1" and this 
complex is capable, as HIF-1, of activating transcription factors from the HRE of target 
genes (Krieg et al. 2000).  Despite high conservation in amino acid sequence and 
hypoxia-dependent activation, HIF-1! and HIF-2! have been shown to exhibit quite 
distinct, non-redundant physiological roles, with some different transcriptional targets 
and differing levels in tissues: HIF-2! shows a more restricted pattern of expression that 
includes the developing lung, vasculature, and catecholamine-producing cells (Semenza, 
2004).  Its differential expression pattern was depicted via immunohistochemical 
staining, molecular analysis, and a number of phenotypic studies (Stroka et al. 2001; 
Wiesener et al. 2002).  HIF-2! has been shown to be prevalent in endothelial cells (ECs) 
and is thought to be an important regulator of vascularisation, as shown by its ability to 
specifically activate the angiopoietin receptor, Tie-2 (Tian et al. 1997).  It was also found 
that the hypoxia-induced proliferative response of pulmonary artery fibroblasts was 
solely HIF-2! dependent (Eul et al. 2006).  This adds further support to its potential role 
in development of the vascular system, and the theory that both HIF-1! and HIF-2! act 
in a cell-specific manner on both common and specific targets (Fig. 3.22).  
Uchida et al. (2004) demonstrated that both HIF-1! and HIF-2! sub-units were 
similarly upregulated by acute hypoxia but differentially regulated by chronic hypoxia, 
with HIF-1! disappearing fairly rapidly, but HIF-2! remaining at a higher and more stable 
level.  This may have been due to a reduction in the stability of HIF-1! mRNA.  This 
finding supports the additional study that was carried out at 6% hypoxia for 1 and 6 h 
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(CHPT 3.3.1.4), with an inability to detect HIF-1! though HIF-2! being present albeit at 
decreased levels following the 6 h exposure.  As has been demonstrated by the above 
studies and by Ginouves et al. (2008), both HIF-1! and HIF-2! show a comparable 
response to hypoxia. Thus, that HIF-2! is also upregulated suggests a similar response 
would likely have been seen with HIF-1! if visualisation of the protein had been 
achieved. 
Another interaction partner that was identified for HIF-1" was HIF-3!.  It has 
been shown to exhibit a completely different expression pattern and levels under hypoxia 
with mRNA levels increasing significantly with the duration of the hypoxia in a variety of 
tissues: lung, heart, kidney and liver (Heidbreder et al. 2003).  This suggests that 
regulation occurs in a very different manner.  However, Li et al. (2006) found that HIF-
3! functions in a complementary rather than a redundant way with HIF-1!, in protection 
against hypoxic damage in alveolar ECs.  This suggests that it may also be involved in 
the angiogenic response seen here.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23 HIF-1! and HIF-2! operate via both common and specific targets to mediate cellular 
effects (Modified from Eul et al. 2006) 
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3.4.2.4 PHD2 is the key O2 sensor and PHD overactivation during chronic 
hypoxia reduces HIF-! levels 
3.4.2.4.1 PHD regulation of HIF 
The contribution of each of the three PHDs to the regulation of HIF remains unclear.  
Using RNA silencing, Appelhoff et al. (2004) showed that each of the three isoforms 
(PHD1-3) contributed in a non-redundant manner to the regulation of both HIF-1! and 
HIF-2!, and that the abundance of the enzyme present under each condition in differing 
cell types determined its influence.  The PHDs have observable specificities for different 
prolyl hydroxylation sites on each HIF! subunit and exhibit differential selectivity 
between both HIF-1! and HIF-2!, modifying the degree and extent of HIF protein 
activation.  They have different expression profiles and subcellular localisation patterns, 
and this supports findings that they are not equally required in vivo (Hirsila et al. 2003).  
All exhibit abundance in specific tissues, along with being widely expressed: PHD2 mRNA 
is most abundant in adipose tissue, PHD3 is most abundant in the heart, and PHD1 is 
expressed to a higher degree in the testes (Oehme et al. 2002).  However, data on 
skeletal muscle upregulation of the PHDs are limited.   
It has recently been demonstrated that PHD2 is the key O2 sensor under hypoxic 
conditions (Berchner-Pfannschmidt et al. 2008), thus despite not being successful in 
being able to evaluate the protein expression of PHD1 and PHD3 via Western blots under 
hypoxia, obtaining data for PHD2 under these circumstances has proven most useful.  
Individual silencing of both PHD1 and PHD3 in a variety of cell types has shown that 
neither have an effect on the stability of HIF under either normoxia or hypoxia (Berra et 
al. 2003).  However, silencing of PHD2 stabilised and activated HIF-1! under both of 
these conditions.  Furthermore, Takeda et al. (2007) illustrated how both PHD1-/- and 
PHD3-/- mice did not show any apparent angiogenic defects, though a conditional 
knockout of PHD2 produced a phenotype with evidence of hyperactive angiogenesis and 
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vasodilatation in a multitude of organs (heart, liver, lung, kidney, brain and testes), 
further suggesting that angiogenesis under hypoxia may occur via capillary splitting. 
3.4.2.4.2 Increased levels of PHDs under chronic hypoxia 
It has been demonstrated that chronic hypoxia causes an increase in the pool of available 
PHDs, overactivating all 3 isoforms and causing a subsequent decrease in HIF-! levels, a 
property deemed necessary for cell survival (Ginouves et al. 2008).  These findings are in 
contrast to acute hypoxia, where PHD inactivation ensures HIF-1! stabilisation.  It is 
after this inactivation that a new O2 homeostasis is established, with increasing levels of 
PHDs and decreasing levels of HIF!.   
Stiehl et al. (2006) showed that PHD2 remained upregulated over 10 days under 
chronically hypoxic conditions in vitro.  Along with this, Huang et al. (2002) observed 
that PHD2 has the highest specific activity toward the primary hydroxylation site of HIF-
1!, and residual binding of recombinant PHD2 to HIF-1! ODD peptides in vitro occurs, 
further suggesting a repressive function of PHD2 on HIF-1! following exposure to chronic 
hypoxia (Stiehl et al. 2006).  These data support findings shown here in the EDL that the 
upregulation of PHD2, as determined by densitometry, was 2.3-fold higher after 10% 
hypoxia for 2 wks when compared to control values (and only had a 0.57x change when 
DMOG was present).  A similar trend was seen in the heart and soleus, though with lower 
fold increases, supporting the notion that PHDs may exhibit different levels in different 
tissues at different time points.  The finding of decreasing levels of HIF-2! after 6 h at 
6% hypoxia, and undetectable levels at 2 wks, along with an inability to detect HIF-1!, 
support the findings that PHD2 is active in the suppression of HIF following a hypoxic 
exposure.  Along with this, PHD2 has been shown to be a direct target gene of HIF-1! as 
it contains a HRE (Metzen et al. 2005). 
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3.4.3 Gene expression under hypoxia 
A multitude of genes are targeted by HIF, some showing distinct, others inter-relating 
functions (Fig. 3.2).  VEGF is known to form many interactions under normoxia and 
hypoxia: it is negatively modulated by one of its receptors, Flt-1, positively regulated by 
another of its receptors, Flk-1, acts on iNOS to increase its expression, and is known to 
be regulated by both HMOX-1 and TGF-!, among many others.  The extent to which 
these interactions are modified under systemic hypoxia remains unknown, though their 
upregulation by HIF-1 illustrates a primary response to the hypoxic stimulus.  Clearly 
evident from the data are the different expression levels seen among tissues, both 
between and within genes, as has been shown for HIF-1" and a range of HIF-regulated 
genes (Stroka et al. 2001; Stiehl et al. 2006).  Of all genes studied, only EPO and iNOS 
were actively up and down-regulated in all tissues, largely without an apparent pattern, 
with the exception of EPO expression in the heart, liver and leukocytes which all showed 
a characteristic initial increase, followed by decreased expression.  Basal gene expression 
levels of EPO and magnitude of change varied within each tissue, ranging from a 9.5-fold 
increase in the liver to a 4000-fold increase in the soleus.  mRNA expression of EPO in 
the liver, heart and leukocytes correlated well with the 3 h time point peak in plasma 
protein (21-fold increase from control values), along with the significantly increased 
mRNA expression at 3 h in the kidney. 
Out of the 7 tissues, the soleus was the only one in which expression levels of all 
genes were changed, either in a positive or negative direction.  The soleus composition 
(above) suggests that it is fairly sensitive to changes in O2 supply and this may be why it 
experiences variations in levels of these hypoxia-regulated genes.  Furthermore, the EDL 
was the only tissue where mostly unchanged levels of gene expression were seen, 
though in 4 genes (iNOS, HIF, EPO and Flt-1) there was an increase in gene expression 
by 1 wk.  Again, its phenotype suggests that it may be less sensitive to changes in the 
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PO2
 of the surrounding environment, and hence hypoxia-regulated genes are 
unresponsive. 
3.4.3.1 EPO mRNA and protein expression 
Before birth, the liver is the main site of EPO production, though in adults the kidney 
produces around 90% of systemic EPO.  This is supported by the differential basal levels 
and fold-change on exposure to hypoxia seen in this study, with the kidney expressing 
average CT levels around 10,000 and the liver being around 1 by 3 h of hypoxia.  Clearly 
evident from this study, a range of tissues have been shown to express EPO, though no 
structural or functional differences of EPO coming from these different sources have been 
described (Wiedemann and Johnson, 2009).  
Until fairly recently, the role of EPO was thought restricted purely to 
erythropoiesis.  However, it has since been shown to possess other functions, namely 
protection of neurons against ischaemic brain injury in stroke patients (Ehrenreich et al. 
2002), significantly improving cardiac function following myocardial infarction by 
reducing myocyte apoptosis (Parsa et al. 2003) and having a protective effect on 
oxidative renal injury in rats (Kasap et al. 2008).  Thus, mRNA expression levels detected 
in the heart and liver in this study may be representative of its protective role in these 
organs.  EPO mRNA has also been shown present in the lung and spleen (Tan et al. 1991, 
Semenza et al. 1990), albeit at very low levels.  The role of these organs for local and 
systemic EPO homeostasis is still largely unkown, and the same may be said about 
expression patterns in the soleus and EDL.  However, as with above, EPO may be 
offering a protective effect against hypoxemia in these tissues.  
The spectrum of different levels of EPO regulation became broader with the 
unexpected finding that there is a link between VEGF and hepatic EPO expression (Tam 
et al. 2006).  Hepatic and systemic inhibition of VEGF, as well as conditional deletion of 
VEGF gene in the liver, induced hepatic EPO expression, which increased the haematocrit 
and led to polycythaemia in rodents.  This was thought to be achieved by interfering with 
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Flk-1 stimulation.  However, there appear to be no similarities in the VEGF, Flk-1 and 
EPO mRNA expression levels in the present study.  
That EPO expression in leukocytes follows a similar pattern to that seen in the 
plasma response bodes well for the use of leukocytes as a circulating indicator of EPO in 
response to systemic hypoxia in humans (CHPT 7).  As EPO is a downstream gene of HIF, 
it is a reasonable expectation that it would act as a suitable surrogate measure for HIF-
upregulation under hypoxic conditions.  
3.4.3.2 Control of EPO by the HIF-system: An emerging role for HIF-2! 
It is well known that HIF-1! is post-translationally regulated under hypoxia, although 
mRNA upregulation has been shown under both hypoxic and normoxic conditions 
(Richard et al. 2000; Kim et al. 2002; Roy et al. 2004).  It has long been thought that 
HIF-1! is the key factor activating EPO transcription and was the original isoform 
identified as binding to the 3’ regulatory element on the HRE of the EPO promoter 
(Semenza et al. 1991).  Using gene silencing in vitro, this being later supported by an in 
vivo model (Gruber et al. 2007), it was subsequently shown that HIF-2! was largely in 
control of the same regulatory sequence on the EPO gene (Warnecke et al. 2004), and 
that HIF-1! knockdown only has a small effect on EPO transcription compared with the 
major reduction observed following HIF-2! inhibition (Gruber et al. 2007).  Whether the 
lack of significant change in HIF-1! mRNA seen here is due to an insufficient hypoxic 
stimulus remains a possibility, though the lack of relationship between HIF-1! and EPO 
mRNA may be due to the above observation: it is HIF-2! that is largely in control of EPO, 
hence examining HIF-2! mRNA expression may provide a better representation of its 
relationship and regulation of EPO.  
3.4.3.3 iNOS mRNA  
HIF-1! protein and mRNA (Thompson et al. 2008) have been shown to upregulate iNOS 
expression both in vitro (Han et al. 2007) and in vivo (Fagan et al. 2001).  An HRE in 
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murine macrophages has been identified and shown to be hypoxia-inducible (Melillo et al. 
1995).  iNOS is known to play a role in the human defence against invading pathogens, 
and along with being upregulated by HIF-1! is under the control by a variety of 
inflammatory factors (Kröncke et al. 1998).  Its role is to synthesise NO as part of the 
cytotoxic defense, which may also initiate vasodilation of blood vessels on spillover, an 
important adaptation under systemic hypoxia to increase blood flow and reconstitute the 
O2 supply to parts of the body.  
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Figure 3.24 NO-dependent mechanisms in and the protective effects of adaptation to hypoxia. SOD 
= superoxide dismutase; GS = glutathione; HSP = heat shock protein; PG = prostaglandins (From 
Manukhina et al. 2006) 
 
iNOS has been associated with ischaemic preconditioning and cardioprotection, whereby 
an episode of ischaemia triggers an early phase of protection against further episodes of 
ischaemia.  Ischaemia is thought to induce transcription factors (HIF and NF-!b) which 
subsequently induce iNOS expression, followed by NO release, offering cardioprotection 
as soon as 24 h following the initial attack (Lowenstein, 1999; Xi et al. 2004).  Figure 
3.23 illustrates the relationships between HIF-1, iNOS and and NO, along with the 
downstream effects, including those of vasoprotection and anti-stress defense.   
 A late response is seen in most tissues illustrated here, suggesting that iNOS is 
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involved in the chronic adaptation to hypoxia.  Interestingly, an early response is seen in 
the leukocytes, suggesting that these peripheral cells may represent an efficient 
circulating marker of hypoxia, adding further support to their use in CHPT 7.  The 
response in the leukocytes is consistent with that seen in the bone marrow, though 
occurring slightly earlier, the bone marrow being one site for leukocyte degradation (King 
et al. 1990).  This suggests that leukocytes may act as sentinel cells, playing a role in 
educating the bone marrow on levels of hypoxia.  
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3.5 Conclusions 
 
Despite both 10% and 12% hypoxia being sufficient to cause hypertrophy of the heart 
(as a response to the increased workload required to pump blood around the body and 
against constricting vessels), only 10% O2 was low enough to induce an angiogenic 
response in the heart and diaphragm of this strain of mouse.  The response seen here is 
thought to be an indirect effect of hypoxia, being mechanically-mediated by stretch due 
to a combination of increased ventilation, a higher total volumetric flow of blood and 
pressure overload.  This observation is supported by the fact that hypoxaemia at this 
level was not low enough to induce blood vessel growth in the hindlimb.  The proposed 
effect of DMOG to enhance any angiogenic growth occurring was not seen in the 
hindlimb, heart or diaphragm, though there is evidence for its effects in the soleus at 
10% hypoxia.  Studies have shown that this strain of mouse is very resistant to both 
systemic hypoxia and local ischaemia, so it is likely that in order to induce a sufficient 
response in the EDL muscle of the hindlimb, the hypoxic stress on the system needs to 
be magnified with the use of an additional stimulus such as exercise.  Angiogenesis has 
been induced under locally hypoxic (ischaemic) conditions in a range of studies.  
However, systemic and local hypoxia may act differently, or have different thresholds for 
inducing capillary growth, and that may be why similar changes are not seen here.  
Systemic hypoxia at 10% was sufficient to induce changes in a variety of HIF-regulated 
genes, namely iNOS and EPO, which were up and down-regulated in all tissues studied. 
The most reactive tissue was the soleus, consistent with it being an oxidative tissue with 
an increased sensitive to changing O2 levels.  Leukocytes appear to be sensitive to gene 
expression alteration under hypoxia, and this gives support to using them as a circulating 
indicator of HIF-regulated hypoxic stress in humans. 
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3.6 Future experiments 
If the hypoxic stimulus threshold for stimulating angiogenesis was not reached due to an 
insufficiently low PO2 of the blood, an obvious experiment to stress the physiological 
system of the animal to a greater degree would be to incorporate an exercise component 
into the hypoxic chamber exposure, for example a running wheel.  Despite the described 
hypoxia-resistance characteristics of the C57Bl6/J mice mentioned above, it may be that 
increasing the hypoxic stress imposed on this strain of mouse to critical levels would be 
sufficient to induce a reponse.  It would also be interesting to record O2 levels in the 
muscle tissue using a hypoxyprobe (O2 sensitive dye) or optodes, an optical sensor 
device that measures oxygenation of a dye with the aid of a chemical transducer, to 
determine differential O2 concentrations within tissue.  To overcome the non-specific 
action of the DMOG, it would be useful to either develop a compound that is specific to 
target PHD 1, 2 and 3, and FIH alone, or explore using knockout mice.  RNA silencing has 
already been used and shown to have success in mouse embryos.  It is still very much in 
its infancy, though with a promising future.  The benefits of using knockout mice over 
chemical ablation include the lack of effects of toxicity which may be present and 
unknown, the fact that knockouts are specific and chemicals may still involve a lack of 
specificity, and finally, that the problem of dosage is not an issue in this instance.  
Investigating HIF-2! mRNA expression (under 10% hypoxia) in tissues studied here, 
would possibly provide a useful indicator of its role in the regulation of EPO. 
 
 
 
 
 
 
 
 
 
 
 
 110 
 
 
 
 
 
 
Chapter 4 
FEMORAL ARTERY LIGATION 
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4.1 Introduction 
Ligation of the femoral artery in the hindlimb of the mouse will cause an area of local 
ischaemia and is an efficient surrogate model used to study the effects of peripheral 
vascular disease in man, on a molecular and physiological level.  Chronic ischaemia in 
humans occurs as a consequence of peripheral arterial occlusive disease (PAD) which 
leads to obstruction of large arteries, e.g. in the leg.  The reduction in blood flow causes 
a chronic deficiency of O2 supply to the surrounding tissues and this ultimately results in 
the development of ulcers and, at worst, gangrene and necrosis of the lower limb (Scholz 
et al. 2003).  Rodent models are used to study limb ischaemia on a relatively acute scale 
as opposed to the usual chronic timescale upon which PAD occurs in humans.  
Nevertheless, these models are invaluable for understanding the molecular mechanisms 
governing these conditions, of which the pathways are possible targets for chemical 
manipulation and clinical investigation. 
Both angiogenesis and arteriogenesis are important mechanisms of restoring 
blood flow following limb ischaemia.  Arteriogenesis is the remodelling of the existing 
arteriolar connections into larger calibre vessels following occlusion of the vessel (Prior et 
al. 2004).  These vessels are microvascular, thin-walled conduits that are composed of 
an endothelial lining, an internal elastic lamina, and one or two layers of smooth muscle 
cells (Longland, 1953).  Arteriogenesis is responsible for the expanded collateral network 
that improves blood flow in distal areas of the affected limb, whereas angiogenesis is 
responsible for the extension of small vessel growth within the immediate ischaemic 
regions, it being an extremely responsive and productive system (Silvestre et al. 2000).  
Angiogenesis is a complex phenomenon which involves capillary sprouting, in contrast to 
the arterial remodelling seen in arteriogenesis.  It consists of several distinct processes, 
which include endothelial migration and proliferation, extracellular proteolysis, 
endothelial differentiation (capillary tube formation) and vascular wall remodelling 
(Buschmann & Schaper, 1999).  
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4.1.1 Hypoxia Inducible Factor (HIF)  
The molecular mechanisms of angiogenesis in limb ischaemia have been thoroughly 
investigated (Tuomisto et al. 2004, Ho et al. 2006) and HIF shown to be extremely 
important in the initiation of new vessel growth via transcriptional activation of a number 
of downstream genes.  As previously described (CHPT 1), HIF is a master regulator of O2 
homeostasis and its activation depends on stabilisation of the O2-dependent degradation 
domain (ODD) of the !-subunit.  The constitutively expressed "-subunit binds with the 
O2-regulated !-subunit and is translocated to the nucleus of the cell where it binds to 
consensus domains of target genes.  After binding to the HRE on target genes, 
transcriptional activation of genes responsible for cellular, whole tissue and whole animal 
adaptation to hypoxia, are activated.  Critical to limb ischaemia, angiogenic responsive 
genes such as VEGF, angiopoietins and MMPs are subsequently activated, initiating new 
blood vessel growth in order to partially restore blood flow in the affected area. 
4.1.2 Therapeutic angiogenesis 
An important challenge for therapeutic angiogenesis is the need to target the angiogenic 
response to ischaemic areas.  Studies report that up to 1000 people per million per year 
develop critical limb ischaemia (Bobek et al. 2006), and a further 150, 000 patients 
require lower limb amputation for the condition.  The endogenous angiogenic response to 
hypoxia seems to be impaired in patients with PAD, and therapeutic angiogenesis seeks 
to augment collateral vessel formation using a variety of possible interventions (Collinson 
and Donnelly, 2004).  By-pass grafting surgery, percutaneous transluminal angioplasty 
and surgical revascularisation are reserved for patients with severe critical limb 
ischaemia (Collinson and Donnelly, 2004; Bobek et al. 2006), though many of these 
patients are poor candidates for these procedures.   
The concept of therapeutic angiogenesis was first introduced in 1989 by a German 
gynaecologist named Michael Hockel (Bobek et al. 2006), who described it as a process 
of improving blood flow to ischaemic tissue by inducing neovascularisation using 
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angiogenic agents, administered by gene transfer, recombinant protein or chemicals 
(Khan et al 2003).  Despite some initial setbacks and negative clinical trial results, a 
substantial amount of progress has been made over recent years in the area of targeting 
angiogenesis therapeutically (Emanueli and Madeddu, 2001; Selke et al. 1998). 
Therapeutic angiogenesis was initially validated in mice, dogs, and pigs and was 
subsequently approved for use in human clinical testing.  A wide range of therapies have 
been utilised, some yielding limited success, others showing a significant improvement in 
vascularisation and alleviation of the ischaemia (Table 4.1).  The studies have used a 
variety of treatments, patient selection criteria and endpoints.  Many advantages and 
disadvantages are associated with all types of therapy.  Gene transfer is useful for 
ensuring persistent expression of the factor.  However, non-specific gene transfer to 
other cell types and lack of regulation of gene expression prove problematic in many 
cases.  One of the main drawbacks of growth factor administration such as VEGF is that it 
renders vessels leaky and unstable (Dvorak et al, 1999).  VEGF and bFGF are also potent 
vasodilators and this may cause unwanted hypotension.  Studies suggest that sole 
administration of VEGF is insufficient to form stable, mature vessels as numerous growth 
factors, such as Ang-1 and TGF-! are required for the formation of stable vessels (Bobek 
et al. 2006).  Treatment with VEGF in the first clinical studies has been well tolerated, 
though there has been variable success of trials and this suggests that multi-agent gene 
therapy may be necessary to achieve sufficiently stable blood vessel growth, and to 
ensure effective clinical outcome in patients.  The possibility of using stem cells is also a 
source of growing excitement (Real et al. 2008).  HIF-1"-transduced endothelial 
progenitor cells (EPCs) were administered to nude mice with hindlimb ischaemia and IHC 
showed enhanced neovascularisation in vivo, along with both limb and toe necrosis being 
significantly reduced, 14 days post transplantation (Jiang et al. 2008). 
A number of chemicals have been used to indirectly target HIF by inhibiting the 
PHDs which regulate HIF-1".  DMOG is a PHD and FIH inhibitor, subsequently 
upregulating HIF activity.  Initial studies in vitro demonstrated its efficiency at inducing 
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HIF-1! (Jaakola et al. 2001).  Subsequent studies have shown its use in enhancing the 
angiogenic response to limb ischaemia (Milkiewicz et al. 2005).  TM6089 and TM6008 are 
two novel compounds that have been shown to induce angiogenesis by binding to the 
active site of PHD2 (Nangaku et al. 2007).  Ethyl 3,4-dihydroxybenzoate (EDHB), 6-
chlor-3-hydroxychinolin-2-carbonic acid-N-carboxymethylamid (S956711) and L-
mimosine (L-mim) all demonstrated similar effects to hypoxia by inducing HIF-1! in both 
human and rodent cells (Warnecke et al. 2003).  Animals treated with EDHB displayed 
significantly increased viability and enhanced exercise performance in hypoxia 
(Kasiganesan et al. 2007).  PR39 is a macrophage-derived peptide that acts in a similar 
way to the above chemicals, inhibiting the degradation of HIF-1! and producing 
accelerated formation of the vasculature in mice (Li et al. 2000).  Directly targeting HIF-
1! has long been an attractive method of upregulation, using the iron chelator 
desferrioxamine or cobalt chloride, leading to an increased muscle capillary supply 
(Tanaka et al. 2005).  
 
Treatment 
 
Outcomes 
Intra-arterial VEGF165 gene transfer Increased collaterals 
Intra-muscular VEGF165 transfer Increased collaterals in all limbs 
Intra-arterial bFGF protein transfer Improved calf blood flow though lack of 
positive results at cessation 
IV bFGF protein transfer Peak walking time increased 
Intra-arterial VEGF gene transfer Improved vascularity 
Intra-muscular VEGF121 gene transfer No change  
 
Table 4.1 Summary of published clinical studies of therapeutic angiogenesis in patients with PAD 
(Adapted from Collinson and Donnelly, 2004) 
 
 
The aim of this study was to evaluate the levels of local hypoxia required to initiate 
angiogenesis, and to elucidate whether chemical manipulation of HIF-1! stability would 
enhance these responses.  
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4.2 Methods 
4.2.1 Study design: Femoral artery ligation 
We chose to exploit the use of DMOG in altering the response to unilateral ligation, both 
in the C57BL6/J and C57BL10/J strains of mouse, to determine efficiency of the drug in 
restoring blood flow in the hindlimb following occlusion of the femoral artery after 1 and 
2 wks, and to determine if there were any differences in strain response. Experiments 
were performed on groups of C57BL6/J and C57BL10/J mice (n=6 in each experimental 
group).  Each group received DMOG (8mg.0.5mL-1 saline) (CHPT 2.1) via i.p. injection 
every other day, with the initial injection 2 days before surgery.  
4.2.1.2 Surgery  
Under aseptic conditions, mice were anaesthetised starting initially with 5% isofluorane 
and decreasing to 2.5% with O2 as a carrier.  0.2mL.100g
-1 Temgesic! was given prior to 
surgery for postoperative analgesia.  The vein was visualised through the skin and an 
incision was made through the skin alongside the vein at the top of the underside of the 
leg (Fig. 4.1).   Fine forceps were used to clear away the fascia and remove connective 
tissue that was attached to the artery and vein.  The forceps were then used to dissect 
down between the artery and vein (also on all sides of the artery) to obtain good 
separation, with care taken to avoid trauma to the adjacent nerve.  The artery was lifted 
up at a minimal distance away from the animal and a piece of suture thread (10,0 
polyamide monofilament) was passed underneath.  A double knot was tied and the 
remaining suture thread trimmed to a minimum.  Two drops of the antibiotic Depocillin!  
(300mg.mL-1) was applied to the exposed area and excess was removed after leaving it 
to be absorbed for a short time.  The wound was closed with 4/5 sutures (6,0 vicryl 
monofilament) and any dried blood removed to minimise the risk of infection.  The mice 
were allowed normal access to food and water to aid recovery.  They were then sacrificed 
after the experimental period of 1 or 2 wks via cervical dislocation.   
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Ligation of the femoral artery was attempted in two different locations along the 
artery to determine whether the placement of the suture affected the degree of 
ischaemia experienced.  Subsequent analysis of the tissue confirmed that ligating the 
artery either above and below the saphenous branch of the artery produced no signifcant 
difference in the degree of capillary growth.   
 
 
         
(National Institute of allergy and infectious disease 
www3.niaid.nih.gov) 
 
Figure 4.1 Location of the area for incision before ligation of the femoral artery 
         
 
On a number of mice, a Transonic! flow probe (probe and meter) was used to confirm 
the absence of blood flow following ligation (Fig. 4.3).  Figure 4.2 illustrates normal blood 
flow.  The ultrasound bounces off red blood cells flowing through the vessel and this 
gives a measurement of flow. 
 
incision 
suture 
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Figure 4.2 Flow probe data obtained by ultrasound from an unligated femoral artery of a C57Bl6/J 
mouse showing presence of blood flow through the artery  
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Figure 4.3 Flow probe data obtained by ultrasound from the ligated femoral artery of a C57Bl6/J 
mouse showing a clear lack of flow  
 
 
4.2.1.3 Tissue processing 
EDL muscles from ipsilateral limbs were taken (CHPT 2.2) and stored on corks at -80°C 
after being snap-frozen in isopentane cooled in liquid nitrogen (CHPT 2.3).  Tissue was 
sectioned and stained (CHPT 2.3), and capillary and fibre numbers (C:F) counted (CHPT 
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2.4) using lectin staining.  On a selection of slides, lectin and DAPI staining were used to 
look for the presence of macrophage nuclei, suggesting infiltration and inflammation.  
 
 119 
4.3 Results 
There was no significant change in the capillary to fibre ratio (C:F) of the EDL muscle in 
C57BL6/J mice that underwent unilateral ligation of the femoral artery at either 1 or 2 
wks (Table 4.2).  There was a significant decrease in the capillary density (CD) for mice 
administered with DMOG during the 1 wk ligation and a significant increase in the mean 
fibre area (MFA) for mice at 1 wk without DMOG.  There was also a significant difference 
between the MFA for mice during the 1 wk ligation ± DMOG when compared to control 
values.  Mean body mass was 25.6g ± 1.06 (±SEM).  
 
 
Experiment C:F 
 
CD  (cap.mm-2) MFA  (!m2) 
 
 
Control       (n=6) 
 
1.26 ± 0.02 
 
885 ± 67 
 
1521 ± 102 
 
Control D    (n=6) 
 
1.26 ± 0.05 
 
856 ± 141 
 
1674 ± 58 
 
1 wk no D     (n=6) 
 
1.31 ± 0.07 
 
736 ± 69 
 
1418 ± 62 
 
1 wk D            (n=6) 
 
1.26 ± 0.05 
 
766 ± 30  
 
1554 ± 90 
 
2 wk no D     (n=7) 
 
1.33 ± 0.05 
 
839 ± 62 
 
1630 ± 69 
 
2 wk D             (n=7) 
 
1.32 ± 0.04 
 
925 ± 44 
 
1501 ± 40 
C:F = capillary to fibre ratio, CD = capillary density, MFA = mean fibre area, mean ± SEM. 
Statistics performed using ANOVA with Dunnetts post hoc test.   'n‘ is defined in the table. D = 
DMOG  
 
Table 4.2 C:F, CD and MFA for the EDL muscle following femoral artery ligation in C57BL6/J mice. 
No significant differences were determined. 
 
The 2 wk ligation was repeated in the C57BL10/J strain of mouse to determine if there 
were any strain-specific differences as shown in Table 4.3.  There was no change in 
capillary growth in the hindlimb with or without DMOG, though, as is shown in both 
strains, there is a tendency for a higher though not significant C:F ratio in the ligated 
limb in both treated and untreated animals. 
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Lectin and DAPI staining were used to test for the presence of leukocytes, which 
would otherwise suggest that inflammation may have been a driving force behind any 
angiogenesis seen.   No evidence of an inflammatory presence was seen. 
 
Experiment C:F 
 
CD  (cap.mm-2) MFA  (!m2) 
 
 
Control     (n=6) 
 
1.25 ± 0.02 
 
1015 ± 59 
 
1367 ± 112 
 
2 wk no D (n=6) 
 
1.31 ± 0.05 
 
961 ± 78 
 
1452 ± 89 
 
2 wk D     (n=6) 
 
1.36 ± 0.07 
 
1032 ± 101 
 
1372 ± 69 
C:F = capillary to fibre ratio, .  CD = capillary density, MFA = mean fibre area, mean ± SEM. 
§=P<0.05 vs. control. Statistics performed using ANOVA with Dunnett’s post test.  'n‘ is defined in 
the table. D = DMOG  
 
Table 4.3. C:F, CD and MFA for the EDL muscle following femoral artery ligation in C57BL10/J 
mice.  No significant difference was seen between any of the groups. 
 
The average body mass for the C57BL6/J strain of mouse was 26.8 ± 0.24g, with the 
average EDL mass being the same as control (9.0 ± 0.2mg).  Average body mass of the 
C57BL10/J mouse was 25.1 ± 0.17g, with an average EDL mass of 9.2 ± 0.01mg. 
As described, previous studies using DMOG have shown a significant increase in 
capillary growth.  This finding was not reproduced here and therefore investigations into 
the purity of the DMOG were carried out (CHPT 2.1).  Due to a slight discrepancy 
between 2 batches of DMOG obtained from different sources, a new batch of the original 
DMOG was synthesised and used in subsequent experiments.  However, as shown in 
Table 4.4, significant capillary supply changes in both DMOG and non-DMOG treated 
C57BL6/J animals were unable to be shown.  
 
 
 
 
 
 
 121 
Experiment C:F 
 
CD  (cap.mm-2) MFA  (!m2) 
 
 
Control       (n=6) 
 
1.26 ± 0.02 
 
885 ± 67 
 
1521 ± 102 
 
Control D    (n=6) 
 
1.26 ± 0.05 
 
856 ± 141 
 
1674 ± 58 
 
2 wk no D  (n=4) 
 
1.25 ± 0.05 
 
639 ± 21§* 
 
1597 ± 62 
 
2 wk D       (n=4) 
 
1.34 ± 0.04 
 
577 ± 22§* 
 
1788 ± 69 
C:F = capillary to fibre ratio, .  CD = capillary density, MFA = mean fibre area, mean ± SEM, 
§=P<0.05 vs. control,, *= P<0.05 vs.control D Statistics performed using ANOVA with Dunnetts as 
a posthoc test.  'n‘ is defined in the table. D = DMOG  
 
Table 4.4 C:F, CD and MFA for the EDL muscle in the femoral artery ligation in C57BL6/J mice 
using newly synthesised DMOG.  
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4.4 Discussion 
The aim of this study was to determine whether use of a chemical upregulator of HIF 
would enhance the angiogenic response occurring following ligation of the femoral artery. 
Previous studies have shown beneficial local effects of HIF enhancement on blood vessel 
growth in vivo under artificial circumstances using polyethylene sponge assays (Willam et 
al. 2002; Warnecke et al. 2003), and the pro-angiogenic effects of DMOG have 
previously been shown by a member of our group (Milkiewicz et al. 2004).  However, a 
number of difficulties arose, based upon the initial inefficiency of the DMOG, due to the 
possible upregulation of anti-angiogenic factors alongside pro-angiogenic factors, and 
finally upon realisation of the limits the use of this strain of mouse may have.   
4.4.1 Effects of ligation in the hindlimb 
Despite neither the C57BL6/J or the C57BL10/J strain of mouse exhibiting a significant 
increase in the capillary to fibre ratio (C:F) in either DMOG or non-DMOG treated limbs at 
2 weeks, there was a tendency for the C:F to be obviously increased compared to the 
control animals.  When the newly synthesised batch of DMOG was trialled these same 
trends were seen, though the difference between the DMOG and non-DMOG treated 
animals was more convincing, with the DMOG-treated animals exhibiting a higher C:F 
compared to those without, though both showing a significantly decreased capillary 
density.  Animals studied at 1 wk showed no obvious change at all.  These data suggest 
that the stimulus switching on blood vessel growth under these conditions was not 
substantial enough.   
 
4.4.1.1 The threshold to induce angiogenesis 
The findings in this study are in accordance with a large number of studies that have 
been unable to show an increase in the capillarity of skeletal muscles in the rat hindlimb 
(Dawson and Hudlicka, 1990; Hudlicka et al. 1994; Cherweck et al. 2000), suggesting 
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that the threshold for inducing angiogenic growth factors under conditions of femoral 
artery ligation is at a higher level than obtained by ligation alone, or/and there is a 
parallel increase in anti-angiogenic factors which inhibit the pro-angiogenic circumstances 
required for new vessel growth.  As discussed in CHPT 3.4.2, the in vivo PO2 threshold to 
induce HIF-activation is unknown, due to difficulty in obtaining reliable methods by which 
to measure tissue PO2.  However, estimates can be made based on extrapolations from 
cell work (Jiang et al. 1996), leading to the suggestion that the tissue hypoxia was 
insufficient in this model (see CHPT 3). 
 
4.4.1.2 Fibre type-specific induction of angiogenesis 
It has been shown that fibre type influences the response to ligation in the rabbit 
(Cherwek et al. 2000).  Despite lack of change in the C:F ratio in either the soleus or TA 
muscle of the hindlimb in this study, Cherwek et al. (2000) observed a much greater 
upregulation of VEGF in the soleus compared to the TA.  These data suggest that 
properties specific to this muscle fibre type such as a higher capillary and mitochondrial 
density make it more sensitive to changes in O2 delivery, and therefore changes in 
growth factors are more likely here when compared to a mixed fibre type such as the TA 
or EDL which may be less sensitive to changes in O2 delivery.  This is supported by the 
finding that long term limitation of blood flow supplying both glycolytic and oxidative 
skeletal muscle fibres affects oxidative fibres more (Dawson and Hudlicka, 1990), further 
suggesting that the degree of resulting O2 delivery was lower due to tissue metabolism 
and thus closer to the threshold level for inducing angiogenic growth.  
 
4.4.1.3 Additional stimuli inducing angiogenesis 
As was postulated for exposure to systemic hypoxia (CHPT 3), an additional stimulus 
may be required to reach the threshold required for switching on capillary growth in the 
EDL and other skeletal muscle, despite an apparent upregulation of angiogenic growth 
factors (Lloyd et al. 2003).  Capillary growth following ligation has been induced with an 
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additional stimulus such as exercise (Deschenes and Ogilvie, 1999; Lloyd et al. 2003), 
although angiogenesis was induced in muscles with a high proportion of oxidative fibres 
such as the medial gastrocnemius as opposed to the EDL with a mixed fibre composition, 
electrical stimulation (Hudlicka et al. 1994), and muscle overload (Deveci and Egginton, 
2002).  However, additional stresses such as these have been shown to induce an 
inflammatory response (Hudlicka et al. 1993).  A method of increasing capillarity using 
electrical stimulation without muscle damage was shown by Hudlicka et al. (1994) 
whereby mild intermittent stimulation allowed the muscle to replete glycogen stores, 
resulting in an improved perfusion pressure and lower muscle fatigue, and an increased 
C:F ratio.  It remains unclear whether angiogenesis under such conditions is due to a 
lowering of the hypoxic threshold or the imposition of muscle work, i.e. the relative 
importance of metabolic or mechanical stimuli for capillary growth.  
4.4.2 The inefficiency of DMOG 
Although investigations were made into the purity of the DMOG, the recorded 
discrepancies between the two batches (CHPT 2.1) may be insignificant based on the fact 
that the C:F ratio appeared to show similar changes after using either.  However, studies 
looking at the effect of femoral artery ligation and an additional stimulus such as exercise 
found changes in oxidative muscles such as the soleus, suggesting that it may be 
beneficial to incorporate this in the future to maximise the potential for observing the 
proposed effect of DMOG.  It is possible that DMOG also has a threshold below which it is 
not activating the HIF system to its full potential, and this may have been the case here 
if the bioavailability was underestimated.  It may also work differently in different 
skeletal muscles, depending on fibre type and depending on the amount or type of PHD 
enzyme present, as different levels have been reported in different tissues (Appelhoff et 
al. 2004).  Differential expression in skeletal muscle has not been explored as yet.    
 These experiments involved repetition of a protocol using DMOG that had 
previously been utilised both in vivo (Mikiewicz et al. 2005) and in vitro, many of the 
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latter experiments taking place in the Ratcliffe Laboratory, Oxford, both with its desired 
effect of demonstrating HIF-1! upregulation.   Mole (unpublished) demonstrated an in 
vitro dose-response curve for dimethyloxalylglycine, confirming that between 200µM and 
500 µM DMOG is required to achieve maximal induction of HIF-1! when lysates from 
stimulated HeLa cells were analysed by HIF-1! Western blot.  It was from these in vitro 
data that in vivo values published in the literature, were extrapolated. The next logical 
step would have been to do a dose response in vivo but time was not permitting.  (This is 
discussed in CHPT 8, Future directions).  
4.4.3 The confounding factor of mouse strain 
The C57BL6/J strain is becoming an increasingly popular model for target gene 
disruption, though literature based on characterisation of the strain-specific phenotypes 
suggest significant differences exist in this strain compared to others such as the Balb/c 
and CD-1 strains.  These differences are thought to influence their response to 
surrounding environmental and imposed experimental conditions.  As described in CHPT 
3.4.2.2, studies have shown that the respiratory response of the C57BL16/J mouse to 
hypoxia is abnormal as this strain rapidly switches to metabolising ketones, a more 
efficient fuel, under hypoxic stress (Zwemer et al. 2007).  Studies into this strain have 
also revealed that the C57BL6/J mouse has a denser network of pre-exisiting collaterals, 
offering a higher degree of protection against ischaemic insult. This resulted in blood flow 
through the femoral artery returning to normal rapidly, following ligation of the femoral 
artery (Zbindeen et al. 2006).  A pre-existing collateral vasculature has been identified in 
various parts of the circulation of a number of species, though the number and size of 
these anastomoses differs between species and tissues (Helisch et al. 2006).  The result 
is that differing degrees of protection against ischaemic insult are offered and thus the 
driving force to reach the threshold which would then initiate angiogenesis, also differs.   
Helisch et al. (2006) studied 3 different strains of mouse (C57BL6/J, Balb/c and 
129S2/Sv) following a femoral artery occlusion, using laser doppler imaging, visible light 
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oximetry, and treadmill testing.  C57BL6/J mice exhibited the most complete recovery as 
this strain appeared to have a high number of visible collaterals immediately following 
ligation, and no tissue hypoxia or damage was seen in these areas when compared to the 
Balb/c strain of mouse.  This confirmed findings of Shireman et al. (2005).  However, it is 
important to remember that along with inter-species differences, there is considerable 
inter-animal variability in the functionality of pre-existing collaterals, despite the animals 
being genetically similar (Zbindeen et al. 2006). 
Results from a further study support the implication that genetic heterogeneity 
plays a major role in determining the response to hypoxic conditions.  Ward et al. (2007) 
found that of 4 different strains of mouse used, C57BL6/J, 129S2/Sv, Balb/c and CD-1, a 
strain-dependent expression of angiogenic growth factors was shown, with the C57BL6/J 
showing only an intermediate increase of angiogenic growth factors, namely VEGF and 
Ang-2, compared with the other strains.  C57BL10/J mice are also known to differ from 
C57BL6/J mice with regard to various hematological and coagulation parameters, as well 
as in their inflammatory response to an infectious challenge (Peters et al. 2002), though 
differences in capillary growth under the ischaemic conditions imposed here were not 
obvious.   
The C57BL6/J strain of mouse therefore appears to be fairly resistant to these 
experimental interventions and, due to the differing intrinsic mechanisms specific to each 
strain, it is difficult to know which is the most suitable surrogate model for human 
disease.  Although these data may prove helpful in providing insights into the magnitude 
of the variety of responses present in humans, a review of gene expression in this model 
would provide extremely useful information to aid understanding of the different 
pathways upregulated, posing further stimulation for research into the most effective and 
beneficial methods of manipulating the molecular pathway underlying ischaemia, and to 
a greater understanding of the disease itself.  
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4.4.4 Trauma following surgery and inflammation-induced angiogenesis  
A variety of responses are seen following ligation of the femoral artery in the mouse and 
it is thought that the role inflammation plays is grossly underestimated.  The variation in 
outcomes among studies is due, among other factors previously discussed, to the 
location of the suture and whether or not both the artery and vein are ligated as a dual 
procedure (Richardson et al. 2001), altering the degree of ischaemia and the amount of 
trauma induced.  Ziv et al. (2004) carried out a longitudinal MRI tracking study 
subsequent to ligation of the femoral artery in the hindlimb of the mouse.  They noted 
that in the early stages of ischaemia, most of the angiogenesis occurring was in the 
subcutaneous fat as opposed to the injured muscle, the former of which showed no 
evidence of damage from the ischaemia.  In the muscle, vascular permeability was 
elevated in the first few days, propagating tissue damage, though it subsequently 
resolved a few days later.  Scholz et al. (2003) showed that ischaemia-induced damage 
following ligation developed gradually, shown by the decay of high-energy phosphates 
and tissue glycogen, and that only 21 days post-surgery was evidence of cell death 
diminished.  There are data to show a lack of muscle necrosis or evidence of 
inflammation in rats, based on macrophage staining (Brown et al. 2003), and our data 
further support this.  
One of the main factors differing in models of femoral artery ligation is the 
location of the suture and thus degree of ischaemia and damage inflicted.  Ziv et al 
(2004) used a location of the ligation further upstream than the present study, and this 
resulted in a much higher degree of ischaemia as evidenced by loss-of-function of the 
hindlimb for the first few days.  However, difficulty in reaching this location due to 
proximity to the abdominal wall, and the presence of copious white adipose tissue, may 
have been responsible for inflicting trauma that led to this inflammation.  Another 
illustration of the effects of extreme ischaemia were shown after the entire left superficial 
femoral artery and vein, from just below of deep femoral arteries to popliteal artery and 
vein, were ligated, cut, and excised (Masaki et al. 2002), resulting in auto-amputation.  
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These effects of ischaemia were not present in our model, as mice regained full use of 
the limb the day after surgery when ligating the artery above and below the saphaenous.   
These data suggest that the degree of ischaemia induced was not extreme 
enough to elicit the significant angiogenic response expected under these conditions, and 
that depending on the size of the incision and the damage caused upon isolation of the 
artery, inflammation and muscle damage can be avoided.  However, a study following 
gene expression after acute hindlimb ischaemia found that inflammation-associated 
genes were also induced after sham surgery, suggesting that the trauma of the operation 
itself has the potential to induce a number of changes in gene expression (Lee et al. 
2004).  
Evidence of inflammation at either 1 or 2 wks in these studies was not seen on 
analysis of WBC infiltration.  However, this does not confirm an initial absence of 
inflammation, or absence of an inflammatory mediated HIF-stimulated pathway 
operating (Fig. 4.4) as opposed to the postulated hypoxia-mediated HIF pathway being 
stimulated, because, as is indicated by the above studies, inflammatory consequences 
were immediately counteracted on a molecular level, and transformation back to a more 
homeostatic environment was evident after a short period of time.  It is therefore 
possible that the angiogenic response seen here was due to a combination of an initial 
inflammation-induced HIF-upregulation, this being superceded and driven by a hypoxia-
induced HIF-response once inflammation had been suppressed.  However, the extent and 
position of the ligation will most likely determine the amount of inflammation induced.  
Due to the less invasive method used here, it is likely that inflammation contributed only 
a minor amount.  
 
4.4.4.1 Differential upregulation of HIF 
There has been substantial interest in the cross-talk between two hypoxia-responsive 
factors: HIF and nuclear factor !B (NF!B).  Although HIF is widely known as being a key 
player in the cellular response to hypoxia, it is one amongst a host of factors sensitive to 
 129 
changes in surrounding O2 concentrations.  NF!B is a family of transcription factors that 
become activated following stimulation by pro-inflammatory factors such as cytokines.  
Despite showing evidence of the independent stimulation of pathways leading to the 
upregulation of hypoxic gene expression, a significant level of cross-talk has been 
demonstrated (Taylor, 2008) (Fig. 4.4), and along with NF!B being implicated in 
maintaining basal levels of HIF-1" gene expression in vivo (Rius et al. 2008), HIF-1" has 
been shown to regulate some of NF!B signalling (Taylor, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Illustration of the cross talk between HIF-1" and NF!B under hypoxia 
(Adapted from Taylor, 2008) 
 
 
4.4.5 Upregulation of anti-angiogenic factors 
A very fine balance exists between pro- and anti-angiogenic factors and the driving 
stimulus for new blood vessel growth that occurs when this balance is disrupted (Figg 
and Folkman, 2008).  The upregulation of anti-angiogenic factors is largely ignored in 
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studies of ischaemia, which usually focus on the changes in pro-angiogenic factors that 
are occuring.  An example is VEGF-A which has 5 isoforms, each of which differ in their 
degree of heparin affinity (Springer et al. 2007).  VEGF splicing in the terminal exon 
results in a family of isoforms that have a 94-98% homology with the mentioned VEGF 
isoforms, but are antiangiogenic and known as VEGFxxxb (Bates et al. 2002).  VEGF165b 
isoforms constitute large percentages of the total VEGF protein in non-angiogenic tissues 
(up to 82% in the colon; Ladomery et al. 2006), though a smaller percentage in 
angiogenic tissues such as the placenta (Carmeliet et al. 1999).  Their amounts in 
skeletal muscle remains unknown.  The balance of pro- to anti-angiogenic VEGF isoforms 
determines the disease state of tissue.  There appears to be a splicing switch in the 
proximal C-terminal which increases the ratio of pro- to anti-angiogenic isoforms of 
VEGF, and is clearly shown to be associated with a number of diseases (Ladomery et al. 
2006).  Thus the regulation of splicing and the switch to a pro-angiogenic state, is a key 
event in the development of many diseases, suggesting possible reasons as to why many 
studies show an upregulation of angiogenic growth factor genes (Tuomisto et al. 2004) 
and proteins (Lloyd et al. 2003) but no capillary growth.  A recent study also showed that 
chronic hypoxia attenuates VEGF-stimulated signalling in primary human coronary artery 
endothelial (HCAE) cells by down-regulating Flk-1 expression, suggesting a possible 
further explanation for the impaired angiogenic responses seen here (Olsezewska-
Pazdrak et al. 2009).   
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4.5 Conclusions 
Ligation of the femoral artery in the hindlimb of the C57BL6/J mouse for either 1 or 2 
wks was insufficient to induce a significant angiogenic response in the skeletal muscle 
with or without the PHD inhibitor, DMOG. There were a number of setbacks which 
impacted on this study: the use of a potentially impure chemical to mimic the effects of 
hypoxia, did not show expected blood vessel growth, and it was later discovered that the 
strain of mouse being used may have been more resistant to ischaemic challenge when 
compared with other strains.  Different studies utilise different ligation points on the 
artery, with those who placed their suture higher than used here obtaining a visual 
physiological retardation of hindlimb and movement.  This suggests that in order to reach 
the potential threshold for HIF activation and a subsequent significant increase in 
capillary growth, the intervention needs to induce a higher degree of ischaemia.  
However, this is confounded by the high degree of inflammation and muscle fibre 
damage that may be incurred.  The role that inflammation played vs hypoxia in this 
model is unknown here.  
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4.6 Future experiments 
An important component of studying the pro-angiogenic response is looking at the anti-
angiogenic factors that are also subsequently upregulated, and which may be preventing 
angiogenesis from occurring.  An example of an anti-angiogenic factor is endothelin 1.  If 
the intervention of ligation of the femoral artery was insufficient, an additional stress on 
system with DMOG may provide a sufficient stimulus in order to induce angiogenesis.  
Using an additional stress such as exercise may also be necessary to enable threshold 
levels required to stimulate blood vessel growth via HIF.  An iliac ligation is an alternate 
method of limiting blood flow to the hindlimb, though may induce an increased level of 
ischaemia due to its higher location. Finally, it would be interesting to study these effects 
in the more responsive soleus muscle of the hindlimb.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 133 
 
 
 
 
 
 
Chapter 5 
EXTIRPATION 
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5.1 Introduction 
Removal of a synergist muscle will induce functional overload in the remaining muscle as 
a compensation for the change in load bearing.  Along with a resulting increase in muscle 
mass, the muscle stretch created by this situation stimulates the sprouting form of 
angiogenesis, whereby abluminal sprouting of endothelial cells (ECs) through the 
basement membrane occurs (Zhou et al. 1998).  This initiates the formation of an 
extended network of capillaries, maintaining blood flow to the elongating muscle fibres 
and providing sufficient O2 supplies required for driving new protein synthesis to support 
an increase in the number of serial sarcomeres (Goldspink et al. 1991).  There are a 
number of models representing how functional overload can be used to induce an 
increase in capillary supply and these models are extremely useful in studying the effects 
of, and recovery shown, following a variety of clinical situations (e.g. muscle ablation).  
Alongside removal of a synergistic muscle, electrical stimulation of the muscle or nerve 
supplying it (Egginton et al. 2001; Hudlicka et al 2003), or increased load bearing with 
the use of an additional weight (Gupta and Zak, 1998; Awede et al.1999), are all 
recognised models used to induce an increased fibre size and capillary growth.   
5.1.2 Sensing stretch 
Blood vessels are constantly subjected to haemodynamic forces such as shear stress, 
transmural pressure and cyclical strain that change during a cardiac cycle.  Muscle 
stretch in capillaries is sensed primarily by stretch-activated ion channels (Lansman et al. 
1987) on ECs which are located at the interface between the blood and the vessel wall.  
Arteries also sense stretch using receptors within smooth muscle cells such as TRPC6, a 
cation channel which is sensitive to deformation (Spassova et al. 2006).  Any alterations 
in stretch or shear induce transformational changes in the vessel wall as a homeostatic 
mechanism to accommodate the new conditions (Lehoux et al. 1998), and this 
remodelling is characterised by altered morphology of the blood vessels.  At the cellular 
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level, mechanical forces exert changes on the cytoskeleton, gene expression and the 
proliferation and survival of cells: when subjected to cyclic stretching, almost every type 
of cell has been found to align nearly perpendicular to the primary stretching axis (Wang 
et al. 2001) and stess fibres are known to assemble in the same direction (Shirinsky et 
al. 1989).  Under elevated shear stress conditions, bovine aortic endothelial cells undergo 
a change in cell morphology, resulting in an increase in central stress fibres and 
fibronectin fibrils (Thoumine et al. 1995a) and a change in the structure and composition 
of the extracellular matrix (ECM) (Thoumine et al. 1995b).  It is assumed that similar 
mechanisms facilitate mechanotransduction of stretch.  
 
 
 
Figure 5.1 Mechanisms of mechanotransduction within and between endothelial cells (From Ingber, 
2006) 
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The cytoskeleton is thought to be the main sensor of mechanical stretch, being 
responsible for transmitting signals throughout the cells (Ingber, 2006).  Stretch-
activated ion channels, integrins, growth factor receptors and the ECM, among numerous 
other structures, have all been shown to contribute to the mechanotransduction response 
(Ingber 2006; Lehoux et al. 1998) (Fig. 5.1).  One proposed model for signal 
transmission is that stretch-sensitive ion channels undergo conformational change when 
the membrane bilayer distorts.  These channels are relatively non-selective, and it was 
shown that stretch induced an increase in intracellular calcium and other divalent cations 
(Lansman et al. 1987, Davis et al. 1992).  Tension-dependent changes in the orientation 
of collagen causes distortion of interconnected basement membrane scaffolds (Fig. 5.2), 
and this in turn induces changes in the cytoskeleton within associated endothelial cells. 
 
 
 
 
Figure 5.2 Illustration of cellular mechano-responsiveness and connections between the ECM, cells, 
cytoskeletal networks, and nuclei: changes are channelled through the cytoskeleton to basal cell-
ECM adhesions.  Red and blue lines represent tension-dependent changes in cytoskeletal structure. 
(From Inger, 2006) 
Collagen 
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5.1.3 Endothelial cell gene responses and capillary network remodelling 
5.1.31 Endothelial cells 
The mechanical stretch imposed on ECs following muscle activity, or in this case 
overload, results in upregulation of a number of genes.  The MAP kinase cascade is a 
major pathway through which signals derived from growth factors and mechanical strain 
are transduced into regulation of gene expression and protein synthesis.  This pathway 
involves sequential phosphorylation and activation of cytoplasmic protein kinases 
(Lehoux et al. 1998).  Diverse pathways link mechanical strain to MAP kinase activation 
in vascular cells, and it is thought that integrins are likely involved in these transmission 
pathways.  Castilla et al. (1999) found an increase in VEGF mRNA in bovine aortic 
endothelial cells, following disruption of intercellular junctions caused by mechanical 
stretch.  Matrix metalloproteinase 2 (MMP-2), a protein involved in the breakdown of 
extracellular matrix, has been shown to be upreguated via the ERK1/2 and JNK pathways 
(Milkiewicz et al. 2007), both of which are critical regulators of cell differentiation, cell 
physiology and neuronal function.   
5.1.3.2 Capillary network remodelling  
Capillary network remodelling is essential to enable physiological adaptation following 
functional overload.  Two morphologically distinct forms of angiogenesis: sprouting and 
splitting, induced by contrasting mechanical stimuli, both lead to the formation of fully 
functional mature capillaries (Hudlicka, 1998).  Muscle stretch and overload stimulates 
abluminal sprouting of endothelial cells through the basement membrane.  These sprouts 
then grow and fuse with other capillaries to form functional anastomoses (Zhou et al. 
1999).  Egginton et al. (2000) have shown that the basement membrane (BM) 
degradation seen here is unique to this form of angiogenesis, occurring only at sprout 
tips.  Following this disruption, the ECs migrate through the gap that is formed into the 
interstitium where they develop central lumens and eventually form anastomoses with 
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other vessels.  This type of migration is seen in response to an external (abluminal) 
stimulus; an internal (luminal) stimulus, such an increased shear stress induced by 
hyperaemia (as a result of exercise or hypoxia, for example) mediates the intraluminal 
splitting form of angiogenesis which occurs without BM breakdown or sprouting. 
5.1.3.3 The role of non-hypoxically inducible HIF in stretch-induced angiogenesis 
These different forms of angiogenesis are accompanied by a differential expression 
pattern of angiogenic mediators (Williams et al. 2006b).  For example, both stretch and 
shear stress increase VEGF, while only stretch increases MMPs (Rivilis et al. 2002) and 
only shear stress increases nitric oxide synthase (NOS) activity (Williams et al. 2006a).  
It was recently shown that the expression of HIF-1! and HIF-2! can also be modulated 
by mechanical forces, along with the known stimulus of low O2 tension (Richard et al. 
2000; Kim et al. 2002).  Milkiewicz et al. (2007) interestingly showed that both HIF-1! 
and HIF-2!, on a protein and mRNA level, played a core role in stretch-induced 
angiogenesis, though not shear-induced splitting angiogenesis, confirming a role noticed 
earlier for HIF-1! (Williams et al. 2006b).  Furthermore, using real-time PCR, Chang et 
al. (2003) showed that levels of HIF-1! mRNA increased 2.1 fold in cultured vascular 
smooth muscle cells after cyclical stretch for 4 hours.  
5.1.4 Skeletal muscle hypertrophy and capillarity 
The structural integrity of the capillary wall is such that capillary distensibility is largely 
determined by support provided by the tissue in which it is located (Kindig et al. 1998).  
In skeletal muscle, capillaries appear not to change a great deal in reponse to changes in 
perfusion pressure (Bosman et al. 1995) and it has been postulated that this is due to 
the structural interactions of the surrounding muscle, coupled with capillary-myocyte 
struts (Kindig et al. 1998).  As sarcomere length increases, the tortuosity of capillaries is 
lowered as they become more highly aligned wih the longtudinal muscle fibre axis.  
James (1981) showed that capillaries in hypertrophied muscle become more highly 
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orientated and further stretching most likely results in a decrease in the luminal diameter 
(Kindig et al. 1998).  A multitude of studies have addressed the issue of whether the 
contortions of these blood vessels are sufficient to induce changes in the blood flow to 
the muscle, thus affecting O2 delivery (Poole et al. 1997; Kindig et al. 1999).  It has been 
shown that resting and maximal levels of blood flow following 2 weeks of extirpation are 
similar, suggesting that increased blood flow is not responsible for initiating expansion of 
the capillary bed following overload, and that the subsequent increase in capillary supply 
normalises any changes in blood flow arising (Egginton et al. 1998).  This adds further 
support to the finding that HIF can be upregulated under normoxic conditions.  
It has been demonstrated that using a mouse model for extirpation mirrors 
changes seen in the well-studied rat model (Williams et al. 2006a), sufficiently for 
conclusions to be drawn based on comparisons with other studies.  It has previously 
been demonstrated that extirpation of the TA results in an increase in the C:F ratio of the 
remaining EDL muscle (Egginton et al. 1998).  Inter-strain variation in mice has not been 
studied under conditions of extirpation, although this was examined in the femoral artery 
ligation model in CHPT 4 with no obvious differences observed.  However, it was thought 
to be beneficial to explore differences between the C57Bl6/J and C57Bl10/J strains of 
mouse, these being most commonly used in studies of this kind, with results often used 
interchangeably on the assumption that there are no strain-specific response to stretch.  
Gene array analysis (Wlliams et al. 2006) showed upregulation of HIF-1!, suggesting 
that it may be responsible for driving capillary growth under normoxic conditions.  
However, mechansims governing its regulation under conditions of stretch may be 
different to those under hypoxia.  Whether DMOG, the oxoglutarate analogue which 
works by inhibiting prolyl-hydroxylases (PHDs) 1–3 and factor inhibiting HIF (FIH), has 
the same effect on HIF levels and downstream effects under conditions of stretch, in 
correspondence with the already known conditions of hypoxia (Milkiewicz et al. 2005), 
was investigated.  This model was used to determine the efficiency of this drug in 
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enhancing muscle capillarity following removal of a synergist muscle in two different 
strains of mouse. 
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5.2 Methods 
5.2.1 Study design: extirpation 
The procedure involved unilateral surgical removal of the tibialis anterior (TA) muscle in 
the mouse hindlimb, then re-suturing the skin to allow recovery for 1 or 2 wks, resulting 
in overload of the synergistic extensor digitorum longus (EDL) muscle.  Experiments 
were performed on groups of C57Bl6/J and C57Bl10/J mice (n=6 in each experimental 
group).  Each group received DMOG (8mg.0.5ml-1 saline) (CHPT 2.1) via i.p. injection 
every other day, with the initial injection 2 days before surgery.  
5.2.1.1 Surgery 
Mice were anaesthetised under aseptic conditions starting with 5% isofluorane and 
decreasing to 2.5% with O2 as a carrier.  0.2ml.100g
-1 Temgesic! was given prior to 
surgery for postoperative analgesia.  An incision was made through the skin at the base 
of the TA tendon and the scalpel used to cut through the skin and fascia, all the way to 
the top of the muscle.  Forceps were used to free the tendon from surrounding fascia and 
lift it, allowing room to cut it free with a scalpel blade.  The muscle was lifted as high as 
possible without inflicting any damage and excised close to the top with one clean slice.  
The end of the cut muscle was put onto the muscle stub to stem the bleeding and induce 
coagulation.  Two drops of antibiotic (300mg.ml-1 Depocilin!) were applied and any 
excess removed after allowing absorption for a short time.  The wound was sealed with 4 
sutures (6,0 vicryl monofilament) and any dried blood removed to minimise the risk of 
infection or irritation for the animal.  Mice were allowed normal access to food and water 
to aid recovery and were sacrificed after the experimental period via cervical dislocation.   
5.2.1.2 Tissue processing 
EDL muscles from surgically affected limbs were taken (CHPT 2.2) and stored on corks at 
-80°C after being snap-frozen in isopentane cooled in liquid nitrogen (CHPT 2.3).  Tissue 
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was sectioned and stained (CHPT 2.3) and capillary and fibre numbers (C:F) counted as 
described in CHPT 2.4, using lectin staining.  
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5.3 Results 
5.3.1 Capillary changes in skeletal muscle following extirpation surgery 
5.3.1.1 Lectin staining 
Extirpation surgery was initially conducted on C57Bl6/J mice over a period of 2 weeks, 
with and without DMOG.  There was a significant increase between the control and 
control DMOG vs. extirpated leg without DMOG (Table 5.1), with an insignificant yet 
noticeably raised capillary to fibre ratio (C:F) in the extirpated leg with DMOG.  There 
was a significant change in the mass of EDL muscle in the extirpated leg compared to 
control (Table 5.3).  With the exception of the capillary density (CD) in the 2 wk no 
DMOG group which showed a significant increase when compared to control and control 
DMOG, the mean fibre are (MFA) or CD did not change significantly from control values 
(see Chapter 3 for a photo of capillary lectin staining). 
 
Experiment C:F  
 
CD (cap.mm-2) MFA  (!m2) 
 
RMEDL (%) 
 
Control        
 
1.26 ± 0.02 
 
885 ± 67 
 
1521 ± 102 
 
0.031± 0.002 
 
Control D  
 
1.26 ± 0.05 
 
937 ± 118 
 
1363 ± 86 
 
0.030± 0.003 
 
2 wk no D  
 
1.36 ± 0.05 §* 
 
1118 ± 76 §* 
 
1262 ± 81 
 
0.062± 0.002§* 
 
2 wk D            
 
1.30 ± 0.03 
 
923 ± 94 
 
1345 ± 234 
 
0.041± 0.002  
 
Table 5.1 Mean C:F, CD and MFA ±SEM for the EDL muscle in the extirpated leg in C57Bl6/J mice 
(n=6).  §=P<0.05 vs. control, *= P<0.05 vs. control DMOG as determined by ANOVA with Dunnetts 
post-hoc test, D=DMOG.  
 
 
Surgery was repeated on C57Bl10/J mice over a period of 2 weeks with and without 
DMOG.  There was a significant increase between control and extirpated C:F values for 
mice with and without DMOG (Table 5.2).  There was a significant increase in muscle 
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mass between the extirpated vs. control muscle (Table 5.3), though no significant 
changes in MFA or CD in this study. 
 
Experiment C:F  
 
CD  
(cap.mm-2) 
MFA  (!m2) 
 
RMEDL (%) 
 
Control       
 
1.23 ± 0.06 
 
990 ± 43 
 
1427 ± 51 
 
0.030±0.001  
 
2 wk no D  
 
1.43 ± 0.04 § 
 
1095 ± 22 
 
1308 ± 40 
 
0.042±0.002§ 
 
2 wk D             
 
1.36 ± 0.02§  
 
907 ± 44 
 
1514 ± 81 
 
0.041±0.001§ 
 
Table 5.2 C:F, CD and MFA for the EDL muscle in the extirpated leg in C57Bl10 mice (n=6) 
§=P<0.05 vs. control, as determined by ANOVA with Dunnetts post-hoc test (mean±SEM shown, 
D=DMOG) 
 
 
 C57Bl6/J 
Mass of EDL (g) 
C57Bl10/J 
Mass of EDL (g) 
Control  
mean±SE 0.009g±0.0004 
 
0.009±0.0007 
DMOG-treated 
mean±SE  0.009±0.0002 0.011±0.0007 
Non-DMOG treated 
mean±SE  0.010±0.0003 0.01±0.0006 
 
Table 5.3 EDL mass (g) in C57Bl6/J and C57Bl10/J mice (n=6) treated with and without DMOG 
(mean±SE, determined using descriptive statistics with excel.  No significant difference as 
determined by ANOVA with Dunnetts post-hoc test) 
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5.4 Discussion 
The aim of this study was to determine whether a differential angiogenic response would 
be seen in either of 2 strains of mice (C57Bl6/J and C57Bl10/J) under conditions created 
by synergist extirpation-induced muscle overload.  The second aim was to determine if 
chemical manipulation of the PHDs (affecting the HIF pathway) under these conditions 
would have a similar effect to that seen under hypoxia, of enhancing HIF availability and 
downstream capillary growth. 
 A limiting factor when using extirpation as a method to induce angiogenesis is that 
a level of inflammation will be present following the invasive nature of the surgery, along 
with factors involved in wound healing.  It has been shown that gene responses 3 days 
post-surgery is the earliest point at which no clinical signs of inflammation are seen 
(Williams et al. 2006b).  Zhou et al. (1999) found no histological evidence of 
inflammation 1 wk following extirpation surgery, suggesting that any angiogenesis at this 
point is likely to be as a result of muscle stretch as opposed to other conflicting factors 
involved in inflammation. 
5.4.1 Effects of extirpation in the hindlimb 
Most studies on extirpation are based on rat models, with the first mouse model being 
demonstrated by Williams et al. (2006a).  Their study confirmed that the mouse model 
can be used comparatively with previous data reported for the rat, allowing cross-species 
comparisons.  
5.4.1.1 Removal of a synergist muscle stimulates capillary growth 
Extirpation in the hindlimb of the C57Bl6/J mouse resulted in a significant increase in 
capillary growth in both non- and DMOG-treated groups of animals.  The increase in C:F 
ratio seen following extirpation surgery is in accordance with other studies (Egginton et 
al. 1998; Zhou et al. 1999; Williams et al. 2006a).  Repetition of the surgery on the 
C57Bl10/J exhibited a similar pattern: the increase in C:F ratio was significantly higher 
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compared to control in both treated and untreated animals, though still lower compared 
to previous values of 1.54 seen in this strain (Williams et al. 2006a).  The change in the 
C67Bl10/J mouse was greater than that seen in the C57Bl6/J mouse (16.3% vs. 7.9% 
increase in non-DMOG treated animals and 10.6% vs. 3.2% respectively, in the DMOG-
treated animals).  Williams et al. (2006a) found that the peak rate of angiogenesis 
occurred between 3 and 7 days in the C57Bl10/J mouse, with only a modest increase 
between 14 and 28 days.  Thus, capillary growth seen here most likely reflects near 
maximum extent of growth that may occur under these conditions.   
 The greater change seen in the C57Bl10/J compared to the C57Bl6/J mice 
illustrates that inter-strain differences do exist, although subtle and statistically 
insignificant.  A differential response may be as a result of differences in fibre type 
composition: it has been suggested that glycolytic fibres have a greater capability for 
angiogenesis, possibly due to their greater girth which is usually supplied by fewer 
capillaries, thus making them more susceptible to hypoxia (Deveci et al. 2001).  This is 
supported by data from Ahmed et al. (1997) who showed that the capillary supply to 
human skeletal muscle was scaled with respect to fibre size, though noted that this was 
independent of fibre type.  Differences in fibre type could easily be explored, though no 
data on differences in composition is presently available.  
 
5.4.1.2 Changes in muscle mass associated with extirpation surgery  
In both cases an increase in EDL muscle mass, although not significant, was observed.  
Overload of the EDL enhances protein synthesis and this is correlated with an increase in 
muscle fibre diameters, a minor change in fibre type, and only a modest change in the 
number of fibres present (Hudlicka et al. 1982; Egginton et al. 1998; Badr et al. 2003).  
There is also an increase in collagen deposition in muscles subjected to stretch during 
limb lengthening (Laurent et al. 1985), as also seen with electrical stimulation (Hansen-
smith et al. 1996), suggesting this may be a common response to increased muscle 
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activity.   
5.4.2 Oxygen supply and demand 
5.4.2.1 Upregulation of protein synthesis and maintenance of blood flow 
Protein metabolism is a metabolically expensive process and is upregulated under 
conditions following extirpation where the number of serial sarcomeres is increased to 
compensate for the increase in load bearing (Goldspink et al. 1995).  However, the O2 
demand enabling this to occur is not thought to be excessive, suggesting that O2 is not 
the limiting factor.  As mentioned above, it has been shown that changes in fibre type 
and size are only subtle (Hudlicka et al. 1982; Egginton et al. 1998; Badr et al. 2003), 
adding support to the notion that changes in metabolism and global O2 consumption are 
minimal following removal of a synergist muscle, and thus hypoxia is not a stimulating 
factor for capillary growth here.  Furthermore, Egginton et al. (1998) showed that resting 
and maximal levels of blood flow following 2 wks of extirpation are similar to controls, 
suggesting that O2 delivery is maintained following surgery and thus is not the major 
factor initiating new blood vessel growth.  The recent observations that HIF can be 
upregulated under non-hypoxic conditions along with the already known hypoxic 
stimulus, lends support to the notion that HIF-stimulated blood vessel growth under 
stretch can occur under normoxic conditions. 
5.4.2.2 Chemical manipulation of the HIF pathway with DMOG: Evidence for the 
upregulation of HIF-1! and HIF-2! under non-hypoxic stretch 
Richard et al. (2000) was one of the first to show an upregulation of HIF-1! protein in 
vitro in vascular smooth muscle cells (VSMCs), under non-hypoxic conditions of the 
introduction of fetal calf serum and serotonin, independently, followed soon after by Kim 
et al. (2002) who illustrated the protein presence under mechanical strain in non-hypoxic 
rat myocardium in vivo.  Furthermore, Chang et al. (2003) showed that HIF-1! mRNA 
also increased under conditions of non-hypoxic stretch in vitro in rat VSMCs.  These 
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studies provide clear evidence for the presence of HIF-1! under conditions of stretch, 
and under conditions whereby O2 supply is maintained (see above), allowing the 
assumption that chemical manipulation of the PHDs and thus HIF levels (DMOG) should 
have a similar effect to what is seen in ischaemia, in facilitating the growth of new 
vessels under conditions of overload.  As is evident here, the desired effect is not seen, 
in fact, the opposite trend was observed.   
5.4.3 DMOG  
5.4.3.1 Multiple targets of DMOG 
DMOG not only targets PHD1-3, but the whole of the prolyl 4-hydroxylase (PHD) family.  
Of these, 2 animal PHD families are known today: collagen PHDs (also known as C-
P4Hs), endoplasmic reticulum luminal enzymes that have a central role in the synthesis 
of all collagens, and HIF-P4Hs, nuclear and cytoplasmic enzymes that play a key role in 
the response of cells to hypoxia (Koivunen et al. 2007).  The C-P4Hs act on Xaa-Pro-Gly 
sequences in collagens and more than 20 collagen-like proteins, leading to their 
degradation.  Collagen deposition is an important part of new skeletal muscle remodelling 
(Winter and Page, 2000) and interference in this process may influence fibre lengthening 
and capillary formation: collagen type IV also forms an important part of the basement 
membrane surrounding the capillary.  It is therefore possible that DMOG interfered with 
the collagen synthesis pathway and thus hindered the subsequent development of 
muscle fibres and capillaries. 
5.4.3.2 The confounding factor of DMOG efficiency 
Investigations made into the efficiency of the DMOG used in these experiments revealed 
that the initial batch used in CHPT 4 was chemically modulated when compared to an 
initial batch.  The newly synthesised batch, from the same source as the original, was 
used in these extirpation experiments.  Results obtained from CHPT 4 suggest that the 
recorded discrepancies between the two batches may be insignificant based on the fact 
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that the C:F ratio in the hindlimb following ligation of the femoral artery in CHPT 4 
appeared to show similar changes following the use of either batch.  It is possible that 
the threshold required to stimulate HIF was not reached, and thus augmentation of the 
HIF system to its full potential was not achieved.  As suggested previously, DMOG may 
also work differently in different skeletal muscles, depending on fibre type composition 
and on the amount or type of PHD enzymes present, which is known to be variable in 
different tissues.  However, differential expression among skeletal muscle has not been 
explored as yet.    
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5.5 Conclusions 
Extirpation in the hindlimb of both the C57Bl6/J and C57Bl10/J strain of mouse was 
successful in inducing an increased capillary growth in the EDL muscle, causing subtle 
changes in muscle mass.  This effect was seen to a greater magnitude in the C57Bl10/J 
strain, suggesting that inter-strain differences may be an important variable to consider 
when comparisons between models and findings are used.  A similar finding was 
observed in the ligation model (CHPT 4), although the general trend was the same.  
DMOG was predicted to enhance the capillary supply to a greater extent than extirpation 
alone.  However, treated animals seemed to express lower C:F ratios than those without 
DMOG, suggesting that DMOG is having an effect on collagen synthesis in the overloaded 
muscle, or that the mechanism by which HIF is acting under conditions of stretch is 
different to those under hypoxia.  
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5.6 Further experiments 
It would be interesting to further examine cross strain variability in the response to 
extirpation using a variety of strains, including those that have already been studied such 
as Balb/C, using muscle fibre type staining as one method of investigating what 
differences may exist.  Enhancing the degree of overload achieved could be explored by 
removing a different muscle such as the plantaris.  This was done by Degens et al. 
(1992) who observed a much greater 32% increase in muscle mass.  It would be useful 
to develop a chemical inhibitor that specifically targeted each of PHD1-3 to overcome any 
confounding factors, such as interference with non-HIF pathways.  Using knockout mice 
to illustrate which of the PHDs are most important in this model would, along with a gene 
array analysis, be a useful track to investigate in order to determine underlying 
differences in phenotypes.  Accordingly, this has been further explored in CHPT 6. 
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Chapter 6 
GENE ARRAYS 
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6.1 introduction 
Gene microarray technology has made it possible to characterise the RNA expression of 
thousands of genes across numerous tissue samples and under varying conditions, and is 
a powerful technology that offers comprehensive profiling of gene expression.  The 
benefits of being able to group together collections of genes that may previously have 
been unknown to operate under postulated conditions are only just being realised. 
6.1.1 Differential involvement of PHDs in capillary growth following muscle 
overload 
HIF was originally known to become active under conditions of hypoxia but it has 
recently been shown that non-hypoxic conditions such as stretch, e.g. induced by 
removal of the synergist muscle in the hindlimb, can also upregulate HIF on both an 
mRNA and protein level (Milkiewicz et al., 2005; Richard et al., ; Williams et al. 2006).  
Under normoxia, modification of the ODD within the HIF protein by members of the 2-
oxo-glutarate-dependent dioxygenase superfamily (PHD 1-3) inhibits HIF activity.  
Appelhoff et al. (2004) showed that each of the three isoforms of PHD contributes in a 
non-redundant manner to the regulation of both HIF-1! and HIF-2!, with each 
expressing a different specificity for hydroxylation sites on the HIF-! subunit, thus 
modifying the degree and extent of HIF activation.  PHD 1-3 have differential localisation 
patterns, exhibiting abundance in specific tissues, further supporting findings that they 
are not equally required in vivo (Hirsila et al. 2003).   
6.1.2 Genetic manipulation of mouse models  
6.1.2.1 Knockouts 
A fundamental goal of biological science is to determine the physiological function of 
identified proteins.  This has been done in a multitude of ways.  In vitro studies provide 
an appropriate way of manipulating and studying a protein in a more simple setting, 
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though it is difficult to draw conclusions when such a large, unknown proportion of the 
system is missing.  A range of inhibitors specific to the PHD pathway are available, and 
have been trialled in a number of animal and cell models.  Ethyl 3,4-dihydroxybenzoate 
(EDHB), 6-chlor-3-hydroxychinolin-2-carbonic acid-N-carboxymethylamid (S956711) and 
L-mimosine (L-mim) all demonstrated similar effects to hypoxia by inducing HIF-1! in 
both human and rodent cells (Warnecke et al. 2003).  However, the unwanted and 
unknown side effects of these chemicals, and manipulation of pathways without being 
fully aware of possible redundancies in the system, are a disadvantage.   
 Developed over two decades ago, genetically modified animals provide a different 
approach to gene manipulation compared to methods already employed, allowing one to 
study the effects of redundancy whilst having the assurance that only the specified gene 
has been interfered with (but still with the possibility of compensation), and that no 
unwanted chemically-induced side effects are present.  The murine model is distinctly 
beneficial over classical genetic subjects (drosophila, yeast etc.) as mice are more closely 
related to humans from a physiological perspective, and mouse embryos can be 
manipulated with ease when compared to other rodent models (Picciotto and Wickman, 
1998).  Genetically manipulated models such as the knockout (K/O), whereby a gene or 
genes are made inoperative by the use of a plasmid or DNA construct, are advantageous 
as they provide greater definition and clarity of the in vivo function of molecules that 
have been studied in vitro, and the resulting phenotypes can be studied at many levels. 
6.1.2.2 PHD knockout mice 
Recent studies of knockout mice have unveiled some interesting phenomena occurring 
when a single PHD is ablated.  PHD1 knockout mice have been shown to lower O2 
consumption in skeletal muscle by reprogramming glucose metabolism from oxidative to 
more anaerobic ATP production (Aragones et al. 2008), resulting in impaired oxidative 
muscle performance through enhanced protection of the myofibres against ischaemia.  
The neuronal phenotype of PHD3 knockout mice was studied and shown to exhibit 
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abnormal sympathoadrenal development and systemic hypotension (Bishop et al. 2008). 
PHD2 K/O mice are embryonically lethal (Schneider et al. 2007), although heterozygous 
mice have been studied and shown to improve tumour perfusion and oxygenation, 
alongside inhibiting tumour cell invasion and metastasis (Mazzone et al. 2009). 
 PHD2 is thought to be the main PHD O2 sensor under hypoxic conditions 
(Berchner-Pfannschmidt et al. 2008), though due to its embryonic lethality as a 
knockdown, PHD1 and PHD3 K/O mice were used alongside wildtype animals in a model 
of extirpation, which has been shown to induce the HIF pathway via stretch as opposed 
to hypoxia (Williams et al 2006; Mikliewicz et al. 2007), to establish relationships 
between genomic and functional responses in skeletal muscle following genetic 
manipulation of molecular pathways leading to HIF-1! stability.  The aim was to elucidate 
whether groups of genes were differentially regulated and to identify common pathways 
within each model, to help elucidate whether complementary or redundant routes exist. 
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6.2 Methods 
6.2.1 Deriving knockouts 
Rederivation was perfomed by staff at the animal unit in Birmingham (BMSU).  Females 
were used for rederivation at about 5 wk old: they were given an i.p. injection of 
Pregnant Mare's Serum Gonadotrophin (PMGS) which mimics FSH.  Two days after they 
were given a second injection of Chorulon (mimics LH) and then mated with male PHD1 
mice (gift of Prof. C. Pugh, University of Oxford).  The following day, mice were checked 
for vaginal plugs, culled and the embryos removed from the oviduct of the mice.  
Clusters of embryos were put into M2 media and hyaluronidase added to remove cells 
that hold the embryos together.  They were then collected and washed 3-5 times before 
being cultured overnight at 37°C in 5% CO2.  The following day, embryos were 
transferred into the oviduct of a pseudo pregnant female which had been mated with a 
sterile male.  The resultant litter was weaned and the surrogate female screened for 
viruses.  Following this, the litters were removed from the isolator and sent for breeding 
to produce a colony. 
6.2.2 Genotyping (carried out at the university of Birmingham, Department of 
Physiology) 
This was used to determine the genotype of the knockout mice by extracting the DNA, 
using PCR to amplify samples, which were run on an agarose gel to identify the products 
and was performed in Birmingham.  
6.2.2.1 Protocol 
Ear clippings were placed in a 1.5ml Eppendorf with 0.5ml lysis buffer (10 mM Tris-HCl 
(Sigma-Aldrich, T5941) pH 8.0, 50mM KCl, 0.3% Tween-20 (Sigma-Aldrich, P5927), 
0.3% NP40 (Sigma-Aldrich, NP40), 1 mM Ethylenediaminetetraacetic acid (EDTA, Sigma-
Aldrich, 43178) and 16!l of 15mg.ml-1 Proteinase K (Roche, 03 115 887 0010) (final 
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concentration of 500!g.ml-1) added.  Samples were incubated at 55°C overnight then 
vortexed to break up remaining tissue.  Tubes were spun at 17,900g for 10 min to pellet 
undigested tissue, the supernatant removed and placed into a newly labelled Eppendorf.  
All reagents were kept at 4°C from this point.  500!l phenol:choloroform (Sigma-Aldrich, 
77617) was added (in a fume hood) and the solution vortexed.  Tubes were centrifuged 
at 17,900g for 10 min, the upper layer removed and 500!l of cold chloroform (Sigma-
Aldrich, C2432) was added. After vortexing, layers were allowed to separate (5-10min), 
then the upper layer removed and kept.  500!l cold isopropanol (Sigma-Aldrich, l9516) 
was added, the tube inverted then centrifuged at 17,900g for 10 min and the 
supernatant discarded.  800!l of 70% ethanol (Sigma-Aldrich, 459836) was added and 
the tubes inverted and flicked to unstick the pellet from the wall.  Samples were 
centrifuged for 10 min at 17,900g, supernatant removed and discarded, then re-spun at 
17,900g for 1 min to allow easier removal of excess liquid.  The pellet was air dried at RT 
for 5-10min and 100!l molecular biology grade water (Fisher Scientific, BP-2484-100) 
added though not mixed, but left at 37°C in the water bath for half an hour.  Samples 
were mixed by aspirating with a micropipette before use.  DNA was stored for short 
periods at 4°C.  
6.2.2.2 Primers for PCR 
To amplify the gene of interest via PCR, primer sequences were provided by the 
Wellcome Laboratory in Oxford and made by Alta Bioscience (University of Birmingham). 
PHD1 knockout and wild type mouse primers: 
WT allele reaction: 
With oligos PHDTFOR2 and PHD1NREV;  
Wt mouse = band at 900 bp, heterozygous mouse = no band 
 
PHDTFOR2: 5’- AGT CCC TCT GGT TCT AGA GTG GGG –3’ 
PHD1NREV: 5’- TCT CAG CAT CTC ATC ACT CCC CTG –3’ 
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Recombinant allele reaction: 
With oligos NEOPHD1N and PHD1NREV; 
Wt mouse = no band; heterozygous = 590 bp 
 
NEOPHD1N: 5’- TTG CAT CGC ATT GTC TGA GTA GGT GT –3’ 
PHD1NREV: 5’- TCT CAG CAT CTC ATC ACT CCC CTG –3’ 
 
PHD3 knockout and wild type mouse primers 
WT allele reaction: 
With oligos mPHD3-1 and mPHD3-2;  
Wt mouse = band at 357 bp, heterozygous = no band 
 
mPHD3-1: 5’- CGA GAT GCC TCT GGG ACA CAT CAT –3’ 
mPHD3-1: 5’- GGA CCG CTC CTT GAC ATA GTA TTT –3’ 
 
Recombinant allele reaction: 
With oligos NEO0770 and NEO1360; 
Wt mouse = no band; heterozygous = band 590 bp 
 
NEO0770: 5’- CGA CGG GCG TTC CTT GCG CAG –3’ 
NEO1360: 5’- CGG ATC GAT CCC CTC AGA AGA AC –3’ 
6.2.2.3 PCR protocol 
A total of 20!l mix per tube was made up of 0.2!l of each primer (4pmol.!l-1), 1!l  
RedTaq (1unit/!l: 1 unit incorporates 10 nmol of total dNTPs into acid-precipitable DNA), 
2!l 10x PCR buffer (100 mM Tris-HCl, pH 8.3, 500 mM KCl, 11mM MgCl2 and 0.1% gelatin: both 
RedTaq and buffer provided by Sigma-Aldrich D4309), 0.5!l deoxynucleotide (dNTP) (10 
mM each of UltraPure dATP, dCTP, dGTP and TTP, Sigma-Aldrich, D7295) and 1!l of 
cDNA, brought to a final volume of 20!l with nuclease-free water (Fisher Scientific, 
BP2484-100).  Samples were denatured by heating to 95°C for 1 min, followed by 30 
cycles of: 95°C for 30 s, 63°C for 30 s, and 72°C for 2 min.  Samples remained at 72°C 
for 10 min and were then held at 4°C until use. 
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6.2.2.4 Gel electrophoresis 
The products of the PCR were run on a 2% agarose gel (made with 1X TAE buffer, see 
below) alongside a 1 Kb Plus DNA Ladder (Invitrogen SKU# 10787-018) to determine 
whether the gene of interest was present. 
 
6.2.2.4.1 Solutions 
50x TAE buffer (1L): 1M glacial acetic acid (Sigma-Aldrich, A9967), 0.5M EDTA pH 8.0 
(Sigma-Aldrich, 43178), 2M TRIZMA base (Sigma-Aldrich, T1503). 
6.2.2.4.2 Protocol 
6g of agarose (Sigma-Aldrich, A9539) and 300ml of 1xTAE buffer were mixed then 
microwaved for 1 min to dissolve the agarose, then left to cool.  3!l ethidium bromide, 
(at a concentration of 10mg.ml-1, Sigma-Aldrich, E1510) was added and swirled to mix, 
making a concentration of 1!l.100ml-1.  The gel was poured into a tank of appropriate 
size, a comb inserted, and left to set for 20-30 min. The gel holder was put into a tank 
filled with 1x TAE buffer, covering the gel by at least 2mm.  The first well was loaded 
with 5!l marker and the remaining wells with 12!l of PCR samples.  The gel was run at 
100V for 20 min, then visualised using UV light and a computer with a gel-imaging 
device (Gene Genius Bio Imaging System with the Gene Snap programme). 
 
 
 
 
Figure 6.1 Illustration of genotyping results run on a gel following PCR: lane 1 = ladder, lane 2-4 = 
heterozygotes, lane 5 = wildtype (WT) (357bp), lane 6 = PHD3 K/O (590bp) 
  1       2     3     4      5      6 
357bp 
590bp 
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6.2.3 Study design: PHD knockouts 
PHD1 K/O, PHD3 K/O and wild type (WT) mice (n=3 in each group) underwent unilateral 
extirpation surgery as described (CHPT 5.2.1.1) and were then sacrificed by cervical 
dislocation after 1 wk.  EDL muscle from the surgically affected leg was removed for 
analysis (see below).  
6.2.3.1 Tissue processing 
EDL muscles from ipsilateral limbs were taken (CHPT 2.2) and stored on corks at -80°C 
after being frozen in isopentane cooled in liquid nitrogen (CHPT 2.3), or directly snap-
frozen in Eppendorf tubes in liquid nitrogen.  Tissue was sectioned and stained (CHPT 
2.3) and capillary and fibre numbers (C:F) counted as described in CHPT 2.4, using lectin 
staining. 
6.2.4 Gene arrays 
6.2.4.1 RNA extraction 
See Methods 2.5 for Qiagen RNA extraction and test for purity.  
6.2.4.2 Gene arrays (carried out at the Wellcome Laboratories in the University of 
Oxford) 
RNA quantity was measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE) and RNA quality checked using RNA6000 Nano Assay on 
Agilent bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA).  An RNA Integrity 
Number (RIN) above 7 indicates that the sample is acceptable, along with demonstrating 
that clear 28S and18S bands are present. 
Commercially available high-density oligonucleotide arrays, from Illumina 
Genome-Wide Expression BeadChips (Mouse Ref-8 v2, Illumina, San Diego, California, 
USA) were used with 25697 probes representing 18118 Mouse transcripts. In brief, 
500ng of total RNAs were reverse transcribed to synthesise first- and second- strand 
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complementary DNA (cDNA), purified on spin columns, and in vitro transcription to 
synthesise biotin-labelled complementary RNA (cRNA).  A total of 750ng of biotin-labelled 
cRNA was hybridised to Mouse Ref-8 Expression BeadChip (Illumina Inc., San Diego, CA) 
at 58°C for 18 h.  The hybridised BeadChip was washed and labelled with streptavidin-
Cy3 according to the manufacturers protocols.  Chips were scanned with Illumina 
BeadScan, and scanned images imported into BeadStudio 3.2.6 (Illumina Inc) for 
analysis.  
A list of differentially expressed transcripts was generated and standard criteria 
applied (see results 6.3.1.2).  The following comparisons were made: (a) WT EXT vs. WT, 
PHD1 K/O vs. WT, PHD1 K/O EXT vs. PHD1 K/O, PHD1 K/O EXT vs. WT EXT, and PHD1 
K/O EXT vs. PHD3 K/O EXT (WT=wildtype, EXT=extirpation, K/O=knockout).  Microarray 
data was interrogated with reference to gene ontology (GO) databases which describe 
gene products in terms of their associated biological processes, cellular components and 
molecular functions, and KEGG pathways, a collection of manually drawn pathway maps 
looking at molecular interaction and reaction networks for metabolism, genetic 
information, cellular processes and human diseases (among others) using the Database 
for Annotation, Visualization and Integrated Discovery (DAVID). 
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6.3 Results 
6.3.1.1 Changes in capillarity  
There was no significant difference between the capillary to fibre ratio (C:F) of WT EXT 
and PHD1 K/O mice vs WT mice (Table 6.1).  Capillary density (CD) was significantly 
raised in both PHD K/O EXT groups, along with PHD3 K/O mice alone.  The mean fibre 
area (MFA) was significantly lowered in all K/O and K/O + EXT animals.  Mean body mass 
for WT animals was 29.1 ± 1.4g, for PHD1 K/O was 32.9 ± 3.2g, and for PHD3 K/O was 
32.3 ± 7.2g.  Mean EDL mass of extirpated leg was 16.0 ± 2mg in PHD1 K/O mice and 
14.0 ± 1.0mg in PHD3 K/O mice (compared to 9.0mg ± 0.4, CHPT 5).  
 
 
 
Experiment 
 
C:F 
 
CD  (cap.mm-2) 
 
MFA (!m2) 
 
WT                         
 
1.29 ± 0.08 
 
555.0 ± 27.5 
 
2068 ± 118.9 
 
WT EXT                 
 
1.37 ± 0.15 
 
703.3 ± 94.5 
 
1854.5 ± 55.3 
 
P1 K/O            
 
1.46 ± 0.01 
 
655.3 ± 11.4  
 
1576.6 ± 104.9§ 
 
P1 K/O EXT     
 
1.34 ± 0.03 
 
753.8 ± 29.5§ 
 
1344.2±46.9§ 
 
P3 K/O   
 
1.36 ± 0.11 
 
788.2 ± 80.2§ 
 
1312.1± 84.5§ 
 
P3 K/O EXT 
 
1.30 ± 0.05  
 
730.1 ± 25.7§ 
 
1388.0 ± 59.6§ 
Table 6.1 C:F and CD for PHD1 knockout (P1 K/O), PHD3 K/O (P3 K/O) and wild type animals with 
and without 1 week of extirpation (EXT), n=3 (mean ± SEM).  §=P<0.01 vs. WT.  Statistics were 
performed by ANOVA using Dunnetts as a post-hoc test. 
 
 
 
6.3.1.2 Gene arrays 
Gene lists were determined using adjusted P<0.05 (Fisher Exact P-values) and fold 
change (FC) of ± 0 to determine which genes were up and down-regulated, with the 
exception of WT vs. WT EXT and PHD1 K/O EXT vs. WT EXT: little change was found in 
gene expression in the former (P-values were all >0.05) so P<0.1 and FC ±1.5 was used, 
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and using P<0.05 for the latter resulted in an unmanageable number of genes for 
analysis with DAVID, so P<0.001 was used, along with an FC of 2  (Appendix VI).  
Functional annotation charts were produced from DAVID using GO terms, and a false 
discovery rate (FDR) of 10% or less as the standard criteria for determining which terms 
were significantly up- or down-regulated (Appendix V).   
Heat maps were created from the gene lists generated (above).  Using functional 
clustering (DAVID) gave an enrichment score (ES) representative of the overall closeness 
of an annotation cluster, after considering each of its members.  The enrichment of each 
cluster is determined by the P-value (above) of each of the groups members, i.e. a 
greater ES is indicative of a group consisting of lower P-values, suggesting that members 
within the group have shown noticeable change, following treatment, in either in a 
positive or negative direction.  Genes from groups with an ES >1.5 were chosen to 
create heat maps, this being used as standard criteria.  
 Colours in the heat map represent the intensity in each sample relative to the 
average intensity across all samples for that particular gene.  The heat map was made 
using z-values, calculated as: 
 
(Sample Intensity - mean intensity for gene)/standard deviation for gene 
 
For example, if a sample had a mean intensity Z=0, it is shown as black on the heat 
map; if it is higher than the average (Z>0) it is shown as red on the heat map, and if 
less than the average (Z<0) it is coloured green.  Converting to Z scores is done to make 
all the genes in the heat map visually comparable, regardless of their overall intensity. 
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6.3.1.2.1 Validity of samples 
6.3.1.2.1.1 RNA quality control (QC) (Carried out at the Wellcome Laboratories at the 
University of Oxford) 
Before carrying out the gene array, QC was carried out for all sample using an RNA 
integrity programme called the Agilent 2100 Bioanalyser which automatically generates 
the ratio of the 18S to 28S ribosomal subunits using its software (Fig 6.2).  It also 
provides an RNA integrity number (RIN) (which should lie between 8 and 10 for a good 
quality sample) as further indication of the quality of the RNA, providing the assessor 
with an accurate determination of the quality of the samples to be used in the gene 
array. 
 
Figure 6.2 Electropherogram indicating regions indicative of RNA quality (see Agilent's 2100 
Bioanalyser website) 
6.3.1.2.1.2 Log intensity plots following gene array 
Scatterplots were made to illustrate which samples were appropriate for use in 
subsequent analyses.  Intensity values were plotted for all probes on the array in one 
sample compared to another.  Fig 6.3 illustrates samples unsuitable for analysis, whereas 
Fig 6.4 illustrates samples which are.  A number of samples were unsuitable for use 
(PHD3 K/O mouse tissue) due to inadequate storage and consequent degradation, hence 
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analyses are not equally balanced with respect to ‘n’.  A tight cluster of points (Fig. 6.4) 
on the diagonal indicates a pair of samples which are very similar: ideally all pairwise 
comparisons should show this.  A much greater spread is seen with the poor quality 
samples indicated in Fig. 6.3. 
 
 
Figure 6.3 Illustration of samples with poor quality 
 
Figure 6.4 Illustration of good quality samples 
Fig 6.5 illustrates the group of outliers (a) and normalised box plots 
 following removal of the degraded samples (b). 
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Figure 6.5(a) Dendrogram illustrating a group of outliers from the rest of the group which were excluded, and (b) Boxplot illustrating normalised 
data following removal of outliers
(a) (b) 
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6.3.1.2.1.3 Principal component analysis (PCA) 
PCA represents a method of summarising the variance present in the gene expression 
data, translating this into 2 dimensions, resulting in a plot with points that represent 
each sample: the more similar the samples are, the closer they are together.  Figure 6.6 
clearly illustrates that PHD3 K/O EXT samples are closely related, along with WT, though 
WT EXT, PHD1 K/O EXT and PHD1 K/O all have samples (within the total of 3) distinctly 
different from each other.  This is most likely due to naturally occurring differences 
between mice (biological variability), or individual differences in response to surgical 
intervention. 
 
Figure 6.6 PCA of all samples in this study to illustrate how related samples are to each other 
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6.3.1.2.2 Validation of knockdown 
Validation of the PHD3 knockdown is shown (Fig 6.7), with a 20 fold lower expression 
when compared to WT.  Each boxplot shows the range of intensities measured for each 
particular probe targeting either PHD1 or PHD3, for all samples with a particular 
genotype (i.e. PHD1 K/O, PHD3 K/O and WT).  The genotypes are represented on the ‘x’ 
axis.  These boxplots represent the spread of expression intensity across these samples, 
and thus give an idea of the success level of the knockdown which was achieved (an 
intensity on the ‘y’ axis of 6 or below is regarded as background noise). 
 
 
Figure 6.7 Log scale intensity plotted against PHD3 gene expression (P3), PHD1 gene expression 
(P1) and wildtype 
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High quality RNA was shipped to Oxford for RNA analysis and due to inadequate storage 
was degraded in nearly all PHD3 groups: only viable data from PHD3 K/O + EXT was 
obtained from PHD3 K/O mice group. 
Unfortunately, less knockdown was seen in the PHD1 K/O mice (Fig. 6.8) as 
illustrated by the spread of values with a log intensity ranging from around 7 to just 
below 8.5.  Values under 6 are recognised as background.  
 
 
Figure 6.8 Log scale intensity plotted against PHD1 gene expression (P1), PHD3 gene expression 
(P3) and wildtype (WT) 
 
6.3.1.2.3 Comparisons between groups 
Heat maps were produced using gene lists adapted with standard criteria (above) and 
are in Appendix IV.  Heat maps were also produced using functional clustering (DAVID) 
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and these identified specific groups of genes significantly upregulated in functional 
groups with an ES >1.5. 
6.3.1.2.3.1 WT EXT vs. WT 
Figure 6.9 demonstrates comparisons in genes between WT animals with and without 
extirpation (as determined by functional clustering with DAVID with an ES >1.5).  Due to 
lack of significant change in genes between groups, the heat map produced from the 
gene list alone was very similar, so only one is shown).  Both groups show a very similar 
response.  This is illustrated further by the grouping of WT EXT next to WT by 
dendrogram bars.  Coloured bars beneath dendrograms illustrate different groups.  
 
 
 
 
Figure 6.9 A heat map illustrating genes up- (red) and down-regulated (green) in 
wildtype (WT) mice with extirpation (EXT) vs. WT alone (n=3 in each group) 
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6.3.1.2.3.2 PHD1 K/O vs. WT 
Figure 6.10 demonstrates reciprocal changes between PHD1 K/O (P1--) mice and WT 
mice very clearly (from functional clusters with an ES >1.5).  However, as noted 
(6.3.1.2.2), it was shown that knockdown of PHD1 was not achieved very successfully.  
This is illustrated here, with the second column (denoted P1--) showing less similarity to 
column 1, also P1 K/O, the opposite of what would be expected for mice with the same 
genotype.  This is further evidenced by dendrogram bars (placed on top of the heat 
map).  These bars are not representative of absolute values, only of relationships 
between experimental groups.  
Obvious reciprocal change between groups is shown as ‘A’: genes related to DNA 
damage response, stress response and antigen processing and presentation are 
upregulated in WT animals and down-regulated in PHD1 K/O mice.  In the sub category 
‘B’ were a collection of genes related to sensory perception and stimulus detection, cell 
communication, and signal transduction: these were all upregulated in PHD1 K/O mice.  
 
6.3.1.2.3.3 PHD1 K/O EXT vs. PHD1 K/O 
Figure 6.11 (from functional clustering) illustrates clear reciprocal changes in gene 
expression levels between PHD1 K/O mice with extirpation as an intervention, and PHD1 
K/O mice alone.  Dendrogram bars at the top of the heat map show clear segmentation 
between the two groups. 
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Figure 6.10 A heat map illustrating genes up- (red) and down-regulated (green) in PHD1 K/O mice 
vs. wildtype (WT), derived from functional clusters with an ES>1.5. (n=3 in each group) 
 
 
A 
B 
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Figure 6.11 A heat map illustrating genes up- (red) and down-regulated (green) PHD1 K/O 
extirpation (EXT) (columns 3-5) vs. PHD1 K/O mice (columns 1-2), derived from functional clusters 
with an ES>1.5. (n=3 in each group) 
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6.3.1.2.3.3 PHD1 K/O EXT vs. WT EXT 
Figure 6.12 (from functional clustering) again clearly illustrates differential and reciprocal 
upregulation of gene expression in PHD1 K/O vs. WT mice, both having had unilateral 
extirpation.  Column 3 further illustrates issues noted (above) that the WT EXT mouse 
genotype overlaps with the WT genotype with inconsistencies, and column 5 relates to 
the partial knockdown of the P1 K/O mouse, as mentioned (6.3.1.2.3.2). 
A subset of genes have been identified where patterns of reciprocal change are 
shown (A, B, C).  Genes in A, involved mainly in glycolysis, are shown to be upregulated 
in WT EXT compared to PHD1 K/O EXT mice.  Similar functions are upregulated in C, 
along with genes related to oxidative stress.  B identifies genes, again upregulated in the 
WT EXT phenotype, that are associated with apoptosis and mitochondrial function.  
 
6.3.1.2.3.4 PHD3 K/O EXT vs. WT EXT 
Input of gene lists into DAVID revealed low ES, <1.5, indicating that although 34 genes 
were classified as upregulated and 23 genes down-regulated, none of these represent 
functional terms that were significantly changed in this intervention.  Thus, a heat map 
was produced using P<0.01 and ± 0 FC (Fig. 6.13).  
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Figure 6.12 A heat map illustrating genes up- (red) and down-regulated (green) in PHD1 K/O EXT 
(columns 4-6) vs. wild type mice with extirpation (WT EXT) mice (columns 1-3), derived from 
functional clusters with an ES>1.5. n=3 in each group 
 
 
 
 
A 
B 
C 
 176 
 
Figure 6.13 A heat map illustrating genes up- (red) and down-regulated (green) in PHD3 K/O mice 
with extirpation (EXT) (columns 4-7) vs. wildtype (WT) EXT mice (columns 1-3), derived from gene 
lists with P<0.01 and ±0 FC. n=3 in each group 
 
6.3.1.2.3.5 PHD1 K/O EXT vs. PHD3 K/O EXT 
Figure 6.14 (from functional clustering) gives a fine illustration of reciprocity in gene 
changes when one or other of the PHD isoforms, 1-3, is ablated.  
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Figure 6.14 A heat map illustrating genes up- (red) and down-regulated (green) PHD1 K/O mice 
with extirpation (EXT) (columns 4-6) vs. PHD3 K/O EXT (columns 1-3), derived from functional 
clusters with an ES>1.5. n=3 in each group 
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6.3.1.2.4 Analysis of upregulated gene expression across groups 
Potentially interesting up- and down-regulated genes identified using criteria (above) and GO terms are shown in Table 6.2 and 6.3, 
respectively. Evidence for an inflammatory response and an increase in metabolism to fuel the observed increase in protein turnover 
and angiogenesis are all seen.  Interestingly, PHD3 is upregulated in the PHD1 K/O EXT model.   
 
 
 WT EXT vs. WT 
 
PHD1 K/O vs. 
WT 
PHD1 K/O EXT 
vs. WT EXT 
PHD1 K/O EXT vs. 
PHD1 K/O 
PHD3 K/O EXT vs. 
WT EXT 
PHD1 K/O EXT vs. 
PHD3 K/O EXT 
       
Angiogenesis  MMP 3, 12   MMP 2, 3, 12, 13 MMP 13, 14 Angiopoietin-like 1 MMP 13 
 IGF  TGF-! TGF-! Schinderin PHD3 
   Syndecan 3 Syndecan 3 Lim and SH3 protein Syndecan 3 
   Rho-GTPase 
activating protein 9 
  Rho-GTPase 
activating protein 9 
   Cd248    
   TIMP-1    
   Tenascin    
   Adam 12    
       
Cell cycle   cDNA sequence 
BC002059 
Endothelial 
differentiation, 
sphingolipid G-
protein coupled 
receptor 5 
Cell division cycle 2 
homolog 
cDNA sequence 
BC025076 
cDNA sequence 
BC006779 
   Cell division cycle 
associated 2 
Cell division cycle 
associated 2 
  
   EGF containing 
fibulin-like ECM 
protein 
MAD2 (mitotic arrest 
deficient, homolog)-
like 1 
  
       
Apoptosis  DNA 
fragmentation 
factor (!) 
 Caspase 1, 4, 8 Kinesin family 
member 5B 
 
 179 
       
Protein 
metabolism  
Procollagen type 
XIV !1 
 Procollagen type V 
!3 
Procollagen type V 
!2 
Dipeptidase 3  
 Ubiquitin specific 
peptidase 
Ubiquitin C Procollagen type 
XVIII !1 
 Kallikrein 1-related 
peptidase 
 
   Cathepsin E, C, S, 
Z 
Cathepsin Z  Cathepsin E, S, Z 
       
Fatty acid 
metabolism  
 Esterase  Phospholipase C, "2 Phospholipase A2 Phospholipase C, "2 
 Phospholipid 
transfer protein 
Acyl-coA 
synthetase 
long-chain 
member 3 
Phospholipid 
transfer protein 
Phospholipid transfer 
protein 
  
 Apolipoprotein B Fatty acid 
binding protein 
7 
Apolipoprotein C-I Apolipoprotein B     
    Elongation of very 
long chain fatty 
acids 
  
       
Immune 
response 
Tenascin N Tenascin R     
   Toll-like receptor 
7, 13 
Toll-like receptor 7, 
13 
 Toll-like receptor 13 
 Chemokine (C-C 
motif) ligand 7, 
8 
 Chemokine (C-X-C 
motif) ligand 4 
Chemokine (C-X-C 
motif) ligand 1 
 Chemokine (C-X-C 
motif) ligand 4 
   Chemokine (C-C 
motif) receptor 5 
Chemokine (C-C 
motif) ligand 4, 8 
 Chemokine (C-C 
motif) ligand 4, 5 
 Interleukin 13 
receptor !1 
 Interleukin 1 #, 
Interleukin 1 
receptor-like 1 
Interleukin 1 
receptor-like 1 
Interleukin 1 
receptor-like 1 
 
   Lymphocyte 
antigen 9 
Lymphocyte antigen 
6, 9, 86 
 Lymphocyte antigen 
9, 86 
   Colony stimulating 
factor 1 and 3 
receptor 
Colony stimulating 
factor 1 and 3 
receptor 
 Colony stimulating 
factor 1 receptor 
  Platelet 
activating factor 
Platelet activating 
factor 
Platelet activating 
factor 
 NF$B 
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acetylhydrolase 
2 
acetylhydrolase 
isoform 1! 
acetylhydrolase 
isoform 1! 
       
Cell adhesion 
molecules 
 Cadherin EGF 
lag 7-pass 
receptor 3 
CD44 antigen PECAM-1   
  Protocadherin " 
subfamily A  
CD53    
   VCAM-1    
   Adam 12    
   Integrin ! 7 Integrin #5   
       
Mitochondrial 
function  
 Cytochrome 
P450, family 2, 
21 
Thromboxane a 
synthase  1 
 Branched chain 
aminotransferase 2, 
mitochondrial 
Electron transferring 
flavoprotein # 
     Translocase of inner 
mitochondrial 
membrane 9, 10 
ATP-synthase, 
mitochondrial F0 
complex 
       
Glycolysis  Aldehyde 
dehydrogenase 
1 
Aldehyde 
dehydrogenase 3 
   
  Aldolase 3, c 
isoform 
    
 
Table 6.2 A subset of upregulated genes identified as potentially interesting following GO analysis.  (Matrix metalloprotease: MMP, transforming 
growth factor !: TGF-!, insulin-like growth factor: IGF, epidermal growth factor: EGF, extracellular matrix: ECM) 
 
 
Common across most comparisons, apoptotic and cell division factors are also shown to decrease, along with mitochondrial function 
and glycolysis-related genes.  PHD1 is down-regulated in the PHD1 K/O, which provides confirmation of its knockdown in this model.  
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6.3.1.2.5 Analysis of down-regulated gene expression across groups 
 
 
 
 WT EXT vs. WT 
 
PHD1 K/O vs. 
WT 
PHD1 K/O EXT vs. 
WT EXT 
PHD1 K/O EXT 
vs. PHD1 K/O 
PHD3 K/O EXT 
vs. WT EXT 
PHD1 K/O EXT vs. 
PHD3 K/O EXT 
       
Apoptosis Dynactin 1  Dynactin 4    
 Growth arrest and 
DNA-damage 
inducible 45 ! 
Growth arrest 
and DNA-damage 
inducible 45 " 
Growth arrest and 
DNA-damage 
inducible 45 ! 
   
 Calpain 2 Bcl-2 binding 
component 
 DNA 
fragmentation 
factor # 
 Apoptotic chromatin 
condensation 
inducer 
       
Cell division  Histone 1    Histone 2 
  Adenosine 
deaminase, #1 
Cell division cycle 34 
homolog 
  CDNA sequence 
BC004044 
  Polymerase 
(DNA-directed) 
iota 
   DNA segment, Chr 4 
  Polymerase 
(DNA-directed) 
$3 
   Cell division cycle 34 
homolog 
       
Mitochondrial 
function 
Cytochrome p450, 
family 2, subfamily 
E 
Mitochondrial 
intermediate 
peptidase 
Mitochondrial 
ribosomal protein 
S12 
  Translocase of inner 
mitochondrial  
membrane 8 
   Isocitrate 
dehydrogenase 3 
  Isocitrate 
dehydrogenase 3 
   Mitochondrial carrier 
homolog 2 
  Mitochondrial carrier 
homolog 2 
   Coenzyme Q5 
homolog, 
methyltransferase 
  Coenzyme Q5 
homolog, 
methyltransferase 
      Mitochondrial 
ribosomal protein L3 
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Glycolysis Aldehyde 
dehydrogenase 
 Phosphorylase 
kinase !1 
  Succinate-coA ligase 
! 
   Pyruvate 
dehydrogenase 
  NADH 
dehydrogenase 1 !, 
6 
      Acetyl-coenzyme A 
dehydrogenase 
       
Angiogenesis     PHD3  
       
Inflammation Guanylate 
nucleotide binding 
protein 1 
     
 macrophage 
activation 2 
     
 
Table 6.3 A subset of down-regulated genes identified as potentially interesting following GO analysis
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6.4 Discussion 
This study was designed to investigate whether relationships between genomic and 
functional responses exist in skeletal muscle, following genetic manipulation of molecular 
pathways leading to HIF-1! stability.  The PHDs have been shown to contribute in a non-
redundant manner to the regulation of HIF-1! (Appelhoff et al. 2004), suggesting that a 
differential gene response should be seen following specific PHD ablation. 
6.4.1 Changes in hindlimb capillarity 
A clear trend exists (as already shown, CHPT 5) between WT and WT EXT mice, with 
extirpation inducing an increase, although not significant, in the capillary to fibre ratio 
(C:F).  Interestingly, in both PHD1 and PHD3 K/O mice, the C:F is noticeably higher, 
(not-significant) in non-intervention animals.  This suggests a trend towards impaired 
angiogenesis in K/O animals with EXT as an intervention, although the reduced (mean 
fibre area) MFA seen in all K/O and K/O EXT mice suggests that a reduction in fibre size 
is responsible for the observed reduction in C:F and increased capillary density (CD).  
Thus, angiogenesis seems to be impaired in both PHD1 K/O and PHD3 K/O mice.  There 
are insufficient existing experimental data on skeletal muscle phenotype in PHD knockout 
mice to support this observation from other studies.  Interestingly, mean muscle mass 
within each knockout group was higher than that observed following extirpation in CHPT 
5, suggestive of enhanced protein synthesis following PHD ablation (see 6.4.2.2.4).  
6.4.2 Gene expression  
6.4.2.1 Validity of samples 
Before and after gene arrays were carried out, the purity and concentration of the 
samples was determined as described (6.3.1.2.1).  On doing so, a number of samples 
were unfortunately eliminated due to degradation that may have occurred because of 
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inadequate storage conditions (freezer breakdown in Oxford).  Between some of the 
remaining samples, namely PHD1 K/O, PHD1 K/O EXT and WT EXT, significant variation 
in the gene expression of samples was seen and may exist due to naturally occurring 
inter-animal variability.  An adequate PHD3 knockdown was achieved, though the 
knockdown in PHD1 animals was not achieved to the level desired, and this may have 
affected the results seen here.  
6.4.2.2 Cross-intervention analysis 
WT mice appeared to exhibit little difference in gene expression when compared to WT 
EXT, evidenced by differential gene expression levels being insignificant (P>0.1), and 
may be due to reasons mentioned above.  Increasing the sample number would greatly 
help to increase confidence.  However, with the exception of WT and WT EXT mice, all 
groups exhibited clear reciprocal changes in gene expression patterns, i.e. where genes 
were up-regulated in one genotype and intervention, the same genes were seen to be  
down-regulated in the contrasting situation, for example  WT extirpation vs. PHD1 K/O 
extirpation. 
6.4.2.2.3 Inflammatory pathways 
A number of key pathways were stimulated which appeared to be upregulated as a 
common response to extirpation in both WT and PHD1 K/O animals.  Genes involved in 
the inflammatory response were increased following extirpation surgery.  Previous 
studies have shown that the earliest point at which no clinical signs of inflammation are 
seen is at 3 days (Williams et al. 2006b), and this is supported by a lack of visual 
inflammation 1 wk following extirpation surgery (Zhou et al. 1999).  Here, inflammatory 
response genes are still significantly upregulated, suggesting that a subclinical 
inflammatory response may still play a role in these early phases (1 wk) post-surgery, 
further suggesting that angiogenesis may be stimulated through inflammatory pathways, 
as well as or instead of the stretch-induced mechanism which is well-known (Egginton et 
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al. 1998; Zhou et al. 1999; Williams et al. 2006a).  In common with another study 
(Williams et al. 2006b), tenascin was upregulated in WT EXT mice, and Toll-like receptors 
7 and 13 were commonly upregulated in PHD1 K/O EXT mice, both of which are known to 
play a role in inflammation.  Tenascin is an ECM glycoprotein that has a number of 
isoforms.  Tenascin N was upregulated in WT EXT mice: despite characterisation of the 
sequence and structure of the molecule, little is known about its physiological role.  
Another isoform, tenascin R, was upregulated in PHD1 K/O mice.  This plays a role in the 
developing and adult nervous system.  Although not upregulated here, tenascin C is a 
mechano-regulated, morphogenic ECM protein associated with tissue remodelling (Fluck 
et al. 2008).   
That NF!B was upregulated in PHD1 K/O EXT vs. PHD3 K/O EXT supports the 
above suggestion that the angiogenesis seen here may be as a result of inflammatory-
induced conditions.  NF!B is a family of transcription factors that become activated 
following stimulation by pro-inflammatory factors such as cytokines, such as those listed 
here (chemokines and interleukins), and it has been implicated in maintaining basal 
levels of HIF-1" gene expression in vivo (Rius et al. 2008) (CHPT 4, Fig. 4.4).  
6.4.2.2.4 Upregulation of energy producing pathways provides fuel for an increase in 
protein synthesis 
Following removal of a synergist muscle, an increase in muscle mass occurs in the 
remaining muscle to compensate for the change in load bearing.  Protein synthesis is an 
energetically expensive process, though required for supporting an increase in the 
number of serial sarcomeres (Goldspink et al. 1991), along with increasing collagen 
deposition in muscles subjected to stretch during limb lengthening (Laurent et al. 1985).   
Common amongst both WT and PHD1 K/O animals was an increase in collagen synthesis, 
evidenced by the upregulation of procollagen (although differing isoforms) in both WT 
EXT and PHD1 K/O EXT.  Cathepsin E, C, S and Z were also upregulated, consistent with 
a model of extirpation (Goldspink et al 1995), in PHD1 K/O EXT mice.  These are 
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prominent proteases involved in protein metabolism, and this suggests a role for these 
enzymes in tissue remodelling during muscle hypertrophy.   
 Fuelling this necessary adaptation following the intervention are an increase in 
fatty acid metabolism, mitochondrial function and glycolysis (Table 6.3), although these 
genes were significantly upregulated in knockout mice only.  The latter finding is 
supportive of a study showing that PHD1 deficiency results in an adaptation from 
oxidative to more anaerobic ATP production (Aragones et al. 2007).  
 6.4.2.2.5 Upregulation of angiogenic factors and cell adhesion molecules 
The muscle stretch created by extirpation stimulates the sprouting form of angiogenesis, 
whereby abluminal sprouting of ECs through the basement membrane occurs (Zhou et 
al. 1998).  This is in contrast to the splitting form of angiogenesis where ECs send 
filopodial processes into the capillary lumen which then join and form a separate branch, 
and this subsequently propogates down the capillary (Zhou et al. 1998), this not 
involving any degradation of the BM.   As expected, none of the significantly regulated 
genes related to angiogenesis were seen in PHD1 K/O mice alone.   
 PHDs act in the regulation of the HIF-! subunit, and have been shown to exhibit 
non-redundant roles in the regulation of this transcription factor (Appelhoff et al. 2004).  
Interestingly, in the PHD1 K/O EXT model, PHD3 is shown to be significantly upregulated, 
alongside PHD1 which is shown to be significantly down-regulated.  The latter finding 
gives support to the absence of gene expression in this model.  Though this significant 
upregulation provides evidence to suggest that there is redundancy acting within this 
system.  
MMPs play a critical role in breaking down the BM of the vessel and the ECM via 
release of ECM-bound growth factors.  The increased vascular permeability due to a 
combination of VEGF and the MMPs enables extravasation of plasma proteins that lay 
down a provisional scaffold for migrating cells (Carmeliet, 2003).  A number of studies 
have shown the necessity of MMPs in sprouting angiogenesis (Rivilis et al. 2002): MMP-2 
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is a well-studied member of the group, and shown to be upregulated here.  It is also 
known to be upregulated by the membrane associated MMP-14.  It has a specificity to 
degrade collagen type IV, the most prevalent protein in skeletal muscle basal lamina 
(Rullman et al. 2009).  MMP-2 has also been shown important for successful regeneration 
of experimentally damaged muscle fibres in the mouse (Kherif et al. 1999). 
Accordingly, MMP-3, 12, 13 and 14 all showed significant upregulation in PHD1 
K/O mice with extirpation, with MMP-3 and 12 also upregulated in WT EXT mice.  The 
MMP-3 gene encodes an enzyme which degrades fibronectin, laminin, collagens III, IV, 
IX, and X, and cartilage proteoglycans and is thought to be involved in wound repair 
(Entrez-gene).  The MMP-12 enzyme degrades soluble and insoluble elastin, whereas 
MMP-13 protein cleaves type II collagen more efficiently than types I and III.  This may 
be involved in articular cartilage turnover and cartilage pathophysiology.  TIMP-1, a 
tissue inhibitor of metalloproteases, has also been shown upregulated under conditions of 
extirpation in the PHD1 K/O animal, in agreement with a recent study showing an  
upregulation of both MMP-2, 14 and TIMP-1 following exercise training in humans 
(Rullman et al. 2009).  Likewise, Heinemeier et al. (2007) and Rivilis et al (2002) found a 
parallel upregulation of TIMP-1 alongside MMP-2 in rat skeletal muscle, suggesting that a 
complex feedback system is operating under conditions of ECM degradation.  
Schinderin and Lim and SH3 protein are upregulated in PHD3 K/O EXT mice.  The 
former is involved in ECM remodelling, and  Lim and SH3 is involved in cell migration, 
indicative that an angiogenic stimulus is prevalent.  
TGF-! regulates cell proliferation, migration, ECM production, and the 
differentiation of a wide variety of cell types (Piek et al. 1999).  It is involved in the 
development of the vascular system and affects the function of ECs (Goumans et al. 
2003), playing a role in the development of new blood vessels.  A positive correlation 
between mechanical loading of cells and TGF-! expression has also been shown in both in 
vitro and in vivo studies, on a large variety of human and animal cell and tissue types 
(Villarreal and Dillmann, 1992; Lindahl et al. 2002; Ruwhof et al. 2000).  Furthermore, 
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Lindahl et al. (2002) demonstrated that promoter activation in procollagen-!1 
(upregulated here in PHD1 K/O EXT mice) cardiac fibroblasts is TGF-" -dependent, so 
their parallel upregulation supports known findings.  
Syndecan 3 is also upregulated in PHD1 K/O EXT mice, when compared to both 
WT EXT and PHD3 K/O EXT.  It is known to play an important role in skeletal muscle 
differentiation (Aird, 2007), though is not thought to play as much of a role in vascular 
development as syndecan-1, which regulates integrin activation during angiogenesis 
(Beauvais et al. 2009). 
Angiopoietin-like receptor 1 is upregulated in PHD3 K/O EXT mice.  Unlike ANG-2, 
these molecules do not bind to the angiopoietin-specific receptor, TIE2, and are known 
as orphan ligands.  They have a potent activity for regulating angiogenesis as 
proangiogenic or antiangiogenic factors, suggesting that their receptors may be 
expressed on endothelial cells (Oike et al. 2004). 
Cell adhesion molecules have been shown to contribute to the 
mechanotransduction response (Ingber 2006; Lehoux et al. 1998) involved in 
transmitting changes in the cytoskeleton within associated ECs into a genomic and 
functional response.  Integrins are heterodimeric transmembrane proteins whose main 
function is as receptors for most of the structural components of the ECM and several 
matrix-associated growth factors and proteases (Hynes, 1992).  Integrin !5 and "7 were 
upregulated in PHD1 K/O EXT mice, along with CD44 antigen, CD53, PECAM-1 and 
VCAM-1.  Both the integrins, PECAM-1 and VCAM-1 have been shown to be important in 
angiogenesis: VCAM-1, expressed on ECs and thought to be upregulated by VEGF (Ding 
et al 2003), and PECAM-1, a 130KDa glycoprotein located mainly along the lateral 
plasma membrane (DeLisser et al. 1997), have both been shown necessary for new 
vessel formation by inhibition of their action in vitro and in vivo.  Adam 12 is another cell 
adhesion molecule which was upregulated here.  It is a transmembrane protein 
containing both a disintegrin and metalloprotease domain, thus it potentially has both 
cell adhesion and protease activities (Primakoff and Myles, 2000).  
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6.4.2.2.6 Down-regulated functions  
A multitude of factors were down-regulated, many of which also exist in the same 
functional categories as those that were also upregulated, including those involved in 
mitochondrial function, glycolysis and cell division.  This suggests that feedback 
mechanisms exist which depress enhanced functions in these specific categories, on 
attainment of a certain level of expression, to maintain homeostasis.  The possibility 
exists that realignment of the pathways involved in any of the above categories (such as 
glycolysis), by both up- and downregulation of genes, may not change the flux through 
the pathway,  particularly if these genes code for elements that do not have an effect on 
the rate limiting step in the pathway (e.g. equilibrium enzymes).  
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6.5 Conclusions 
Specific ablation of PHD1, with the added intervention of extirpation surgery, results in 
the upregulation of a number of genes involved in the inflammatory response, glycolysis 
and mitochondrial metabolism, the latter two possibly providing the fuel for an enhanced 
protein synthesis in response to the induced overload.  Angiogenic and cell adhesion 
genes are also seen to be increased, suggestive of a permissive environment for new 
blood vessel growth.  However, histological evidence suggests that this is not translated 
into a physiological angiogenic response, as evidenced by the lack of significant increase 
in the C:F of the EDL in the hindlimb.  Skeletal muscle hypertrophy is clearly evident 
from the change in EDL muscle mass, thus this is suggestive of a dissociation between an 
increase in muscle mass and new blood vessel growth, i.e. a time lag between gene 
expression, translation and activity.  The possibility exists that a number of anti-
angiogenic factors have also been upregulated, which have yet to be defined, and this 
means that the angiogenic balance is not permissive in the direction of new blood vessel 
growth, though this remains to be determined.  PHD3 was significantly upreglated in the 
PHD1 knockout mouse, suggesting that in agreement with published literature, these two 
may act in a non-redundant manner.  
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6.6 Future directions 
One of the main drawbacks of this study was the low number of animals that were used.  
Increasing animal number in future studies may increase statistical significance, and 
improve confidence in the findings of inter-variability, naturally occurring in vivo.   
Had time permitted, it would have been useful to undertake more extensive data 
mining of the genomic response by combining microarray data and subjecting it to 
parsimonious clustering analysis.  This would provide empirical evidence for consistent 
gene up-regulation that could be validated by more quantitative genomic (qRT-PCR) and 
proteomic (multiplex ELISA) methodologies. 
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Chapter 7 
SYSTEMIC HYPOXIA 
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7.1 Introduction 
 
The ability to translate the effect of animal models, and in particular the murine 
response, into a functional human response is a controversial and still largely 
undetermined area in many cases.  I therefore undertook a translational study to 
investigate the similarities in systemic response to hypoxia in both mouse and man. 
Following determination of the time course of HIF-1! and HIF-1! activated gene 
expression in several tissues in the mouse, including leukocytes (see CHPT 3), the 
objective of this part of my thesis was to observe if this HIF-driven gene expression in 
leukocytes (already observed in the murine model on a carefully selected number of 
genes) could be used as a viable indicator of the systemic response to hypoxia in man, 
thus possessing potential for use as hypoxia-responsive indicators.  This parallel 
response to systemic hypoxia in both mouse and man (an upregulation of HIF-regulated 
gene expression under hypoxia in leukocytes) could serve as a useful indication of the 
potential this murine model has to mirror the human response.  In addition, I wanted to 
determine if the parameters studied in humans could be used as a potential set of 
markers for fitness at altitude, when related to altitude sickness and O2 saturation of the 
blood, the latter an area of contention that has been studied for many years and remains 
an active area of research.   
Due to my long-term fascination with high altitude physiology and response in 
man, along with my affiliation with a high altitude research group based in Birmingham, I 
decided that this would be an ideal opportunity to conduct a study in a murine model 
that allowed partial translation into the human response to hypoxia.  The Birmingham 
Medical Expeditionary Society (BMRES) comprises a group of physicians who formed a 
charitable research group 25 years ago, interested in investigating mechanisms of 
altitude illness and how the body adapts to high altitude; I have been a member for 4 
years.  I was presented with an opportunity to design a follow-up to a chronic high-
altitude exposure study in Bolivia performed by the group.  The plan was to incorporate 
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an acute high altitude exposure phase, providing a contrast between the acute setting in 
the hypoxic chamber and the chronic setting of a slower ascent to the high altitude 
plateau in Chile.  From these data, one may be able to predict the response of an 
individual on ascent to altitude in the field, by studying their response in the laboratory.  
The original design for the study involved collaborating with part of the Chilean army, a 
group of whom would have also been subjects in the chronic exposure part of this study.  
This wasn’t eventually feasible which is unfortunate as it would have added greater 
power to the study. 
 
“Severe O2 deprivation at extreme altitudes is only tolerated due to an enormous 
increase in ventilation which protects the alveolar PO2 against decreasing inspired values“ 
(West, 1990).  This is known as the hypoxic ventilatory response (HVR).  After acute 
exposure to hypobaric conditions, the increase in ventilation occurs within seconds, 
reaching full intensity within minutes, and a ventilatory acclimatisation occurs after 
continuous exposure over days (Lahiri et al. 2000).  It is known that some people with a 
rapid HVR at altitude are less likely to suffer with the effects of hypoxia (Matsuzawa et al. 
1989).  Hyperventilation causes an increase in the affinity of Hb for O2, increasing O2 
uploading by the pulmonary capillaries (West, 1990).  Pulmonary vasculature O2 sensors 
initiate regulation of the hypoxic pulmonary vasoconstrictor response which results in 
improved ventilation–perfusion matching, and cardiac output (CO) increases in response 
to the increase demand for O2. 
7.1.1 Physiological impairment caused by ascent to altitude 
O2 deprivation resulting from high altitude exposure in lowlanders impairs mental and 
physical performance, quality of sleep and general well being.  West (2005) noted that 
symptoms were relieved on administration of O2.  Rapid ascent to high altitude may 
result in a condition known as acute mountain sickness (AMS).  The main features of 
AMS are headache, accompanied by one or more other symptoms such as light-
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headedness, dizziness, loss of appetite, nausea, vomiting, fatigue, lassitude, 
breathlessness and difficulty sleeping (Hackett and Roach, 2001).  The lowest altitude at 
which individuals appear to be affected is around 2500m (Ward, Milledge and West, 
1995).  Clinical conditions observed after rapid ascent include an accumulation of fluid: 
high altitude pulmonary edema (HAPE) or high altitude cerebral edema (HACE).  Ascent 
to high altitude results in an increase in production of reactive O2 (ROS) and nitrogen 
species such as superoxide, hydrogen peroxide, hydroxyl radicals, nitric oxide, and 
peroxynitrite which directly stimulate central CO2 chemoreceptors in the brain stem 
(Mulkey et al. 2003).  These free radicals are known to cause oxidative damage to lipids, 
proteins and DNA that is thought to be associated with high altitude illness: Bailey 
(2003) found a greater increase in free radical-mediated biomarkers of lipid peroxidation 
and sarcolemmal membrane permeability in subjects diagnosed with clinical AMS. 
 There have been several scoring systems used to diagnose and quantify mountain 
sickness. These include the Lake Louise Score (LL) (Appendix IV) which is sensitive 
enough to detect AMS, along with the Environmental Symptom Questionnaire (ESQ) 
(Appendix IV), both consisting of a multitude of questions which attempt to illustrate the 
degree of suffering by the subject.  
7.1.2 Stimulation and control of erythropoiesis in response to hypoxia 
Occurring slower in onset than its cardiopulmonary counterparts, an increase in the 
number of RBC in the blood (polycythaemia) is a well-known feature of acclimatisation 
that was first reported by Viault in 1890 (Smith et al. 2008).  The main determinant of 
erythropoiesis is the release of the glycoprotein hormone erythropoietin (EPO), mainly 
from interstitial fibroblasts in the kidneys of the adult (Chavez et al. 2006), in response 
to local O2 tensions.  Very low O2 tensions in vitro have been shown to be required for 
EPO stimulation, e.g. incubation of hepatic cells with 7mmHg PO2 for 24 hours (Goldberg 
et al. 1988).  Following its release into the circulation, it binds to EPO receptors on 
erythrocyte progenitor cells and stimulates increased production of RBCs (Zhu et al. 
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2002).  The control of EPO synthesis is achieved at a transcriptional level by hypoxia-
inducible factor (HIF) (Pugh et al. 1991; Maxwell et al. 1993), a transcription factor that 
rapidly accumulates in the nucleus under hypoxia (Fig, 7.1).  HIF induces the 
transcription of a large number of hypoxia-related genes, although it is itself regulated at 
a post-translational level (Stolze et al. 2006) (CHPT 1).  An increasingly recognised role 
for HIF-2! is its dominant role in the regulation of EPO over HIF-1! (Gruber et al. 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Adapted from Jewell et al. 2001) 
Figure 7.1 Schematic diagram of the rapid HIF regulation during normoxia, hypoxia, and 
reoxygenation.  In normoxia, the pVHL (von Hippel-Lindau protein) binds to HIF-! and recruits it to 
the ubiquitination machinery (Ub) where it is degraded. After exposure to hypoxia, HIF-! 
production increases causing its accumulation in the nucleus where it dimerises with the HIF-" sub-
unit. This functional HIF complex induces transcription of a variety of O2-regulated genes. Upon 
reoxygenation, HIF proteins undergo efficient proteasomal degradation. 
 
 
The increase in red blood cell count (RBCC) following EPO up-regulation augments the 
O2-carrying capacity of arterial blood (Soliz et al. 2005).  It has been shown that the 
increase in EPO is altitude dependent: altitudes greater than 2100m appear to be a 
threshold for stimulating a sustained EPO release in man (Ge et al. 2002).  The EPO 
concentration in the blood has been shown to increase as soon as 90 min after the 
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inspiratory PO2 is lowered (Eckhardt et al. 1989), to rise progressively during the first 24 
to 48 h, and then decline towards baseline levels over 1-2 weeks (Richalet et al, 1994; 
Abbrecht and Littell, 1972).  This decline continues despite sustained hypoxia and occurs 
before the expansion of the RBCC.  However, haemoglobin (Hb) and haematocrit (Hct) 
have been shown to be elevated within days of ascent (Richalet et al, 1994): the spleen 
has been reported to serve as a dynamic reservoir for RBC storage, sequestering 200-
250ml of densely packed RBCs.  Up to 50% of which may be released during acute 
hypoxia (Bakovic et al. 2005).  Acute hypoxia has been shown to play a key role in 
triggering splenic contraction (Richardson et al. 2005; de Bruijn et al. 2008). 
7.1.3 The multifaceted regulatory role of HIF in response to hypoxia 
Inadequate inspiratory O2 triggers a multifaceted cellular response driven by HIF, 
governing a global transcriptional response to hypoxia amongst different cell and tissue 
types.  This further enables the body to adapt and acclimatise to the surrounding low O2 
environment.  Changes induced include shifts in metabolic pathways such as up-
regulation of glycolysis, alongside the previously mentioned up-regulation of 
erythropoiesis.  HIF is an extremely labile protein in normoxia, but in hypoxia HIF-1! 
degradation is reduced, resulting in increased intracellular levels (Fig. 7.2).  Within 2 min 
of hypoxic exposure, HIF protein accumulates in the nucleus (Fig. 7.1).  These features 
make studying HIF-protein levels a challenge. 
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Figure 7.2 Graph showing HIF-1! kinetics compared with the decrease in O2 concentration in the 
medium during the first 5 min of hypoxia in nuclear extracts of a human epithelial carcinoma celll 
line (HeLaS3 cells) exposed to 0.5% O2 using tonometry (mixing a fluid with the appropriate gas 
concentration) (From Jewell et al. 2001) 
 
 
 
7.1.3.1 Control of downstream genes by HIF-1 and HIF-2 
Despite high conservation in amino acid sequence and hypoxia-dependent activation, 
HIF-1! and HIF-2! have been shown to exhibit quite distinct, non-redundant 
physiological roles, with some different transcriptional targets and differing levels in 
tissues (Stroka et al. 2001).  As HIF-2! has been shown to play an important role in the 
regulation of EPO, it is important to consider downstream consequences arising from its 
activation, alongside HIF-1!.  A multitude of genes are targeted by both HIF isoforms 
that are of interest in this study (CHPT 1, Table 1.1) and which may provide a surrogate 
representation of HIF activation, also forming interactions between themselves (CHPT 3, 
Fig 3.1). 
7.1.4 Individual variability in the EPO response to hypoxia and its association 
with AMS 
EPO production under hypoxia is governed by a great deal of inter-individual variability 
(Ge et al. 2001) although the cause of this remains largely unknown.  However, 
Jedlickova et al. (2003) found evidence indicating that this variability was not genetically 
determined.  Sutherland et al. (unpublished) studied plasma EPO concentration in 
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subjects taken to 5200m over 4 days and found that EPO 'responders‘, i.e. those who 
experienced a rapid increase in their plasma EPO concentration, suffered less with acute 
mountain sickness (AMS) compared to ‘non–responders‘.  This is logical: individuals who 
experience a more rapid increase in EPO are able to increase their RBCC and thus O2-
carrying capacity faster than those who are slower with a lower magnitude of response, 
thus predisposing them to a lower risk of developing sickness at altitude.  This remains 
an area of controversy:  a number of studies found no change in EPO levels in AMS+ vs. 
AMS-subjects at altitude (Tissot van Patot et al. 2005, Basu et al. 2007), while AMS+ 
subjects had an increased EPO level when compared to well subjects (Huang et al. 
2008).  In addition, a number of studies that have found significantly increased EPO 
levels in subjects who developed HAPE (Basu et al. 2007; Pavliceck et al. 2000).  EPO 
has been widely studied for its role in improving athletic performance after altitude 
exposure: ‘living high, training low’.  It has been shown that athletes who were non-
responders, i.e. who did not show an improvement in performance following a sojourn at 
altitude, had a smaller and less sustained increase in EPO when compared to ‘responders’ 
(Chapman et al. 1998).  This is consistent with the original hypothesis.  Discrepancy 
among studies may reflect the fact that EPO has been shown to be a key factor 
modulating not only an increase in RBCC, but also affecting the HVR, carotid body 
activity, and hypoxic ventilatory acclimatisation (Soliz et al. 2005).   
7.1.5 Diurnal EPO variation, and associations with sex and age 
Erythropoietin production at altitude seems mainly influenced by changes in pH and the 
affinity of O2 for haemoglobin.  However, a number of studies have demonstrated diurnal 
variations in EPO expression: Klausen et al. (1996) showed that the lowest 
concentrations were seen between 8am and 4pm, with peaks occurring at 4am.  It is 
logical that EPO peaks coincide with the observation that many people experience a 
significant drop in their blood O2 saturation while sleeping, especially if cheyne stoke 
breathing is occurring (oscillation in the pattern of ventilation between apnea and 
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tachypnea under hypoxic conditions), and this theory is supported by a study done by 
Cahan et al. (1992), who found that EPO peaked at similar time points in their study.  
Thus, it is seemingly important to maintain a constant sampling time point following a 
period of rest to normalise O2 saturations, and that sampling should most suitably occur 
in the waking hours, providing a more true representation of EPO levels as a reflection of 
the resting O2 saturation, as opposed to under the more hypoxic induction experienced 
when sleeping. 
Women and female animals are well known to cope better than males when 
exposed to decreased PO2 at high altitude and this coincides with the observation that 
women are less susceptible to hypoxia-related illness at sea level (Soliz et al. 2000).  
Soliz et al. (2009) were the first to demonstrate that EPO modulates hypoxic ventilation 
in a sex-dependent manner, both in mouse and man.  They found that EPO acts at both 
the brain stem in the central respiratory centres, and the carotid body cells at the 
periphery.  It is well known that the ovarian steroids, progesterone and oestrogen, are 
potent ventilatory stimulants (Lefter et al. 2007), and data on illness at altitude (AMS, 
HACE and HAPE) suggest that these steroids play a protective role (Basnyat and 
Murdoch, 2003).  Mukundan et al. (2002) found that both hormones can directly 
influence the expression of EPO. 
A study done in 1981 by Peterson et al. showed that the HVR strongly decreased 
with age, by 50% in a group of 65-79 year olds when compared to a younger age group.  
The production of endogenous thiols are known to modulate the production of EPO, and a 
further study has shown that plasma thiol decreases with age, and corresponding shifts 
in the plasma redox state (i.e. the amount of damaging free radicals present) are 
thought to contribute to age-related impairment of EPO responses (Hildebrandt et al. 
2002). 
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7.1.6 Normobaric hypoxia vs. hypobaric hypoxia 
There are as yet no studies to date that expose subjects to an equal time treatment of 
both normobaric and hypobaric hypoxia with a crossover experimental design.  A number 
of studies have looked at the intermittent hypoxic response under both normobaric and 
hypobaric conditions, (i.e. short periods of time at hypoxia followed by a soujourn at 
normoxia) and some suggest that the physiological response of humans to hypobaric 
hypoxia is markedly different to that under normobaric hypoxic conditions.  Savourey et 
al. (2003) found that hypobaric hypoxia leads to a greater hypoxemia, hypocapnia, blood 
alkalosis and a lower O2 arterial saturation when compared to normobaric exposure, and 
that intermittent hypobaric hypoxic exposure is more likely to aid acclimatisation.  
However, this is a controversial area with other studies finding intermittent normobaric 
hypoxia successful at aiding acclimatisation, the latter a useful practise for example in 
training army personnel (Muza, 2007).  This is clearly an area that needs further 
investigation. 
 
The first set of experiments were conducted to determine if it is possible to determine 
the susceptibility of an individual to AMS on exposure to high altitude, based on their 
plasma EPO response.  The second part was used to determine if leukocytes could be 
used as a viable, minimally invasive surrogate marker of activation of the HIF-system 
under hypoxia.  Leukocytes are the first nucleated cells, after pulmonary cells, to be 
exposed to O2 tension variations (Mounier et al. 2008), and their life-span remains 
unchanged under hypoxic conditions (Birks et al. 1975).  They express a variety of HIF-
regulated genes, and as measuring HIF protein proved too labile in this study to be a 
useful marker, gene expression of HIF-1! and a collection of downstream genes 
regulated by HIF under hypoxia was deemed the most likely to provide an accurate 
representation of systemic HIF activation.  Subsequently, the downstream gene response 
was evaluated to determine if any relationship exists with AMS at altitude.  
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7.2 Methods 
7.2.1 Experimental design 
Twenty subjects participated in a two-part study involving an acute and chronic exposure 
to hypoxia; all subjects were members of the BMRES who volunteered themselves for the 
study.  Each subject signed a consent form to enable their inclusion in the study and 
ethical approval was obtained from the South Birmingham Ethics Committee.  In the 
acute exposure (phase I), baseline normoxic measurements were made in a laboratory 
followed by 6-hour exposure to 12% O2 in a normobaric hypoxic chamber (the equivalent 
of about 4600m), maintained at room temperature (RT).  This altitude was chosen as it 
is greater than that deemed necessary for EPO induction, it follows a similar altitude to a 
number of studies in this area, and subjects were to be based at a similar altitude in 
Chile, phase II.  Measurements were repeated at the end of the hypoxic exposure.  
Subsequently, the study involved a chronic exposure (phase II).  Baseline measurements 
were taken in Chile at sea level in Arica, and at Parinacota (4392m), 4 days post-altitude 
exposure.  The ascent profile is shown in Fig. 7.3.  Subjects comprised 6 female and 14 
male with a mean age of 43 ± 17 years, and a mean body mass of 75.7 ± 10.4kg. 
 
 
Figure 7.3 Ascent profile in Chile. (* indicates where blood samples were taken) 
 
* 
* 
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During the experimental sampling and measurement period, the degree of AMS was 
determined using the LL and ESQ scoring systems.  An arbitrary value of a LL score (self 
+ clinical) of >=3 plus a headache, was used alongside an ESQ score of >=0.7 to 
diagnose those suffering with AMS, as has been used in a number of studies (Tissot van 
Patot et al. 2005; Roeggla et al. 1996; Maggiorini et al. 1998; Dellasanta et al. 2007).  
The following calculation was used to determine the ESQ score, with the score per 
question represented as ‘Q’: 
 
ESQscore=(Q1*0.489+Q2*0.465+Q3*0.446+Q4*0.346+Q5*0.501+Q6*0.519+Q7*0.387 
+Q8*0.347+Q9*0.413+Q10*0.692+Q11*0.584)/25.95*5 
 
Oxygen saturation was measured using a pulse oximeter, a non-invasive method of 
determining the percentage of haemoglobin (Hb) saturated with O2.  The PO2 and PCO2 
were determined from venous and arterialised capillary blood samples (ear lobe: these 
samples were only able to be collected during phase I), along with haematocrit (Hct) and 
Hb levels (Appendix III), which were obtained in both phases.  Venous blood for plasma 
and leukocytes was drawn and processed as described in 7.2.1.2 and 7.2.1.3. 
7.2.2 Plasma separation from blood 
Blood was drawn into a 10ml purple top vacutainer tube by a trained physician who was 
an expert phlebotomist,at a constant time point of in the morning, both in the acute and 
chronic phase of the study, and centrifuged at RT for 30 min at 400g.  Plasma was 
withdrawn and aliquoted into Eppendorf tubes which were then flash frozen in liquid 
nitrogen and stored at -80°C.  ELISAs were used to analyse EPO, VEGF and sFlt-1 
expression at each time point (R&D Systems, DEP00, DVE00 and DVR100), the kit being 
used as per the manufacturer’s instructions (CHPT 2.7).  The kit for VEGF measures 
VEGF165, an isoform of VEGF-A and this is the isoform that is referred to for the rest of 
the chapter. 
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7.2.3 mRNA extraction from leukocytes 
PaxGene tubes (PreAnalytix, 762165) were used to store 2.5ml blood for subsequent 
mRNA extraction.  PaxGene tubes contain a stabilising agent that halts further change in 
gene expression, allowing quantification of gene expression at the time of the blood 
sample.  The PreAnalytix blood RNA extraction kit (BD Biosciences, 762174) was used 
according to the manufacturers instructions.  cDNA was made and RT-PCR carried out 
(CHPT 2.6).  The following genes were analysed for their expression under normoxic and 
hypoxic conditions: HIF-1! (Hs00936368_m1), EPO (Hs01071097_m1), VEGF-A 
(Hs00900055_m1), Flk-1 (Hs009211700_m1), HMOX-1 (Hs01110250_m1), iNOS 
(Hs00167248_m1), and ALD-A (Hs00605108_g1).   A selection of probes for carbonic 
anhydrase IX (CAIX) and sFlt were trialed under a variety of conditions using different 
controls, though attempts to study gene expression in leukocytes were not successful for 
these genes. 
 
See Appendix II for details on HIF nuclear extraction from leukocytes. 
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7.3 Results 
For raw data showing absolute data plots of mRNA gene expression, Hct, Hb, PO2 and 
PCO2 values, and plasma protein values, see Appendix III. 
7.3.1 Changes on a physiological level 
7.3.1.1 AMS 
The criteria used to diagnose AMS was a LL score of >=3 and an ESQ score of >=0.7.  
Based on this, a small proportion of individuals were categorised (Table 7.1) with 4 out of 
the total 10 subjects diagnosed with AMS, suffering during both the acute and chronic 
exposure. 
 
AMS in phase I and II AMS in phase I only AMS in phase II only 
 
3, 12, 18, 20 9, 10, 16 11, 21, 22 
 
Table. 7.1 Individuals diagnosed with AMS based on the LL and ESQ scoring systems as described 
(anonymised ID shown) 
 
7.3.1.2 Oxygen saturation 
As expected, O2 saturation was lowered under hypoxic conditions as demonstrated by 
changes in O2 saturation (pulse oximetry) and the PO2 content of the blood (Fig. 7.4).  
Unfortunately, the latter sample could not be obtained during phase II due to logistical 
difficulties in the field.  Measurements with the pulse oximeter showed a mean of 97.7 ± 
0.17% in normoxia and 82.3 ± 1.5% in hypoxia, phase I and 98.8 ± 0.09% at sea level 
and 88.5 ± 1.1% at high altitude in phase II, both of these being significantly lowered 
(P<0.0001).  Mean PO2 was in phase I was 42.1 ± 1.0mmHg.
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(a)       Phase I           Phase II 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 Change in % O2 saturation as seen with (a) finger pulse oximeter and (b) in the PO2 of an arterialised blood (phase I only), individual 
values shown, with means for each group calculated. * = P<0.0001 as determined with a paired t-test (n=20) 
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7.3.2 Changes on a molecular level: plasma protein 
7.3.2.1 Changes in plasma EPO protein under acute and chronic hypoxia 
All individuals showed a rise in plasma EPO (Fig. 7.5) that was significant when analysed with a paired t-test. However, the relative 
change was different (with the exception of one individual) in phase I compared to phase II (Fig. 7.6).  While the magnitude of 
change was much greater in phase II when compared to phase I (Fig. 7.7), the range was still large. 
 
 
Table 7.2 Mean plasma EPO (mIU/ml) 
(±SEM, determined by paired t-test) 
 
(a)  Phase I            (b) Phase II 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5 Relative fold changes in plasma EPO concentration in (a) phase I and (b) II as determined using an ELISA (n=20) 
 Normoxia Hypoxia P-value 
Phase I 8.50 ± 1.13 18.34 ± 1.44 <0.0001 
Phase II 11.21 ± 1.02 59.94 ± 7.50 <0.0001 
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Figure 7.6 Relative fold change in plasma [EPO] in individuals between phase I and phase II on exposure to hypoxia (ELISA) 
Figure 7.7 Spread of change in plasma [EPO] between phase I and II. ** = P<0.0001, as determined by paired t-test 
Solid black line 
represents the 
median 
** 
** 
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Figure 7.8 Relative changes in plasma [EPO] (mIU/ml) between phase I and II.  * indicates those classified as EPO responders based on the 
arbitrary cut off (explained in the text). 
 
Differentiating responders from non-responders in the acute exposure of phase I was difficult as inter-individual results were similar 
(Fig. 7.8).  A more obvious separation was apparent in phase II, responders being separated from non-responders based on a 40% 
increase from the mean protein concentration, an arbitrary value based on the lower limit of the response: this 40% cut-off clearly 
partitioned the EPO responders with a mean of 106.1±11.58mIU/ml from the non-responders with a mean of 44.3 ± 4.3mIU/ml 
(P=0.05, as determined by paired t-test).  Individuals falling within the ‘response’ category are indicated in Fig. 7.8 (*). 
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7.3.2.2 Change in plasma VEGF 
Plasma VEGF concentration showed a differential response under acute compared with chronic exposure, as evidenced by the 
relative fold change (Fig. 7.9).  After studying the data, a representative value of ±20% was used to indicate whether there had 
been a notable change in plasma protein expression.  (This value was also used for sFlt plasma protein expression).  Seven subjects 
showed a down-regulation, 6 subjects an up-regulation and 7 subjects showed no change in plasma [VEGF] during phase I.  Eleven 
subjects showed a decrease in plasma VEGF in phase II, (6 of these showing a similar response to acute hypoxia), with 9 subjects 
showing no change at all (5 of these individuals having showed a similar response under acute conditions) (see Table 7.2).  A 
comparison of the change in plasma VEGF under acute and chronic hypoxia is shown in Fig. 7.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.9 Relative fold changes in plasma [VEGF] in (a) Phase I (b) Phase II as determined using an ELISA
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Figure 7.10 Change in VEGF plasma [protein] during phase I and phase II (pg/ml) (determined by 
ELISA) what is the scale on the ordinate? 
 
 
7.3.2.3 Change in plasma sFlt 
As with VEGF, changes in plasma sFlt under acute and chronic hypoxia appeared to 
differ, a varied response being shown under the former and a more blunted response 
under the latter conditions.  Using a representative value of ±20% change in expression 
to distinguish responders from non-responders, 8 subjects showed an increase in protein 
expression under acute hypoxia compared to 6 subjects under chronic hypoxia, with 6 of 
these being the same subjects.  No subject showed a decrease in expression under 
chronic conditions compared to 6 who did so under acute hypoxia.  Fourteen subjects 
showed no change under chronic conditions, with 6 of these being the same under acute 
hypoxia (see Table 7.2).  Relative fold change in protein expression is shown (Fig. 7.11) 
along with the change in protein concentration, a comparison between phase I and II 
(Fig. 7.12). 
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Figure 7.11 Relative fold change in plasma [sFlt-1] in (a) phase I and (b) phase II as determined using an ELISA 
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Figure 4.12 Change in sFlt [protein] (pg/ml) (as determined by ELISA) 
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7.3.2.4 Inconsistent changes in plasma EPO, VEGF and sFlt 
Table 7.3 illustrates individual changes seen in plasma protein levels of EPO, VEGF and 
sFlt during phase I and phase II.  It is evident that although all individuals experienced 
an increase in EPO levels, a varied relationship exists between EPO and corresponding 
VEGF and sFlt levels.  Three individuals showed no change in levels of both VEGF and 
sFlt, 9 individuals show the same change of either an increase or decrease in both phase 
I and II, and the remainder exhibit prolific variation in response.  All subjects either 
decreased or maintained VEGF levels in phase II. 
 
Table 7.3 Individual response in plasma protein levels. ! indicates an increase, " a decrease and # 
no change (with ±20% change levels as defined in 7.3.2.2) 
 
Subject 
no.  
Plasma 
EPO: 
chamber 
Plasma 
EPO: 
4330m 
Plasma 
VEGF: 
chamber 
Plasma 
VEGF: 
4330m 
Plasma 
sFLT: 
chamber 
Plasma 
sFLT: 
4330m 
2 !  !  "  "  "  !  
3 !  !  !  "  "  !  
4 !  !  !  #  "  #  
5 !  !  !  #  !  #  
6 !  !  #  #  #  #  
8 !  !  "  "  !  !  
9 !  !  #  "  !  #  
10 !  !  #  "  #  #  
11 !  !  "  "  !  #  
12 !  !  #  #  #  #  
13 !  !  "  "  !  #  
14 !  !  !  "  "  #  
15 !  !  "  "  #  #  
16 !  !  !  "  !  #  
17 !  !  "  #  #  #  
18 !  !  #  #  "  #  
19 !  !  #  #  !  !  
20 !  !  #  #  #  #  
21 !  !  !  #  "  !  
22 !  !  "  "  !  !  
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7.3.2.4.1 Relationship between EPO and sFlt 
Although regression analyses indicate a weak relationship (R2=0.109, phase I; R2=0.040, 
phase II), on plotting the relative change in plasma EPO and sFlt protein a positive 
relationship was seen both phase I and phase II, although this does not reach statistical 
significance (Fig. 7.13).  sFLT is shown as relative change in pg/ml, EPO as mIU/ml 
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Figure 7.13 Regression analyses of change in plasma EPO [protein] against sFlt plasma [protein] 
(a) phase I and (b) phase II  
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7.3.2.4.3 Relationship between plasma VEGF and EPO protein 
There was no significant relationship between changes in plasma EPO and VEGF in phase 
I (P=0.912, R2=0.001) or phase II (P=0.636, R2=0.013, Fig. 7.14). VEGF is shown as 
relative change in pg/ml, EPO as mIU/ml 
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Figure 7.14 Regression analyses of change in plasma [EPO] vs. change in plasma [VEGF] protein in 
(a) phase I and (b) phase II 
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7.3.2.4.3 Relationship between VEGF and sFlt 
A significant relationship was seen between changes in plasma VEGF vs. sFlt protein in 
phase I (R2=0.327, P=0.011).  No significant relationship was found between VEGF and 
sFlt in phase II (R2=0.027, P=0.512, Fig. 7.15).  These relationships are further 
illustrated in Fig. 7.16.   sFLT is shown as relative change in pg/ml, VEGF as pg/ml. 
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Figure 7.15 Regression analyses showing change in plasma [sFLT] protein vs. VEGF plasma 
[protein] in (a) phase I and (b) phase II.  
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.16 Illustration of the changing relationship between plasma VEGF and sFlt protein during 
(a) phase I and (b) phase II, protein levels as determined by ELISA 
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7.3.2.5 Plasma protein changes in AMS+ and AMS- individuals 
Mean protein concentration generally varied between well subjects and those diagnosed 
with AMS (Table 7.4).  The mean of plasma EPO in phase I showed little change, 
although subjects with AMS in phase II showed a trend for higher levels of EPO plasma 
protein.  Plasma VEGF levels showed greater a change in phase II with sick individuals 
tending to show lower levels.  A consistent fall in VEGF levels under hypoxia compared 
with normoxia was observed in Phase II in most subjects, though a number remained 
unchanged.  sFlt showed a different relationship in phase II compared with phase I, with 
slightly higher levels in sick subjects in phase II, along with the majority of subjects 
showing increased levels.  However, none of these differences were statistically 
significant using an unpaired t-test. 
 
Protein AMS Phase I Phase II 
 
EPO (mIU/ml) + 17.8 ± 3.14 70.2 ± 12.8 
 - 19.6 ± 1.77 56.1 ± 8.6 
VEGF (pg/ml) + 81.3 ± 20.4 26.6 ± 3.5 
 - 91.4 ± 19.3 44.9 ± 11.4 
sFlt (pg/ml) + 227.2 ± 74.4 111.8 ±10.1 
 - 271.5 ± 54.2 105.8 ± 6.4 
 
Table 7.4 Mean plasma protein concentration values for EPO, VEGF and sFlt during phase I and II 
(± SEM), as determined by ELISA. AMS+ n=7, AMS- n=13. 
 
  
 219 
7.3.3 Changes on a molecular level: hypoxia-regulated gene expression 
Criteria of ±40% were used to determine whether subjects had shown a change in leukocyte gene expression. 
7.3.3.1 Changes in leukocyte Aldolase-A  (ALD-A) gene expression 
As is clearly shown, the magnitude of change occurring was greater under chronic hypoxia (Fig. 7.17).  However, the individual 
changes were not correlated between phases of the study (Table 7.3).  Two out of the 6 individuals who showed no change in 
expression did so in both phases, while 5 of the 9 subjects who increased ALD-A levels in phase I and 3 of the 5 subjects who 
showed a decrease in phase I showed no change in phase II. 
 
(a)                      (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.17 Relative fold change in leukocyte ALD-A gene expression during (a) phase I and (b) phase II as determined by qRT-PCR 
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7.3.3.2 Changes in leukocyte inducible nitric oxide synthase (iNOS) gene expression 
A great deal of variability was seen in the leukocyte iNOS mRNA response to hypoxia (Fig. 7.18).  In phase I, 8 subjects showed no 
change compared to one individual in phase II.  Of the 5 subjects that showed increased iNOS levels in phase I, 2 of these also did 
so in phase II, and 3 of the 7 who showed a decrease in phase I showed a similar response in phase II. 
 
(a)               (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.18 Relative fold change in leukocyte gene iNOS expression during (a) phase I and (b) phase II as determined by qRT-PCR 
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7.3.3.3 Changes in leukocyte haemoxygenase (HMOX-1) gene expression 
Chronic hypoxia had a greater effect on the magnitude of HMOX-1 gene expression in the leukocytes (Appendix III).  Eleven 
subjects increased their expression by >=40%: 2 of these showed the same response in phase I, and 8 subjects showed a decrease 
in expression.  Three of these individuals exhibited the same response in phase I (Fig. 7.19).  Only 1 person showed no change, 
compared with 8 who remained unchanged under acute hypoxia conditions. 
 
(a)              (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.19 Relative fold change in leukocyte HMOX-1 gene expression during (a) phase I and (b) phase II as determined by qRT-PCR 
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7.3.3.4 Changes in leukocyte fms-like tyrosine kinase-1 (Flk-1) gene expression 
Individuals exhibited similar changes in Flk-1 leukocyte gene expression under both chronic and acute hypoxia (Appendix III).  
Seven subjects showed no change in phase I: four of these had the same response in phase II, ten showed an increase in phase I, 5 
showing the same response in phase II; and 3 decreased their expression in both phases (Fig. 7.20). 
 
 
(a)              (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.20 Relative fold change in leukocyte Flk-1 gene expression during (a) phase I and (b) phase II as determined by qRT-PCR 
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7.3.3.5 Changes in leukocyte vascular endothelial growth factor (VEGF) gene expression 
Hypoxia generally failed to induce a prominent change in leukocyte VEGF gene expression under either acute or chronic hypoxia 
(Fig. 7.21, Appendix III).  Fourteen of the 20 subjects showed unchanged values in phase I, with 7 of these showing the same 
response in phase II.  Only 3 subjects showed an increase in phase I, compared to 6 in phase II, with the remaining 2 and 3 
showing a decrease in phase I and II, respectively. 
 
(a)                (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.21 Relative fold change in leukocyte VEGF gene expression during (a) phase I and (b) phase II as determined by qRT-PCR 
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7.3.3.6 Changes in leukocyte erythropoietin (EPO) gene expression 
Little correlation was shown in the individual response between phase I and II (Fig. 7.22, Table 7.3).  Nine subjects showed 
unchanged levels during phase I compared with 5 during phase II.  Only 7 subjects showed an increase of >=40% in phase I 
compared to 13 in phase II, with 4 and 2 subjects in phase I and II, respectively, showing a decline in expression. 
 
(a)               (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.22 Relative fold change in leukocyte EPO gene expression during (a) phase I and (b) phase II as determined by qRT-PCR 
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7.3.3.7 Changes in leukocyte hypoxia inducible factor-1! (HIF-!) gene expression 
Leukocyte HIF-1! mRNA expression remained unchanged in 9 individuals during phase I, with 3 of these also lacking a response in 
phase II (Fig. 7.23, Table 7.3).  Similar numbers, 6 and 7 subjects in phase I and II respectively, showed an increase (4 of these 
being the same individuals); 5 individuals showed a decrease in expression, with 2 showing the same response out of 8 individuals 
who decreased expression in phase II. 
 
(a)               (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.23 Relative fold change in leukocyte HIF-1! gene expression during (a) phase I and (b) phase II, determined by qRT-PCR 
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7.3.3.8 Summary of changes in mRNA levels of genes regulated by HIF-1! 
Table 7.5 clearly demonstrates the undefined relationship that exists between HIF-1! and a selection of its target genes expressed 
in leukocytes, with arrows indicating the directionality of change based on ± 40%. 
 
 
 
Table 7.5 Change in gene expression (mRNA) during Phase I and phase II with " indicating an increase, # a decrease (based on a 40%± change) 
and $ no change 
 HIF: 
I  
HIF: 
II 
EPO: 
I 
 
EPO: 
II 
VEGF: 
I 
VEGF: 
II 
ALD-
A: I 
ALD-
A: II 
iNOS: 
I 
iNOS: 
II 
FLK-
1: I 
FLK-
1: 
II 
HMOX: 
I 
HMOX: 
II 
2 !  !  !  "  !  !  !  "  !  #  "  "  !  #  
3 "  #  #  "  !  "  "  #  "  "  !  !  !  !  
4 #  !  "  "  !  !  #  "  "  #  "  "  "  "  
5 !  "  "  "  !  "  "  "  #  "  !  #  !  #  
6 #  #  !  "  "  !  #  #  !  "  !  #  #  !  
8 !  #  !  "  "  !  "  #  #  "  "  !  !  !  
9 !  !  #  !  !  !  !  "  !  #  !  !  !  !  
10 #  !  !  "  #  !  #  #  #  #  #  !  !  "  
11 !  !  #  !  !  !  "  "  #  #  "  "  !  !  
12 !  #  "  "  !  "  "  #  #  "  "  "  !  "  
13 !  "  !  #  #  !  #  "  !  #  !  !  !  !  
14 "  "  !  !  !  !  !  "  "  #  "  !  !  !  
15 "  "  #  "  #  "  "  "  !  "  "  !  !  !  
16 #  #  !  "  "  !  #  #  "  "  "  !  "  "  
17 #  #  !  "  !  !  !  !  !  "  "  "  !  "  
18 "  #  "  "  !  !  "  #  !  "  !  !  !  !  
19 !  "  "  !  !  #  !  "  "  !  !  "  !  "  
20 !  #  "  !  !  #  !  !  !  "  "  !  !  !  
21 "  "  "  #  !  "  "  "  #  "  #  "  !  #  
22 "  "  !  "  !  "  "  "  #  #  #  #  !  "  
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7.3.4 Association between physiological and molecular 
changes 
7.3.4.1 Relationship between plasma EPO expression and individuals diagnosed 
with AMS 
There appears to be no relationship between individuals diagnosed as suffering with AMS 
on the basis of questionnaires and the magnitude of their physiological plasma (EPO) 
response.  All subjects exhibited either a 1 or 2-fold change in Phase I, though this was 
similar to the majority of other non-AMS individuals.  The change ranged from 2 to 10-
fold in phase II, again showing no difference when compared to non-AMS individuals. 
 
7.3.4.2 Relationship between changes in plasma EPO with changes in PO2, Hct, 
Hb and O2 saturation (%) 
7.3.4.2.1 Phase I 
There was no evidence for a relationship between changes in plasma EPO and blood O2 
tension (P=0.6823, R2=0.01) (Fig. 7.25).  Interestingly, there was a significant trend for 
individuals with lower Hct and Hb values to have a higher induction of EPO (Fig 7.26).  It 
seems plausible that this increased EPO response resulted from a poorer capacity to 
transport O2 and hence a greater hypoxic signal to the EPO-producing tissues.  This is in 
line with a weak negative relationship with O2 saturation (Fig 7.24). 
 
7.3.4.2.2 Phase II 
Unfortunately, the PO2 of arterial blood was not obtained.  There was again a strong 
negative relationship between change in EPO with Hct and Hb (both P<0.0001) (Fig. 
7.27).  This reinforces the observation made in phase I.  There were two outliers as 
shown in Fig 7.26 (red circle).  Both of these subjects had AMS in this phase, and were 
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also outliers when characterised by the leukocyte mRNA response.  There was a further 
outlier (denoted by red arrow, Fig 7.26) though this subject was not characterised by any 
of the mentioned features.  As in phase I, there was a negative relationship with O2 
saturation (R2=0.237, P<0.05) (Fig. 7.24).  The same two outliers had the lowest O2 
saturation in phase II (Fig 7.24, red circle).  Unfortunately, the PO2 of arterial blood was 
not obtained in phase II. 
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Figure 7.24 Relationship between O2 saturation and plasma EPO protein response in (a) phase I 
and (b) phase II 
(a) (b) 
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Figure 7.25 Relationship between change in plasma EPO [protein] in phase I with (a) PO2 (b) Hct (P<0.0001) and (c) Hb (P<0.0001), as 
determined using regression analyses 
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Figure 7.26 Relationship between change in plasma EPO [protein] in phase II with (a) Hct (P< 0.0001) and (b) Hb (P< 0.0001), determined using 
regression analyses. (Red circles and arrows denote outliers, as explained above). 
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7.3.4.3 Regression analyses of changes in plasma EPO with downstream hypoxia-activated gene expression 
By observing the relationship between plasma EPO protein and the mRNA expression of HIF-1!-regulated genes it was hoped to 
determine if EPO protein, acting as a surrogate marker of HIF-1! activation, had an influence on downstream gene expression.  
Analysis of regression coefficients (Table 7.6) indicates little evident relationship, with the exception of VEGF mRNA expression 
where there was a trend towards a positive relationship (Fig. 7.27, P=0.0562). 
 
Gene Regression Equation 
Phase I                        Phase II 
R2 value 
Phase I       Phase II 
P-value 
Phase I          Phase II 
ALD-A Y=-40.828 + 3.181 * X Y=2.704 – 0.041 * X 0.066 0.136 0.2752 0.1102 
iNOS Y=--0.053 + 0.027 * X Y=0.366 – 0.005 * X 0.006 0.037 0.7567 0.4158 
HMOX-1 Y=433.571 – 85.436 * X Y=-663.031 - -2.938 * X 0.095 2.953E-4 0.1859 0.9427 
VEGF Y=-268.01 + 29.283 * X Y=598.73 – 1.16 * X 0.188 0.001 0.0562 0.9082 
Flk-1 Y=0.997 – 0.077 * X Y=0.242 – 0.008 *X 0.122 0.007 0.1319 0.7332 
EPO Y=0.323 – 0.03 * X Y=3.987 – 0.045 * X 0.152 0.041 0.0890 0.3935 
HIF Y=-0.004 - 0.012 * X Y=0.043 – 0.001 * X 0.004 0.088 0.7807 0.2041 
 
 
Table 7.6 Regression values for changes in plasma EPO protein plotted against changes in mRNA expression of HIF-target genes where Y is the 
gene of interest and X is [EPO] 
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Figure 7.27 (a) A positive relationship between changes in VEGF mRNA and plasma EPO 
protein in phase I (P=0.0562), and (b) illustration of the lack of relationship between 
changes in iNOS mRNA and EPO plasma protein in phase I (P=0.7567) 
 
 
Outliers were present in the majority of regression analyses graphs, and 
subsequent identification of these individuals reveals that they were outliers in 
many gene responses also (Table 7.7).  However, correlation of these outliers to 
AMS scores or % O2 saturation revealed that none of the outliers from phase I 
had suffered with AMS, though 3 out of the 6 outliers from phase II had been 
diagnosed with AMS (subject no. 3, 18 and 21).  As seen, subjects 5 and 6 were 
common to both phases.  Furthermore, regression analyses of plasma VEGF with 
leukocyte VEGF mRNA expression also revealed 2 of the 6 previous outliers who 
had AMS in phase II (subject no. 3 and 21).  Classification of subjects who were 
EPO responders revealed that 3 of these were also shown to be outliers here (no. 
6, 18 and 21). 
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Outliers common to Phase I 
Subject no.     Genes involved 
Outliers common to phase II 
Subject no.     Genes involved 
  3 iNOS, VEGF, EPO 
5 iNOS, HMOX-1 5 ALD-A, Flk-1, HIF-1 
6 Flk-1, VEGF, HIF-1 6 ALD-A, iNOS, VEGF, EPO 
22 Flk-1, HIF-1 15 ALD-A, VEGF, EPO 
  18 ALD-A, iNOS, VEGF, HIF-1, 
EPO 
  21 VEGF, EPO 
 
Table 7.7 Illustration of ‘outliers’ (denoted by subject no.) revealed in regression analyses 
of EPO plasma protein with leukocyte mRNA changes.        Indicates subjects who were 
outliers in both phases.  
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7.4 Discussion 
The first part of this study was designed to determine if EPO ‘responders’ could be 
differentiated from ‘non-responders’ by studying changes in plasma protein levels 
on exposure to hypoxia, and subsequently correlating these changes with AMS 
scores and O2 saturation levels.  It has previously been shown that subjects who 
experienced a rapid rise in EPO production on exposure to low O2 levels suffered 
less with AMS (Sutherland, unpublished), possibly due to their enhanced O2-
carrying capacity as a result of an increased Hct, and thus [Hb].  The second part 
of the study was used to determine if leukocytes can be used as a circulating 
indicator of HIF-1! activation under hypoxia by studying the mRNA expression of 
HIF-1! along with a variety of HIF-activated genes, and correlating these findings 
with AMS scores.  Due to difficulties in measuring HIF-protein, EPO protein was 
used as a surrogate indicator of HIF-activation.  The objective was to test 
whether the findings from these responses would provide information about 
whether someone is likely to cope better under systemic hypoxia conditions, and 
thus at high altitude, following on from the observation in CHPT 3 that leukocytes 
could be used as a viable indicator of HIF-driven gene expression under hypoxic 
conditions. 
7.4.1 Physiological changes under systemic hypoxia 
7.4.1.1 Sickness at altitude 
On ascent, there is an maximum altitude where an individual can cope sufficiently 
with the lowered O2 levels.  Extending above this exists a zone whereby the body 
can tolerate the lower O2 levels, though is not acclimatised.  There is not enough 
O2 in this upper zone for the body to function properly and symptoms of hypoxic 
distress occur: this presents as acute mountain sickness.  The scoring system 
used to distinguish subjects suffering with AMS in this study identified 10 out of 
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the 20 total subjects, 4 of these appearing in both phase I and II.   A degree of 
controversy exists on determining which scoring system(s) should be used to 
diagnose those with clinical AMS.  Some studies use a LL score of >=5, though 
using this in our study category eliminated 3 subjects detected using the ESQ 
who also exhibited notable changes in gene expression.  A number of studies 
have criticised the ESQ scoring system of containing superfluous questions and 
being validated against only a single item (Maggiorini et al. 1998; Dellasanta et 
al. 2007).  However, as it identified the same individuals as the LL criteria did in 
this study, it was decided to utilise both systems. 
7.4.1.2 Gender difference and sickness at altitude 
Alveolar ventilation and the HVR have been shown to be greater in females than 
males.  This may be due to ovarian hormones, for administration of progesterone 
and oestrogen has been shown to enhance both alveolar ventilation and the HVR 
(Aitken et al. 1986; Tatsumi et al. 1991; Lefter et al. 2007).  Thus, one may 
expect there to be a gender differential response at altitude, particularly 
depending on the part of the menstruation cycle the female is in (higher levels of 
progesterone during the luteal phase of the cycle) or whether or not the 
individual was taking the contraceptive pill, the former shown as a more efficient 
adaptation to the surrounding hypoxia and thus lower levels of AMS.   Three out 
of the 10 AMS+ individuals were females, suggesting that cycle time-points may 
be important and that increasing population size in this study could yield some 
interesting information concerning the relationship between hormones and 
response to hypoxia.  As an addition to a future study, finding out the cycle phase 
each individual female was in could aid in understanding this differential 
response. 
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7.4.1.3 Age effect at altitude 
As described (introduction), links have been postulated between the effect aging 
has on the body and its ability to cope at altitude when compared to the younger 
generation.  There was no evidence in this study to suggest that the older 
members of the group (72 years old) coped in a different manner to the rest of 
the population, based on the fact that their O2 saturations and AMS scores were 
not outstanding. 
7.4.2 Response and adaptation to hypoxia: the HIF 
system 
Studies of human physiological adaptation to altitude have long sought to 
determine whether genetic factors play a part in determining how well a person 
responds on exposure to lowered O2 availability.  The phenotype possessed by 
Western people is distinct from that shown by native populations such as Tibetan 
high altitude residents, who may have been subject to natural selection based on 
their capacity to have adapted to life at high altitude. 
             HIF is a highly conserved heterodimer, playing a central role in O2 
homeostasis.  More than 40 of the HIF-regulated genes have been identified to 
play a key role in the response to hypoxia (Moore et al. 2006) and variation has 
been shown to occur in these genes by studying single nucleotide polymorphisms 
(SNPs) (Howell et al. 2002; Hanaoka et al. 2003), which alters circulating plasma 
levels and thus the individuals response to hypoxia.  However, further studies are 
required to confirm whether the genetic variants seen in HIF-targeted pathways 
do protect some individuals more than others. 
 Observation of HIF-1! protein changes on exposure to hypoxia was not 
possible because of a difficulty in preventing its degradation due to its very short 
half-life on exposure to normoxia.  It is recognised that HIF-1! activates EPO by 
binding to the 3’ regulatory element on the HRE of the EPO promoter (Semenza 
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et al. 1991), and more recently that HIF-2! affects control via the same 
regulatory sequence on the EPO gene (Warnecke et al. 2007).  Consequently, 
HIF-1! knockdown only has a small effect on EPO transcription.  Available 
evidence is consistent with a working hypothesis that HIF is the key O2 sensor in 
hypoxia and that it is in direct control of EPO under these conditions.  This 
provides the rationale for using EPO as a surrogate measure of HIF activation, 
and studying the transcriptional activation of downstream genes known to contain 
the HRE bound by HIF. 
 
7.4.3 Molecular effects of systemic hypoxia 
7.4.3.1 EPO plasma protein: using EPO as a surrogate marker for HIF 
activation and hypoxic up-regulation 
In agreement with a well-established phenomenon, subjects in this study 
experienced a rise in plasma EPO levels on exposure to hypoxia.  The literature 
suggests that plasma EPO levels result from de novo synthesis of EPO in the 
kidney as opposed to release from preformed-stores (Schooley and Mahlmann, 
1972; Scholz et al. 1990) though its synthesis is dependent on available iron 
stores. 
The time course of the EPO response is consistent with the greater mean 
significant increase in concentration seen in the chronic hypoxia exposure of 
phase II, a 434% increase, when compared to the 116% increase in the acute 
exposure of phase I.  This time course is in accordance with a number of studies 
in rodents (Clemons et al. 1987; Schooley et al. 1972), although in contrast, data 
shown in CHPT 3.3.2.2 shows plasma EPO in a mouse model rose to its highest 
value by 3 h, but fell significantly thereafter. 
The differing environments created by the chamber in phase I compared 
to the change in ambient temperature and other surrounding conditions 
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experienced high in the mountains, including the conditions on ascent (i.e. 
physical activity) and duration of exposure, may be in part responsible for the 
noticeable differences between the acute and chronic setting in this study.  The 
differential response between the normobaric hypoxic environment and the 
hypobaric hypoxic environment was observed by Savourey et al. (2003, see 
introduction). 
7.4.3.1.2 Classifying EPO responders and looking at correlations with 
altitude sickness 
Individuals experienced different fold changes in each phase of the study, with all 
but one showing a greater relative increase in phase II.  The observation that 
there is a variable inter-individual EPO response supports previous findings (Ge et 
al. 2001), and this enabled subjects to be grouped accordingly, i.e. individuals 
could be grouped based on whether they experience a prominent plasma EPO 
response or not (Chapman et al. 1998).  It is evident from the data that 
differentiating responders from non-responders in the acute exposure of phase I 
was difficult, possibly due to an insufficient hypoxic stimulus or length of 
exposure, meaning that inter-individual differences were less obvious.  Data from 
the chronic hypoxia of phase II enables separation into arbitrary high-responder 
and low-responder groups, allowing a more meaningful correlation with previous 
data sets that were also obtained in the field, as opposed to the chamber: 
responders were separated from non-responders based on a 40% increase from 
the mean protein concentration of values lying on the lower limit of response.  
Fig. 7.8 clearly shows a separation between the two.  There was a statistical 
significance between the mean of the EPO responders vs. non-responders 
(P<0.05), grouping 5 subjects out of the total 20: three of these had AMS, and 
interestingly, 3 out of these were also shown to be outliers on analysis of the 
mRNA response of a number of HIF-regulated genes in leukocytes. 
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Looking at changes in mean [EPO] for AMS+ and AMS- individuals 
revealed little change in phase I, though a higher [EPO] for AMS+ compared to 
AMS- subjects in phase II.  Though not significant, this suggests that EPO 
‘responders’, i.e. those with higher levels of EPO, include a larger number of 
AMS+ individuals. 
It is thus reasonable to suggest that EPO responders are more likely to 
suffer with AMS when compared to non-responders, though a more highly 
powered study is required to validate this proposal.  This conclusion contradicts 
the hypothesis that increased EPO levels lead to increased RBC production and an 
enhanced O2 carrying capacity, thus decreasing susceptibility to hypoxia-induced 
AMS.  Rather, EPO levels seem to reflect those individuals with the greatest level 
of tissue hypoxia.  This is compatible with the finding, as discussed below, that 
subjects with the lowest Hb values had the highest EPO response. 
7.4.3.1.2 Relationship between EPO and AMS with O2 saturation and 
haematological changes 
7.4.3.1.2.1 Oxygen saturation 
It is widely thought that the level of erythropoietic activity in mammals is 
ultimately determined by the ratio of O2 supply to demand in tissues producing 
erythropoietin.  It has been suggested that O2 saturation is a more important 
determinant of the EPO response than O2 tension (Weil et al. 1968; Pavlicek et al. 
2000).  This finding has been replicated in the present study with a negative 
relationship shown: the lower the O2 blood saturation, the higher the change in 
plasma EPO.  This relationship was stronger and significant in the chronic hypoxia 
of phase II, with 2 outliers that were consistent in having both the lowest Hct and 
Hb scores: they had the lowest O2 saturations along with the greatest change in 
plasma EPO.  One of the individuals was categorised as suffering with AMS in this 
phase, with both being labelled outliers in the leukocyte mRNA response.  This 
suggests that changes in circulating O2 levels was not a proximate cause of 
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altitude illness as low O2 saturations can only be attributed to one of the seven 
AMS+ individuals, though low O2 levels are a cause of higher circulating EPO 
levels.  However, there was no significant difference or noticeable variation from 
mean O2 saturation values for AMS+ subjects and EPO responders, suggesting 
that O2 level is an unreliable determinant of sickness at altitude.  A possible 
explanation for this counterintuitive result is that the O2 saturation values were 
determined by external application of a saturation-measuring device to a finger.  
The values were visible to the subject who was readily able to increase O2 
saturation values by taking a few deep breaths.  In this way, subjects who had 
been suffering with hypoxia were able to temporarily reverse this.  In the same 
way, subjects who demonstrate cheyne stoking while asleep may have apparently 
normal respiration patterns when awake.  Clearly, the EPO response is not 
confined to the level of hypoxia when fully awake and consciously or 
subconsciously hyperventilating.  
 
 
7.4.3.1.2.2 Changes in Hct and Hb 
A negative relationship is seen between absolute Hct, Hb and plasma EPO in the 
hypoxic exposure of both phases, showing that subjects with a higher Hct and 
thus Hb have an increased carrying capacity for O2.  This suggests that the 
stimulus for EPO up-regulation is less than in individuals who have a low Hct and 
Hb: it is in the latter that the greatest change in EPO is seen from normoxia.  The 
two outliers described in 7.4.3.1.2.1 are also seen here, their low Hct and Hb 
levels correlating with low O2 saturations. 
There is evidence that contraction of the spleen on exposure to hypoxia 
can increase the RBCC (Kam et al. 1999).  The spleen is known to contract under 
hypoxia causing release of stored RBCs (Richardson et al. 2005; Bakovic et al. 
2005).  This increase is not evident in phase I of these studies (see Appendix III) 
and may be due to the circumstances surrounding the acute hypoxic exposure: 
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individuals were sedentary or supine for most of the 6 hour exposure, having no 
physiological imperative to move, and thus would have been under different 
autonomic control when compared to the more active situation in the field. 
The association between EPO levels and Hct from the literature is variable.  
A lot of the data come from early studies where some groups demonstrated 
marked polycythaemia on exposure to hypoxia (Barcroft et al. 1923; Hurtado et 
al. 1945; Merino, 1950), and others found no change in RBCC until a significant 
amount of time at altitude had passed: during the 1st two months at altitude, 
Reynafarje et al. (1959) were unable to detect an increase in RBCC, though 
following this and up until 6 months post-altitude exposure, Hct began to 
increase.  This observation is supported by a shorter study by Faura et al. (1969) 
who found that the Hct changed very little following seven days at altitude.  In a 
meta-analysis conducted by Sawka et al. (2000), greater evidence pointed to an 
unaltered volume of RBC.  These discrepancies were thought to be due to the 
different methods used to assess volume, but this has since been since been 
disregarded (Sawka et al. 2000). 
Possibilities for discrepancies between data sets involve 
haemoconcentration leading to a decrease in plasma volume (McLean et al. 
2006), due to dehydration which is known to increase under hypoxia, and 
possibly due to changes in oncotic balance, as proteins have been shown to leave 
the vascular space due to an increased capillary permeability (Sawka et al. 
2000).  However, these findings are controversial.  The degree of 
haemoconcentration relates to the magnitude of hypoxic stress imposed, thus 
differing degrees will be seen in these studies as different altitudes have been 
studied (Sawka et al. 2000) 
Along with these observations under chronic hypoxia, there has been a 
wealth of studies looking at the effect of ‘living high, training low’ as a mechanism 
for increasing RBCC and thus athletic ability and performance: some have shown 
that 4 weeks of intermittent hypoxic training have no effect on RBCC, despite 
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increasing EPO levels (Gore et al. 2006), where others have shown that a 
maximal period of 4 weeks is required to reap any benefits (Wilber et al. 2007).  
The former observation lends support to the argument that a longer period is 
required for blood volume expansion, including an increase in Hct: Pugh (1964) 
observed that the largest volume expansion in an altitude acclimatisation study 
over 5000m for 4 months, and that changes opposing this may be due to 
haemoconcentration due to reasons mentioned above. 
It is possible to propose a time line over which EPO and Hct are induced 
(Fig. 7.28), which suggests that the time points looked at in this study, along 
with data from above studies, fall short of maximal responses seen in both of 
these haematological variables.  This study merely provides a dynamic snapshot 
of changes occurring, not an end-point assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.28 Time course of hypothesised EPO (solid line) and Hct (dotted line) changes 
under hypoxia, with approximate timing of phase I and II 
 
 
 
C
h
a
n
g
e
 i
n
 E
P
O
/H
c
t 
Time course (days) 
Phase I 
Phase II 
EPO 
Hct 
 242 
7.4.3.2 Inability to predict the hypoxic response of 
an individual using leukocytes as a circulating 
marker of gene expression 
The expression of HIF-1! has been well documented in circulating leukocytes 
(Khahil et al. 2008; Mounier et al. 2008; Pialoux et al. 2009), along with the 
expression of its downstream target genes.  Circulating leukocytes have the 
ability to mirror the body’s tissues and organs in health and disease (Dhahbi et 
al. 2007), and were deemed a useful indicator of gene up-regulation under 
hypoxic conditions, as hypoxia has been shown to cause their up-regulation 
(Sanidas et al. 2000).  However, one main factor must be taken into account: a 
shift will be continually occurring of the type and number of circulating 
leukocytes.  Leukocytes are composed of polynuclear neutrophils (60–70%), 
lymphocytes (30%), monocytes (5%), polynuclear eosinophils (2%), and 
polynuclear basophils (<1%) (Testart-Paillet et al. 2007).  It is impossible to 
ascertain which members of the population were involved in the hypoxic response 
without a differential count, which is not reported in studies showing up-
regulation of these genes, nor was such a count conducted here.  Individual 
differential counts are extremely variable.  However, studies showing differential 
leukocyte counts following exposure to hypoxia have revealed unremarkable 
changes (Bolling et al. 1997; Bailey et al. 2000).  The life span of leukocytes 
ranges from 6 hours to around many years for some T lymphocytes, depending 
on the type of leukocyte studied (Van Dyke et al. 1951).  Hypoxia is known to 
decrease neutrophil apoptosis (Hannah et al. 1995), an otherwise major 
mechanism in the resolution of acute inflammation (Mecklenburgh et al. 2002).  
In concert with their relative abundance under normal conditions, this suggests 
that the leukocyte population under hypoxia may be largely made up of 
neutrophils, and that our results are largely reflecting neutrophil gene expression. 
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It is important to consider the fact that circulating leukocytes and the 
genes they express can be altered not only by hypoxic but inflammatory 
conditions (Baudry et al. 1998).  There is evidence that hypoxia can induce an 
inflammatory response in immune cells and endothelial cells, validated by the 
finding that levels of circulating interleukins and C-reactive protein are 
upregulated in response to hypoxic conditions at high altitude (Hartmann et al. 
2002).   Distinguishing between stimulation of these genes by either of the two 
conditions was not possible in this study.  An acute stimulus of 12% hypoxia has 
also been shown to alter the morphology of the circulating leukocyte, inducing 
crater-like formations and a disruption of the cellular membrane (Sanidas et al. 
2000).  How this impacts on gene expression remains unknown. 
7.4.3.2.1 Significant inter- and intra-individual variability in gene 
expression under hypoxia 
There was a large amount of inter-individual variation that occurred in the HIF-1! 
leukocyte response to hypoxia, in agreement with previous studies (Mounier et al. 
2006, 2008), and this may reflect the above observations of a changing leukocyte 
population due to varying life spans.  This variability may also be explained by 
DNA sequence variations resulting from HIF-1! gene polymorphisms in the 
promoter region of the HIF-1! gene (Prior et al. 2006).  Other studies have 
shown an up-regulation during the first 2 h of hypoxia, followed by a down–
regulation of expression, with suggestions that the naturally occurring antisense 
HIF-1! is responsible for these changes (Pialoux et al. 2009).  This is consistent 
with antisense levels increasing in proportion to HIF-1! mRNA expression 
(Mounier et al. 2006).   As our study only followed HIF-1! gene expression after 
6 hours in phase I, and 4 days in phase II, it is possible that down-regulation of 
HIF-1! had already occurred. 
As with HIF-1!, a large variation was shown in HIF-regulated gene mRNA 
expression, with an inability to reveal consistent changes across any of the gene 
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responses for an individual, or to enable a correlation with HIF-1! mRNA 
expression.  This again may be linked with the varying life span of the leukocyte 
and/or down-regulation of HIF expression at the time points chosen for this 
study. 
 
7.4.3.2.2 Using HIF-1! mRNA to predict the plasma EPO response 
HIF-1! is a post-translationally regulated protein (Brahimi-Horn et al. 2005, 
Kaelin and Ratcliffe, 2008), although its regulation on a transcriptional level has 
also been described (Milkiwiecz et al. 2005; Mounier et al. 2008; Pialoux et al. 
2009).  Indeed, when studied along a time course of 12 h, it has been shown that 
plasma EPO levels, and VEGF, follow similar kinetics to that of HIF-1! mRNA 
levels, suggesting that regulation may occur on a transcriptional level (Pialoux et 
al. 2009).  In agreement with a previous study (Mounier et al. 2006), prediction 
of whether an individual will be an EPO responder or a non-responder at altitude 
from HIF-1! mRNA levels was not possible.  The variable positive and negative 
response of HIF-1! mRNA levels did not correlate with the consistent rise in 
plasma EPO levels in this study. 
7.4.3.2.3 Using plasma EPO protein to predict the HIF-regulated gene 
response 
Little is known of the effect HIF-1! mRNA expression has on HIF-1! protein levels 
under these circumstances, and it is unfortunate that HIF protein levels could not 
be assayed in this study.  Mounier et al. (2006) found variable, though generally 
unchanged levels of HIF-1! protein along with mRNA levels.  Based on this 
uncertainty, it is difficult to determine whether using EPO as a surrogate measure 
for HIF-protein activation is appropriate. 
Regression analyses of EPO protein with downstream gene responses 
showed little association between the two, with only VEGF mRNA expression 
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showing a weak correlation.  However, there were a number of individuals 
consistently appearing as outliers in a number of genes.  Out of these 6 outliers, 
3 were diagnosed with AMS and 3 were part of a group of 5 EPO responders 
identified.  Two of these outliers were common to both phases of the study.  This 
suggests that although none of the individual genes per se are able to be used as 
a valid discriminator defining the EPO response to hypoxia or susceptibility to 
AMS, the possibility exists of being able to predict either of these rises with an 
enhanced number of factors studied, and/or increasing the sample number to 
increase the power of the study. 
7.4.3.3 VEGF and sFlt plasma protein 
The VEGF and associated sFlt plasma protein response to hypoxia is one that has 
long been studied, with widespread failure for a conclusive end-point to be 
reached.  Possible reasons for this include the fact that some investigations have 
looked at total circulating VEGF protein and others only at free VEGF, i.e. VEGF 
that is not bound to its cognate receptors, and studies have used samples 
inconsistently from either plasma or serum, another factor which may alter the 
outcome.   Studying VEGF in blood plasma rather than serum is recommended, 
as one storage site for VEGF is platelets and VEGF release has been shown to 
increase on clotting, thus levels may reflect blood platelet counts in addition to 
any hypoxia-induced response (Jelkmann, 2001).  A further confounding factor is 
that the time period after exposure to high altitude differs in many of these 
studies.  Because of this, data from different studies has been shown to vary by 
up to three orders of magnitude (Jelkmann, 2001).  In this study, an ELISA kit 
that measures only free VEGF-A in the plasma was used.  
7.4.3.3.1 Changes in VEGF 
VEGF is a vascular permeability factor and its gene expression has been shown to 
increase under hypoxia both in vitro (Gleadle et al. 1995) and in an in vivo mouse 
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model (Marti and Risau, 1998).  A link has therefore been postulated between a 
hypoxia-induced increase in vascular leakage in the brain and lungs, 
subsequently leading to HACE or HAPE, respectively, due to its known 
characteristic of increasing membrane permeability (Behzadian et al. 2003).  A 
greater amount of free VEGF is seen in some AMS+ subjects, suggesting it may 
contribute to the pathology of high altitude illness.  Studies generally find that 
VEGF levels increase in plasma under hypoxia, though evidence for the 
association between either AMS and/or clinical oedema is weak and remains so 
following this study: In phase I, a variable individual response in plasma VEGF 
was seen, subjects exhibiting both positive and negative changes.  In phase II, 
however, effects were more consistent and there were only negative or 
unchanged values, suggesting that the response is different under chronic 
compared to the acute exposure to hypoxia, becoming blunted following a longer 
time exposure.  Alternatively, the response may be due to the differing 
environment provided by the hypobaric vs. the normobaric exposure to hypoxia, 
as discussed earlier (see Introduction). 
These results are consistent with a number of previous studies, 
demonstrating continued uncertainty surrounding the VEGF response of an 
individual to hypoxia. The failure to be able to correlate altitude sickness or other 
parameters studied (such as PO2) has been seen previously (Nilles et al.2009, 
Pavlicek et al. 2000), although one study has found that individuals suffering with 
AMS have a higher amount of free plasma VEGF (Tissot van Patot et al. 2005).   
Inconsistent changes were also shown in AMS+ subjects and EPO 
responders in relation to VEGF, with no apparent correlation being seen.  One 
explanation for the variation seen in the above-mentioned studies is the differing 
time scales upon which they occurred: all were based at a similar height of 
between 4000-4200m, though from 1 day of exposure (Pavlicek et al. 2000) to 2 
days (Maloney et al. 2000, Nilles et al.2009).  Plasma samples for VEGF on the 
chronic study time point here were taken on day 4 and at the slightly more 
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elevated altitude of 4392m.  Taken together, the timescale of the adaptive 
physiological response may therefore play a role in determining the different 
outcomes seen in these studies. 
It is important to be aware of the role that the immune system can play in 
VEGF activation, with the possibility that any plasma VEGF seen may have been 
induced by inflammatory factors, as well as or instead of hypoxia.  
Schobersberger et al. (2000) found a significant long-lasting increase in serum 
VEGF that was accompanied by activation of the immune system (increased 
levels of interleukin-6 and neopterin), although Pavlicek et al. (2000) provided 
evidence against any clinically relevant inflammation in the development of HAPE 
which can occur as a subsequent development of AMS. 
7.4.3.3.2 Changes in sFlt 
Tissot van Patot et al. (2005) showed a decrease in the amount of circulating sFlt 
in subjects diagnosed with AMS, along with the above-mentioned increase in free 
plasma VEGF, supporting the proposed hypothesis that more VEGF is therefore 
available to participate in the pathology surrounding HACE and HAPE (as less 
sFLT is available to titrate the effect of the free VEGF). 
Our study showed largely unchanged levels of sFlt in both AMS+ and AMS- 
subjects during both phases.  This finding does not provide support to the above 
theory.  The response of both sFlt and VEGF was more blunted in phase II with 
only unidirectional changes occurring, though in a negative direction for VEGF and 
in a positive direction for sFLT when compared to baseline values for each phase.  
This indicates that there is less bioavailable VEGF to participate in the proposed 
pathogenesis associated with HACE or HAPE under chronic hypoxia, suggesting 
that either (i) a feedback mechanism is operating which acts to maintain fairly 
constant levels of VEGF activity, similar to those under normoxia, after a 
prolonged period of exposure to hypoxia (i.e. 4 days here), (ii) that the hypoxic 
stimulus to induce changes in levels of VEGF and sFlt was inadequate, or (iii) that 
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the time frame associated with exposure to hypoxia, either normobaric or 
particularly hypobaric, was too long to see the acute changes previously 
reported: Tissot van Patot et al. (2005) found changes occurring following a 20 h 
exposure. 
Regression analyses between EPO and sFlt indicated a positive 
relationship, although not significant, allowing us to postulate a possible influence 
of EPO, and indirectly HIF, upon sFlt.  However, no relationship was shown 
between EPO and the HIF-responsive VEGF, suggesting that in vivo regulation is 
likely to be multi-factorial. 
 
7.4.3.4 Confounding factors from the study 
7.4.3.4.1 Control of EPO by the HIF-system: An emerging role for HIF-2! 
There is firm evidence that HIF-1! is the key factor activating EPO transcription. 
However, HIF-2!, which shares 48% sequence homology with HIF-1! (Tian et al. 
1997), 
is now also known to play an important role in controlling EPO production, and 
controversy exists around which of the two isoforms plays the greater role.  HIF-
1! was the original isoform identified as binding to the 3’ regulatory element on 
the HRE of the EPO promoter (Semenza et al. 1991).  Using gene silencing in 
vitro, and later supported by an in vivo model (Gruber et al. 2007), it was 
subsequently shown that HIF-2! was largely in control of the same regulatory 
sequence on the EPO gene (Warnecke et al. 2004).  The role of HIF-1! protein in 
the control of EPO remains controversial, but an ELISA to measure HIF-2! protein 
levels was not available.  In addition, Mounier et al. (2006) were not able to 
determine HIF-2! mRNA levels in leukocytes, suggesting that it is not expressed, 
therefore its presence here was not able to be determined.  HIF-2! is in control of 
the same genes as HIF-1!, in this study, though without further insight to its 
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presence in this study, establishing whether the EPO expression was under the 
control of HIF-1 or HIF-2, remains unclear. 
7.4.3.4.2 Controversy surrounding the determination of clinical AMS 
Scoring systems used to determine whether an individual is suffering from AMS 
or not are deemed insufficient by many for assessing whether physical symptoms 
evident are a result of the altitude or other surrounding factors that may be 
present.  The LL system has long been used and is useful on many clinical levels, 
along with the ESQ.  However, studying changes on a molecular level requires a 
more intimate approach to accurately identify who is ill and who is not, so that 
confidence in correlating changes on a protein and haematological level with 
sickness can be increased. 
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7.5 Conclusion 
Acute responses to hypoxia are those occurring practically instantaneously with 
the environmental change.  Acclimatory responses are defined as adjustments 
requiring some fraction of the organism’s lifetime, from minutes to days, to reach 
a new steady state (Hochachka et al. 1998).  It is evident that many of the 
changes occurring during the acute exposure of phase I are different in 
magnitude and directionality when compared to the chronic exposure of phase II, 
and these changes may be attributed to the different environment provided by 
normobaric vs. hypobaric hypoxia.  The change in EPO seen here is a good 
indicator of the physiological response to hypoxia, though no significant 
correlation could be made with sex or age of the subject and the degree of their 
response.  EPO responders were shown to increase EPO levels faster, though this 
was not translated into increased Hct and Hb levels as the literature would 
suggest, or to individuals suffering less with AMS.  This suggests that the system 
is influenced by a range of factors which influence feedback mechanisms, making 
pathways less straightforward than previously thought.  Biological feedback 
mechanisms and possible genetic variations also mean that translation of this 
change into a downstream cascade system modulated by HIF produces a very 
variable response, clearly shown as inter-individual variation in and between 
proteins and genes and this suggests that multiple metrics are required to 
measure response to hypoxia resulting in AMS.  The plasma VEGF and sFlt 
response shown has added to the confusion surrounding theories of links with 
illness at altitude, either in the form of AMS or the more serious HACE or HAPE, 
with no definitive associations being seen in the acute exposure, and although a 
decrease in plasma VEGF was seen with a corresponding increase in sFLT under 
chronic hypoxia, no correlations could be made with individuals suffering with 
AMS.  The idea of using circulating leukocytes as an indicator of the hypoxic 
activation of genes was deemed logical following observation of their upregulation 
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in murine leukocytes, and leukocytes have been known to efficiently represent 
the body’s tissues and organs in health and disease, so could be assumed to be 
an efficient measure of the systemic hypoxic response.  However, their 
heterogeneity in relation to type and lifespan causes difficulties in their collective 
use for assessing response to hypoxia.  
 
 252 
7.6 Future directions 
An important future step would be to carry out counts of leukocytes and a 
platelet count, to determine whether an inflammatory-based immune response 
was present in response to hypoxia, which may otherwise influence the gene 
response seen.  A differential count of leukocytes would also be useful to 
determine whether one species of leukocyte made up the majority of the 
population present, and whether this influenced the results seen, based on their 
relative half-lifes, for example, a species of leukocyte with a short half life may 
show a different level of gene expression when compared to a leukocyte with a 
longer half life.   Furthermore, study of the variety of factors implicated in an 
immune response to confirm whether inflammation may also be playing a role in 
activation of these HIF-regulated proteins and genes may be insightful.  It would 
be beneficial (on a study that encompasses as many factors as this) to 
incorporate larger subject numbers to increase the power in this study and 
provide more definite evidence for each of the changes observed, alongside 
increasing the selection of genes studied and evaluating changes in these genes 
on a protein level as well.  Developing a more efficient AMS scoring system would 
represent a more pragmatic approach to defining sickness at altitude.  Finally, as 
new technologies are revolutionising the study of adaptation of the human body 
to stress, comprehensive gene screening and comparisons between situations of 
hypoxia and normoxia could resolve these issues.  
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8 Discussion 
 
When challenged with the situation of low O2 in the surrounding environment, be 
it local or systemic, the body undergoes a series of adaptations which 
subsequently aid acclimatisation.  On a physiological level, an increase in 
ventilation rate and cardiac output ensue in response to acute hypoxia, followed 
closely by an upregulation of factors on a molecular level when hypoxic conditions 
are maintained.  These mediate erythropoietic, metabolic and angiogenic 
changes, among many others.  Central to controlling changes on both these 
levels is a transcription factor which acts as a global effector of change under 
both hypoxic and normoxic conditions, HIF.  A common theme among 
experiments in CHPT 3 and 5 was to elucidate what level of local hypoxia or 
systemic hypoxaemia was necessary to initiate angiogenesis, and whether use of 
a chemical stabiliser of HIF would enhance this response. Studying these models 
is not only useful for deducing the necessary conditions for initiating blood vessel 
growth, but act as valuable surrogate measure for clinical conditions such as 
peripheral vascular disease and chronic obstructive pulmonary disease, 
respectively.  
Systemic changes to hypoxia are evidenced in CHPT 3 by an increase in 
capillarity in the diaphragm and heart of mice under conditions of 10% hypoxia.  
This illustrates how angiogenesis, presumably mediated by HIF although not 
confirmed here, can be upregulated not only under conditions of hypoxia, but also 
stretch as a consequence of a increased ventilation and greater overload, 
respectively.  HIF-mediated upregulation under non-hypoxic conditions has been 
demonstrated previously (Kim et al. 2002; Williams et al. 2006b; Milkiewicz et al. 
2007).  That similar angiogenic effects weren’t seen in the EDL of the hindlimb 
suggests the need for a greater hypoxic stimulus, such as may be achieved with 
exercise.  Elucidating the PO2 required for HIF activation in vivo and the 
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subsequent induction of angiogenesis is an area of controversy due to difficulties 
in securing accurate measurements of tissue PO2, but it may well be that the 
threshold for activating HIF was not reached here.  However, a muscle with a 
more oxidative fibre type, the soleus, was more responsive to hypoxaemia than 
the mixed fibre type of EDL.  This has been shown in other studies (Deveci et al. 
2001, 2002) suggesting that fibre type plays a crucial role in determining tissue 
responsiveness.  Consistent with this finding, the mRNA response following 
exposure to 10% hypoxia was most significantly altered in the soleus. 
HIF availability is under tight control under both normoxia and hypoxia by 
members of the PHD family, PHD 1-3.  Following from previous observations that 
chemical manipulation of the PHDs can alter HIF-1! stability (Jaakola et al. 2001; 
Warnecke et al. 2003; Milkiewicz et al. 2005), experiments were conducted to 
elucidate whether the finding of an increased capillarity in the hindlimb of the 
mouse following ligation of the femoral artery and treatment with the PHD 
inhibitor, DMOG, would be seen in both a model of systemic hypoxia and 
overload, along with a replicated finding in the femoral ischaemia model.  In both 
models of the hypoxic induction of HIF (systemic and local), no evidence for an 
enhanced capillarity was seen in the hindlimb following treatment with DMOG.  
This primarily suggests that the threshold for inducing HIF-1 may not have been 
reached as tissue hypoxia was insufficient: the position of the ligation may have 
an influence upon the degree of ischaemia.  Ziv et al (2004) ligated the artery 
further upstream than our study, inducing a higher degree of ischaemia (as 
evidenced by loss of limb function).  The confounding factor here though is the 
possibility of inflammation due to the more invasive nature of the surgery, which 
can also play a role in inducing angiogenesis (NF"B-mediated HIF-1 activation).  
Alternatively, a less well studied area when observing angiogenesis following 
ischaemia is the upregulation of a number of anti-angiogenic factors (e.g. 
thrombospondin-1, endostatin, and angiostatin) alongside pro-angiogenic factors.  
In this case, it emphasises the delicate balance determining whether 
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angiogenesis is activated or not remained, the ‘angiogenic switch’, which is still 
unresolved.     
HIF-1! has been shown to be upregulated under conditions of stretch, 
such as those experienced following removal of a synergist muscle in the 
hindlimb (extirpation), resulting in angiogenesis.  So examining whether a similar 
response would be seen following manipulation of HIF-1! stability as with femoral 
artery ligation (Milkiewicz et al. 2005), may help to shed light on the presence of 
alternate pathways leading to the upregulation of HIF in response to different 
physiological challenges.  The hypothesised response of an enhanced capillarity, 
greater than that achieved by extirpation alone, was not evident.  This suggests 
that under conditions of stretch, HIF is either acting via a different pathway, or 
DMOG is impacting on the regulatory system in an unfavourable way: DMOG has 
been shown to have an affect on other members of the PHD family involved in 
collagen synthesis, namely C-P4Hs (Koivunen et al. 2007), a necessary 
component of recovery following extirpation (in angiogenesis and increased 
sarcomere length) (Laurent et al. 1985; Winter and Page, 2000).  It proved, it 
may be the case that the potential of such chemical manipulation as therapeutic 
angiotherapy is limited.  
Confounding factors impacted upon each of the other studies: subsequent 
to both the systemic and acute hypoxia studies (CHPT 3 and 5), it was realised 
that the strain of mouse being used was particularly resistant to both challenge 
by systemic hypoxia and ischaemia, modulating its metabolic fuel and ventilation 
under systemic hypoxia, and possessing an innately greater CD in skeletal 
hindlimb muscles, translating into a greater capacity to maintain sufficient O2 
delivery under systemic hypoxia, and the ability to rapidly restore blood flow 
following occlusion of the artery.  Thus, this strain of mouse has been shown less 
useful in these studies as reaching a level of local hypoxia suitable for HIF 
activation without imposing dangerous levels of systemic hypoxaemia is a 
challenge.   
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A variation of the strain was used (C57Bl10/J) in both the femoral artery 
ligation and extirpation models, and an enhanced response was seen in this strain 
when compared to C57Bl6/J.  This clearly illustrates that inter-strain differences 
do exist, albeit subtle and statistically insignificant, though it would be interesting 
to investigate factors such as variability in fibre type composition which may be 
responsible for this response. 
 The viability of DMOG was also questioned and found to be slightly different 
in molecular structure (using NMR and MS) to that used in previous experiments 
(Milkiewicz et al. 2005).  However, repetition of experiments with a newly 
synthesised batch again failed to produce an enhanced C:F in affected limbs, 
suggesting that DMOG also has a threshold below which it is not activating the 
HIF system to its full potential, and this may have been the case here if the 
bioavailability was underestimated.  
 The unwanted and unknown side effects of the use of chemicals to 
manipulate biological pathways, without being fully aware of possible 
redundancies in the system, are a disadvantage.  The use of genetically modified 
animals, allowing one to study the effects of redundancy whilst having the 
assurance that only the specified gene has been directly interfered with, has been 
revolutional for many studies, and was used here to identify the differential 
response of animals with either PHD1 or PHD3 gene ablation.  In vitro data has 
shown that PHDs contribute in a non-redundant manner to the regulation of HIF-
1! (Appelhoff et al. 2004), so the effect of manipulating either of these pathways 
should help to elucidate whether a similar scenario exists in the more complex, 
interactive situation in vivo.  The reciprocal gene changes seen in PHD1 and PHD3 
K/O mice shows that redundancy is present.  Significant upregulation of genes 
involved in protein remodelling was evident by muscle hypertrophy (suggesting 
that protein remodelling is occurring downstream of gene expression), though 
translation of the observed angiogenic gene response into downstream 
physiological effects was lacking, giving support to the complexity of the 
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angiogenic response, and suggesting, as mentioned above, that anti-angiogenic 
factors may play a role in inhibiting pro-angiogenic signal from being 
physiologically active. 
The well-studied erythropoietic adaptations following systemic hypoxia 
were clearly evidenced by the increased plasma EPO in the mouse by 3 h post-
hypoxia (CHPT 3) and by raised levels of a greater magnitude in humans 
following both an acute and chronic exposure to hypoxia (CHPT 4).  EPO 
‘responders’ were shown to increase EPO levels faster, though this wasn’t 
translated into increased Hct and Hb levels, adding to the literature controversy 
associated with the multitude of variables in each study affecting the outcome.  
No significant relationship was seen between EPO levels and AMS+ subjects, 
although there was a trend for sickness to be associated with a greater increase 
in plasma [EPO].  This is in accordance with lower Hct and Hb levels, allowing one 
to hypothesise that individuals who suffer at altitude do so due to impaired 
polycythaemia and thus insufficient blood O2-carrying capacity, despite having 
higher levels of EPO.   
As EPO is known to be regulated by HIF (Semenza et al. 1991), it was 
deemed a suitable surrogate indicator demonstrating HIF upregulation, as 
studying HIF directly proved too difficult.  As HIF is known to be regulated on a 
post-translational level under hypoxia (Brahimi-Horn et al. 2005; Kaelin and 
Ratcliffe, 2008), the lack of change in mRNA transcripts was expected, as seen.  
Data from CHPT 3 encouraged the use of leucocytes as a circulating marker of the 
systemic hypoxic response in humans, as the expression of HIF-1 ! and its 
downstream target genes have been identified here (Khahil et al. 2008; Mounier 
et al. 2008; Pialoux et al. 2009).  A number of HIF-regulated genes were seen to 
change, e.g. the leucocyte EPO mRNA response mirrored the plasma [EPO], 
giving support to the proposed utility of this approach in humans.  A greater 
variability was seen in human leucocyte mRNA response in the selected genes, 
though the study confirmed that leucocytes do appear to be sensitive to gene 
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expression alteration under hypoxia.  This variability may be naturally occurring 
or because of the differing half-life of the leucocyte population, meaning that 
gene expression differed with each new population.  Biological feedback 
mechanisms and possible genetic variations (DNA sequence variations resulting 
from HIF-1! gene polymorphisms in the promoter region of the HIF-1! gene) 
have been observed (Prior et al. 2006) mean that translation of this change into a 
downstream cascade modulated by HIF produces a very variable response.  
Whether the mRNA response seen here is translated into a protein response 
remains to be determined, though it may be that regulation of a number of these 
genes occurs post-translationally, suggesting that the mRNA response may not 
be a true indicator of an individuals hypoxic response.  Thus, the idea of using 
circulating leucocytes as an indicator of the hypoxic activation of genes seems 
logical as they have been known to efficiently represent the body’s tissues and 
organs in health and disease.  However, their feasibility in relation to varying life 
spans remains controversial, and accurate determination of AMS susceptibility is 
likely to require a panel of responsive indices. 
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Future work 
A range of difficulties encountered in these studies provides the basis for future 
experiments, which may help explain discrepancies observed.  One major factor 
highlighted is the effect mouse strain can have upon the response and outcome 
to differing experimental and thus environmental stimuli.  Animal models have 
long been used to model disease, and one of the primary aims of research is to 
find an animal model that can be used as a surrogate model to mirror the human 
response to disease, as experimenting on human subjects is not always feasible.  
Carrying out a broad study to incorporate a variety of mouse strains in order to 
determine differential responses to imposed conditions, may help to identify the 
most suitable strains available for proposed models.  
 The HIF system is complicated and variable, and one of the big problems 
in trying to understand its biology is its lability, meaning that isolation of this 
normoxically-degraded and hypoxically-upregulated protein is a major challenge, 
as was found here.  This could be overcome by conducting experiments in a 
hypoxic chamber that would prevent the otherwise inevitable exposure to 
normoxia.  Another issue in understanding its downstream effects are 
encountered due to the wide range of factors that also impact upon HIF-regulated 
genes, presumably in an interactive manner.  Within the systems studied here it 
is possible that inflammation played a role in initiating angiogenesis, as evidenced 
by upregulation of inflammatory factors (CHPT 6) 1 wk following extirpation, 
when histological evidence of angiogenesis has been shown.  To proteins under 
HIF control under these circumstances, and to elucidate which pathways are 
activated e.g. hypoxia and/or inflammation, it may prove necessary to perform 
nuclear pull down assays, allowing the detection of proteins that bind in vitro to 
an immobilised HIF recombinant protein.  The disadvantages of this approach are 
that although in vitro experiments provide large amounts of useful data, they are 
 261 
not able to replicate the complexity of the in vivo environment, but may highlight 
some of the important pathways and/or cellular mechanisms in operation here.  
Laser capture microdissection (LCM) is a method for isolating specific cells 
of interest from microscopic regions of tissue that has been sectioned, allowing 
the selection of cells with a minimum resolution of several microns and also 
allowing the analysis of cells of interest that are free of neighbouring 
contaminants which may otherwise confound experimental results (Edwards, 
2007).  These cells can then be used in a wide range of downstream assays such 
as LOH (loss of heterozygosity) studies, gene expression analysis at the mRNA 
level or in a wide range of proteomic assays such as 2D gel analysis, Western 
blotting, reverse phase protein array and protein profiling.  Many of these have 
already been used on tissue and leucocyte samples here, though the advantages 
of studying isolated cells include the speed of isolation, the fact that no lesions 
are incurred on isolation, and the ability to study a small subset of cells provides 
an accurate assessment of gene expression levels that may be critical to 
understanding their mechanisms of action.  This technique would be very useful 
when combined with a study of the anti-angiogenic factors present under 
conditions of femoral artery ligation, which may represent the confounding factor 
inhibiting angiogenesis under conditions that otherwise should provide a pro-
angiogenic environment.  For example, VEGF165b is an inhibitory form of VEGF 
that has been shown to constitute large percentages of the total VEGF protein in 
non-angiogenic tissues (Ladomery et al. 2006), the balance of pro- to anti-
angiogenic VEGF isoforms apparently determining the disease state of tissue, and 
thus whether or not the angiogenic switch is activated in a positive direction.  
PHD2 is the key O2 sensor exhibiting regulation over HIF-1! (Berchner-
Pfannschmidt et al. 2008), though its ablation leads to embryonic lethality.  More 
is known about the function of this PHD in vitro than the other two enzymes, so 
investigating its presence in a new in vivo model would be extremely beneficial.  
In adult mice deficient for PHD2 by conditional knockout, HIF-1! accumulated in 
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both the kidney and liver, inducing EPO expression (Takeda et al. 2008).  
Generating PHD2 knockouts with somatic mutations is possible by Cre-mediated 
recombination and this would be interesting to provide comparisons with the 
PHD1 and PHD3 knockout mice already used with muscle extirpation, where 
hypoxia is thought to play no role, and also to observe responses in the femoral 
artery ligation or an iliac ligation model, where hypoxia is thought to be the key 
factor initiating the angiogenic response.  
 My studies with DMOG did not yield useful data. Whether this was due to 
lack of potency in the preparations given to me or to model used remains to be 
determined. As outlined previously, the in vitro model described by Jaakola et al. 
(2001) would answer the first question.  Regarding the mouse model, the 
pharmacological and toxicological properties of DMOG have not been fully 
investigated.  The effect of varying doses of DMOG on vitals (including measuring 
temperature via an anal probe, heart rate using an ECG, and blood pressure 
using a saline-filled catheter inserted into the left ventricle via the carotid artery 
connected to a blood pressure monitor) in the murine model are necessary.  Once 
established, Western Blotting and mRNA quantification of HIF and PHD expression 
in the heart and skeletal leg muscles could be performed. Time course studies 
would be necessary to fully understand its effects.  
Factors determining how well an individual fares on exposure to altitude 
are still largely undetermined, possibly as a multitude of factors are responsible 
for an individuals response, and looking at many components of the complex 
system in vivo at one time is too complicated.  Thus, research groups have only 
tried to identify one aspect at a time.  Gene array technology has made it 
possible to characterise the RNA expression of thousands of genes across 
numerous tissue samples and under varying conditions, and would prove very 
useful in assessing changes at a gene expression level, that occur in sick vs. well 
individuals under the systemic hypoxia at altitude to help uncover the multi-
faceted response that seems to be occurring.  
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Appendix I 
 
A.1.1 Mean mouse mass (g) 12% hypoxia ± SEM (n=6 per group) 
 
 
Day 
1 wk 
DMOG 
1 wk 
no 
DMOG 
2 wk 
DMOG 
2 wk no 
DMOG 
4 wk 
DMOG 
4 wk 
no 
DMOG 
0 
25.6 ± 
1.03 
26.8 ± 
0.52 
26.0 ± 
1.2 
25.0 ± 
1.13 26.2 ± 0.19 24.8 ± 0.46 
3 
25.1 ± 
0.68 
26.2 
±1.12 
24.6 ± 
0.4 
23.7 ± 
0.49 25.1 ± 0.69 24.1 ± 1.06 
5 
26.0 ± 
0.89 
26.2 ± 
0.34 
25.7 ± 
0.12 
24.4 ± 
0.99 25.6 ± 0.72 24.5 ±0.88 
7  
 26.7 ± 
0.79 
25.2 ± 
0.25 26.0 ± 0.45 25.0 ± 0.75 
10  
 26.7 ± 
0.61 
25.2 ± 
0.85 26.5 ± 1.11 25.1 ± 1.03 
12  
 27.3 ± 
1.05 
25.9 ± 
0.1 26.8 ± 0.85 25.4 ± 0.97 
 
14  
   
27.6 ± 0.96 25.8 ± 0.26 
 
17  
   
27.7 ± 0.71 25.8 ± 0.49 
 
19  
   
28.3 ± 0.64 26.5 ± 0.47 
 
21  
   
28.4 ± 0.62 26.6 ± 0.77 
 
24  
   
28.1 ± 0.2 26.4 ± 1.14 
 
26  
   
27.8 ± 0.33 26.0 ± 0.65 
 
 
A.1.2 Mean mouse mass (g) under 10% hypoxia ± SEM (n=12 per group) 
 
 
 
Day 2 wk DMOG 2 wk no DMOG 
 
0 25.3 ± 0.65 25.5 ± 0.94 
 
3 24.1 ± 1.02 § 24.6 ± 0.68 § 
 
5 24.5 ± 0.48 § 24.1 ± 0.71 § 
 
7 25.3 ± 0.22 25.1 ± 0.78 
 
10 25.0 ± 0.88 25.3 ± 1.14 
 
12 25.6 ± 0.57 25.2 ± 0.72 
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Appendix II 
 
A.2.1 HIF protein extraction from WBCs 
A.2.1.1 White blood cell isolation from whole blood 
 
All centrifugation steps were carried out at RT.  Blood was drawn into two 10ml 
purple top vacutainer tubes (EDTA-treated) and tubes inverted several times.  
Blood was diluted and mixed 1:1 with cold 1xPBS.  20ml of this was layered upon 
an equal volume of Histopaque 1077 (Sigma, 10771) in 2x50ml falcon tubes.  
Tubes were spun at RT for 30 min at 400 RCF.  Following centrifugation, a 
generous layer of the opaque interface (buffy layer) from each tube was removed 
using a pasteur pipette, and combined into one 50ml tube on ice.  20ml 1xPBS 
was added and mixed.  Tubes were spun for 10 mins at 250 RCF.  The 
supernatant was removed, the pellet resuspended with 10ml 1xPBS in a 15ml 
tube and spun for 10 mins at 250 RCF.  The supernatant was removed and 
resuspended with 10ml 1XPBS, then spun for 10 min at 250 RCF.  The 
supernatant was removed and the pellet resuspended in 250!l 1xPBS and 
protease inhibitors (PI was made up during last 10 min spin).  The sample was 
transferred to an eppendorf and frozen in liquid nitrogen, then stored at -80°C.  
 
A.2.1.2 HIF nuclear protein extraction 
HIF-1 resides in the nucleus under hypoxic conditions and thus a nuclear 
extraction buffer was used to isolate the protein.  
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A.2.1.2.1 Solutions 
 
Lysis Buffer A- 1ml 
 HEPES           100µl 
 MgCl2, NaF  100µl 
 KCl   100ul 
 DTT   5µl 
 NP-40   10µl 
 Na3VO4  10µl 
 Protease Inhibitors 140µl 
 PMSF   1µl 
 H20   535µl 
 
Lysis Buffer B- 1ml 
 HEPES  200µl 
 MgCl2, NaF  100µl 
 NaCl   100ul 
 DTT   5µl 
 Glycerol  250µl 
 Na3VO4  10µl 
 Protease Inhibitors 140µl 
 PMSF   1µl 
 H20   195µl 
 
 
To make 50 ml of the following: 
 
1.19g 100mM HEPES pH 7.9  
15mM MgCl2, 50mM NaF  
0.15g MgCl2 
0.1g NaF  
0.37g 100mM KCl  
1.84g 200mM Na3VO4 (100x) 
(Adjust to pH 10, then boil till colourless.  Repeat until it remains colourless) 
12.27g 4.2M NaCl  
10% NP-40 (100x) 
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0.5ml: 
17.4mg (in EtOH) 200mM PMSF (0.5ml) (freeze) 
 
200!l: 
3mg 100mM DTT (keep frozen) 
 
Protease inhibitor cocktail (make fresh daily or freeze, according to 
manufacturers guidelines) 
A.2.1.2.2 Protocol 
Eppendorfs were brought to RT on ice from -80°C and spun for 5 mins at 1000 
RCF at 4°C.  The supernatant was removed and 1ml of buffer A added to the cell 
pellet which was then vortexed to break up the pellet.  The sample was spun at 
16,000 RCF for 5 min at 4°C.  The cystolic supernatant was removed, 100!l of 
buffer B added and the sample vortexed.  Samples were left on ice for 20 mins 
before a final vortex and subsequent centrifugation at 16,000 RCF for 5 min at 4 
°C.  The supernatant was aliquoted to eppendorfs and frozen at -80°C. 
 
A.2.1.3 HIF ELISA 
HIF protein was analysed using a HIF transcription ELISA kit (Panomics, EK1020) 
as per the manufacturers instructions.  
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A.3.1 Data from exposure to 12% in the normobaric hypoxic chamber, Phase I  
A.3.1.1 Venous blood 
Subject  Hb [g/dl]  Hct [%]  PCO2 (mmHg)  PO2 (mmHg) 
Number  NORM HYP  NORM HYP  NORM HYP  NORM HYP 
2  15.9 14.0  45.0 44.5  49.0 43.2  31.0 22.7 
3  13.3 14.9  40.0 41.0  43.8 31.8  28.4 36.2 
4  13.0 16.3  41.5 42.5  44.5 40.9  30.3 24.3 
5  13.3 14.5  42.0 43.0  54.3 36.0  31.1 30.1 
6  13.9 16.4  42.0 42.0  49.8 36.6  23.9 25.5 
8  17.5 19.1  44.0 48.0  52.1 38.2  21.3 27.3 
9  15.8 16.6  46.0 50.0  46.6 46.1  36.5 25.0 
10  14.3 14.8  43.0 43.5  44.7 41.1  36.7 20.8 
11  14.3 15.5  44.0 47.0  40.1 34.0  68.3 49.7 
12  11.8 12.8  37.5 38.0  43.6 38.8  30.3 36.0 
13  11.3 13.7  36.0 39.0  43.7 33.3  27.9 32.8 
14  13.1 13.5  39.0 38.0  49.8 40.0  30.1 34.4 
15  13.6 14.5  42.0 43.3  45.9 44.7  42.1 27.4 
16  12.4 13.4  39.5 39.5  41.5 39.7  47.6 30.7 
17  13.6 16.0  40.0 43.0  48.0 42.1  25.3 20.2 
18  13.4 15.0  39.0 42.0  50.3 42.6  29.6 16.8 
19  16.2 17.4  48.0 49.0  39.1 42.4  56.3 23.3 
20  14.7 15.7  45.0 46.0  46.6 39.7  39.4 27.4 
21  14.8 14.5  43.0 42.5  47.4 43.3  21.9 19.2 
22  14.5 15.8  44.0 46.0  45.6 45.6  51.3 30.0 
Hb: haemoglobin, Hct: haematocrit, PCO2: partial pressure carbon dioxide, PO2, partial pressure oxygen, (blue= subjects with AMS) 
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A.3.1.2 Arterialised capillary 
 
 
Subject  Hb [g/dl]  Hct [%]  PCO2 (mmHg)  PO2 (mmHg) 
Number  NORM HYP  NORM HYP  NORM HYP  NORM HYP 
2  14.5 14.7  43.0 45.0  35.5 26.4  78.8 34.8 
3  13.6 13.8  41.5 42.0  33.5 28.2  92.7 48.0 
4  14.8 15.0  43.0 45.0  34.4 22.5  86.8 39.9 
5  14.3 13.3  43.0 42.0  37.6 29.8  70.8 43.2 
6  15.0 14.2  45.0 43.0  37.8 30.5  66.2 33.4 
8  15.7 14.7  43.0 45.3  35.9 29.3  64.3 38.3 
9  17.0 17.3  50.0 52.5  38.3 33.0  86.4 40.7 
10  15.0 14.2  46.0 45.0  35.7 26.6  81.1 45.6 
11  14.5 15.5  45.0 47.0  37.1 28.5  92.8 36.1 
12  11.5 12.6  40.0 38.0  35.5 24.8  76.0 40.6 
13  12.3 12.4  41.0 41.0  32.8 26.9  103.3 49.8 
14  13.5 13.4  39.5 40.0  37.2 34.0  87.2 44.3 
15  13.0 13.3  49.5 44.0  41.5 32.5  79.9 46.7 
16  13.4 13.9  38.8 41.0  33.5 31.2  92.7 45.2 
17  13.4 16.0  41.0 44.0  38.2 30.8  84.0 46.2 
18  11.4 13.6  39.0 42.0  32.7 28.3  74.7 38.4 
19  15.5 15.7  49.0 48.5  31.1 30.7  105.0 43.2 
20  15.4 15.6  47.5 46.0  37.0 30.8  78.7 45.5 
21  13.8 14.3  43.0 44.0  37.0 31.1  68.6 39.6 
22  14.6 15.6  44.5 47.5  42.1 35.5  101.6 41.9 
  
Hb: haemoglobin, Hct: haematocrit, PCO2: partial pressure carbon dioxide, PO2, partial pressure oxygen, (blue= subjects 
with AMS) 
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A.3.2 Data from exposure to 4392m, Phase II 
A.3.2.1 Venous blood 
 
 
Subject  Hb [g/dl]  Hct [%] 
Number  NORM HYP  NORM HYP 
2  14 15.8  43 45 
3  13.6 15.2  41 45 
4  15.5 18.5  43 49 
5  15.2 15  43 43 
6  14.2 14.5  45 40 
8  16.5 17  45 46 
9  17.3 20.3  49 55 
10  15.9 17.5  44 46 
11  17.2 16.1  46 46 
12  14.6 14.2  43 40 
13  12.6 14.4  42 41 
14  15.7 15  40 41 
15  16.2 16.7  45 45 
16  13.3 16.4  40 48 
17  14.4 17.6  40 46 
18  13.1 13.8  39 37 
19  18.9 17.3  50 48 
20  14.6 18.5  45 49 
21  16.2 16.3  42 45 
22  17.4 16.7  48 46 
  
 Hb: haemoglobin, Hct: haematocrit, PCO2: partial pressure carbon dioxide, PO2, partial pressure oxygen, (blue= subjects with AMS) 
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A.3.3 AMS scores and O2 saturation 
A.3.3.1 Phase I 
 
Normoxia                                                                     Hypoxia 
 
 
  
 
 
LL: lake louise criteria, ESQ: environmental symptoms questionnaire, Y: yes, N: no, SaO2: oxygen saturation (pulse oximetry) 
Blue fill indicates those diagnosed with AMS 
 
No. 
LL-
self 
LL 
clinical 
LL 
total ESQ  
Head- 
ache SaO2 (%) 
2 0 0 0 0.000 N 98 
3 1 0 1 0.090 Y 96 
4 0 0 0 0.000 N 97 
5 0 0 0 0.000 N 99 
6 0 0 0 0.000 N 97 
8 0 0 0 0.000 N 97 
9 0 0 0 0.000 N 97 
10 0 0 0 0.000 N 97 
11 0 0 0 0.000 N 98 
12 4 0 0 0.000 N 98 
13 1 0 1 0.067 N 98 
14 0 0 0 0.000 N 98 
15 0 0 0 0.000 N 98 
16 0 0 0 0.000 N 99 
17 0 0 0 0.000 N 97 
18 1 0 1 0.000 N 98 
19 0 0 0 0.000 N 98 
20 0 0 0 0.000 N 97 
21 0 0 0 0.000 N 98 
22 0 0 0 0.000 N 98 
No. 
LL-
self 
LL 
clinical 
LL 
total  ESQ 
Head- 
ache 
SaO2 
(%) 
2 0 0 0 0.000 N 76 
3 9 1 10 2.360 Y 93 
4 0 0 0 0.000 N 83 
5 1 0 1 0.090 Y 79 
6 1 0 1 0.090 Y 68 
8 2 0 2 0.270 Y 76 
9 3 1 4 0.457 Y 78 
10 4 1 5 0.462 Y 81 
11 3 1 4 0.487 N 82 
12 2 1 3 0.090 Y 89 
13 2 0 2 0.239 Y 86 
14 1 0 1 0.179 Y 81 
15 1 0 1 0.000 N 83 
16 7 1 8 1.597 Y 82 
17 1 0 1 0.090 Y 91 
18 5 1 6 0.658 Y 72 
19 1 0 1 0.094 Y 94 
20 8 1 9 2.386 Y 85 
21 2 0 2 0.184 Y 84 
22 1 0 1 0.094 Y 83 
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A.3.3.2 Phase II  
            
Normoxia                                                         Hypoxia 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LL: lake 
louise criteria, ESQ: environmental symptoms questionnaire, Y: yes, N: no, SaO2: oxygen saturation (pulse oximetry) 
Blue fill indicates those diagnosed with AMS 
 
No. 
LL-
self 
LL 
clinical 
LL 
total ESQ  
Head- 
ache 
SaO2 
(%) 
2 0 1 1 n/r N 99 
3 0 0 0 n/r N 99 
4 0 0 0 n/r Y 99 
5 0 1 1 n/r N 99 
6 0 0 0 n/r N 98 
8 1 0 1 n/r N 99 
9 0 0 0 n/r N 99 
10 0 0 0 n/r N 98 
11 0 0 0 n/r N 99 
12 2 0 2 n/r Y 98 
13 0 0 0 n/r Y 99 
14 0 0 0 n/r N 99 
15 0 0 0 n/r Y 98 
16 0 0 0 n/r N 99 
17 0 0 0 n/r N 99 
18 1 0 1 n/r N 99 
19 0 0 0 n/r N 99 
20 4 1 5 n/r Y 98 
21 0 0 0 n/r N 99 
22 0 0 0 n/r N 99 
No. 
LL-
self 
LL 
clinical 
LL 
total  ESQ 
Head- 
ache 
SaO2 
(%) 
2 0 2 2 0.000 N 90 
3 2 2 4 0.472 Y 83 
4 1 1 2 0.000 N 84 
5 1 0 1 0.100 N 91 
6 1 1 2 0.075 N 79 
8 2 1 3 0.000 N 87 
9 0 0 0 0.000 N 93 
10 1 0 1 0.000 Y 90 
11 4 1 5 0.277 Y 90 
12 3 0 3 0.258 Y 87 
13 0 0 0 0.000 N 88 
14 1 0 1 0.090 Y 93 
15 3 1 4 n/r N 90 
16 0 0 0 0.000 N 91 
17 0 0 0 0.000 N 92 
18 7 1 8 0.895 Y 77 
19 0 0 0 0.000 N 95 
20 6 1 7 1.125 Y 89 
21 5 0 5 0.461 Y 91 
22 6 1 7 0.858 Y 88 
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A.3.4 Plasma protein concentrations as determined by ELISA 
 
A.3.4.1 EPO (mIU/ml)  
 
        
  Phase I   Phase II   
Subject no.  Normoxia Hypoxia Normoxia Hypoxia 
2 9.4 12.8 8.3 36.5 
3 4.4 15.6 15.7 48.9 
4 8.6 13.4 7.1 17.8 
5 6.7 13.9 16.4 50.6 
6 6.4 27.1 10.8 136.9 
8 10.5 25.1 22 92.3 
9 7.6 11.9 6.7 10.8 
10 4.9 14.6 8.7 39.6 
11 3.6 17.1 6.9 53.8 
12 9.2 25.0 7.7 51.5 
13 15.8 24.7 16 62.9 
14 12.0 21.2 13.7 65.2 
15 5.9 17.7 8.3 42.7 
16 27.4 33.2 18.3 57.5 
17 7.6 17.2 11.2 29.4 
18 7.9 15.1 10.8 130.8 
19 6.6 13.1 5.2 65.3 
20 4.4 9.6 8.6 32.2 
21 4.6 8.7 13.8 96.8 
22 8.9 27.3 7.8 77.2 
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A.3.4.2 sFLT  (pg/ml) 
 
        
  Phase I   Phase II   
Subject no.  Normoxia Hypoxia Normoxia Hypoxia 
2 94 82 75 109 
3 100 73 89 154 
4 274 139 46 57 
5 92 124 72 94 
6 101 100 105 133 
8 73 494 40 66 
9 102 191 109 122 
10 94 117 106 123 
11 116 388 94 110 
12 136 116 56 65 
13 122 252 76 95 
14 233 159 95 103 
15 150 119 116 128 
16 239 437 104 127 
17 494 614 94 112 
18 130 84 95 109 
19 234 591 80 108 
20 539 572 88 110 
21 209 107 84 128 
22 206 361 72 106 
 
 
 
 
 275 
A.3.4.3 VEGF  (pg/ml) 
 
        
  Phase I  Phase II   
Subject no.  Normoxia Hypoxia Normoxia Hypoxia 
2 49 283 64 11 
3 100 66 86 23 
4 165 29 31 12 
5 44 22 41 37 
6 51 56 57 44 
8 32 79 48 23 
9 82 62 46 36 
10 64 60 23 13 
11 20 56 81 28 
12 110 150 24 23 
13 29 64 225 166 
14 224 127 98 37 
15 85 127 112 79 
16 51 12 181 58 
17 20 84 46 36 
18 67 58 80 21 
19 120 145 38 32 
20 131 160 16 18 
21 101 30 45 46 
22 47 87 68 28 
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Appendix IV 
 
Lake Louise AMS Scoring System 
 
Time am pm am pm am pm am pm am pm 
Headache 
None at all 
Mild headache 
Moderate headache 
Severe headache, incapacitating 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
Gastrointestinal symptoms 
Good appetite 
Poor appetite ot nausea 
Moderate nausea or vomiting 
Severe, incapacitating nausea and 
vomiting 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
Fatigue and/or weakness 
Not tired or weak 
Mild fatigue/weakness 
Moderate fatigue/weakness 
Severe fatigue/weakness 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
Dizziness/lightheadedness 
None 
Mild 
Moderate 
Severe, capacitating 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
Difficulty Sleeping 
Slept as well as usual 
Did not sleep as well as usual 
Woke many times, poor night's 
sleep 
Could not sleep at all 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
 
 
 277 
Environmental symptoms questionnaire 
 
 
Please mark each:  0  Not at all 1 Slight  2 Somewhat 3 Moderate  4 Quite a bit 5 Extreme 
 
 am pm am pm am pm am pm am pm 
 
I feel lightheaded           
I have a headache           
I feel dizzy           
I feel faint           
My vision is dim           
My coordination is off           
I feel weak           
I feel sick to my stomach           
I’ve lost my appetite           
I feel sick           
I feel hungover           
Total           
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Appendix V 
A.5.1 Gene lists 
A.5.1.1 WT vs. WT EXT 
A.5.1.1.2 Upregulated 
Gene symbol 
 
Gene name 
Anln 
ANILLIN, ACTIN BINDING PROTEIN (SCRAPS HOMOLOG, 
DROSOPHILA) 
Pltp PHOSPHOLIPID TRANSFER PROTEIN 
Serinc3 SERINE INCORPORATOR 3 
C1qtnf3 C1Q AND TUMOR NECROSIS FACTOR RELATED PROTEIN 3 
Lyzs LYSOZYME 
Ms4a7 MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 7 
Tnn TENASCIN N 
Cldn10 DNA SEGMENT, CHR 14, ERATO DOI 728, EXPRESSED 
Dlk1 DELTA-LIKE 1 HOMOLOG (DROSOPHILA) 
Ggcx GAMMA-GLUTAMYL CARBOXYLASE 
Eif2s3y 
EUKARYOTIC TRANSLATION INITIATION FACTOR 2, SUBUNIT 3, 
STRUCTURAL GENE Y-LINKED 
Ugt1a10 UDP GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A10 
Apobec1 APOLIPOPROTEIN B EDITING COMPLEX 1 
Ccl12 CHEMOKINE (C-C MOTIF) LIGAND 12 
Atp2c1 RIKEN CDNA 1700121J11 GENE 
Epm2aip1 EPM2A (LAFORIN) INTERACTING PROTEIN 1 
AA881470 EST AA881470 
Cbr2 CARBONYL REDUCTASE 2 
Fscn1 
FASCIN HOMOLOG 1, ACTIN BUNDLING PROTEIN 
(STRONGYLOCENTROTUS) PURPURATUS) 
Adamts4 
A DISINTEGRIN-LIKE AND METALLOPEPTIDASE (REPROLYSIN TYPE) 
WITH THROMBOSPONDIN TYPE 1 MOTIF, 4 
Lcn2 LIPOCALIN 2 
Emb EMBIGIN 
Sfrp2 SECRETED FRIZZLED-RELATED SEQUENCE PROTEIN 2 
Unc93b1 UNC-93 HOMOLOG B1 (C. ELEGANS) 
Gdpd3 
GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE DOMAIN 
CONTAINING 3 
Dnaic1 DYNEIN, AXONEMAL, INTERMEDIATE CHAIN 1 
Ccl7 CHEMOKINE (C-C MOTIF) LIGAND 7 
Vamp8 VESICLE-ASSOCIATED MEMBRANE PROTEIN 8 
Mmp12 MATRIX METALLOPEPTIDASE 12 
Fhl3 FOUR AND A HALF LIM DOMAINS 3 
Capg CAPPING PROTEIN (ACTIN FILAMENT), GELSOLIN-LIKE 
4930583H14Rik RIKEN CDNA 4930583H14 GENE 
Prc1 PROTEIN REGULATOR OF CYTOKINESIS 1 
Chrng CHOLINERGIC RECEPTOR, NICOTINIC, GAMMA POLYPEPTIDE 
Usp39 UBIQUITIN SPECIFIC PEPTIDASE 39 
Mt3 METALLOTHIONEIN 3 
Igfbp4 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4 
C4b COMPLEMENT COMPONENT 4B (CHILDO BLOOD GROUP) 
Tomm22 RING FINGER PROTEIN 13 
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Cfl1 COFILIN 1, NON-MUSCLE 
Myo1f MYOSIN IF 
Mest MESODERM SPECIFIC TRANSCRIPT 
Col14a1 PROCOLLAGEN, TYPE XIV, ALPHA 1 
Mmp3 MATRIX METALLOPEPTIDASE 3 
Ankrd2 ANKYRIN REPEAT DOMAIN 2 (STRETCH RESPONSIVE MUSCLE) 
Apoe APOLIPOPROTEIN E 
Col3a1 PROCOLLAGEN, TYPE III, ALPHA 1 
H2-Ab1 HISTOCOMPATIBILITY 2, CLASS II ANTIGEN A, BETA 1 
Clec4n C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER N 
Lrrc15 LEUCINE RICH REPEAT CONTAINING 15 
Ccl8 CHEMOKINE (C-C MOTIF) LIGAND 8 
2810021J22Rik RIKEN CDNA 2810021J22 GENE 
Serpina3n 
SERINE (OR CYSTEINE) PEPTIDASE INHIBITOR, CLADE A, MEMBER 
3N 
Pkig PROTEIN KINASE INHIBITOR, GAMMA 
Junb JUN-B ONCOGENE 
Il13ra1 INTERLEUKIN 13 RECEPTOR, ALPHA 1 
 
 
A.5.1.1.2 Down-regulated 
Gene symbol 
 
Gene name 
Xist INACTIVE X SPECIFIC TRANSCRIPTS 
Gadd45a GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE 45 ALPHA 
H2-K1 HISTOCOMPATIBILITY 2, K1, K REGION 
H2-T23 HISTOCOMPATIBILITY 2, T REGION LOCUS 23 
Cdo1 CYSTEINE DIOXYGENASE 1, CYTOSOLIC 
Slc15a2 
SOLUTE CARRIER FAMILY 15 (H+/PEPTIDE TRANSPORTER), 
MEMBER 2 
Capn2 CALPAIN 2 
1110020G09Rik RIKEN CDNA 1110020G09 GENE 
EG633640 SIMILAR TO CG10866-PA 
Aldh1a7 ALDEHYDE DEHYDROGENASE FAMILY 1, SUBFAMILY A7 
Indo INDOLEAMINE-PYRROLE 2,3 DIOXYGENASE 
Cfd COMPLEMENT FACTOR D (ADIPSIN) 
Myl3 MYOSIN, LIGHT POLYPEPTIDE 3 
Zfp68 ZINC FINGER PROTEIN 68 
Tmc7 TRANSMEMBRANE CHANNEL-LIKE GENE FAMILY 7 
Mup2 MAJOR URINARY PROTEIN 2 
Cyp2e1 CYTOCHROME P450, FAMILY 2, SUBFAMILY E, POLYPEPTIDE 1 
Gbp4 MACROPHAGE ACTIVATION 2 
Riok1 RIO KINASE 1 (YEAST) 
Mal 
MYELIN AND LYMPHOCYTE PROTEIN, T-CELL DIFFERENTIATION 
PROTEIN 
Gvin1 GTPASE, VERY LARGE INTERFERON INDUCIBLE 1 
Serpina3g 
SERINE (OR CYSTEINE) PEPTIDASE INHIBITOR, CLADE A, MEMBER 
3G 
EG546166 HYPOTHETICAL PROTEIN LOC546166 
Gbp1 GUANYLATE NUCLEOTIDE BINDING PROTEIN 1 
Dctn1 DYNACTIN 1 
2610206B13Rik RIKEN CDNA 2810449K13 GENE 
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A.5.1.2 PHD1 K/O vs. WT 
A.5.1.2.1 Upregulated 
 
Gene symbol 
 
Gene name 
Olfr299 OLFACTORY RECEPTOR 299 
V1rf2 VOMERONASAL 1 RECEPTOR, F2 
EG432743 HYPOTHETICAL GENE SUPPORTED BY AK077314 
Cyp21a1 CYTOCHROME P450, FAMILY 21, SUBFAMILY A, POLYPEPTIDE 1 
Olfr536 OLFACTORY RECEPTOR 536 
Olfr121 OLFACTORY RECEPTOR 121 
1300012G16Rik RIKEN CDNA 1300012G16 GENE 
Olfr1245 OLFACTORY RECEPTOR 1245 
BC002059 CDNA SEQUENCE BC002059 
2010309E21Rik RIKEN CDNA 2010309E21 GENE 
4921510J17Rik RIKEN CDNA 4921510J17 GENE 
Kctd8 POTASSIUM CHANNEL TETRAMERISATION DOMAIN CONTAINING 8 
Olfr884 OLFACTORY RECEPTOR 884 
BC060632 CDNA SEQUENCE BC060632 
4930521A18Rik RIKEN CDNA 4930521A18 GENE 
Gpr128 G PROTEIN-COUPLED RECEPTOR 128 
Timm22 TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 22 
HOMOLOG (YEAST) 
Olfr725 OLFACTORY RECEPTOR 725 
4933421E11Rik RIKEN CDNA 4933421E11 GENE 
Pafah2 PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE 2 
Pdyn PRODYNORPHIN 
Lgi1 LEUCINE-RICH REPEAT LGI FAMILY, MEMBER 1 
Gpr142 G PROTEIN-COUPLED RECEPTOR 142 
Pknox2 PBX/KNOTTED 1 HOMEOBOX 2 
Dffb DNA FRAGMENTATION FACTOR, BETA SUBUNIT 
Cysltr2 CYSTEINYL LEUKOTRIENE RECEPTOR 2 
Olfr624 OLFACTORY RECEPTOR 624 
Fabp7 FATTY ACID BINDING PROTEIN 7, BRAIN 
1700109H08Rik RIKEN CDNA 1700109H08 GENE 
Olfr103 OLFACTORY RECEPTOR 103 
Elmo1 RIKEN CDNA C230095H21 GENE 
Hhip HEDGEHOG-INTERACTING PROTEIN 
Trpv1 TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY 
V, MEMBER 1 
Evx1 EVEN SKIPPED HOMEOTIC GENE 1 HOMOLOG 
Btnl2 BUTYROPHILIN-LIKE 2 
H2-M10.2 HISTOCOMPATIBILITY 2, M REGION LOCUS 10.2 
Blm BLOOM SYNDROME HOMOLOG (HUMAN) 
Olfr593 OLFACTORY RECEPTOR 593 
Rps6kb1 RIBOSOMAL PROTEIN S6 KINASE, POLYPEPTIDE 1 
Zp1 ZONA PELLUCIDA GLYCOPROTEIN 1 
Speer8-ps1 SPERMATOGENESIS ASSOCIATED GLUTAMATE (E)-RICH PROTEIN 
8, PSEUDOGENE 1 
Olfr556 OLFACTORY RECEPTOR 556 
Atm ATAXIA TELANGIECTASIA MUTATED HOMOLOG (HUMAN) 
Padi3 PEPTIDYL ARGININE DEIMINASE, TYPE III 
F12 COAGULATION FACTOR XII (HAGEMAN FACTOR) 
Itlnb INTELECTIN B 
Hrasls5 HRAS-LIKE SUPPRESSOR FAMILY, MEMBER 5 
Ezh2 ENHANCER OF ZESTE HOMOLOG 2 (DROSOPHILA) 
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Olfr63 OLFACTORY RECEPTOR 63 
Olfr203 OLFACTORY RECEPTOR 203 
Ror1 RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTOR 1 
Eif4e1b GENE MODEL 273, (NCBI) 
Otc ORNITHINE TRANSCARBAMYLASE 
Olfr3 OLFACTORY RECEPTOR 3 
Polr3k POLYMERASE (RNA) III (DNA DIRECTED) POLYPEPTIDE K 
Mrgprd MAS-RELATED GPR, MEMBER D 
Stx19 RIKEN CDNA A030009B12 GENE 
Aldh1a2 ALDEHYDE DEHYDROGENASE FAMILY 1, SUBFAMILY A2 
Btc BETACELLULIN, EPIDERMAL GROWTH FACTOR FAMILY MEMBER 
Pcsk4 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 4 
Uts2 UROTENSIN 2 
Nphs2 NEPHROSIS 2 HOMOLOG, PODOCIN (HUMAN) 
Gm397 GENE MODEL 397, (NCBI) 
Mlstd1 MALE STERILITY DOMAIN CONTAINING 1 
Lin28 LIN-28 HOMOLOG (C. ELEGANS) 
Olfr450 OLFACTORY RECEPTOR 450 
V1rd3 VOMERONASAL 1 RECEPTOR, D3 
Yars TYROSYL-TRNA SYNTHETASE 
1700025E21Rik RIKEN CDNA 1700016K02 GENE 
Muc10 MUCIN 10, SUBMANDIBULAR GLAND SALIVARY MUCIN 
Aldoc ALDOLASE 3, C ISOFORM 
Cacng5 CALCIUM CHANNEL, VOLTAGE-DEPENDENT, GAMMA SUBUNIT 5 
Olfr313 OLFACTORY RECEPTOR 313 
Foxp2 RIKEN CDNA 2810043D05 GENE 
Olig3 OLIGODENDROCYTE TRANSCRIPTION FACTOR 3 
Pdcl2 RIKEN CDNA 1700010B22 GENE 
Cyp2c29 CYTOCHROME P450, FAMILY 2, SUBFAMILY C, POLYPEPTIDE 29 
LOC621852 SIMILAR TO SIMILAR TO TESTIS EXPRESSED HOMEOBOX 2 
Zfp54 ZINC FINGER PROTEIN 54 
Mdm1 TRANSFORMED MOUSE 3T3 CELL DOUBLE MINUTE 1 
Fbxw11 F-BOX AND WD-40 DOMAIN PROTEIN 11 
Tnrc4 TRINUCLEOTIDE REPEAT CONTAINING 4 
Nbn NIBRIN 
4930433I11Rik RIKEN CDNA 4930433I11 GENE 
Rchy1 RING FINGER AND CHY ZINC FINGER DOMAIN CONTAINING 1 
Hrh3 HISTAMINE RECEPTOR H 3 
Pnmt PHENYLETHANOLAMINE-N-METHYLTRANSFERASE 
Rap1gap RAP1, GTPASE-ACTIVATING PROTEIN 1 
Acsl3 ACYL-COA SYNTHETASE LONG-CHAIN FAMILY MEMBER 3 
Sumf2 SULFATASE MODIFYING FACTOR 2 
Gdpd3 
GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE DOMAIN 
CONTAINING 3 
Tac4 TACHYKININ 4 
Spata16 SPERMATOGENESIS ASSOCIATED 16 
Olfr646 OLFACTORY RECEPTOR 646 
Gp9 GLYCOPROTEIN 9 (PLATELET) 
Olfr1463 OLFACTORY RECEPTOR 1463 
Cth CYSTATHIONASE (CYSTATHIONINE GAMMA-LYASE) 
1110005A03Rik RIKEN CDNA 1110005A03 GENE 
Olfr1497 OLFACTORY RECEPTOR 1497 
Thnsl1 EXPRESSED SEQUENCE AW413632 
Enam ENAMELIN 
Prrt3 PROLINE-RICH TRANSMEMBRANE PROTEIN 3 
Glmn GLOMULIN, FKBP ASSOCIATED PROTEIN 
Mical1 
MICROTUBULE ASSOCIATED MONOXYGENASE, CALPONIN AND LIM 
DOMAIN CONTAINING 1 
Ceacam14 CEA-RELATED CELL ADHESION MOLECULE 14 
D19Ertd386e DNA SEGMENT, CHR 19, ERATO DOI 386, EXPRESSED 
Adh5 ALCOHOL DEHYDROGENASE 5 (CLASS III), CHI POLYPEPTIDE 
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Tnr TENASCIN R 
Lsm11 U7 SNRNP-SPECIFIC SM-LIKE PROTEIN LSM11 
Negr1 NEURONAL GROWTH REGULATOR 1 
Syt13 SYNAPTOTAGMIN XIII 
Es1 ESTERASE 1 
 
 
A.5.1.2.2 Down-regulated 
 
Gadd45a GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE 45 ALPHA 
Csf1 COLONY STIMULATING FACTOR 1 (MACROPHAGE) 
Slc8a1 
SOLUTE CARRIER FAMILY 8 (SODIUM/CALCIUM 
EXCHANGER), MEMBER 1 
Slc25a17 
SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, 
PEROXISOMAL MEMBRANE PROTEIN), MEMBER 17 
Sema3f 
SEMA DOMAIN, IMMUNOGLOBULIN DOMAIN (IG), SHORT 
BASIC DOMAIN, SECRETED, (SEMAPHORIN) 3 F 
Ap1g1 ADAPTOR PROTEIN COMPLEX AP-1, GAMMA 1 SUBUNIT 
Fbxo7 F-BOX ONLY PROTEIN 7 
Foxc1 FORKHEAD BOX C1 
Arrdc3 ARRESTIN DOMAIN CONTAINING 3 
2700094K13Rik RIKEN CDNA 2700094K13 GENE 
Zfp30 ZINC FINGER PROTEIN 30 
Mgat1 MANNOSIDE ACETYLGLUCOSAMINYLTRANSFERASE 1 
2310037I24Rik RIKEN CDNA 2310037I24 GENE 
2210009G21Rik RIKEN CDNA 2410004I22 GENE 
Akap10 A KINASE (PRKA) ANCHOR PROTEIN 10 
Riok1 RIO KINASE 1 (YEAST) 
Gvin1 GTPASE, VERY LARGE INTERFERON INDUCIBLE 1 
Espn ESPIN 
Cog2 COMPONENT OF OLIGOMERIC GOLGI COMPLEX 2 
Eml3 ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 3 
EG546166 HYPOTHETICAL PROTEIN LOC546166 
EG630499 SIMILAR TO HISTOCOMPATIBILITY 2, Q REGION LOCUS 10 
Adarb1 ADENOSINE DEAMINASE, RNA-SPECIFIC, B1 
Psmb9 
PROTEOSOME (PROSOME, MACROPAIN) SUBUNIT, BETA 
TYPE 9 (LARGE MULTIFUNCTIONAL PEPTIDASE 2) 
Poli POLYMERASE (DNA DIRECTED), IOTA 
Zfp275 ZINC FINGER PROTEIN 275 
Bbc3 BCL-2 BINDING COMPONENT 3 
Taf6 
TAF6 RNA POLYMERASE II, TATA BOX BINDING PROTEIN 
(TBP)-ASSOCIATED FACTOR 
B2m BETA-2 MICROGLOBULIN 
Pmaip1 
PHORBOL-12-MYRISTATE-13-ACETATE-INDUCED PROTEIN 
1 
H2-K1 HISTOCOMPATIBILITY 2, K1, K REGION 
Ddx21 DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 21 
1700102P08Rik RIKEN CDNA 1700102P08 GENE 
Trim36 TRIPARTITE MOTIF-CONTAINING 36 
Avpr1a ARGININE VASOPRESSIN RECEPTOR 1A 
Lhfp LIPOMA HMGIC FUSION PARTNER 
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Trim30 TRIPARTITE MOTIF PROTEIN 30 
Musk MUSCLE, SKELETAL, RECEPTOR TYROSINE KINASE 
Slc25a16 
SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, 
GRAVES DISEASE AUTOANTIGEN), MEMBER 16 
Tmem16f TRANSMEMBRANE PROTEIN 16F 
Tef THYROTROPH EMBRYONIC FACTOR 
Commd8 COMM DOMAIN CONTAINING 8 
Jag1 JAGGED 1 
Ift140 
INTRAFLAGELLAR TRANSPORT 140 HOMOLOG 
(CHLAMYDOMONAS) 
Cyfip1 CYTOPLASMIC FMR1 INTERACTING PROTEIN 1 
Dusp18 DUAL SPECIFICITY PHOSPHATASE 18 
Nkd1 RIKEN CDNA 2810434J10 GENE 
Coil COILIN 
Galnt2 EXPRESSED SEQUENCE AI480629 
Mipep MITOCHONDRIAL INTERMEDIATE PEPTIDASE 
4930550C14Rik RIKEN CDNA 4930550C14 GENE 
Pold3 
POLYMERASE (DNA-DIRECTED), DELTA 3, ACCESSORY 
SUBUNIT 
Gadd45a GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE 45 ALPHA 
Csf1 COLONY STIMULATING FACTOR 1 (MACROPHAGE) 
Slc8a1 
SOLUTE CARRIER FAMILY 8 (SODIUM/CALCIUM 
EXCHANGER), MEMBER 1 
Slc25a17 
SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, 
PEROXISOMAL MEMBRANE PROTEIN), MEMBER 17 
Sema3f 
SEMA DOMAIN, IMMUNOGLOBULIN DOMAIN (IG), SHORT 
BASIC DOMAIN, SECRETED, (SEMAPHORIN) 3 F 
Ap1g1 ADAPTOR PROTEIN COMPLEX AP-1, GAMMA 1 SUBUNIT 
Fbxo7 F-BOX ONLY PROTEIN 7 
Foxc1 FORKHEAD BOX C1 
Arrdc3 ARRESTIN DOMAIN CONTAINING 3 
2700094K13Rik RIKEN CDNA 2700094K13 GENE 
Zfp30 ZINC FINGER PROTEIN 30 
Mgat1 MANNOSIDE ACETYLGLUCOSAMINYLTRANSFERASE 1 
2310037I24Rik RIKEN CDNA 2310037I24 GENE 
2210009G21Rik RIKEN CDNA 2410004I22 GENE 
Akap10 A KINASE (PRKA) ANCHOR PROTEIN 10 
Riok1 RIO KINASE 1 (YEAST) 
Gvin1 GTPASE, VERY LARGE INTERFERON INDUCIBLE 1 
Espn ESPIN 
Cog2 COMPONENT OF OLIGOMERIC GOLGI COMPLEX 2 
Eml3 ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 3 
EG546166 HYPOTHETICAL PROTEIN LOC546166 
EG630499 SIMILAR TO HISTOCOMPATIBILITY 2, Q REGION LOCUS 10 
Adarb1 ADENOSINE DEAMINASE, RNA-SPECIFIC, B1 
Psmb9 
PROTEOSOME (PROSOME, MACROPAIN) SUBUNIT, BETA 
TYPE 9 (LARGE MULTIFUNCTIONAL PEPTIDASE 2) 
Poli POLYMERASE (DNA DIRECTED), IOTA 
Zfp275 ZINC FINGER PROTEIN 275 
Bbc3 BCL-2 BINDING COMPONENT 3 
Taf6 
TAF6 RNA POLYMERASE II, TATA BOX BINDING PROTEIN 
(TBP)-ASSOCIATED FACTOR 
B2m BETA-2 MICROGLOBULIN 
Pmaip1 
PHORBOL-12-MYRISTATE-13-ACETATE-INDUCED PROTEIN 
1 
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H2-K1 HISTOCOMPATIBILITY 2, K1, K REGION 
Ddx21 DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 21 
1700102P08Rik RIKEN CDNA 1700102P08 GENE 
Trim36 TRIPARTITE MOTIF-CONTAINING 36 
Avpr1a ARGININE VASOPRESSIN RECEPTOR 1A 
Lhfp LIPOMA HMGIC FUSION PARTNER 
Trim30 TRIPARTITE MOTIF PROTEIN 30 
Musk MUSCLE, SKELETAL, RECEPTOR TYROSINE KINASE 
Slc25a16 
SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, 
GRAVES DISEASE AUTOANTIGEN), MEMBER 16 
Tmem16f TRANSMEMBRANE PROTEIN 16F 
Tef THYROTROPH EMBRYONIC FACTOR 
Commd8 COMM DOMAIN CONTAINING 8 
Jag1 JAGGED 1 
Ift140 
INTRAFLAGELLAR TRANSPORT 140 HOMOLOG 
(CHLAMYDOMONAS) 
Cyfip1 CYTOPLASMIC FMR1 INTERACTING PROTEIN 1 
Dusp18 DUAL SPECIFICITY PHOSPHATASE 18 
Nkd1 RIKEN CDNA 2810434J10 GENE 
Coil COILIN 
Galnt2 EXPRESSED SEQUENCE AI480629 
Mipep MITOCHONDRIAL INTERMEDIATE PEPTIDASE 
4930550C14Rik RIKEN CDNA 4930550C14 GENE 
Pold3 
POLYMERASE (DNA-DIRECTED), DELTA 3, ACCESSORY 
SUBUNIT 
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A.5.1.3 PHD1 K/O EXT vs. PHD1 K/O 
A.5.1.3.1 Upregulated 
Def6 DIFFERENTIALLY EXPRESSED IN FDCP 6 
Lyzs LYSOZYME 
Fes FELINE SARCOMA ONCOGENE 
Slc8a1 
SOLUTE CARRIER FAMILY 8 (SODIUM/CALCIUM EXCHANGER), 
MEMBER 1 
Casp4 CASPASE 4, APOPTOSIS-RELATED CYSTEINE PEPTIDASE 
Abca1 ATP-BINDING CASSETTE, SUB-FAMILY A (ABC1), MEMBER 1 
Cdc2a CELL DIVISION CYCLE 2 HOMOLOG A (S. POMBE) 
Birc5 BACULOVIRAL IAP REPEAT-CONTAINING 5 
Apobec1 APOLIPOPROTEIN B EDITING COMPLEX 1 
Pafah1b3 
PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE, ISOFORM 
1B, ALPHA1 SUBUNIT 
Htatip2 HIV-1 TAT INTERACTIVE PROTEIN 2, HOMOLOG (HUMAN) 
Pscdbp 
PLECKSTRIN HOMOLOGY, SEC7 AND COILED-COIL DOMAINS, 
BINDING PROTEIN 
Msln MESOTHELIN 
Mx2 MYXOVIRUS (INFLUENZA VIRUS) RESISTANCE 2 
Pml PROMYELOCYTIC LEUKEMIA 
Git2 G PROTEIN-COUPLED RECEPTOR KINASE-INTERACTOR 2 
Cd84 CD84 ANTIGEN 
Slc15a3 SOLUTE CARRIER FAMILY 15, MEMBER 3 
Nfkbiz 
NUCLEAR FACTOR OF KAPPA LIGHT POLYPEPTIDE GENE 
ENHANCER IN B-CELLS INHIBITOR, ZETA 
Vat1 
VESICLE AMINE TRANSPORT PROTEIN 1 HOMOLOG (T 
CALIFORNICA) 
Kctd10 
POTASSIUM CHANNEL TETRAMERISATION DOMAIN 
CONTAINING 10 
A630077B13Rik RIKEN CDNA A630077B13 GENE 
Csf3r COLONY STIMULATING FACTOR 3 RECEPTOR (GRANULOCYTE) 
Gmfg GLIA MATURATION FACTOR, GAMMA 
Tgfb3 TRANSFORMING GROWTH FACTOR, BETA 3 
Lypla3 LYSOPHOSPHOLIPASE 3 
Coro1a CORONIN, ACTIN BINDING PROTEIN 1A 
Btk BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE 
Pecam1 PLATELET/ENDOTHELIAL CELL ADHESION MOLECULE 1 
Actn4 ACTININ ALPHA 4 
Mobkl2a MOB1, MPS ONE BINDER KINASE ACTIVATOR-LIKE 2A (YEAST) 
Foxp1 FORKHEAD BOX P1 
Coro1c CORONIN, ACTIN BINDING PROTEIN 1C 
Klhl6 KELCH-LIKE 6 (DROSOPHILA) 
Emilin2 ELASTIN MICROFIBRIL INTERFACER 2 
Arl11 ADP-RIBOSYLATION FACTOR-LIKE 11 
Rab8b RAB8B, MEMBER RAS ONCOGENE FAMILY 
Tlr13 TOLL-LIKE RECEPTOR 13 
Jag1 JAGGED 1 
Ap2a2 ADAPTOR PROTEIN COMPLEX AP-2, ALPHA 2 SUBUNIT 
Cyfip1 CYTOPLASMIC FMR1 INTERACTING PROTEIN 1 
Ccl4 CHEMOKINE (C-C MOTIF) LIGAND 4 
Agpat4 1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 1 
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(LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE, DELTA) 
Lst1 LEUKOCYTE SPECIFIC TRANSCRIPT 1 
Il1rl1 INTERLEUKIN 1 RECEPTOR-LIKE 1 
Ep400 E1A BINDING PROTEIN P400 
Rab8a RAB8A, MEMBER RAS ONCOGENE FAMILY 
Kcnab2 
POTASSIUM VOLTAGE-GATED CHANNEL, SHAKER-RELATED 
SUBFAMILY, BETA MEMBER 2 
1200013B08Rik RIKEN CDNA 1200013B08 GENE 
Litaf LPS-INDUCED TN FACTOR 
Cggbp1 CGG TRIPLET REPEAT BINDING PROTEIN 1 
Gpr124 G PROTEIN-COUPLED RECEPTOR 124 
Slc35e3 RIKEN CDNA 9330166G04 GENE 
Gns GLUCOSAMINE (N-ACETYL)-6-SULFATASE 
Serpinb6a 
SERINE (OR CYSTEINE) PEPTIDASE INHIBITOR, CLADE B, 
MEMBER 6A 
Anln 
ANILLIN, ACTIN BINDING PROTEIN (SCRAPS HOMOLOG, 
DROSOPHILA) 
Hn1 
HEMATOLOGICAL AND NEUROLOGICAL EXPRESSED SEQUENCE 
1 
Ms4a7 MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 7 
Csf1 COLONY STIMULATING FACTOR 1 (MACROPHAGE) 
Itga5 INTEGRIN ALPHA 5 (FIBRONECTIN RECEPTOR ALPHA) 
Ly86 LYMPHOCYTE ANTIGEN 86 
Mad2l1 
MAD2 (MITOTIC ARREST DEFICIENT, HOMOLOG)-LIKE 1 
(YEAST) 
Sh3bgrl3 SH3 DOMAIN BINDING GLUTAMIC ACID-RICH PROTEIN-LIKE 3 
Grn GRANULIN 
Plcg2 PHOSPHOLIPASE C, GAMMA 2 
Pros1 PROTEIN S (ALPHA) 
Bnc2 BASONUCLIN 2 
Rrbp1 RIKEN CDNA 5730465C04 GENE 
Ttyh3 TWEETY HOMOLOG 3 (DROSOPHILA) 
Kcnk13 POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 13 
Eml3 ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 3 
Snx1 SORTING NEXIN 1 
Bcl3 B-CELL LEUKEMIA/LYMPHOMA 3 
Slc11a1 
SOLUTE CARRIER FAMILY 11 (PROTON-COUPLED DIVALENT 
METAL ION TRANSPORTERS), MEMBER 1 
Dbnl DREBRIN-LIKE 
AY078069 CDNA SEQUENCE AY078069 
Lsp1 LYMPHOCYTE SPECIFIC 1 
C4b COMPLEMENT COMPONENT 4B (CHILDO BLOOD GROUP) 
4930570C03Rik RIKEN CDNA 4930570C03 GENE 
Cxcl1 CHEMOKINE (C-X-C MOTIF) LIGAND 1 
Flna FILAMIN, ALPHA 
Aif1 ALLOGRAFT INFLAMMATORY FACTOR 1 
S100a4 S100 CALCIUM BINDING PROTEIN A4 
Glipr2 GLI PATHOGENESIS-RELATED 2 
Tcirg1 
T-CELL, IMMUNE REGULATOR 1, ATPASE, H+ TRANSPORTING, 
LYSOSOMAL V0 PROTEIN A3 
Laptm5 LYSOSOMAL-ASSOCIATED PROTEIN TRANSMEMBRANE 5 
Mest MESODERM SPECIFIC TRANSCRIPT 
Trem2 TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2C 
P2ry6 PYRIMIDINERGIC RECEPTOR P2Y, G-PROTEIN COUPLED, 6 
Soat1 STEROL O-ACYLTRANSFERASE 1 
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Casp1 CASPASE 1 
Csrp2 CYSTEINE AND GLYCINE-RICH PROTEIN 2 
C1qb 
COMPLEMENT COMPONENT 1, Q SUBCOMPONENT, BETA 
POLYPEPTIDE 
C3 COMPLEMENT COMPONENT 3 
Dpep2 DIPEPTIDASE 2 
Irak3 INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 3 
Cerk CERAMIDE KINASE 
Ugcg UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE 
Ncf4 NEUTROPHIL CYTOSOLIC FACTOR 4 
Ccl8 CHEMOKINE (C-C MOTIF) LIGAND 8 
Ccnb1 CYCLIN B1 
Arrb2 ARRESTIN, BETA 2 
Sh3bp2 SH3-DOMAIN BINDING PROTEIN 2 
Limk1 LIM-DOMAIN CONTAINING, PROTEIN KINASE 
1200002N14Rik RIKEN CDNA 1200002N14 GENE 
Plac8 PLACENTA-SPECIFIC 8 
Hexa HEXOSAMINIDASE A 
Cdca2 CELL DIVISION CYCLE ASSOCIATED 2 
Slc29a3 
SOLUTE CARRIER FAMILY 29 (NUCLEOSIDE TRANSPORTERS), 
MEMBER 3 
C1qtnf3 C1Q AND TUMOR NECROSIS FACTOR RELATED PROTEIN 3 
0610007P14Rik RIKEN CDNA 0610007P14 GENE 
Cant1 CALCIUM ACTIVATED NUCLEOTIDASE 1 
Scotin SCOTIN GENE 
Cacnb3 CALCIUM CHANNEL, VOLTAGE-DEPENDENT, BETA 3 SUBUNIT 
Lgals3 LECTIN, GALACTOSE BINDING, SOLUBLE 3 
Tlr7 TOLL-LIKE RECEPTOR 7 
Drctnnb1a DOWN-REGULATED BY CTNNB1, A 
Ly9 LYMPHOCYTE ANTIGEN 9 
Myo9b MYOSIN IXB 
H28 HISTOCOMPATIBILITY 28 
Gpr177 G PROTEIN-COUPLED RECEPTOR 177 
Prkcd PROTEIN KINASE C, DELTA 
Sla SRC-LIKE ADAPTOR 
Man2a1 MANNOSIDASE 2, ALPHA 1 
Unc93b1 UNC-93 HOMOLOG B1 (C. ELEGANS) 
Usp18 UBIQUITIN SPECIFIC PEPTIDASE 18 
Cotl1 RIKEN CDNA 2010004C08 GENE 
Chrng CHOLINERGIC RECEPTOR, NICOTINIC, GAMMA POLYPEPTIDE 
Rhog RAS HOMOLOG GENE FAMILY, MEMBER G 
Esco2 ESTABLISHMENT OF COHESION 1 HOMOLOG 2 (S. CEREVISIAE) 
C920005C14Rik RIKEN CDNA C920005C14 GENE 
Uap1l1 UDP-N-ACTEYLGLUCOSAMINE PYROPHOSPHORYLASE 1-LIKE 1 
Arpc1b ACTIN RELATED PROTEIN 2/3 COMPLEX, SUBUNIT 1B 
Ctsz CATHEPSIN Z 
Lmnb1 LAMIN B1 
Cd44 CD44 ANTIGEN 
Adam19 
A DISINTEGRIN AND METALLOPEPTIDASE DOMAIN 19 (MELTRIN 
BETA) 
Cap1 CAP, ADENYLATE CYCLASE-ASSOCIATED PROTEIN 1 (YEAST) 
Sec61a1 SEC61 ALPHA 1 SUBUNIT (S. CEREVISIAE) 
9130404D14Rik RIKEN CDNA 9130404D14 GENE 
Bok BCL-2-RELATED OVARIAN KILLER PROTEIN 
Gldc DNA SEGMENT, CHR 19, WAYNE STATE UNIVERSITY 57, 
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EXPRESSED 
Tspyl3 TSPY-LIKE 3 
Cd68 CD68 ANTIGEN 
Mmp13 MATRIX METALLOPEPTIDASE 13 
Lxn LATEXIN 
Fchsd2 FCH AND DOUBLE SH3 DOMAINS 2 
Mbc2 MEMBRANE BOUND C2 DOMAIN CONTAINING PROTEIN 
Agrn AGRIN 
C2 COMPLEMENT COMPONENT 2 (WITHIN H-2S) 
Ly6a LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS A 
Manba RIKEN CDNA 2410030O07 GENE 
BC017643 CDNA SEQUENCE BC017643 
Mgl1 
MACROPHAGE GALACTOSE N-ACETYL-GALACTOSAMINE 
SPECIFIC LECTIN 1 
Nfatc4 
NUCLEAR FACTOR OF ACTIVATED T-CELLS, CYTOPLASMIC, 
CALCINEURIN-DEPENDENT 4 
Rab32 RAB32, MEMBER RAS ONCOGENE FAMILY 
Ankfy1 ANKYRIN REPEAT AND FYVE DOMAIN CONTAINING 1 
Ptbp1 POLYPYRIMIDINE TRACT BINDING PROTEIN 1 
Kif2c EST X83316 
Pltp PHOSPHOLIPID TRANSFER PROTEIN 
Galk1 GALACTOKINASE 1 
Fxyd5 FXYD DOMAIN-CONTAINING ION TRANSPORT REGULATOR 5 
Slc2a6 
SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE 
TRANSPORTER), MEMBER 6 
Ugcgl1 RIKEN CDNA 0910001L17 GENE 
Txndc5 THIOREDOXIN DOMAIN CONTAINING 5 
Ccl5 CHEMOKINE (C-C MOTIF) LIGAND 5 
Rnase6 RIBONUCLEASE, RNASE A FAMILY, 6 
Oasl2 2'-5' OLIGOADENYLATE SYNTHETASE-LIKE 2 
Col5a2 PROCOLLAGEN, TYPE V, ALPHA 2 
Sdc3 SYNDECAN 3 
Mgat1 MANNOSIDE ACETYLGLUCOSAMINYLTRANSFERASE 1 
BC025575 CDNA SEQUENCE BC025575 
Cbr2 CARBONYL REDUCTASE 2 
Irf7 INTERFERON REGULATORY FACTOR 7 
Mmp14 MATRIX METALLOPEPTIDASE 14 (MEMBRANE-INSERTED) 
Oas2 2'-5' OLIGOADENYLATE SYNTHETASE 2 
Cx3cr1 CHEMOKINE (C-X3-C) RECEPTOR 1 
Sfrp2 SECRETED FRIZZLED-RELATED SEQUENCE PROTEIN 2 
Adamts5 
A DISINTEGRIN-LIKE AND METALLOPEPTIDASE (REPROLYSIN 
TYPE) WITH THROMBOSPONDIN TYPE 1 MOTIF, 5 
(AGGRECANASE-2) 
Upp1 URIDINE PHOSPHORYLASE 1 
Zyx ZYXIN 
Elovl1 
ELONGATION OF VERY LONG CHAIN FATTY ACIDS (FEN1/ELO2, 
SUR4/ELO3, YEAST)-LIKE 1 
Casp8 CASPASE 8 
BC026590 CDNA SEQUENCE BC026590 
Ccl7 CHEMOKINE (C-C MOTIF) LIGAND 7 
Ecm1 EXTRACELLULAR MATRIX PROTEIN 1 
Ube1l UBIQUITIN-ACTIVATING ENZYME E1-LIKE 
Hp HAPTOGLOBIN 
Igfbp4 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4 
Rps6ka1 RIBOSOMAL PROTEIN S6 KINASE POLYPEPTIDE 1 
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Stard5 DNA SEGMENT, CHR 7, ERATO DOI 152, EXPRESSED 
Lass5 LONGEVITY ASSURANCE HOMOLOG 5 (S. CEREVISIAE) 
Gm2a GM2 GANGLIOSIDE ACTIVATOR PROTEIN 
Cx3cl1 CHEMOKINE (C-X3-C MOTIF) LIGAND 1 
Lrp12 LOW DENSITY LIPOPROTEIN-RELATED PROTEIN 12 
BC038286 CDNA SEQUENCE BC038286 
Oas1g 2'-5' OLIGOADENYLATE SYNTHETASE 1G 
Abi3 ABI GENE FAMILY, MEMBER 3 
Tyrobp TYRO PROTEIN TYROSINE KINASE BINDING PROTEIN 
Spag5 SPERM ASSOCIATED ANTIGEN 5 
Btg1 B-CELL TRANSLOCATION GENE 1, ANTI-PROLIFERATIVE 
Myd88 MYELOID DIFFERENTIATION PRIMARY RESPONSE GENE 88 
BC004728 CDNA SEQUENCE BC004728 
Ext1 EXOSTOSES (MULTIPLE) 1 
Ift140 
INTRAFLAGELLAR TRANSPORT 140 HOMOLOG 
(CHLAMYDOMONAS) 
Rassf4 RIKEN CDNA 3830411C14 GENE 
Alox5ap ARACHIDONATE 5-LIPOXYGENASE ACTIVATING PROTEIN 
Aebp1 AE BINDING PROTEIN 1 
Tbc1d5 TBC1 DOMAIN FAMILY, MEMBER 5 
Clec4n C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER N 
Lgals3bp 
LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 3 BINDING 
PROTEIN 
Cstb CYSTATIN B 
Gpnmb GLYCOPROTEIN (TRANSMEMBRANE) NMB 
Ly6e LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS E 
Slc27a3 
SOLUTE CARRIER FAMILY 27 (FATTY ACID TRANSPORTER), 
MEMBER 3 
Serpina3n 
SERINE (OR CYSTEINE) PEPTIDASE INHIBITOR, CLADE A, 
MEMBER 3N 
Man2b1 MANNOSIDASE 2, ALPHA B1 
Spc25 
SPINDLE POLE BODY COMPONENT 25 HOMOLOG (S. 
CEREVISIAE) 
Cd52 CD52 ANTIGEN 
 
A.5.1.3.2 Down-regulated 
 
Klf12 KRUPPEL-LIKE FACTOR 12 
Olfr299 OLFACTORY RECEPTOR 299 
Rdh13 RETINOL DEHYDROGENASE 13 (ALL-TRANS AND 9-CIS) 
Pdlim5 PDZ AND LIM DOMAIN 5 
Dffb DNA FRAGMENTATION FACTOR, BETA SUBUNIT 
Cysltr2 CYSTEINYL LEUKOTRIENE RECEPTOR 2 
Stx19 RIKEN CDNA A030009B12 GENE 
1700007I06Rik RIKEN CDNA 1700007I06 GENE 
Tpm3 TROPOMYOSIN 5 
Dsg1b DESMOGLEIN 1 BETA 
Olig3 OLIGODENDROCYTE TRANSCRIPTION FACTOR 3 
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A.5.1.4 PHD1 K/O EXT vs. WT EXT 
A.5.1.4.1 Upregulated genes 
 
Cdca2 CELL DIVISION CYCLE ASSOCIATED 2 
Csf1r COLONY STIMULATING FACTOR 1 RECEPTOR 
Lyzs LYSOZYME 
Tpx2 
TPX2, MICROTUBULE-ASSOCIATED PROTEIN HOMOLOG (XENOPUS 
LAEVIS) 
Aldh3b1 ALDEHYDE DEHYDROGENASE 3 FAMILY, MEMBER B1 
Ncf1 NEUTROPHIL CYTOSOLIC FACTOR 1 
Lasp1 LIM AND SH3 PROTEIN 1 
Scotin SCOTIN GENE 
Efemp2 
EPIDERMAL GROWTH FACTOR-CONTAINING FIBULIN-LIKE 
EXTRACELLULAR MATRIX PROTEIN 2 
Lgals3 LECTIN, GALACTOSE BINDING, SOLUBLE 3 
Tlr7 TOLL-LIKE RECEPTOR 7 
Scara3 SCAVENGER RECEPTOR CLASS A, MEMBER 3 
Incenp INNER CENTROMERE PROTEIN 
Pqlc3 PQ LOOP REPEAT CONTAINING 
Ly9 LYMPHOCYTE ANTIGEN 9 
Bst2 BONE MARROW STROMAL CELL ANTIGEN 2 
Pafah1b3 
PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE, ISOFORM 1B, 
ALPHA1 SUBUNIT 
Pscdbp 
PLECKSTRIN HOMOLOGY, SEC7 AND COILED-COIL DOMAINS, BINDING 
PROTEIN 
Apoc1 APOLIPOPROTEIN C-I 
Mx2 MYXOVIRUS (INFLUENZA VIRUS) RESISTANCE 2 
Itgb7 INTEGRIN BETA 7 
Rac3 RAS-RELATED C3 BOTULINUM SUBSTRATE 3 
Cd84 CD84 ANTIGEN 
Slc15a3 SOLUTE CARRIER FAMILY 15, MEMBER 3 
Ctse CATHEPSIN E 
Il1b INTERLEUKIN 1 BETA 
Ifit3 INTERFERON-INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEATS 3 
Vat1 VESICLE AMINE TRANSPORT PROTEIN 1 HOMOLOG (T CALIFORNICA) 
Rbp1 RETINOL BINDING PROTEIN 1, CELLULAR 
Emr1 
EGF-LIKE MODULE CONTAINING, MUCIN-LIKE, HORMONE RECEPTOR-
LIKE SEQUENCE 1 
Csf3r COLONY STIMULATING FACTOR 3 RECEPTOR (GRANULOCYTE) 
Clic1 CHLORIDE INTRACELLULAR CHANNEL 1 
Gmfg GLIA MATURATION FACTOR, GAMMA 
Coro1a CORONIN, ACTIN BINDING PROTEIN 1A 
Scara5 SCAVENGER RECEPTOR CLASS A, MEMBER 5 (PUTATIVE) 
Nmi N-MCY (AND STAT) INTERACTOR 
Ctsc CATHEPSIN C 
Prg2 PROTEOGLYCAN 2, BONE MARROW 
Unc93b1 UNC-93 HOMOLOG B1 (C. ELEGANS) 
Samsn1 SAM DOMAIN, SH3 DOMAIN AND NUCLEAR LOCALIZATION SIGNALS, 1 
Usp18 UBIQUITIN SPECIFIC PEPTIDASE 18 
Lgals9 LECTIN, GALACTOSE BINDING, SOLUBLE 9 
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Edg5 
ENDOTHELIAL DIFFERENTIATION, SPHINGOLIPID G-PROTEIN-COUPLED 
RECEPTOR, 5 
Btk BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE 
Lyl1 LYMPHOBLASTOMIC LEUKEMIA 
Cotl1 RIKEN CDNA 2010004C08 GENE 
4930583H14
Rik RIKEN CDNA 4930583H14 GENE 
Ifitm6 INTERFERON INDUCED TRANSMEMBRANE PROTEIN 6 
Ccr5 CHEMOKINE (C-C MOTIF) RECEPTOR 5 
Actn4 ACTININ ALPHA 4 
C920005C14
Rik RIKEN CDNA C920005C14 GENE 
Cxcr4 CHEMOKINE (C-X-C MOTIF) RECEPTOR 4 
Epb4.1l3 ERYTHROCYTE PROTEIN BAND 4.1-LIKE 3 
Ctss CATHEPSIN S 
Ctsz CATHEPSIN Z 
Cxcl4 CHEMOKINE (C-X-C MOTIF) LIGAND 4 
Rod1 ROD1 REGULATOR OF DIFFERENTIATION 1 (S. POMBE) 
Adam12 A DISINTEGRIN AND METALLOPEPTIDASE DOMAIN 12 (MELTRIN ALPHA) 
Epb4.1l1 ERYTHROCYTE PROTEIN BAND 4.1-LIKE 1 
Cd44 CD44 ANTIGEN 
Arl11 ADP-RIBOSYLATION FACTOR-LIKE 11 
Tlr13 TOLL-LIKE RECEPTOR 13 
Ccl4 CHEMOKINE (C-C MOTIF) LIGAND 4 
Gldc DNA SEGMENT, CHR 19, WAYNE STATE UNIVERSITY 57, EXPRESSED 
Lst1 LEUKOCYTE SPECIFIC TRANSCRIPT 1 
Il1rl1 INTERLEUKIN 1 RECEPTOR-LIKE 1 
Cd53 CD53 ANTIGEN 
Cd68 CD68 ANTIGEN 
Chi3l3 CHITINASE 3-LIKE 3 
Tor3a TORSIN FAMILY 3, MEMBER A 
1200013B08
Rik RIKEN CDNA 1200013B08 GENE 
Mlkl MIXED LINEAGE KINASE DOMAIN-LIKE 
Mmp13 MATRIX METALLOPEPTIDASE 13 
Lpxn LEUPAXIN 
Slc9a3r1 
SOLUTE CARRIER FAMILY 9 (SODIUM/HYDROGEN EXCHANGER), 
ISOFORM 3 REGULATOR 1 
C2 COMPLEMENT COMPONENT 2 (WITHIN H-2S) 
Myo1g MYOSIN IG 
Slfn1 SCHLAFEN 1 
Mgl1 
MACROPHAGE GALACTOSE N-ACETYL-GALACTOSAMINE SPECIFIC LECTIN 
1 
Fzd1 FRIZZLED HOMOLOG 1 (DROSOPHILA) 
Pltp PHOSPHOLIPID TRANSFER PROTEIN 
Enpp1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 
Tbxas1 THROMBOXANE A SYNTHASE 1, PLATELET 
Ms4a7 MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 7 
Slc2a6 
SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), 
MEMBER 6 
Ada ADENOSINE DEAMINASE 
BC026585 CDNA SEQUENCE BC026585 
Klra17 KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY A, MEMBER 17 
Napsa NAPSIN A ASPARTIC PEPTIDASE 
Sp100 NUCLEAR ANTIGEN SP100 
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Ccl5 CHEMOKINE (C-C MOTIF) LIGAND 5 
Fcgr1 FC RECEPTOR, IGG, HIGH AFFINITY I 
Arhgap9 RHO GTPASE ACTIVATING PROTEIN 9 
Rnase6 RIBONUCLEASE, RNASE A FAMILY, 6 
Col5a3 PROCOLLAGEN, TYPE V, ALPHA 3 
Oasl2 2'-5' OLIGOADENYLATE SYNTHETASE-LIKE 2 
Ly86 LYMPHOCYTE ANTIGEN 86 
Sdc3 SYNDECAN 3 
Sh3bgrl3 SH3 DOMAIN BINDING GLUTAMIC ACID-RICH PROTEIN-LIKE 3 
Pvrl2 POLIOVIRUS RECEPTOR-RELATED 2 
4732435N03
Rik RIKEN CDNA 4732435N03 GENE 
Grn GRANULIN 
Plcg2 PHOSPHOLIPASE C, GAMMA 2 
E430002G05
Rik RIKEN CDNA E430002G05 GENE 
Ptpn18 PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 18 
Renbp RENIN BINDING PROTEIN 
Gpr120 G PROTEIN-COUPLED RECEPTOR 120 
Irf7 INTERFERON REGULATORY FACTOR 7 
Vav1 VAV 1 ONCOGENE 
Oas2 2'-5' OLIGOADENYLATE SYNTHETASE 2 
Fpr-rs2 FORMYL PEPTIDE RECEPTOR, RELATED SEQUENCE 2 
Slc11a1 
SOLUTE CARRIER FAMILY 11 (PROTON-COUPLED DIVALENT METAL ION 
TRANSPORTERS), MEMBER 1 
Ccl7 CHEMOKINE (C-C MOTIF) LIGAND 7 
Ugt1a6a UDP GLUCURONOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A6A 
Capg CAPPING PROTEIN (ACTIN FILAMENT), GELSOLIN-LIKE 
Ube1l UBIQUITIN-ACTIVATING ENZYME E1-LIKE 
Lhfpl2 LIPOMA HMGIC FUSION PARTNER-LIKE 2 
Lcp2 LYMPHOCYTE CYTOSOLIC PROTEIN 2 
Tmem8 TRANSMEMBRANE PROTEIN 8 (FIVE MEMBRANE-SPANNING DOMAINS) 
Saa3 SERUM AMYLOID A 3 
Ccl2 CHEMOKINE (C-C MOTIF) LIGAND 2 
Olfml1 OLFACTOMEDIN-LIKE 1 
Blvrb BILIVERDIN REDUCTASE B (FLAVIN REDUCTASE (NADPH)) 
Clec4a3 C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER A3 
Phf11 PHD FINGER PROTEIN 11 
Parp14 RIKEN CDNA 1600029O10 GENE 
2810417H13
Rik RIKEN CDNA 2810417H13 GENE 
Antxr1 ANTHRAX TOXIN RECEPTOR 1 
Lilrb4 
LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY B, MEMBER 
4 
Oas1g 2'-5' OLIGOADENYLATE SYNTHETASE 1G 
Aif1 ALLOGRAFT INFLAMMATORY FACTOR 1 
Gpr114 G PROTEIN-COUPLED RECEPTOR 114 
Glipr2 GLI PATHOGENESIS-RELATED 2 
Ms4a6d MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 6D 
Cd14 CD14 ANTIGEN 
Tyrobp TYRO PROTEIN TYROSINE KINASE BINDING PROTEIN 
Rabep1 RABAPTIN, RAB GTPASE BINDING EFFECTOR PROTEIN 1 
C1qa COMPLEMENT COMPONENT 1, Q SUBCOMPONENT, ALPHA POLYPEPTIDE 
Mmp3 MATRIX METALLOPEPTIDASE 3 
Anxa8 ANNEXIN A8 
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Rassf4 RIKEN CDNA 3830411C14 GENE 
D14Ertd668
e DNA SEGMENT, CHR 14, ERATO DOI 668, EXPRESSED 
Hcst HEMATOPOIETIC CELL SIGNAL TRANSDUCER 
Col18a1 PROCOLLAGEN, TYPE XVIII, ALPHA 1 
Trem2 TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2C 
P2ry6 PYRIMIDINERGIC RECEPTOR P2Y, G-PROTEIN COUPLED, 6 
Soat1 STEROL O-ACYLTRANSFERASE 1 
Casp1 CASPASE 1 
C1qb COMPLEMENT COMPONENT 1, Q SUBCOMPONENT, BETA POLYPEPTIDE 
Slc44a1 SOLUTE CARRIER FAMILY 44, MEMBER 1 
BC029169 CDNA SEQUENCE BC029169 
Clec4n C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER N 
Efna5 EPHRIN A5 
Lgals3bp LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 3 BINDING PROTEIN 
Ly6e LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS E 
Gpnmb GLYCOPROTEIN (TRANSMEMBRANE) NMB 
Ncf4 NEUTROPHIL CYTOSOLIC FACTOR 4 
Abcg1 ATP-BINDING CASSETTE, SUB-FAMILY G (WHITE), MEMBER 1 
Atp6v1d ATPASE, H+ TRANSPORTING, LYSOSOMAL V1 SUBUNIT D 
Tgfb1i1 TRANSFORMING GROWTH FACTOR BETA 1 INDUCED TRANSCRIPT 1 
Plac8 PLACENTA-SPECIFIC 8 
1200002N14
Rik RIKEN CDNA 1200002N14 GENE 
Cd52 CD52 ANTIGEN 
Ifit2 INTERFERON-INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEATS 2 
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A.5.1.4.1 Downregulated genes 
 
Mtch2 MITOCHONDRIAL CARRIER HOMOLOG 2 (C. ELEGANS) 
Slc25a11 
SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER 
OXOGLUTARATE CARRIER), MEMBER 11 
Coro6 CORONIN, ACTIN BINDING PROTEIN 6 
Acn9 ACN9 HOMOLOG (S. CEREVISIAE) 
Ncoa4 NUCLEAR RECEPTOR COACTIVATOR 4 
Zfp289 ZINC FINGER PROTEIN 289 
Lpin1 LIPIN 1 
Coq5 COENZYME Q5 HOMOLOG, METHYLTRANSFERASE (YEAST) 
Fbxo32 F-BOX ONLY PROTEIN 32 
8230402K04Rik RIKEN CDNA 8230402K04 GENE 
Tspyl1 TESTIS-SPECIFIC PROTEIN, Y-ENCODED-LIKE 1 
Gadd45g GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE 45 GAMMA 
Mrps12 MITOCHONDRIAL RIBOSOMAL PROTEIN S12 
Ech1 ENOYL COENZYME A HYDRATASE 1, PEROXISOMAL 
Idh3g ISOCITRATE DEHYDROGENASE 3 (NAD+), GAMMA 
Snca SYNUCLEIN, ALPHA 
Tmem66 TRANSMEMBRANE PROTEIN 66 
Sgk3 SERUM/GLUCOCORTICOID REGULATED KINASE 3 
Apip APAF1 INTERACTING PROTEIN 
Chpt1 CHOLINE PHOSPHOTRANSFERASE 1 
1700034H14Rik RIKEN CDNA 1700034H14 GENE 
Slc35e4 SOLUTE CARRIER FAMILY 35, MEMBER E4 
Tpd52l1 TUMOR PROTEIN D52-LIKE 1 
Vgll2 VESTIGIAL LIKE 2 HOMOLOG (DROSOPHILA) 
Rfc4 REPLICATION FACTOR C (ACTIVATOR 1) 4 
5230400G24Rik RIKEN CDNA 5230400G24 GENE 
Phospho1 PHOSPHATASE, ORPHAN 1 
Alas2 AMINOLEVULINIC ACID SYNTHASE 2, ERYTHROID 
Ush2a 
USHER SYNDROME 2A (AUTOSOMAL RECESSIVE, MILD) 
HOMOLOG (HUMAN) 
Nit2 NITRILASE FAMILY, MEMBER 2 
Arl6ip2 
ADP-RIBOSYLATION FACTOR-LIKE 6 INTERACTING PROTEIN 
2 
Sar1b SAR1 GENE HOMOLOG B (S. CEREVISIAE) 
Kif17 KINESIN FAMILY MEMBER 17 
Gpr146 G PROTEIN-COUPLED RECEPTOR 146 
1700102P08Rik RIKEN CDNA 1700102P08 GENE 
Gba2 GLUCOSIDASE BETA 2 
Lmcd1 LIM AND CYSTEINE-RICH DOMAINS 1 
2410166I05Rik RIKEN CDNA 2410166I05 GENE 
Klf12 KRUPPEL-LIKE FACTOR 12 
2010311D03Rik EXPRESSED SEQUENCE AI314967 
S3-12 PLASMA MEMBRANE ASSOCIATED PROTEIN, S3-12 
Synj2bp SYNAPTOJANIN 2 BINDING PROTEIN 
Adsl ADENYLOSUCCINATE LYASE 
Oxct1 3-OXOACID COA TRANSFERASE 1 
Syngr2 SYNAPTOGYRIN 2 
Pdlim5 PDZ AND LIM DOMAIN 5 
Dctn4 DYNACTIN 4 
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Psmd8 
PROTEASOME (PROSOME, MACROPAIN) 26S SUBUNIT, NON-
ATPASE, 8 
Ldb3 LIM DOMAIN BINDING 3 
Nudt2 
NUDIX (NUCLEOSIDE DIPHOSPHATE LINKED MOIETY X)-TYPE 
MOTIF 2 
Uros UROPORPHYRINOGEN III SYNTHASE 
Sgcg 
SARCOGLYCAN, GAMMA (DYSTROPHIN-ASSOCIATED 
GLYCOPROTEIN) 
Phka1 PHOSPHORYLASE KINASE ALPHA 1 
Pdhb PYRUVATE DEHYDROGENASE (LIPOAMIDE) BETA 
Hist1h2bh HISTONE 1, H2BH 
Atp5f1 
ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F0 
COMPLEX, SUBUNIT B, ISOFORM 1 
Mllt3 DNA SEGMENT, CHR 4, ERATO DOI 321, EXPRESSED 
Cdc34 CELL DIVISION CYCLE 34 HOMOLOG (S. CEREVISIAE) 
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A.5.1.5 PHD3 K/O EXT vs. WT EXT 
A.5.1.5.1 Upregulated genes 
 
Pla2g12a PHOSPHOLIPASE A2, GROUP XIIA 
C1qtnf3 C1Q AND TUMOR NECROSIS FACTOR RELATED PROTEIN 3 
Lasp1 LIM AND SH3 PROTEIN 1 
Klk1b22 KALLIKREIN 1-RELATED PEPTIDASE B22 
Cxxc4 CXXC FINGER 4 
EG633640 SIMILAR TO CG10866-PA 
Fdxr FERREDOXIN REDUCTASE 
Timm10 
TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 10 
HOMOLOG (YEAST) 
Timm9 
TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 9 
HOMOLOG (YEAST) 
Btbd11 BTB (POZ) DOMAIN CONTAINING 11 
Nipsnap1 
4-NITROPHENYLPHOSPHATASE DOMAIN AND NON-NEURONAL 
SNAP25-LIKE PROTEIN HOMOLOG 1 (C. ELEGANS) 
Dpep3 DIPEPTIDASE 3 
Atm ATAXIA TELANGIECTASIA MUTATED HOMOLOG (HUMAN) 
Myl3 MYOSIN, LIGHT POLYPEPTIDE 3 
Car11 CARBONIC ANHYDRASE 11 
E430002G05Rik RIKEN CDNA E430002G05 GENE 
Il1rl1 INTERLEUKIN 1 RECEPTOR-LIKE 1 
Myl2 MYOSIN, LIGHT POLYPEPTIDE 2, REGULATORY, CARDIAC, SLOW 
Bcat2 BRANCHED CHAIN AMINOTRANSFERASE 2, MITOCHONDRIAL 
Moxd1 MONOOXYGENASE, DBH-LIKE 1 
Klk1b27 KALLIKREIN 1-RELATED PEPTIDASE B27 
Riok1 RIO KINASE 1 (YEAST) 
Cpne8 COPINE VIII 
Lrrc15 LEUCINE RICH REPEAT CONTAINING 15 
Nrn1 NEURITIN 1 
Angptl1 ANGIOPOIETIN-LIKE 1 
Dll3 DELTA-LIKE 3 (DROSOPHILA) 
Atp6v1d ATPASE, H+ TRANSPORTING, LYSOSOMAL V1 SUBUNIT D 
Kif5b KINESIN FAMILY MEMBER 5B 
Magea2 MELANOMA ANTIGEN, FAMILY A, 2 
Scin SCINDERIN 
Grwd1 GLUTAMATE-RICH WD REPEAT CONTAINING 1 
2610206B13Rik RIKEN CDNA 2810449K13 GENE 
BC025076 CDNA SEQUENCE BC025076 
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A.5.1.5.1 Downregulated genes 
 
Olfr142 OLFACTORY RECEPTOR 142 
Egln3 EGL NINE HOMOLOG 3 (C. ELEGANS) 
Tas2r110 TASTE RECEPTOR, TYPE 2, MEMBER 110 
Serinc3 SERINE INCORPORATOR 3 
AA881470 EST AA881470 
Pon3 PARAOXONASE 3 
Iqgap2 HYPOTHETICAL PROTEIN A630053O10 
Slc6a18 
SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER), 
MEMBER 18 
Arrdc1 ARRESTIN DOMAIN CONTAINING 1 
Hoxa11 HOMEO BOX A11 
Cdkl4 CYCLIN-DEPENDENT KINASE-LIKE 4 
Klf12 KRUPPEL-LIKE FACTOR 12 
Ggtla1 GAMMA-GLUTAMYLTRANSFERASE-LIKE ACTIVITY 1 
Dyrk2 
DUAL-SPECIFICITY TYROSINE-(Y)-PHOSPHORYLATION REGULATED 
KINASE 2 
B4galt3 
UDP-GAL:BETAGLCNAC BETA 1,4-GALACTOSYLTRANSFERASE, 
POLYPEPTIDE 3 
Gdpd3 
GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE DOMAIN 
CONTAINING 3 
Rbm14 RNA BINDING MOTIF PROTEIN 14 
Sfxn3 SIDEROFLEXIN 3 
Csrp1 CYSTEINE AND GLYCINE-RICH PROTEIN 1 
Slc20a1 SOLUTE CARRIER FAMILY 20, MEMBER 1 
Srrm1 SERINE/ARGININE REPETITIVE MATRIX 1 
Eif4e EUKARYOTIC TRANSLATION INITIATION FACTOR 4E 
Mus81 MUS81 ENDONUCLEASE HOMOLOG (YEAST) 
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A.5.1.6 PHD1 K/O EXT vs. PHD3 K/O EXT 
A.5.1.6.1 Upregulated 
 
Slc29a3 
SOLUTE CARRIER FAMILY 29 (NUCLEOSIDE TRANSPORTERS), 
MEMBER 3 
Csf1r COLONY STIMULATING FACTOR 1 RECEPTOR 
Serinc3 SERINE INCORPORATOR 3 
Lyzs LYSOZYME 
Tpx2 
TPX2, MICROTUBULE-ASSOCIATED PROTEIN HOMOLOG 
(XENOPUS LAEVIS) 
Ncf1 NEUTROPHIL CYTOSOLIC FACTOR 1 
Ticam2 TOLL-LIKE RECEPTOR ADAPTOR MOLECULE 2 
Ly9 LYMPHOCYTE ANTIGEN 9 
Apobec1 APOLIPOPROTEIN B EDITING COMPLEX 1 
Bst2 BONE MARROW STROMAL CELL ANTIGEN 2 
Stat2 SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 2 
H28 HISTOCOMPATIBILITY 28 
Mx2 MYXOVIRUS (INFLUENZA VIRUS) RESISTANCE 2 
Itgb7 INTEGRIN BETA 7 
Kif21b KINESIN FAMILY MEMBER 21B 
H2-Ea HISTOCOMPATIBILITY 2, CLASS II ANTIGEN E ALPHA 
Cd84 CD84 ANTIGEN 
Arl4c ADP-RIBOSYLATION FACTOR-LIKE 4C 
Slc15a3 SOLUTE CARRIER FAMILY 15, MEMBER 3 
Ctse CATHEPSIN E 
Unc13d UNC-13 HOMOLOG D (C. ELEGANS) 
Lrmp LYMPHOID-RESTRICTED MEMBRANE PROTEIN 
2310016F22Rik RIKEN CDNA 2310016F22 GENE 
Nfkbiz 
NUCLEAR FACTOR OF KAPPA LIGHT POLYPEPTIDE GENE 
ENHANCER IN B-CELLS INHIBITOR, ZETA 
Adar ADENOSINE DEAMINASE, RNA-SPECIFIC 
2010110P09Rik RIKEN CDNA 2010110P09 GENE 
Ifit3 
INTERFERON-INDUCED PROTEIN WITH TETRATRICOPEPTIDE 
REPEATS 3 
Aoah ACYLOXYACYL HYDROLASE 
Glycam1 GLYCOSYLATION DEPENDENT CELL ADHESION MOLECULE 1 
Emr1 
EGF-LIKE MODULE CONTAINING, MUCIN-LIKE, HORMONE 
RECEPTOR-LIKE SEQUENCE 1 
Clic1 CHLORIDE INTRACELLULAR CHANNEL 1 
Gmfg GLIA MATURATION FACTOR, GAMMA 
Coro1a CORONIN, ACTIN BINDING PROTEIN 1A 
Ednrb ENDOTHELIN RECEPTOR TYPE B 
Prg2 PROTEOGLYCAN 2, BONE MARROW 
Unc93b1 UNC-93 HOMOLOG B1 (C. ELEGANS) 
Usp18 UBIQUITIN SPECIFIC PEPTIDASE 18 
Lgals9 LECTIN, GALACTOSE BINDING, SOLUBLE 9 
Cenpi FSH PRIMARY RESPONSE 1 
Btk BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE 
Ms4a6b MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 6B 
Spire1 SPIRE HOMOLOG 1 (DROSOPHILA) 
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Pecam1 PLATELET/ENDOTHELIAL CELL ADHESION MOLECULE 1 
Egln3 EGL NINE HOMOLOG 3 (C. ELEGANS) 
4930583H14Rik RIKEN CDNA 4930583H14 GENE 
Tnfrsf11a 
TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 
11A 
Btnl2 BUTYROPHILIN-LIKE 2 
Ifitm6 INTERFERON INDUCED TRANSMEMBRANE PROTEIN 6 
Wnt2 WINGLESS-RELATED MMTV INTEGRATION SITE 2 
Dcp1b DCP1 DECAPPING ENZYME HOMOLOG B (S. CEREVISIAE) 
Cxcr4 CHEMOKINE (C-X-C MOTIF) RECEPTOR 4 
Fyb FYN BINDING PROTEIN 
Ctss CATHEPSIN S 
Ctsz CATHEPSIN Z 
Cxcl4 CHEMOKINE (C-X-C MOTIF) LIGAND 4 
Epb4.1l1 ERYTHROCYTE PROTEIN BAND 4.1-LIKE 1 
Hexb HEXOSAMINIDASE B 
Tlr13 TOLL-LIKE RECEPTOR 13 
Ccl4 CHEMOKINE (C-C MOTIF) LIGAND 4 
Bok BCL-2-RELATED OVARIAN KILLER PROTEIN 
Lst1 LEUKOCYTE SPECIFIC TRANSCRIPT 1 
Cd53 CD53 ANTIGEN 
Chi3l3 CHITINASE 3-LIKE 3 
Tor3a TORSIN FAMILY 3, MEMBER A 
1200013B08Rik RIKEN CDNA 1200013B08 GENE 
Mlkl MIXED LINEAGE KINASE DOMAIN-LIKE 
Ptprc PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, C 
Mmp13 MATRIX METALLOPEPTIDASE 13 
Gtf2e2 
GENERAL TRANSCRIPTION FACTOR II E, POLYPEPTIDE 2 (BETA 
SUBUNIT) 
Lpxn LEUPAXIN 
Slc9a3r1 
SOLUTE CARRIER FAMILY 9 (SODIUM/HYDROGEN EXCHANGER), 
ISOFORM 3 REGULATOR 1 
Sgpl1 SPHINGOSINE PHOSPHATE LYASE 1 
5830472M02Rik RIKEN CDNA 5830472M02 GENE 
Myo1g MYOSIN IG 
Slfn1 SCHLAFEN 1 
Mgl1 
MACROPHAGE GALACTOSE N-ACETYL-GALACTOSAMINE 
SPECIFIC LECTIN 1 
Mus81 MUS81 ENDONUCLEASE HOMOLOG (YEAST) 
Map4k4 NCK INTERACTING KINASE 
Ptpra PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, A 
Pltp PHOSPHOLIPID TRANSFER PROTEIN 
BC006779 CDNA SEQUENCE BC006779 
Iqgap2 HYPOTHETICAL PROTEIN A630053O10 
Ada ADENOSINE DEAMINASE 
BC026585 CDNA SEQUENCE BC026585 
Klra17 KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY A, MEMBER 17 
Ccl5 CHEMOKINE (C-C MOTIF) LIGAND 5 
Fcgr1 FC RECEPTOR, IGG, HIGH AFFINITY I 
Gal GALANIN 
Sepp1 SELENOPROTEIN P, PLASMA, 1 
Arhgap9 RHO GTPASE ACTIVATING PROTEIN 9 
Rnase6 RIBONUCLEASE, RNASE A FAMILY, 6 
Csrp1 CYSTEINE AND GLYCINE-RICH PROTEIN 1 
Pgrmc1 PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1 
 300 
Oasl2 2'-5' OLIGOADENYLATE SYNTHETASE-LIKE 2 
Ly86 LYMPHOCYTE ANTIGEN 86 
Sdc3 SYNDECAN 3 
Grn GRANULIN 
AA881470 EST AA881470 
Plcg2 PHOSPHOLIPASE C, GAMMA 2 
Ptpn18 PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 18 
Was WISKOTT-ALDRICH SYNDROME HOMOLOG (HUMAN) 
Kcnk13 POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 13 
Irf7 INTERFERON REGULATORY FACTOR 7 
Mgea5 MENINGIOMA EXPRESSED ANTIGEN 5 (HYALURONIDASE) 
Cx3cr1 CHEMOKINE (C-X3-C) RECEPTOR 1 
Oas2 2'-5' OLIGOADENYLATE SYNTHETASE 2 
Fpr-rs2 FORMYL PEPTIDE RECEPTOR, RELATED SEQUENCE 2 
Klra18 KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY A, MEMBER 18 
Snx1 SORTING NEXIN 1 
Upp1 URIDINE PHOSPHORYLASE 1 
Rbm14 RNA BINDING MOTIF PROTEIN 14 
Gdpd3 
GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE DOMAIN 
CONTAINING 3 
Slc11a1 
SOLUTE CARRIER FAMILY 11 (PROTON-COUPLED DIVALENT 
METAL ION TRANSPORTERS), MEMBER 1 
Ss18 SYNOVIAL SARCOMA TRANSLOCATION, CHROMOSOME 18 
Lhfpl2 LIPOMA HMGIC FUSION PARTNER-LIKE 2 
Tmem8 
TRANSMEMBRANE PROTEIN 8 (FIVE MEMBRANE-SPANNING 
DOMAINS) 
Saa3 SERUM AMYLOID A 3 
Hp HAPTOGLOBIN 
Oasl1 2'-5' OLIGOADENYLATE SYNTHETASE-LIKE 1 
Clec4a3 C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER A3 
Phf11 PHD FINGER PROTEIN 11 
Cfl1 COFILIN 1, NON-MUSCLE 
Oas1g 2'-5' OLIGOADENYLATE SYNTHETASE 1G 
Ela1 ELASTASE 1, PANCREATIC 
Aif1 ALLOGRAFT INFLAMMATORY FACTOR 1 
Tyrobp TYRO PROTEIN TYROSINE KINASE BINDING PROTEIN 
Rabep1 RABAPTIN, RAB GTPASE BINDING EFFECTOR PROTEIN 1 
Tcirg1 
T-CELL, IMMUNE REGULATOR 1, ATPASE, H+ TRANSPORTING, 
LYSOSOMAL V0 PROTEIN A3 
Myo1f MYOSIN IF 
C1qa 
COMPLEMENT COMPONENT 1, Q SUBCOMPONENT, ALPHA 
POLYPEPTIDE 
Anxa8 ANNEXIN A8 
Hcls1 HEMATOPOIETIC CELL SPECIFIC LYN SUBSTRATE 1 
Rassf4 RIKEN CDNA 3830411C14 GENE 
D14Ertd668e DNA SEGMENT, CHR 14, ERATO DOI 668, EXPRESSED 
Stac2 SH3 AND CYSTEINE RICH DOMAIN 2 
Trem2 TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2C 
Stxbp2 SYNTAXIN BINDING PROTEIN 2 
Gpr65 G-PROTEIN COUPLED RECEPTOR 65 
C3 COMPLEMENT COMPONENT 3 
H2-Ab1 HISTOCOMPATIBILITY 2, CLASS II ANTIGEN A, BETA 1 
Tspan32 TETRASPANIN 32 
Rarg RETINOIC ACID RECEPTOR, GAMMA 
Lgals3bp LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 3 BINDING PROTEIN 
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Ly6e LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS E 
Ncf4 NEUTROPHIL CYTOSOLIC FACTOR 4 
Abcg1 ATP-BINDING CASSETTE, SUB-FAMILY G (WHITE), MEMBER 1 
Arrb2 ARRESTIN, BETA 2 
Pkig PROTEIN KINASE INHIBITOR, GAMMA 
Plac8 PLACENTA-SPECIFIC 8 
1200002N14Rik RIKEN CDNA 1200002N14 GENE 
Ifit2 
INTERFERON-INDUCED PROTEIN WITH TETRATRICOPEPTIDE 
REPEATS 2 
 
A.5.1.6.2 Down-regulated 
 
Mtch2 MITOCHONDRIAL CARRIER HOMOLOG 2 (C. ELEGANS) 
Pla2g12a PHOSPHOLIPASE A2, GROUP XIIA 
Coro6 CORONIN, ACTIN BINDING PROTEIN 6 
Slc25a11 
SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER 
OXOGLUTARATE CARRIER), MEMBER 11 
Atp5s 
ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F0 
COMPLEX, SUBUNIT S 
Ncoa4 NUCLEAR RECEPTOR COACTIVATOR 4 
Gphn GEPHYRIN 
Mreg WHN-DEPENDENT TRANSCRIPT 2 
Uchl5 UBIQUITIN CARBOXYL-TERMINAL ESTERASE L5 
EG633640 SIMILAR TO CG10866-PA 
Ech1 ENOYL COENZYME A HYDRATASE 1, PEROXISOMAL 
Ndufa6 
NADH DEHYDROGENASE (UBIQUINONE) 1 ALPHA SUBCOMPLEX, 
6 (B14) 
Idh3g ISOCITRATE DEHYDROGENASE 3 (NAD+), GAMMA 
Adk ADENOSINE KINASE 
Rab5a RIKEN CDNA 2410015H04 GENE 
Timm8b 
TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 8 
HOMOLOG B (YEAST) 
Sgk3 SERUM/GLUCOCORTICOID REGULATED KINASE 3 
Scnm1 SODIUM CHANNEL MODIFIER 1 
Apip APAF1 INTERACTING PROTEIN 
Acadm ACETYL-COENZYME A DEHYDROGENASE, MEDIUM CHAIN 
1810049H13Rik RIKEN CDNA 1810049H13 GENE 
Chpt1 CHOLINE PHOSPHOTRANSFERASE 1 
Als2 
AMYOTROPHIC LATERAL SCLEROSIS 2 (JUVENILE) HOMOLOG 
(HUMAN) 
Ndufc1 
NADH DEHYDROGENASE (UBIQUINONE) 1, SUBCOMPLEX 
UNKNOWN, 1 
Acin1 APOPTOTIC CHROMATIN CONDENSATION INDUCER 1 
Wbp1 WW DOMAIN BINDING PROTEIN 1 
A330049M08Rik RIKEN CDNA A330049M08 GENE 
0610006I08Rik RIKEN CDNA 0610006I08 GENE 
Nit2 NITRILASE FAMILY, MEMBER 2 
Txlnb TAXILIN BETA 
Arl6ip2 ADP-RIBOSYLATION FACTOR-LIKE 6 INTERACTING PROTEIN 2 
Ptp4a2 PROTEIN TYROSINE PHOSPHATASE 4A2 
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Lypla1 LYSOPHOSPHOLIPASE 1 
Slc15a2 
SOLUTE CARRIER FAMILY 15 (H+/PEPTIDE TRANSPORTER), 
MEMBER 2 
Hba-a1 HEMOGLOBIN ALPHA, ADULT CHAIN 1 
Kif21a KINESIN FAMILY MEMBER 21A 
Nrbf2 NUCLEAR RECEPTOR BINDING FACTOR 2 PSEUDOGENE 
Gpr37l1 DNA SEGMENT, KIST 8 
1190002H23Rik RIKEN CDNA 1190002H23 GENE 
Mrpl3 MITOCHONDRIAL RIBOSOMAL PROTEIN L3 
E2f6 E2F TRANSCRIPTION FACTOR 6 
Gatad1 GATA ZINC FINGER DOMAIN CONTAINING 1 
Rpo1-3 RNA POLYMERASE 1-3 
Mrpl53 MITOCHONDRIAL RIBOSOMAL PROTEIN L53 
Hist1h2bm HISTONE 2, H3C1 
Tef THYROTROPH EMBRYONIC FACTOR 
Csda COLD SHOCK DOMAIN PROTEIN A 
Mcm6 
MINICHROMOSOME MAINTENANCE DEFICIENT 6 (MIS5 
HOMOLOG, S. POMBE) (S. CEREVISIAE) 
Hr HAIRLESS 
Car11 CARBONIC ANHYDRASE 11 
Pdlim5 PDZ AND LIM DOMAIN 5 
Slc25a34 SOLUTE CARRIER FAMILY 25, MEMBER 34 
Ube2g1 
UBIQUITIN-CONJUGATING ENZYME E2G 1 (UBC7 HOMOLOG, C. 
ELEGANS) 
Nudt2 
NUDIX (NUCLEOSIDE DIPHOSPHATE LINKED MOIETY X)-TYPE 
MOTIF 2 
Mbp MYELIN BASIC PROTEIN 
Sgcg 
SARCOGLYCAN, GAMMA (DYSTROPHIN-ASSOCIATED 
GLYCOPROTEIN) 
Decr1 2,4-DIENOYL COA REDUCTASE 1, MITOCHONDRIAL 
Atp1b1 ATPASE, NA+/K+ TRANSPORTING, BETA 1 POLYPEPTIDE 
AI597479 EXPRESSED SEQUENCE AI597479 
Hist1h2bh HISTONE 1, H2BH 
Tceb1 TRANSCRIPTION ELONGATION FACTOR B (SIII), POLYPEPTIDE 1 
Atp5f1 
ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F0 
COMPLEX, SUBUNIT B, ISOFORM 1 
Grwd1 GLUTAMATE-RICH WD REPEAT CONTAINING 1 
Pde6d PHOSPHODIESTERASE 6D, CGMP-SPECIFIC, ROD, DELTA 
Mrps31 MITOCHONDRIAL RIBOSOMAL PROTEIN S31 
Mtrf1 MITOCHONDRIAL TRANSLATIONAL RELEASE FACTOR 1 
2310039H08Rik RIKEN CDNA 2310039H08 GENE 
Hint3 HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 3 
Acn9 ACN9 HOMOLOG (S. CEREVISIAE) 
Ythdf2 YTH DOMAIN FAMILY 2 
Lpin1 LIPIN 1 
Coq5 COENZYME Q5 HOMOLOG, METHYLTRANSFERASE (YEAST) 
Klk1b22 KALLIKREIN 1-RELATED PEPTIDASE B22 
Gsto1 GLUTATHIONE S-TRANSFERASE OMEGA 1 
Mat2b EXPRESSED SEQUENCE AI182287 
Fbxo32 F-BOX ONLY PROTEIN 32 
8230402K04Rik RIKEN CDNA 8230402K04 GENE 
Ubc UBIQUITIN C 
Mrps12 MITOCHONDRIAL RIBOSOMAL PROTEIN S12 
Prdx3 PEROXIREDOXIN 3 
BC004044 CDNA SEQUENCE BC004044 
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Snca SYNUCLEIN, ALPHA 
Rps6ka5 RIBOSOMAL PROTEIN S6 KINASE, POLYPEPTIDE 5 
Tmem126a TRANSMEMBRANE PROTEIN 126A 
Zfp30 ZINC FINGER PROTEIN 30 
Etfa ELECTRON TRANSFERRING FLAVOPROTEIN, ALPHA POLYPEPTIDE 
A430005L14Rik RIKEN CDNA A430005L14 GENE 
Cldn15 CLAUDIN 15 
LOC654426 
ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F0 
COMPLEX, SUBUNIT F PSEUDOGENE 
Homer1 HOMER HOMOLOG 1 (DROSOPHILA) 
Hist1h2bk HISTONE 1, H2BK 
Ndufa5 
NADH DEHYDROGENASE (UBIQUINONE) 1 ALPHA SUBCOMPLEX, 
5 
Dtna DYSTROBREVIN ALPHA 
Mkks MCKUSICK-KAUFMAN SYNDROME PROTEIN 
Narg1l NMDA RECEPTOR REGULATED 1-LIKE 
Riok1 RIO KINASE 1 (YEAST) 
1700034H14Rik RIKEN CDNA 1700034H14 GENE 
Cutc CUTC COPPER TRANSPORTER HOMOLOG (E.COLI) 
Cldn1 CLAUDIN 1 
Greb1 RIKEN CDNA 5730583K22 GENE 
Tpd52l1 TUMOR PROTEIN D52-LIKE 1 
Cops8 EXPRESSED SEQUENCE AA408242 
D10Jhu81e 
DNA SEGMENT, CHR 10, JOHNS HOPKINS UNIVERSITY 81 
EXPRESSED 
Rfc4 REPLICATION FACTOR C (ACTIVATOR 1) 4 
5230400G24Rik RIKEN CDNA 5230400G24 GENE 
Dars ASPARTYL-TRNA SYNTHETASE 
Sh3kbp1 SH3-DOMAIN KINASE BINDING PROTEIN 1 
Ush2a 
USHER SYNDROME 2A (AUTOSOMAL RECESSIVE, MILD) 
HOMOLOG (HUMAN) 
Taf6 
TAF6 RNA POLYMERASE II, TATA BOX BINDING PROTEIN (TBP)-
ASSOCIATED FACTOR 
Sar1b SAR1 GENE HOMOLOG B (S. CEREVISIAE) 
Atp5j 
ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F0 
COMPLEX, SUBUNIT F 
Kif17 KINESIN FAMILY MEMBER 17 
Suclg1 SUCCINATE-COA LIGASE, GDP-FORMING, ALPHA SUBUNIT 
Lmcd1 LIM AND CYSTEINE-RICH DOMAINS 1 
2410166I05Rik RIKEN CDNA 2410166I05 GENE 
Slc25a16 
SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, 
GRAVES DISEASE AUTOANTIGEN), MEMBER 16 
2010311D03Rik EXPRESSED SEQUENCE AI314967 
S3-12 PLASMA MEMBRANE ASSOCIATED PROTEIN, S3-12 
Egln1 EGL NINE HOMOLOG 1 (C. ELEGANS) 
Synj2bp SYNAPTOJANIN 2 BINDING PROTEIN 
Znhit3 ZINC FINGER, HIT TYPE 3 
Oxct1 3-OXOACID COA TRANSFERASE 1 
Ccbl2 CYSTEINE CONJUGATE-BETA LYASE 2 
Adsl ADENYLOSUCCINATE LYASE 
Immp2l 
IMP2 INNER MITOCHONDRIAL MEMBRANE PEPTIDASE-LIKE (S. 
CEREVISIAE) 
Stra13 STIMULATED BY RETINOIC ACID 13 
Sra1 STEROID RECEPTOR RNA ACTIVATOR 1 
Sirt5 SIRTUIN 5 (SILENT MATING TYPE INFORMATION REGULATION 2 
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HOMOLOG) 5 (S. CEREVISIAE) 
Bola3 BOLA-LIKE 3 (E. COLI) 
Rala 
V-RAL SIMIAN LEUKEMIA VIRAL ONCOGENE HOMOLOG A (RAS 
RELATED) 
Psmb7 PROTEASOME (PROSOME, MACROPAIN) SUBUNIT, BETA TYPE 7 
Bcat2 BRANCHED CHAIN AMINOTRANSFERASE 2, MITOCHONDRIAL 
Rdh14 RIKEN CDNA 3110030G19 GENE 
Psmd8 
PROTEASOME (PROSOME, MACROPAIN) 26S SUBUNIT, NON-
ATPASE, 8 
Tnfrsf10b 
TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 
10B 
Kbtbd4 KELCH REPEAT AND BTB (POZ) DOMAIN CONTAINING 4 
Art5 ADP-RIBOSYLTRANSFERASE 5 
Pdcd5 PROGRAMMED CELL DEATH 5 
Uros UROPORPHYRINOGEN III SYNTHASE 
Suv39h1 SUPPRESSOR OF VARIEGATION 3-9 HOMOLOG 1 (DROSOPHILA) 
Myoc MYOCILIN 
Lcmt1 LEUCINE CARBOXYL METHYLTRANSFERASE 1 
Gm561 GENE MODEL 561, (NCBI) 
Mllt3 DNA SEGMENT, CHR 4, ERATO DOI 321, EXPRESSED 
Cdc34 CELL DIVISION CYCLE 34 HOMOLOG (S. CEREVISIAE) 
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Appendix VI 
A.6.1 Functional tables from DAVID 
The following colours represent mutual changes across comparison groups: 
terms in: P1 K/O EXT vs. WT EXT, P1 K/O EXT vs. P1 K/O, P1 K/O EXT vs. P3 K/O 
EXT 
 
  
 
 
 
A.6.1.1 WT EXT vs. WT  
Using standard criteria (described) was inadequate for differentiating up and 
downregulated genes in this group as the P-value across all genes was insignificant, 
i.e. >0.05.  Instead, genes were distinguished on the basis of fold change only, 
classified on greater or less than 1 fold.  Based on this, 56 genes were up and 26 
downregulated, as obtained by DAVID analysis.  Table A.6.1 illustrates functional 
clusters upregulated (FDR < 10).  Only the immune response and immune system 
processes were down regulated in WT mice with EXT when compared to WT alone.  
 
 
TERM No. of genes 
cytoskeletal protein binding 7 
actin binding 6 
protein binding 28 
response to wounding 6 
cytokinesis 3 
chemokine activity 3 
inflammatory response 5 
 
Table A.6.1 Functional annotation charts for upregulated genes in WT EXT when compared to 
WT (colours described 7.3.1.2) 
 
terms in: WT EXT vs. WT, P1 K/O EXT vs. P1 
K/O 
 
terms in: P1 K/O EXT vs. P3 K/O 
EXT 
 
 terms in: WT EXT vs. WT, P1 K/O EXT vs. P1 
K/O 
 
terms in: P1 K/O EXT vs. P1 K/OP1 K/O EXT vs.  WT 
EXT 
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A.6.1.2 PHD1 K/O vs. WT 
Using the standard criteria, 129 genes were up (A.6.2) and 53 genes were 
downregulated, though as with the above, none were clustered into groups based 
on function, from the DAVID output.  None of the upregulated function terms in 
were common amongst any of the other comparisons.  ‘Response to endogenous 
stimulus’ was the only downregulated term. 
 
Term Count 
G-protein coupled receptor protein signaling pathway 31 
G-protein coupled receptor activity 29 
rhodopsin-like receptor activity 27 
neurological system process 27 
system process 28 
sensory perception 24 
transmembrane receptor activity 30 
sensory perception of smell 21 
olfactory receptor activity 21 
sensory perception of chemical stimulus 21 
cell surface receptor linked signal transduction 33 
signal transduction 41 
cell communication 41 
receptor activity 31 
 
Table A.6.2 Functional annotation charts for upregulated genes in PHD1 K/O when compared 
to WT (no colours indicates no similarity between other comparison groups) 
 
 
A.6.1.3 PHD1 K/O EXT vs. PHD1 K/O 
Using a P-value of 0.001 and a fold change of ± 0 showed an upregulation of 219 
genes (A.6.3) and a downregulation of 11.  Using P<0.05 gave a list encompassing 
a number of genes too large to be used in the DAVID analysis.  Table illustrates the 
large range of functional terms upregulated in PHD1 K/O EXT mice when compared 
to PHD1 K/O alone.  Many of these terms were common amongst other groups, as 
indicated by colour labelling. None of the downregulated genes could be clustered 
into terms.  
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Term Count 
immune response 29 
immune system process 35 
protein binding 104 
inflammatory response 17 
response to wounding 19 
response to external stimulus 22 
defense response 26 
innate immune response 10 
cytoskeletal protein binding 17 
actin binding 14 
ceramide metabolic process 6 
sphingoid metabolic process 6 
immunoglobulin mediated immune response 8 
B cell mediated immunity 8 
chemokine activity 6 
chemokine receptor binding 6 
immune effector process 10 
response to stress 24 
adaptive immune response 8 
lymphocyte mediated immunity 8 
positive regulation of biological process 27 
leukocyte mediated immunity 8 
sphingolipid metabolic process 6 
membrane invagination 10 
endocytosis 10 
positive regulation of immune system process 8 
mitosis 10 
activation of immune response 7 
M phase of mitotic cell cycle 10 
binding 147 
G-protein-coupled receptor binding 6 
humoral immune response mediated by immunoglobulin 5 
regulation of immune system process 8 
positive regulation of multicellular organismal process 8 
regulation of multicellular organismal process 12 
membrane organization and biogenesis 11 
positive regulation of immune response 7 
acute inflammatory response 6 
M phase 10 
regulation of immune response 7 
mitotic cell cycle 10 
complement activation, classical pathway 4 
positive regulation of cellular process 21 
proteolysis 19 
lipid metabolic process 17 
lipid binding 12 
 
Table A.6.3 Functional annotation charts for upregulated genes in PHD1 K/O EXT 
when compared to PHD1 K/O (colours described 6.3.1.2) 
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A.6.1.4 PHD1 K/O EXT vs. WT EXT 
A fold change of ±0 was used as few genes had a P-value <0.05: 164 genes were 
upregulated and 59 genes downregulated in PHD1 K/O EXT mice.  Table A.6.4 
illustrates upregulated functions in PHD1 K/O mice with extirpation when compared 
with WT EXT mice (FDR < 10).  Only one function fitted the criteria in 
downregulated genes: cofactor metabolic processes. 
TERM No. of genes 
immune response 29 
immune system process 34 
response to wounding 20 
inflammatory response 17 
response to external stimulus 23 
defense response 27 
chemotaxis 9 
taxis 9 
carbohydrate binding 13 
innate immune response 8 
response to stress 21 
response to other organism 9 
G-protein-coupled receptor binding 6 
chemokine activity 5 
chemokine receptor binding 5 
multi-organism process 10 
inorganic anion transport 8 
locomotory behavior 9 
phosphate transport 6 
acute inflammatory response 6 
lipid binding 12 
polysaccharide binding 6 
protein binding 69 
anion transport 8 
pattern binding 6 
response to biotic stimulus 9 
cell adhesion 15 
biological adhesion 15 
sugar binding 8 
response to stimulus 45 
actin binding 9 
behavior 10 
binding 116 
phospholipid binding 8 
immunoglobulin mediated immune response 5 
B cell mediated immunity 5 
 
Table A.6.4 Functional annotation charts for upregulated genes in PHD1 K/O EXT when 
compared to WT EXT.  (colours described 6.3.1.2) 
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A.6.1.6 PHD1 EXT K/O vs. PHD3 EXT K/O 
Using the standard criteria, 151 genes were up and 188 genes were downregulated. 
Table A.6.6 indicates functional terms upregulated and table A.6.7 downregulated, 
in PHD1 K/O EXT when compared to PHD3 K/O EXT mice.  
Term Count 
immune response 26 
immune system process 31 
response to wounding 17 
inflammatory response 14 
defense response 23 
response to external stimulus 18 
response to stress 20 
antigen processing and presentation of exogenous peptide  5 
antigen processing and presentation of exogenous antigen 5 
adaptive immune response 7 
lymphocyte mediated immunity 7 
leukocyte mediated immunity 7 
multi-organism process 10 
response to stimulus 46 
antigen processing and presentation of peptide antigen 5 
response to other organism 8 
beta-N-acetylhexosaminidase activity 3 
antigen processing and presentation of peptide antigen  4 
antigen processing and presentation of exogenous peptide 4 
immune effector process 7 
innate immune response 6 
positive regulation of immune response 6 
positive regulation of immune system process 6 
antigen processing and presentation of peptide antigen  4 
immunoglobulin mediated immune response 5 
regulation of immune response 6 
B cell mediated immunity 5 
regulation of immune system process 6 
protein binding 62 
catabolic process 13 
positive regulation of multicellular organismal process 6 
acute inflammatory response 5 
lipid binding 10 
response to biotic stimulus 8 
 
Table A.6.6 Functional annotation charts for upregulated genes in PHD1 K/O when compared 
to PHD3 K/O EXT.  (colours described 6.3.1.2) 
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Term Count 
cofactor metabolic process 9 
coenzyme metabolic process 8 
metabolic process 75 
catalytic activity 56 
cofactor biosynthetic process 6 
identical protein binding 8 
chromatin assembly 5 
pyrophosphatase activity 11 
 
Table A.6.7 Functional annotation charts for downregulated genes in PHD1 K/O when 
compared to PHD3 K/O EXT.  (colours described 6.3.1.2) 
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Appendix VII 
 
 
 
 A heat map illustrating genes up- (red) and downregulated (green) in PHD1 K/O mice 
(colums 1-2) vs.WT (columns 3-5) using a P-value of 0.05 and ± 0 FC 
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A heat map illustrating genes up- (red) and downregulated (green) in PHD1 K/O EXT 
(columns 3-5) vs. PHD1 K/O mice (columns 1 and 2) using a P-value of 0.05 and ± 0 FC 
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A heat map illustrating genes up- (red) and downregulated (green) in PHD1 K/O EXT 
(columns 4-6) vs. WT EXT (columns 1-3) using a P-value of 0.001 and a FC of ± 2 
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A heat map illustrating genes up- (red) and downregulated (green) in PHD1 K/O EXT 
(columns 1-3) vs. PHD3 K/O EXT (columns 4-7) using a P-value of 0.001 and a FC of ± 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
